
<html lang="en"     class="pb-page"  data-request-id="33781ccc-abb0-42c4-aba6-049a03770b59"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";issue:issue:10.1021/jmcmar.2020.63.issue-24;requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;article:article:10.1021/acs.jmedchem.0c01340;wgroup:string:ACHS website Group;website:website:acspubs;pageGroup:string:Publication Pages;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="citation_journal_title" content="Journal of Medicinal Chemistry" /></meta><meta name="dc.Title" content="Peptide Ligands Specifically Targeting HER2 Receptor and the Role Played by a Synthetic Model System of the Receptor Extracellular Domain: Hypothesized Future Perspectives" /></meta><meta name="dc.Creator" content="Stefania De  Luca" /></meta><meta name="dc.Creator" content="Valentina  Verdoliva" /></meta><meta name="dc.Creator" content="Michele  Saviano" /></meta><meta name="dc.Description" content="A short (Fab)trastuzumab-derived peptide specific for HER2 receptor was identified. Its affinity for the model system HER2-DIVMP was found in a nanomolar range. The structural determinants responsi..." /></meta><meta name="Description" content="A short (Fab)trastuzumab-derived peptide specific for HER2 receptor was identified. Its affinity for the model system HER2-DIVMP was found in a nanomolar range. The structural determinants responsi..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="November 23, 2020" /></meta><meta name="dc.Type" content="review-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.0c01340" /></meta><meta name="dc.Language" content="en" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="Â© 2020 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.0c01340" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.0c01340" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.0c01340" /></link>
        
    
    

<title>Peptide Ligands Specifically Targeting HER2 Receptor and the Role Played by a Synthetic Model System of the Receptor Extracellular Domain: Hypothesized Future Perspectives | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.0c01340" /></meta><meta property="og:title" content="Peptide Ligands Specifically Targeting HER2 Receptor and the Role Played by a Synthetic Model System of the Receptor Extracellular Domain: Hypothesized Future Perspectives" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01340/20201218/images/large/jm0c01340_0016.jpeg" /></meta><meta property="og:description" content="A short (Fab)trastuzumab-derived peptide specific for HER2 receptor was identified. Its affinity for the model system HER2-DIVMP was found in a nanomolar range. The structural determinants responsible for the interaction between this ligand (A9) and HER2-DIVMP were investigated by both computational and NMR analysis. Next, the possibility of using A9 as HER2- specific probe for the nuclear medicine imaging was evaluated by conjugating A9 with the DTPA chelator and radiolabeling it with 111In. The developed probe retained a nanomolar affinity to HER2-overexpressing cancer cells, however, some unspecific binding also occurred. The peptide internalization into cells by receptor-mediated endocytosis was also studied. Future perspectives are aimed at using A9 as a probe for molecular imaging diagnostics as well as active targeting of anticancer drugs. Lead structure optimization is needed to minimize the percentage of A9 unspecific binding and to increase the binding affinity to the receptor." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.0c01340"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c01340">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=âtrueâ></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=âtrueâ></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=âtrueâ></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=âtrueâ></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-15/achre4.2021.54.issue-15/20210803/achre4.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-30/aamick.2021.13.issue-30/20210804/aamick.2021.13.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-15/acncdm.2021.12.issue-15/20210804/acncdm.2021.12.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-8/amlcef.2021.3.issue-8/20210802/amlcef.2021.3.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-30/acsodf.2021.6.issue-30/20210803/acsodf.2021.6.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-30/ascecg.2021.9.issue-30/20210802/ascecg.2021.9.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-30/ancham.2021.93.issue-30/20210803/ancham.2021.93.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-30/bichaw.2021.60.issue-30/20210803/bichaw.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-28/cgeabj.2021.99.issue-28/20210802/cgeabj.2021.99.issue-28.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-8/cgdefu.2021.21.issue-8/20210804/cgdefu.2021.21.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-15/esthag.2021.55.issue-15/20210803/esthag.2021.55.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-30/iecred.2021.60.issue-30/20210804/iecred.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-15/inocaj.2021.60.issue-15/20210802/inocaj.2021.60.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-30/jafcau.2021.69.issue-30/20210804/jafcau.2021.69.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-30/jacsat.2021.143.issue-30/20210804/jacsat.2021.143.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-8/jamsef.2021.32.issue-8/20210804/jamsef.2021.32.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-30/langd5.2021.37.issue-30/20210803/langd5.2021.37.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-8/mpohbp.2021.18.issue-8/20210802/mpohbp.2021.18.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.0c01340&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.0c01340&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.0c01340&amp;href=/doi/10.1021/acs.jmedchem.0c01340" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2020</span><span class="cit-fg-volume">, 63</span><span class="cit-fg-issue">, 24</span><span class="cit-fg-pageRange">, 15333-15343</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/63/24" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.0c01337" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Perspective</span><a href="/doi/10.1021/acs.jmedchem.0c01344" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Peptide Ligands Specifically Targeting HER2 Receptor and the Role Played by a Synthetic Model System of the Receptor Extracellular Domain: Hypothesized Future Perspectives</span></h1><ul class="loa"><li><span><span class="hlFld-ContribAuthor">Stefania De Luca</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Stefania De Luca</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Institute of Biostructures and Bioimaging, National Research Council, 80134 Naples, Italy</div></div><span class="conrtib-corresp"><strong>*</strong>Phone: +390812534514. E-mail: <a href="/cdn-cgi/l/email-protection#087b7c6d6e69666169266c6d647d6b69486b667a26617c"><span class="__cf_email__" data-cfemail="0b787f6e6d6a65626a256f6e677e686a4b68657925627f">[emailÂ protected]</span></a></span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Stefania+De++Luca">Stefania De Luca</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath1">View Biography</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-7078-1696" title="Orcid link">http://orcid.org/0000-0002-7078-1696</a></div></div></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor">Valentina Verdoliva</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Valentina Verdoliva</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Institute of Biostructures and Bioimaging, National Research Council, 80134 Naples, Italy</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Valentina++Verdoliva">Valentina Verdoliva</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath2">View Biography</a></span></div></div></span></li><span class="comma-separator">,Â andÂ </span><li><span><span class="hlFld-ContribAuthor">Michele Saviano</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Michele Saviano</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Institute of Crystallography, National Research Council, 70126 Bari, Italy</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Michele++Saviano">Michele Saviano</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath3">View Biography</a></span></div></div></span></li><span class="comma-separator"></span></ul><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.0c01340&amp;href=/doi/10.1021%2Facs.jmedchem.0c01340" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2020</span></span><span class="cit-volume">, 63</span><span class="cit-issue">, 24</span><span class="cit-pageRange">, 15333â15343</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">November 23, 2020</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>31 July 2020</li><li><span class="item_label"><b>Published</b> online</span>23 November 2020</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 24 December 2020</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.0c01340" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c01340</a></div><div class="article_header-article-copyright"><strong>Copyright Â© 2020 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D15333%26pageCount%3D11%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DStefania%2BDe%2BLuca%252C%2BValentina%2BVerdoliva%252C%2BMichele%2BSaviano%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D63%26issueNum%3D24%26contentID%3Dacs.jmedchem.0c01340%26title%3DPeptide%2BLigands%2BSpecifically%2BTargeting%2BHER2%2BReceptor%2Band%2Bthe%2BRole%2BPlayed%2Bby%2Ba%2BSynthetic%2BModel%2BSystem%2Bof%2Bthe%2BReceptor%2BExtracellular%2BDomain%253A%2BHypothesized%2BFuture%2BPerspectives%26numPages%3D11%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D15343%26publicationDate%3DDecember%2B2020">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.0c01340"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">744</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val">-</div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.0c01340" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Peptide Ligands Specifically Targeting HER2 Receptor and the Role Played by a Synthetic Model System of the Receptor Extracellular Domain: Hypothesized Future Perspectives&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Stefania&quot;,&quot;last_name&quot;:&quot;De Luca&quot;},{&quot;first_name&quot;:&quot;Valentina&quot;,&quot;last_name&quot;:&quot;Verdoliva&quot;},{&quot;first_name&quot;:&quot;Michele&quot;,&quot;last_name&quot;:&quot;Saviano&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2020&quot;,&quot;month&quot;:&quot;11&quot;,&quot;day&quot;:&quot;23&quot;,&quot;issue&quot;:&quot;24&quot;,&quot;volume&quot;:&quot;63&quot;,&quot;pages&quot;:&quot;15333-15343&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.0c01340&quot;},&quot;abstract&quot;:&quot;A short (Fab)trastuzumab-derived peptide specific for HER2 receptor was identified. Its affinity for the model system HER2-DIVMP was found in a nanomolar range. The structural determinants responsible for the interaction between this ligand (A9) and HER2-DIVMP were investigated by both computational and NMR analysis. Next, the possibility of using A9 as HER2- specific probe for the nuclear medicine imaging was evaluated by conjugating A9 with the DTPA chelator and radiolabeling it with 111In. The developed probe retained a nanomolar affinity to HER2-overexpressing cancer cells, however, some unspecific binding also occurred. The peptide internalization into cells by receptor-mediated endocytosis was also studied. Future perspectives are aimed at using A9 as a probe for molecular imaging diagnostics as well as active targeting of anticancer drugs. Lead structure optimization is needed to minimize the percentage of A9 unspecific binding and to increase the binding affinity to the receptor.&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c01340&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c01340" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c01340&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c01340" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c01340&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c01340" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.0c01340&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c01340&amp;href=/doi/10.1021/acs.jmedchem.0c01340" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.0c01340" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.0c01340" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (7 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c01340&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.0c01340%26sid%3Dliteratum%253Aachs%26pmid%3D33226807%26genre%3Darticle%26aulast%3DLuca%26date%3D2020%26atitle%3DPeptide%2BLigands%2BSpecifically%2BTargeting%2BHER2%2BReceptor%2Band%2Bthe%2BRole%2BPlayed%2Bby%2Ba%2BSynthetic%2BModel%2BSystem%2Bof%2Bthe%2BReceptor%2BExtracellular%2BDomain%253A%2BHypothesized%2BFuture%2BPerspectives%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D63%26issue%3D24%26spage%3D15333%26epage%3D15343%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=292544" title="Targeting">Targeting</a>,</li><li><a href="/action/doSearch?ConceptID=292258" title="Cancer">Cancer</a>,</li><li><a href="/action/doSearch?ConceptID=292524" title="Peptides and proteins">Peptides and proteins</a>,</li><li><a href="/action/doSearch?ConceptID=292366" title="Ligands">Ligands</a>,</li><li><a href="/action/doSearch?ConceptID=292186" title="Receptors">Receptors</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/63/24" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/jmcmar.2020.63.issue-24/20201224/jmcmar.2020.63.issue-24.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="_i1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01340/20201218/images/medium/jm0c01340_0016.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01340/20201218/images/large/jm0c01340_0016.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01340&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">A short (Fab)trastuzumab-derived peptide specific for HER2 receptor was identified. Its affinity for the model system HER2-DIVMP was found in a nanomolar range. The structural determinants responsible for the interaction between this ligand (A9) and HER2-DIVMP were investigated by both computational and NMR analysis. Next, the possibility of using A9 as HER2- specific probe for the nuclear medicine imaging was evaluated by conjugating A9 with the DTPA chelator and radiolabeling it with <sup>111</sup>In. The developed probe retained a nanomolar affinity to HER2-overexpressing cancer cells, however, some unspecific binding also occurred. The peptide internalization into cells by receptor-mediated endocytosis was also studied. Future perspectives are aimed at using A9 as a probe for molecular imaging diagnostics as well as active targeting of anticancer drugs. Lead structure optimization is needed to minimize the percentage of A9 unspecific binding and to increase the binding affinity to the receptor.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_67854" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_67854" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">HER2 is a member of the ErbB or epidermal growth factor receptor (EGFR) family,<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> structurally characterized by an N-terminal extracellular binding domain (ECD), an intracellular tyrosine kinase domain, and transmembrane Î± helix portion (TM). HER2 overexpression or gene amplification induces its dimerization with other ErbB receptors, and it results in constant activation of HER signaling pathways. High levels of HER2 are associated with an aggressive phenotype of breast cancer, while other tumors, in which expression of HER2 has predictive value, include lung, ovarian, as well as adenocarcinomas of the colon and salivary gland.<a onclick="showRef(event, 'ref2 ref3 ref4 ref5 ref6 ref7 ref8 ref9 ref10 ref11 ref12 ref13 ref14 ref15'); return false;" href="javascript:void(0);" class="ref ref2 ref3 ref4 ref5 ref6 ref7 ref8 ref9 ref10 ref11 ref12 ref13 ref14 ref15">(2â15)</a> HER2 has been extensively investigated in cancer research,<a onclick="showRef(event, 'ref16 ref17'); return false;" href="javascript:void(0);" class="ref ref16 ref17">(16,17)</a> in order to develop specific therapies, such as immunotherapy directed against its extracellular domain (EDC).</div><div class="NLM_p">Both antibodies, trastuzumab (Herceptin) and pertuzumab (Perjeta), target different portions of the receptor ECD (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>) and are employed in therapy in combination with other cytotoxic drugs.<a onclick="showRef(event, 'ref18 ref19 ref20 ref21 ref22 ref23 ref24'); return false;" href="javascript:void(0);" class="ref ref18 ref19 ref20 ref21 ref22 ref23 ref24">(18â24)</a></div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01340/20201218/images/medium/jm0c01340_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01340/20201218/images/large/jm0c01340_0001.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Superimposition of the crystal structure of pertuzumab (yellow) in complex with human HER2 ECD (green), and trastuzumab (pink) bound in complex with human HER2 ECD (blue).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01340/20201218/images/large/jm0c01340_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01340&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">In addition, an alternative strategy to naked antibody-targeted therapy was developed. It consists of conjugating specific antibodies, their fragments, and affibodies to various anticancer agents in order to target them on HER2 positive tumor cells.<a onclick="showRef(event, 'ref25 ref26 ref27'); return false;" href="javascript:void(0);" class="ref ref25 ref26 ref27">(25â27)</a> Trastuzumab-MCC-DM1 (T-DM1) was approved by FDA (Kadcyla, February 2013) and was obtained by coupling of trastuzumab to a derivative of maytansine <i>via</i> thioether bond (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>), an antimicrotubule agent, which is specifically delivered to the cancer tissues overexpressing HER2 receptor.<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a></div><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01340/20201218/images/medium/jm0c01340_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01340/20201218/images/large/jm0c01340_0002.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Structure of of T-DM1.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01340/20201218/images/large/jm0c01340_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01340&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Although monoclonal antibodies are stable molecules and have high affinity to their cognate antigens, they present high manufacturing costs and various undesirable effects, such as poor efficacy for applications targeting the brain, as they fail to cross the bloodâbrain barrier.</div><div class="NLM_p">Peptide ligands, instead, have low molecular weight and can be considered more suitable targeting agents because their production is less expensive and faster and they are generally not immunogenic.<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a> Moreover, they generally show excellent tumor penetration, sufficient stability <i>in vivo</i>, low bone marrow accumulation, relatively fast blood clearance,<a onclick="showRef(event, 'ref30'); return false;" href="javascript:void(0);" class="ref ref30">(30)</a> and appreciably higher tumor-to-organ ratios (<i>i.e.</i>, better sensitivity for molecular imaging) than antibodies.<a onclick="showRef(event, 'ref31 ref32'); return false;" href="javascript:void(0);" class="ref ref31 ref32">(31,32)</a> For all these requisites, small peptides are particularly attractive candidates to delivery drugs <i>via</i> therapies acting through the receptor recognition as well as probes for molecular imaging.</div><div class="NLM_p">We have developed some Trastuzumab (Fab)-derived peptides, directed against the HER2 receptor, evaluating their affinity toward HER2-DIVMP, a specific model system of HER2 domain IV. The adopted screening methodology allowed the selection of highly specific peptide ligands for this domain. This excludes potentially misleading contribution from binding to other portions of the receptor target. For some of the investigated molecules, in particular A9 peptide (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>), the dissociation constant was found in the low nanomolar range.<a onclick="showRef(event, 'ref33 ref34 ref35'); return false;" href="javascript:void(0);" class="ref ref33 ref34 ref35">(33â35)</a></div><figure id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01340/20201218/images/medium/jm0c01340_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01340/20201218/images/large/jm0c01340_0003.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. A9 peptide in stick representation (blue) selected from the Fab-heavy chain of trastuzumab (in green ribbon representation) and its amino acids sequences.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01340/20201218/images/large/jm0c01340_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01340&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">To the best of our knowledge, the A9 peptide is the only low molecular weight compound able to target the HER2 receptor with such a high affinity that is so far available. This opens a number of new scenarios to be explored, all of which are based on the possibility of using the A9 peptide instead of antibodies or other high molecular weight compounds to target HER2 overexpressing tumors. The great advantage of dealing with A9 comes from the deep investigation that was performed on the interacting process with its receptor target. It was crucial to identify  the key interacting amino acid residues responsible for the stability of the biomolecular complex.<a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(36)</a> The positive impact of the performed study was readily detected to choose the peptide site where to introduce a radioactive reporter for nuclear medicine studies.<a onclick="showRef(event, 'ref37'); return false;" href="javascript:void(0);" class="ref ref37">(37)</a> In general, the conjugation of A9 ligand to a probe can be easily addressed because the sensitive amino acid residues in contact with the receptor HER2 were fully characterized. In principle, the A9 peptide can be used to build up HER2-specific probes for (i) molecular imaging-based diagnostics, (ii) active targeting of anticancer drugs, and (iii) combined imaging and therapy (intraoperative imaging and theranostics).</div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i3">Obtained Results</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_40871" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_40871" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec2_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i4" class="anchor-spacer"></div><h3 class="article-section__title" id="_i4"> HER2-DIVMP Receptor Model: Development and Validation</h3><div class="NLM_p">An analysis of the published X-ray structure of the rat extracellular region of HER2 (sHER2) alone<a onclick="showRef(event, 'ref38'); return false;" href="javascript:void(0);" class="ref ref38">(38)</a> suggests that the domain IV is able to fold in its stabilized conformation, also as a standalone structural domain, that means it can  interact in the absence of the whole protein. Most significantly, the conformation of domain IV is found to be unchanged upon interaction with the Fab region of the monoclonal antibody trastuzumab, with the exception of the segment protein encompassing 581â590 residues, which is found disordered, not even present in the crystal structure (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1N8Z">1N8Z</a>) (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>).</div><figure id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01340/20201218/images/medium/jm0c01340_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01340/20201218/images/large/jm0c01340_0004.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. (A) Stick representation of HER2 557â607 segment in complex with Fab of trastuzumab. (B) Crystal structure of rat HER2 ECD.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01340/20201218/images/large/jm0c01340_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01340&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">On the basis of this evidence, a peptide was designed to mimic domain IV of the receptor. It contains two modified peptides that correspond to 557â580 and to 591â607 segments of human HER2, while they do not contain the disordered regiuon 581â590. The two chains were connected <i>via</i> a disulfide bridge between Cys578 and Cys601, already present in the natural protein, while a second bridge links Cys565 and Cys574 intramolecularly. The peptide was acetylated (N-terminus) and amidated (C-terminus) in order to protect the molecule against the protease degradation and also to reduce any potential effects arising from charged terminations. To simplify the oxidation of the desired intramolecular disulfide bridge, Cys604 was replaced by a Ser residue, so that we arrived at the final peptide sequence, named HER2-DIVMP (<i>i.e.</i>, HER2-domain IV-mimicking peptide) shown in <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>. Computational studies, based on molecular dynamics (MD), investigated the preserved stability of the system model, in absence of the whole protein, as well as the role of the segment 581â590 on the conformation of domain IV, for which it was found not crucial.<a onclick="showRef(event, 'ref34'); return false;" href="javascript:void(0);" class="ref ref34">(34)</a></div><figure id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01340/20201218/images/medium/jm0c01340_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01340/20201218/images/large/jm0c01340_0005.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Stick representation (pink and green) (A) of HER2-DIVMP and its amino acid sequence (B).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01340/20201218/images/large/jm0c01340_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01340&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Different synthetic strategies were explored for obtaining HER2-DIVMP with a good yield. First, the synthesis for preparing HER2-DIVMP was performed by using orthogonal protection groups onto cysteine residues involved into bridge formation, so that oxidation was chemically achieved on selected sulfhydryl pairs. This protocol provided the desired heterodimer with a poor yield, particularly because it consists of several synthetic and purification steps. The most efficient turned out to be a one-step cysteine co-oxidation procedure in slightly basic aqueous buffer. Under these conditions, the peptide chains, fully unprotected on the sulfhydryl groups, could spontaneously fold in their natural conformation, forming the heterodimer with the correct pattern of disulfide bridges (<a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>).<a onclick="showRef(event, 'ref39'); return false;" href="javascript:void(0);" class="ref ref39">(39)</a></div><figure id="sch1" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01340/20201218/images/medium/jm0c01340_0015.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01340/20201218/images/large/jm0c01340_0015.jpeg" id="gr15" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of Peptide HER2-DIVMP</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01340/20201218/images/large/jm0c01340_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01340&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The peculiaruty of HER2-DIVMP to self-assemble and fold under native conditions, on one hand simplifies its synthetic protocol, while on the other it validates its design.</div><div class="NLM_p">The receptor model was investigated by SPR (surface plasmon resonance) experiments performed on the trastuzumab/HER2-DIVMP complex. These allowed for the estimation of the kinetic and thermodynamic constants of the interaction process under investigation. The experiments were designed assuming the receptor model as the ligand of the complex and the antibody trastuzumab as the analyte. Biotinylated HER2-DIVMP at its N-terminal extremity was bound to a streptavidin coated sensor chip, then a series of antibody solutions were injected and the sensorgrams were registered (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>).<a onclick="showRef(event, 'ref34'); return false;" href="javascript:void(0);" class="ref ref34">(34)</a></div><figure id="fig6" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01340/20201218/images/medium/jm0c01340_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01340/20201218/images/large/jm0c01340_0006.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Sensorgrams (best fit) of kinetic interaction of Biot-HER2-DIVMP with trastuzumab (A). Sensorgrams (best fit) of kinetic interaction of Biot-HER2-DIVMP with A9 peptide.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01340/20201218/images/large/jm0c01340_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01340&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The study provided a nanomolar dissociation constant for the complex, thus validating HER2-DIVMP as a robust model system of domain IV of the extracellular receptor.</div><div class="NLM_p last">Moreover, a fast and credible screening methodology for estimating the binding constant of potential ligans toward HER-DIVMP was also developed.</div></div><div id="sec2_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i6" class="anchor-spacer"></div><h3 class="article-section__title" id="_i6"> Selected HER2-Specific Peptide Ligands: Validation Performed <i>via</i> Receptor Model Approach</h3><div class="NLM_p">The synthetic peptide HER2-DIVMP, specifically mimicking domain IV of HER2 receptor, was employed for selecting ligands directed against the receptor target. Among them, peptide A9 belongs to the interaction region of the trastuzumab  Fab heavy chain.</div><div class="NLM_p">Screening was performed by adopting the receptor fragment approach through two methodologies: the fluorescence spectroscopy and surface plasmon resonance (SPR) techniques (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>A).</div><div class="NLM_p">Fluorescence studies easily allow evaluation of the interaction process between two biomolecules when a natural fluorophore is included into only one of the interacting moieties. Indeed, fluorescence modifications can be followed as the binding reaches the saturation and the signal becomes constant. In our case, natural fluorophores, such as tyrosyl and tryptophanyl residues, are present in both sequences, the HER2-DIVMP receptor model and the peptide ligand, therefore, modification of the intrinsic fluorescence of phenolic and indolic groups was detected by subtracting the contribution generated by the two molecules from the total emission signal.</div><div class="NLM_p">In particular, the binding experiments were performed by executing fluorescence titrations according to the limiting reagent method and exiting the mixture at 280 nm. This wavelength excites both fluorophores tyrosine and tryptophane. Increasing amounts of the peptide ligand were added to a buffered solution containing the receptor synthetic model in a fixed concentration. For some of the investigated molecules, in particular A9 peptide, the dissociation constant was found in the low nanomolar range so that a potentially good candidate was selected for targeting the receptor (<a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>).<a onclick="showRef(event, 'ref33'); return false;" href="javascript:void(0);" class="ref ref33">(33)</a> Subsequently, SPR-based binding studies were also implemented to further investigate the interaction between A9 and the HER2-DIVMP receptor model. Similarly to what was already done in a previous experiment, the model system HER2-DIVMP was chemically bound to the sensor chip, while the interacting peptide A9 was flown in solution (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>B). The value of the dissociation constant calculated by using the Langmuirian model was in the same range of that calculated by the fluorescence titrations<a onclick="showRef(event, 'ref40'); return false;" href="javascript:void(0);" class="ref ref40">(40)</a></div><figure id="fig7" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01340/20201218/images/medium/jm0c01340_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01340/20201218/images/large/jm0c01340_0007.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Titration curve of HER2-DIVMP with A9 peptide.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01340/20201218/images/large/jm0c01340_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01340&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">Taking into consideration the similar results obtained by using different techniques to study the binding affinity of the peptide ligand A9 toward the receptor fragment HER2-DIVMP, we could conclude that a promising ligand candidate was selected to be employed for receptor-mediated drug delivery therapy.</div></div><div id="sec2_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i7" class="anchor-spacer"></div><h3 class="article-section__title" id="_i7"> Structural Investigation of the Molecular Interaction between A9 Ligand and HER2-DIVMP Model System: Computational Method and Validation <i>via</i> NMR Study</h3><div class="NLM_p">The interacting portion of A9 peptide within the synthetic model HER2-DIVMP was also studied. To this scope, molecular dynamic simulations were successful, giving us structural insights. We started from the data obtained by fluorescence experiments.</div><div class="NLM_p">Fluorescence experiments<a onclick="showRef(event, 'ref33'); return false;" href="javascript:void(0);" class="ref ref33">(33)</a> indicated that, upon ligandâreceptor binding, the conformational features generated an energy transfer from the donor tyrosine of the receptor model to the tryptophan of the A9 ligand. These experimental results revealed that the distance between Y568 of HER2-DIVMP and W35 of A9 is shorter than 18 Ã.</div><div class="NLM_p"><a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>A illustrates the fluorescence emission spectra of the receptor fragment HER2-DIVMP upon both excitation, at 280 and 295 nm. The tryptophan is selectively excited at 295 nm, while both emission fluorescence of tyrosine and tryptophan is registered upon excitation at 280 nm. Clearly, the subtraction of the two spectra (1 from 2) takes the contribution of the tyrosine into account.</div><figure id="fig8" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01340/20201218/images/medium/jm0c01340_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01340/20201218/images/large/jm0c01340_0008.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Fluorescence signals of HER2-DIVMP alone (A) and interacting with A9 (B); Æ<sub>ex</sub> = 280 nm (1 and 4) and pÆ<sub>ex</sub> = 295 nm (2 and 5). The difference spectra, 3 and 6, express the contribution of the Tyr residue.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01340/20201218/images/large/jm0c01340_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01340&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p"><a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>B shows the emission spectra of the HER2-DIVMP/A9 complex (1:1) is related to both excitations, 280 and 295 nm. Again, the difference spectrum, obtained by subtraction of 5 from 4, takes the contribution of tyrosine into account. Because a decreased contribution was observed, we could conclude that a further energy was transferred from Y568 to W35.</div><div class="NLM_p">The first <i>in silico</i> model of the A9/HER2-DIVMP was built by taking in consideration the crystallographic structure of HER2-ECD in complex with trastuzumab (Fab) (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1N8Z">1N8Z</a>).<a onclick="showRef(event, 'ref38'); return false;" href="javascript:void(0);" class="ref ref38">(38)</a> This model, called Model X-ray, was simulated without any positional restraints. It ended with A9, which detached itself from the receptor model and freely shifted into the solvent. Moreover, the distance between Y568âW35 reached an apparent equilibrium value of around 19â20 Ã. These data allowed us to infer that the A9 conformation, during the MD simulation of the X-ray structure model, did not meet the experimental requirement of having a distance Y568âW35 smaller than 18 Ã.</div><div class="NLM_p">Subsequently, the investigation of the binding process between the peptide ligand and the receptor model was continued by using a docking approach. Although two main interacting areas were provided by docking analysis, essentially one of these met the requested spatial distance between Y568 and W35 (<18 Ã). Therefore, it was further analyzed by MD simulations. The simulation results show that the complex was to be stable and the equilibrium has to be reached only after 10 ns (<a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">9</a></a>). Visual inspection of the trajectory proved that A9 peptide never dissociated from the receptor model during the chosen simulation time. In addition, the A9/HER2-DIVMP complex was stabilized when the distance Y568âW35, evaluated as a function of the analysis duration, reached a value of 7â8 Ã, in agreement with the experimental hypothesis (distance Y568âW35 < 18 Ã). It prompted us to consider the docking cluster as a reliable model representative of the bimolecular complex under investigation.<a onclick="showRef(event, 'ref41'); return false;" href="javascript:void(0);" class="ref ref41">(41)</a></div><figure id="fig9" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01340/20201218/images/medium/jm0c01340_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01340/20201218/images/large/jm0c01340_0009.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. MD structure of the complex between HER2-DIVMP (orange ribbon with green amino acid residues involvend in the interaction) and A9 (purple stick representation).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01340/20201218/images/large/jm0c01340_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01340&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">It is characterized by the stable hydrogen bonds between C565, E598, and H567 of HER2-DIVMP. In particular, the interaction <i>via</i> hydrogen bond between H567 and W35 of A9 is responsible for the close proximity between the W35 and Y568 rings during the entire simulation time of the model. In addition, a further interaction occurs between K569 with V29 of A9, which is thought to involve van der Waals forces of the aliphatic chain of K569 (<a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">10</a></a>)</div><figure id="fig10" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01340/20201218/images/medium/jm0c01340_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01340/20201218/images/large/jm0c01340_0010.jpeg" id="gr10" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 10. MD model of the complex between HER2-DIVMP (blue ribbon) and A9 (green stick). The amino acid sequence of A9 is shown interacting with amino acid residues of HER2-DIVMP.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01340/20201218/images/large/jm0c01340_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01340&amp;id=fig10"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The bound conformation of A9 was further investigated by transferred nuclear Overhauser effect spectroscopy (trNOESY) experiments, typically employed to study interacting processes at molecular level, both in solution and cellular environments.<a onclick="showRef(event, 'ref40'); return false;" href="javascript:void(0);" class="ref ref40">(40)</a> Spectra of A9 in the presence of HER2-DIVMP were registered and most of trNOE contacts were related to residues encompassing the segment between Val29 to Val33, thus indicating a helix orientation of the peptide in this region. CYANA treatment of the found NOE constraints led to a set of three-dimensional models that were clustered by structure sanalogy. Within the elaborated models, A9 is characterized by a largely disordered structure, except for the single helical segment in the sequence encompassing residues Val29âVal33 (<a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">11</a></a>A).</div><figure id="fig11" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Figure 11</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01340/20201218/images/medium/jm0c01340_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01340/20201218/images/large/jm0c01340_0011.jpeg" id="gr11" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 11. NMR resolution structure of A9 peptide obtaned in complex with HER2-DIVMP (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6SON">6SON</a>) (A). Superimposition of A9 NMR structure (pink) and A9MD structure (blue); the side chain of the residues responsible of the interaction with HER2-DIVMP are labeled (B).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01340/20201218/images/large/jm0c01340_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01340&amp;id=fig11"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">This turn is stabilized by a hydrogen bond between the backbone carbonyl oxygen of Thr31 and the amide hydrogen of Asp28. Upon comparison with the structures provided by docking calculation and molecular dynamic simulations, the lowest energy NMR conformer of A9 was found to be overlapping quite well in the <i>in silico</i> corresponding A9 molecular structure. Although in the absence of paricular restraints (<i>i.e.</i>, Î§1 restraints), A9 NMR model displays the interacting residues, such as Val29 and Trp35, in the same three-dimensional orientation as in the A9/HER2-DIVMP complex that was built using computational docking studies (<a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">11</a></a>B).</div><div class="NLM_p last">The fine accordance of the NMR structural data with the interaction model obtained through computational docking studies further validates the gained insights of the ligand/receptor binding mode.</div></div><div id="sec2_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i8" class="anchor-spacer"></div><h3 class="article-section__title" id="_i8"> Development of Radiolabeled A9 Peptide Ligand and Its Employment As Imaging Probe</h3><div class="NLM_p">The peptide A9 was considered to be a good candidate for developing an HER2-specific radioactive probe. In this context, its ability to be internalized is worth investigating because the accumulation of radioactive nuclide in the targeted tissues implies an increase in diagnostic imaging sensitivity as well as the efficacy of HER2-specific radiotherapy.</div><div class="NLM_p">For these purposes, the presence of A9 peptide in the cytoplasmic fraction of HER2-positive human breast cancer BT474 cells was investigated. A9 peptide, biotinylated at its N-terminus, was isolated from the cytoplasmic cell lysate by using streptavidin-coated magnetic beads that strongly catch any biotinylated substrate.</div><div class="NLM_p">In a subsequent step, after several treatments and the detachment procedure from the beads, the mixture was analyzed by liquid chromatographyâtandem mass spectrometry (LC-MS/MS), in the multiple-reaction monitoring (MRM) mode. This assay allows the identification of a diagnostic fragment ion that can be selectively monitored. Indeed, as a pilot experiment, the fragmentation pattern of a synthetic Biot-A9 was also investigated and the same intense ion fragment was identified (477.8 <i>m</i>/<i>z</i>). These results allowed us to claim the internalization of A9 peptide (<a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">12</a></a>).</div><figure id="fig12" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Figure 12</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01340/20201218/images/medium/jm0c01340_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01340/20201218/images/large/jm0c01340_0012.jpeg" id="gr12" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 12. Schematic view of the crucial stemps of the affinity tag experiments and mass spectrometry analysis: (a) MS/MS spectra of the [M + 2H]<sup>2+</sup> precursor of biotinylated A9 at 615.2m/z. (b) SRM plot of the selected transition at <i>m</i>/<i>z</i> 615.2â477.8.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01340/20201218/images/large/jm0c01340_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01340&amp;id=fig12"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Next, we focused on the design and synthesis of an A9-derivative bound to a chelating agent able to coordinate radioactive metals for applications both in cancer diagnosis and therapy through nuclear medicine techniques.<a onclick="showRef(event, 'ref42'); return false;" href="javascript:void(0);" class="ref ref42">(42)</a></div><div class="NLM_p">The A9 peptide, amidated at the C-terminus, was bound with an acyclic chelator at its N-terminus (<a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">13</a></a>), and these peptide modifications also represent a good strategy for further stabilization of the peptide molecule against exopeptidases. The acyclic DTPA was chosen as a chelator, because it is routinely used to provide <i>in vitro</i> and <i>in vivo</i> stable complexes of the radioactive isotope <sup>111</sup>In.<a onclick="showRef(event, 'ref43 ref44'); return false;" href="javascript:void(0);" class="ref ref43 ref44">(43,44)</a></div><figure id="fig13" data-index="14" class="article__inlineFigure"><h2 class="fig-label">Figure 13</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01340/20201218/images/medium/jm0c01340_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01340/20201218/images/large/jm0c01340_0013.jpeg" id="gr13" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 13. Chemical structure of DTPA-A9 conjugate and MD structure of the conjugate <sup>111</sup>In-DTPA-A9.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01340/20201218/images/large/jm0c01340_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01340&amp;id=fig13"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The position within the peptide in which to link the chelating agent was chosen on the basis of 3D structure of the complex HER2-DIVMP/<sup>111</sup>In-DTPA-A9. It was modeled starting from the previously performed molecular dynamics (MD) study of the complex HER2-DIVMP/A9 and the structure of <sup>111</sup>In-DTPA taken from the Cambridge Structural Database.<a onclick="showRef(event, 'ref45'); return false;" href="javascript:void(0);" class="ref ref45">(45)</a> The built model complex clearly showed that the functionalization of A9 at its N-terminus with the chelator DTPA does not interfere on peptideâreceptor interaction (<a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">13</a></a>).</div><div class="NLM_p">The site-specific conjugation of DTPA chelator to A9 allowed the subsequent labeling with the radionuclide <sup>111</sup>In, with the final aim of evaluating <sup>111</sup>In-DTPA-A9 binding to living HER2-expressing cancer cells <i>in vitro.</i> In particular, the LigandTracer technique was employed to measure the dissociation constant of the radioactive probe toward HER2-expressing BT474 cells; in <a data-tab="pane-pcw-Figures" href="#fig14" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig14" id="" class=" internalNav">14</a></a>, the Interaction Map is shown, and the best fitting of the collected data was obtained with a 1:2 interaction model.</div><figure id="fig14" data-index="15" class="article__inlineFigure"><h2 class="fig-label">Figure 14</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01340/20201218/images/medium/jm0c01340_0014.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01340/20201218/images/large/jm0c01340_0014.jpeg" id="gr14" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 14. Interaction Maps of <sup>111</sup>In-DTPA-A9 interaction with HER2-expressing BT474 cells. Concentrations of <sup>111</sup>In-DTPA-A9 were 4, 12, and 36 nM. Fitting binding LigandTracer curves to 1:2 interaction models suggest the presence of two interactions, one stronger (4.9 nM) and one weaker but predominant (103 nM).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01340/20201218/images/large/jm0c01340_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01340&amp;id=fig14"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The results revealed the presence of two ligand binding sites on the receptor target, one with affinity of (<i>K</i><sub>D</sub> = 4.9 nM) and one with weaker affinity (<i>K</i><sub>D</sub> = 103 nM) (<a data-tab="pane-pcw-Figures" href="#fig14" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig14" id="" class=" internalNav">14</a></a>).</div><div class="NLM_p last">To investigate this phenomenon, the LigandTracer experiment was repeated in the presence of a large excess of Trastuzumab. Under these conditions, the antibody totally displaced the radioactive A9-based probe, with a consequent disappearance of the high affinity signal, while the lower affinity signal survived. Moreover, an additional LigandTracer experiment was performed, measuring the affinity of <sup>111</sup>In-DTPA-SA9 to Her2-positive BT474 cell. The probe consists of a scrambled conjugate, in the sense that the peptide sequence contains the same amino acids residues as A9 but collocated in different positions. In this latter experiment, only the low affinity interaction (<i>K</i><sub>D</sub> = 103 nM) between the two molecules was registered, thus proving that it is not an Her2-specific interaction. Taking all these date into consideration, we could conclude that the highest affinity interaction is target-specific (4.9 nM), while the other interaction (103 nM) might be typical of peptide sequences containing the same residues as A9.<a onclick="showRef(event, 'ref46 ref47'); return false;" href="javascript:void(0);" class="ref ref46 ref47">(46,47)</a></div></div><div id="sec2_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i9" class="anchor-spacer"></div><h3 class="article-section__title" id="_i9"> <i>In Vivo</i> Studies of <sup>111</sup>In-DTPA-A9</h3><div class="NLM_p">Because off-target interaction with blood and normal tissue might lead to an undesirable accumulation of an imaging probe, the biodistribution of <sup>111</sup>In-DTPA-A9 in normal mice was evaluated.<a onclick="showRef(event, 'ref37'); return false;" href="javascript:void(0);" class="ref ref37">(37)</a></div><div class="NLM_p">Particularly, a weaker non-HER2-specific interaction found in the Interaction Map experiments might be an additional reason for undesirable accumulation of the radioactive probe <sup>111</sup>In-DTPA-A9 in normal tissues, thus reducing the imaging contrast and the sensitivity of the <i>in vivo</i> diagnostic. Therefore, we measured biodistribution of <sup>111</sup>In-DTPA-A9 in BALB/c nu/nu mice 1 h after the injection time. The clearance from the blood was rapid, suggesting that the metal complex <sup>111</sup>In-DTPA was stable and no transchelation of transferrin occurred. Radioactivity accumulation in organs, such as liver, lung, and bones, where breast cancer finds ita major metastatic sites, was low and it proved that <sup>111</sup>In-DTPA-A9 has a favorable biodistribution profile (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>). Moreover, the <i>in vivo</i> data also suggest that the low affinity unspecific interaction of the developed probe is not characterized by abnormal accumulation in healthy organs and tissues.</div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. Presented Data Refer to Values of Three Animals</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="char" char="Â±" /></col><col align="char" char="Â±" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">organ</th><th class="colsep0 rowsep0" align="center" char="Â±">% ID/g</th><th class="colsep0 rowsep0" align="center" char="Â±">% ID/organ (sample)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">blood</td><td class="colsep0 rowsep0" align="char" char="Â±">0.24Â Â±Â 0.04</td><td class="colsep0 rowsep0" align="char" char="Â±">Â </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">lung</td><td class="colsep0 rowsep0" align="char" char="Â±">0.5Â Â±Â 0.3</td><td class="colsep0 rowsep0" align="char" char="Â±">0.06Â Â±Â 0.03</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">liver</td><td class="colsep0 rowsep0" align="char" char="Â±">0.44Â Â±Â 0.04</td><td class="colsep0 rowsep0" align="char" char="Â±">0.47Â Â±Â 0.03</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">spleen</td><td class="colsep0 rowsep0" align="char" char="Â±">0.22Â Â±Â 0.01</td><td class="colsep0 rowsep0" align="char" char="Â±">0.02Â Â±Â 0.01</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">stomach</td><td class="colsep0 rowsep0" align="char" char="Â±">0.27Â Â±Â 0.07</td><td class="colsep0 rowsep0" align="char" char="Â±">0.05Â Â±Â 0.06</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">pancreas</td><td class="colsep0 rowsep0" align="char" char="Â±">0.13Â Â±Â 0.03</td><td class="colsep0 rowsep0" align="char" char="Â±">0.01Â Â±Â 0.00</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">brain</td><td class="colsep0 rowsep0" align="char" char="Â±">0.03Â Â±Â 0.03</td><td class="colsep0 rowsep0" align="char" char="Â±">0.00Â Â±Â 0.01</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">kidney</td><td class="colsep0 rowsep0" align="char" char="Â±">7.0Â Â±Â 0.6</td><td class="colsep0 rowsep0" align="char" char="Â±">2.00Â Â±Â 0.1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">muscle</td><td class="colsep0 rowsep0" align="char" char="Â±">0.01Â Â±Â 0.01</td><td class="colsep0 rowsep0" align="char" char="Â±">0.04Â Â±Â 0.01</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">bone</td><td class="colsep0 rowsep0" align="char" char="Â±">0.16Â Â±Â 0.13</td><td class="colsep0 rowsep0" align="char" char="Â±">0.01Â Â±Â 0.01</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">GI tract (with content)</td><td class="colsep0 rowsep0" align="char" char="Â±">Â </td><td class="colsep0 rowsep0" align="char" char="Â±">0.83Â Â±Â 0.48</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">carcass</td><td class="colsep0 rowsep0" align="char" char="Â±">Â </td><td class="colsep0 rowsep0" align="char" char="Â±">3.47Â Â±Â 1.01</td></tr></tbody></table></div></div><div class="NLM_p last">The <i>in vivo</i> stability of <sup>111</sup>In-DTPA-A9 seems good because it was comparable to that of another <sup>111</sup>In-based probe currently in preparation for clinical study.<a onclick="showRef(event, 'ref48 ref49 ref50'); return false;" href="javascript:void(0);" class="ref ref48 ref49 ref50">(48â50)</a></div></div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i11">Perspectives</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_20237" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_20237" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">All of the studies performed so far have confirmed that A9 peptide is able to specifically bind the HER2-positive human breast cancer, with a subsequent internalization into the cell cytoplasm. Moreover, the conjugation of DTPA to the N-terminus of A9 <i>via</i> amide bond enabled the synthesis of a probe that was labeled with <sup>111</sup>In and able to bind HER2-expressing cells with a nanomolar affinity. The biodistribution data collected for the experiments performed in normal mice suggested that <sup>111</sup>In-DTPA-A9 clears rapidly from the blood and does not bind other tissues to any relevant extent. The results obtained allowed us to consider <sup>111</sup>In-DTPA-A9 as a good starting point for developing other HER2-imaging probes, characterized by the presence of optimized ligands useful for targeting HER2-positive tumor tissues.</div><div id="sec3_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i12" class="anchor-spacer"></div><h3 class="article-section__title" id="_i12"> Optimization of A9 Peptide As Basis for Future Outcomes</h3><div class="NLM_p">The optimization of the A9 peptide sequence has two objectives. The first aim is to increase its binding affinity to the receptor target. This requisite is fundamental when the ligand is employed for magnetic resonance imaging (MRI) applications. In this regard, it is worth remembering that, compared with other medical imaging techniques, MRI has an obvious disadvantage of low sensitivity, in other words, the injection dosage of the probe (contrast agent) should be very high. An increased binding affinity of the ligand to its biological target would enhance the image contrast, avoiding the high concentration required for the contrast agent, <i>i.e.</i>, the paramagnetic metal complex. The second parameter to affect is A9 hydrophobicity, which should be decreased because it could also be responsible, at least in part, for the unspecific binding. We plan to perform lead optimization studies in order to select peptide ligands endowed with enhanced receptor binding affinity on the basis of the previously performed computational study, which allowed identification of the structural determinants in charge of the binding between A9 and the model system HER2-DIVMP. In the recent past,<a onclick="showRef(event, 'ref51 ref52'); return false;" href="javascript:void(0);" class="ref ref51 ref52">(51,52)</a> several examples of the poly valency effect have been reported in literature in order to demonstrate that dimeric or multimeric peptide systems show improved properties compared with monomer analogues. In this regard, we could first explore the effects of dimerization as a strategy to increase the potency of the peptide A9. By taking advantage of the availability of a mimetic extracellular domain of the HER2 receptor, saturation transfer difference NMR studies could be performed to assess on an experimental basis the interaction between the ligand and the receptor and to validate/refine modeling derived key binding interactions.</div><div class="NLM_p">Among the strategies to decrease hydrophobicity and enhance solubility, PEGylation will be considered first, as it is known to improve lifetime and retention in the circulation, in addition to solubility, without altering the bioactive conformation of the peptide.<a onclick="showRef(event, 'ref53 ref54'); return false;" href="javascript:void(0);" class="ref ref53 ref54">(53,54)</a></div><div class="NLM_p">The approaches to improve binding affinity and solubility can be combined. To summarize, dendritic structures will be designed because they represent ideal scaffolds for the multimerization of bioactive molecules because of their defined structures, versatility in drug delivery, and high functionality. They enable the synthesis of compounds of high valency, including delivering therapeutic and targeting and diagnostic agents together in a single system. Thus, we will develop a synthetic route which should fulfill the following requirements: (i) a high flexibility in molecular design allowing the multimerization of peptides, (ii) the possibility to insert PEG spacers to modulate the distance between the dendron surface functionalities, the blood half-life, and the hydrophilicity of the scaffolds, (iii) the possibility to introduce functional groups for radiolabeling, labeling with NIR dyes (<i>e.g.</i>, cyanine), or conjugation with drugs, and (iv) an efficient synthesis able to give the desired products in a cost-effective manner.</div><div class="NLM_p last">The binding affinity of new A9 dimers/multimers or PEGylated derivatives will be first evaluated toward the HER2-DIVMP model system, fully representative of domain IV of the receptor. Their conjugates with the imaging reporter (NM or optical) will also be assessed. We will study this interaction by using fluorescence spectroscopy, a fast and sensitive technique to investigate biological interaction.</div></div><div id="sec3_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i13" class="anchor-spacer"></div><h3 class="article-section__title" id="_i13"> A9-Based Molecular Probe for Image-Guided Surgical Resection of Tumors (Intraoperative Imaging)</h3><div class="NLM_p last">In the course of tumor removal, surgeons rely only on the means of visual inspection and palpation to distinguish tumors from surrounding tissue. While human eyes cannot see deeper than the tissue surface, human touch may not be able to detect small tumor nodes. In intraoperative imaging, the goal is to label cancer cells with a NIR fluorescent dye, such as to be easily recognized from background healthy tissue when illuminated at the suitable wavelength. NIR fluorescent dyes with intraoperative imaging systems offer pseudocolor distinction between tumor and adjacent normal tissue to improve accuracy of resection and potentially reduce the incidence of positive surgical margins.<a onclick="showRef(event, 'ref55'); return false;" href="javascript:void(0);" class="ref ref55">(55)</a> In this context, the conjugation of A9 or its analogues with a suitable NIR dye will enable the visualization of HER2-overexpressing tumors in the operating theater. For a stable labeling of tumors, the molecular probe should ideally be taken up by HER2-overexpressing cells so as to be retained for a long time.</div></div><div id="sec3_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i14" class="anchor-spacer"></div><h3 class="article-section__title" id="_i14"> Functionalization of A9 Peptide with Chelators for Radioisotopes: <sup>68</sup>Ga for Molecular Imaging <i>via</i> Positron Emission Tomography (PET) and Cu<sup>2+</sup> Radioisotopes for Theragnostics</h3><div class="NLM_p">Peptide A9 and/or improved analogues can be functionalized with a chelator suitable to coordinate for <sup>68</sup>Ga for detection by positron emission tomography (PET). The chosen chelator is based on 6-bis(hydroxycarbonylmethyl)amino-1,4- bis(hydroxycarbonylmethyl)-6-methylperhydro-1,4-diazepine (AAZTA) and will be bound to the targeting peptide:<a onclick="showRef(event, 'ref56'); return false;" href="javascript:void(0);" class="ref ref56">(56)</a> This chelator binds <sup>68</sup>Ga rapidly and selectively in acetate buffer at pH 4â7 and shows clear advantages over other chelators because very harsh conditions potentially detrimental to the molecular probe can be avoided.<a onclick="showRef(event, 'ref57'); return false;" href="javascript:void(0);" class="ref ref57">(57)</a> In addition to <sup>68</sup>Ga, it has been shown that AAZTA is a good chelator also for In(III) and Cu(II), widening the range of radioisotopes that could be exploited for diagnosis and therapy.<a onclick="showRef(event, 'ref58'); return false;" href="javascript:void(0);" class="ref ref58">(58)</a> Very interestingly, the possibility to functionalize peptide A9 with copper complexes paves the way for theranognostics approaches to cancer treatment.<a onclick="showRef(event, 'ref59'); return false;" href="javascript:void(0);" class="ref ref59">(59)</a> According to this strategy, both a diagnostic radioisotope (<i>i.e.</i>, <sup>64</sup>Cu) and a therapeutic radioisotope (<i>i.e.</i>, <sup>67</sup>Cu) should be loaded onto the same vector targeting HER2. This way, real-time monitoring of the therapeutic dose that is delivered to the targeted site can be achieved, together with the evaluation of on/off target delivery. In summary, a peptide could be functionalized with AAZTA tetramermers.<a onclick="showRef(event, 'ref60'); return false;" href="javascript:void(0);" class="ref ref60">(60)</a> Thus, a single targeting ligand can be loaded with up to four copper ions, with varying <sup>64</sup>Cu to <sup>67</sup>Cu ratios as desired for optimal treatment. Because of the addition of the tetrameric unit, the molecular weight of the AAZTA4-A9 molecular probe will increase, potentially altering the pharmacokinetics. Longer blood lifetime and imaging windows are expected, which could represent a further advantage. Within the scope of the current project, the tetrameric <sup>68</sup>Ga molecular probe will be used to assess biodistribution and imaging specificity in the BALB-NeuT breast cancer model.<a onclick="showRef(event, 'ref60'); return false;" href="javascript:void(0);" class="ref ref60">(60)</a></div><div class="NLM_p last">Concerning the binding affinity of each radiolabeled compound, it can be evaluated <i>in vitro</i> by employing the LigandTracer technology,<a onclick="showRef(event, 'ref37'); return false;" href="javascript:void(0);" class="ref ref37">(37)</a> which enables monitoring of ligandâreceptor interactions on cells in real-time (<i>e.g.</i> onâoff rates, affinity or retention of ligands to cellâsurface receptors) and the assessment of kinetic affinity.</div></div><div id="sec3_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i15" class="anchor-spacer"></div><h3 class="article-section__title" id="_i15"> Functionalization of Nanosystems with Peptide A9 for Active Targeting of Drugs and Visualization of Their Delivery by Magnetic Resonance Imaging (MRI)</h3><div class="NLM_p">A recently published article<a onclick="showRef(event, 'ref61'); return false;" href="javascript:void(0);" class="ref ref61">(61)</a> reports on an anti-HER2 peptide conjugated to theranostic ligand-targeting liposome for selective bioimaging of HER2 positive breast cancer. In this article, the authors have pointed out the importance of developing new targeting ligands, such as a peptide, to improve therapies aimed at delivering drugs through the target-mediated approach. They show high penetration level and improved blood clearance due to their relatively low molecular weight. In particular, they have selected a novel peptide against HER2 with high cell penetration rate, which was screened from a phage display peptide library. The sequence of this peptide molecule is unknown, but it seems bigger than 15-mer.</div><div class="NLM_p">Taking into consideration these results, we plan to implement our synthetic short peptide for the same purposes.</div><div class="NLM_p">Visualization and quantification of drug delivery to the target site is critical to personalize the treatment. Active targeting (or active release) of the drug is critical to reduce off-target side effects.<a onclick="showRef(event, 'ref62'); return false;" href="javascript:void(0);" class="ref ref62">(62)</a> An approach to achieve both visualization of drug delivery and active targeting is based on phospholipid-based nanosystems (liposomes/micelles with hydrodynamic radius around 20 nm) incorporating both an anticancer drug (<i>e.g.</i>, doxorubicin, whose inclusion into the inner cavity of liposomes is well-established) and an MRI contrast agents. The MRI contrast agent is based on the amphiphilic Gd(III)-complex Gd-DOTAMA(C18)2, which is inserted into the phospholipid membrane. By this strategy, a single nanosystem can bring multiple copies of the contrast agents on site, thus circumventing the inherent low sensitivity of MRI in molecular imaging applications.<a onclick="showRef(event, 'ref63 ref64 ref65'); return false;" href="javascript:void(0);" class="ref ref63 ref64 ref65">(63â65)</a> To achieve active targeting for HER2 positive tumors, the external surface of the liposomes could be decorated with the A9 targeting sequence. The A9 targeting sequence will be linked to the liposome through a polyethylene glycol spacer to avoid sterical hindrance that could decrease binding affinity.</div><div class="NLM_p last">The system will initially be evaluated against our HER2-DIVMP soluble receptor fragment to check whether the high binding affinity is maintained. Next, the recognition of the receptor will be evaluated on HER2-expressing cells, and finally the accumulation of the MRI labeled, active targeted nanosystem in the tumor of BALB-NeuT mice will be assessed <i>in vivo</i> and compared to that of an analogous, nontargeted system.</div></div></div><div class="NLM_back"><div class="article_supporting-info" id=""></div><div class="testing" data-doi="10.1021/acs.jmedchem.0c01340" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_35260" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_35260" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Author</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Stefania De Luca</span> - <span class="hlFld-Affiliation affiliation">Institute
of Biostructures and Bioimaging, National
Research Council, 80134 Naples, Italy</span>;Â 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-7078-1696" title="Orcid link">http://orcid.org/0000-0002-7078-1696</a>;Â 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#3142455457505f58501f55545d44525071525f431f5845"><span class="__cf_email__" data-cfemail="c0b3b4a5a6a1aea9a1eea4a5acb5a3a180a3aeb2eea9b4">[emailÂ protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Valentina Verdoliva</span> - <span class="hlFld-Affiliation affiliation">Institute
of Biostructures and Bioimaging, National
Research Council, 80134 Naples, Italy</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Michele Saviano</span> - <span class="hlFld-Affiliation affiliation">Institute
of Crystallography, National Research Council, 70126 Bari, Italy</span></div></li></ul></li><li><span class="author-information-subsection-header">Author Contributions</span><p>(The manuscript was written through contributions of all authors. S.D.L. conceptualized manuscript and performed the writing. All authors have given approval to the final version of the manuscript.</p></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no competing financial interest.<br /></br></div></li></ul></div><div class="bio" rid="ath1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="biographies">Biographies</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_72674" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_72674" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><figure id="ath1" data-index="16" class="article__inlineFigure"><h2 class="fig-label">Stefania De Luca</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01340&amp;id=bio1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Stefania De Luca</b> graduated in Chemistry at University âFederico IIâ of Naples. She had a grant at the National Institute for the Study and Cure of Cancer âG. Pascaleâ, Naples. January to August, 2001, she was a Scientific Visitor in the group of Professor M. Bradley, University of Southampton, UK, and in November, 2001, she obtained a Ph.D. degree in Chemistry. She held several postdoctoral positions with a grant at Neuroscience Laboratory âRita Levi-Montalciniâ. In 2006, she was recruited from the Italian National Research Council (CNR), where she is a research assistant. She was the principle Investigator of Synthetic Unit for the project âChemokine receptor as biological markersâ. Her activity is mainly focused on synthetic chemistry to develop bioactive molecules as well as on chemicalâphysical characterization of biological systems.</p></figure></div><div class="bio" rid="ath2"><figure id="ath2" data-index="17" class="article__inlineFigure"><h2 class="fig-label">Valentina Verdoliva</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01340&amp;id=bio2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Valentina Verdoliva</b> graduated in Pharmaceutical Sciences in 2018 at the University of Naples âFederico IIâ, under the supervision of Dr. S. De Luca. She is currently a postdoctoral fellow in the National Research Council (CNR) in Naples. Her current interests are mainly focused on the synthesis of modified peptide molecules and new biologically active molecules that were already the subject of scientific publications.</p></figure></div><div class="bio" rid="ath3"><figure id="ath3" data-index="18" class="article__inlineFigure"><h2 class="fig-label">Michele Saviano</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01340&amp;id=bio3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Michele Saviano</b> received his Ph.D. in Industrial Chemistry at University of Naples, in 1988. From May 2010, he is a Director of the Institute of Crystallography (CNR). His research is mainly focused on chemistry of bioactive systems: the relationships between structure and activity of numerous bioactive systems have been the subject of his investigations. He is the author of full papers published in international journals, patents, and many lectures to national and international congresses.</p></figure></div><div class="ack" id="ACK-d7e1003-autogenerated"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i20">Acknowledgments</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_28878" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_28878" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">A special thank to Shioban Nott for her great language editing help. We also gratefully acknowledge CNCCS Scarl âCollection of National Chemical Compounds and Screening Centerâ for financial support.</p></div><table summary="" class="NLM_def-list" id="dl1"><tr><td colspan="2" class="NLM_title">Abbreviations Used</td></tr><tr><td class="NLM_term">HER2</td><td class="NLM_def"><p class="first last">human epidermal growth factor receptor 2</p></td></tr><tr><td class="NLM_term">DIVMP</td><td class="NLM_def"><p class="first last">domain IV micro protein</p></td></tr><tr><td class="NLM_term">EDC</td><td class="NLM_def"><p class="first last">extracellular drug conjugate</p></td></tr><tr><td class="NLM_term">DTPA</td><td class="NLM_def"><p class="first last">diethylene triamine pentaacetic acid</p></td></tr><tr><td class="NLM_term">T-DM1</td><td class="NLM_def"><p class="first last">ado-trastuzumab emtansine</p></td></tr><tr><td class="NLM_term">DM1</td><td class="NLM_def"><p class="first last"><i>N</i>2â²-deacetyl-<i>N</i>2â²-(3-mercapto-1-oxopropyl)maytansine</p></td></tr><tr><td class="NLM_term">MCC</td><td class="NLM_def"><p class="first last">4-(<i>N</i>-maleimidomethyl)cyclohexane-1-carboxylate</p></td></tr><tr><td class="NLM_term">FDA</td><td class="NLM_def"><p class="first last">Food and Drug Administration</p></td></tr><tr><td class="NLM_term">CYANA</td><td class="NLM_def"><p class="first last">combined assignment and dynamics algorithm for NMR applications</p></td></tr><tr><td class="NLM_term">NOE</td><td class="NLM_def"><p class="first last">nuclear Overhauser effect</p></td></tr><tr><td class="NLM_term">trNOE</td><td class="NLM_def"><p class="first last">transferred nuclear Overhauser effect</p></td></tr><tr><td class="NLM_term">PEG</td><td class="NLM_def"><p class="first last">polyethylene glycol</p></td></tr><tr><td class="NLM_term">trNOESY</td><td class="NLM_def"><p class="first last">transferred nuclear overhauser enhancement spectroscopy in the rotating frame</p></td></tr><tr><td class="NLM_term">NMR</td><td class="NLM_def"><p class="first last">nuclear magnetic resonance</p></td></tr><tr><td class="NLM_term">NIR</td><td class="NLM_def"><p class="first last">near-infrared</p></td></tr><tr><td class="NLM_term">MRI</td><td class="NLM_def"><p class="first last">magnetic resonance imaging</p></td></tr></table><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i22">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_12061" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_12061" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 65 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yarden, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sliwkowski, M. X.</span></span> <span> </span><span class="NLM_article-title">Untangling the ErbB signalling network</span>. <i>Nat. Rev. Mol. Cell Biol.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">127</span>â <span class="NLM_lpage">137</span>, <span class="refDoi">Â DOI: 10.1038/35052073</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01340&amp;key=10.1038%2F35052073" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01340&amp;key=11252954" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01340&amp;key=1%3ACAS%3A528%3ADC%252BD3MXivVWnt7k%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2001&pages=127-137&author=Y.+Yardenauthor=M.+X.+Sliwkowski&title=Untangling+the+ErbB+signalling+network&doi=10.1038%2F35052073"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Untangling the ErbB signalling network</span></div><div class="casAuthors">Yarden, Yosef; Sliwkowski, Mark X.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Molecular Cell Biology</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">127-137</span>CODEN:
                <span class="NLM_cas:coden">NRMCBP</span>;
        ISSN:<span class="NLM_cas:issn">1471-0072</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review, with 112 refs.  When epidermal growth factor and its relatives bind the ErbB family of receptors, they trigger a rich network of signaling pathways, culminating in responses ranging from cell division to death, motility to adhesion.  The network is often dysregulated in cancer and lends credence to the mantra that mol. understanding yields clin. benefit: over 25,000 women with breast cancer have now been treated with Herceptin, a recombinant antibody designed to block the receptor ErbB2.  Likewise, small-mol. enzyme inhibitors and monoclonal antibodies to ErbB1 are in advanced phases of clin. testing.  What can this pathway teach us about translating basic science into clin. use.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGovhWL1HObvNrVg90H21EOLACvtfcHk0lg5uC7XJlDOTQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXivVWnt7k%253D&md5=1561a9666f77fce888be821399870cd6</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1038%2F35052073&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F35052073%26sid%3Dliteratum%253Aachs%26aulast%3DYarden%26aufirst%3DY.%26aulast%3DSliwkowski%26aufirst%3DM.%2BX.%26atitle%3DUntangling%2520the%2520ErbB%2520signalling%2520network%26jtitle%3DNat.%2520Rev.%2520Mol.%2520Cell%2520Biol.%26date%3D2001%26volume%3D2%26spage%3D127%26epage%3D137%26doi%3D10.1038%2F35052073" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Niehans, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singleton, T. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dykoski, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kiang, D. T.</span></span> <span> </span><span class="NLM_article-title">Stability of HER-2/neu expression over time and at multiple metastatic sites</span>. <i>J. Natl. Cancer Inst.</i> <span class="NLM_year" style="font-weight: bold;">1993</span>,  <span class="NLM_volume"><i>85</i></span>,  <span class="NLM_fpage">1230</span>â <span class="NLM_lpage">1235</span>, <span class="refDoi">Â DOI: 10.1093/jnci/85.15.1230</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01340&amp;key=10.1093%2Fjnci%2F85.15.1230" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01340&amp;key=8101229" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01340&amp;key=1%3ACAS%3A280%3ADyaK3szitlWntw%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=85&publication_year=1993&pages=1230-1235&author=G.+A.+Niehansauthor=T.+P.+Singletonauthor=D.+Dykoskiauthor=D.+T.+Kiang&title=Stability+of+HER-2%2Fneu+expression+over+time+and+at+multiple+metastatic+sites&doi=10.1093%2Fjnci%2F85.15.1230"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Stability of HER-2/neu expression over time and at multiple metastatic sites</span></div><div class="casAuthors">Niehans G A; Singleton T P; Dykoski D; Kiang D T</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the National Cancer Institute</span>
        (<span class="NLM_cas:date">1993</span>),
    <span class="NLM_cas:volume">85</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">1230-5</span>
        ISSN:<span class="NLM_cas:issn">0027-8874</span>.
    </div><div class="casAbstract">BACKGROUND:  Amplification and over-expression of the HER-2/neu oncogene (also known as c-erbB-2) occurs in 20%-30% of invasive breast carcinomas.  The extent to which HER-2/neu expression changes over time in association with tumor progression or is heterogeneous at different metastatic sites has received only limited study.  PURPOSE:  Our purpose was to determine whether primary tumors differ from metastases in HER-2/neu protein content or whether metastases are heterogeneous in regard to HER-2/neu expression.  METHODS:  In a retrospective study, we examined tumor tissue obtained at autopsy from two to five metastatic organ sites in each of 30 patients who died with metastatic breast carcinoma.  Using an immunoperoxidase technique, we stained archival formalin-fixed, paraffin-embedded tissue sections with a monoclonal antibody to the 185-kilodalton protein product (p185) of the HER-2/neu gene.  RESULTS:  The tissue from eight of 30 patients showed strong diffuse reactivity for p185 at all metastatic sites examined.  Tissues from six patients showed faint staining and tissues from 15 were negative, again with a congruent staining pattern.  A single case showed discordant staining, in that two of four metastases showed faint staining, whereas the other two showed strong immunoreactivity.  In 14 cases, we were able to obtain paraffin blocks from the original biopsy or surgical resection of the primary breast lesion.  For these 14 patients, the average length of time between initial diagnosis and death was 4 years (range, 2-9).  There was good correlation between results from autopsy and original surgical tissues.  CONCLUSIONS:  Expression of HER-2/neu appears to be relatively stable over time and is generally congruent at different metastatic sites.  IMPLICATIONS:  The fact that p185 immunoreactivity is rarely heterogeneous is encouraging, both for the potential use of HER-2/neu-related proteins as serum tumor markers and for innovative therapies targeted at p185 expression.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTvT3ZMfUDd95agfuraLLzSfW6udTcc2eYccB4T4h4_x7ntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK3szitlWntw%253D%253D&md5=012292a70380d2aa4905099741b03916</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1093%2Fjnci%2F85.15.1230&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fjnci%252F85.15.1230%26sid%3Dliteratum%253Aachs%26aulast%3DNiehans%26aufirst%3DG.%2BA.%26aulast%3DSingleton%26aufirst%3DT.%2BP.%26aulast%3DDykoski%26aufirst%3DD.%26aulast%3DKiang%26aufirst%3DD.%2BT.%26atitle%3DStability%2520of%2520HER-2%252Fneu%2520expression%2520over%2520time%2520and%2520at%2520multiple%2520metastatic%2520sites%26jtitle%3DJ.%2520Natl.%2520Cancer%2520Inst.%26date%3D1993%26volume%3D85%26spage%3D1230%26epage%3D1235%26doi%3D10.1093%2Fjnci%2F85.15.1230" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Neve, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lane, H. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hynes, N. E.</span></span> <span> </span><span class="NLM_article-title">The role of overexpressed HER2 in transformation</span>. <i>Ann. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">S9</span>â <span class="NLM_lpage">S13</span>, <span class="refDoi">Â DOI: 10.1093/annonc/12.suppl_1.S9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01340&amp;key=10.1093%2Fannonc%2F12.suppl_1.S9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01340&amp;key=11521729" title="">PubMed</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2001&pages=S9-S13&author=R.+M.+Neveauthor=H.+A.+Laneauthor=N.+E.+Hynes&title=The+role+of+overexpressed+HER2+in+transformation&doi=10.1093%2Fannonc%2F12.suppl_1.S9"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1093%2Fannonc%2F12.suppl_1.S9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fannonc%252F12.suppl_1.S9%26sid%3Dliteratum%253Aachs%26aulast%3DNeve%26aufirst%3DR.%2BM.%26aulast%3DLane%26aufirst%3DH.%2BA.%26aulast%3DHynes%26aufirst%3DN.%2BE.%26atitle%3DThe%2520role%2520of%2520overexpressed%2520HER2%2520in%2520transformation%26jtitle%3DAnn.%2520Oncol.%26date%3D2001%26volume%3D12%26spage%3DS9%26epage%3DS13%26doi%3D10.1093%2Fannonc%2F12.suppl_1.S9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Slamon, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clark, G. M S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levin, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ullrich, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McGuire, W. L.</span></span> <span> </span><span class="NLM_article-title">Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">1987</span>,  <span class="NLM_volume"><i>235</i></span>,  <span class="NLM_fpage">177</span>â <span class="NLM_lpage">182</span>, <span class="refDoi">Â DOI: 10.1126/science.3798106</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01340&amp;key=10.1126%2Fscience.3798106" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01340&amp;key=3798106" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01340&amp;key=1%3ACAS%3A528%3ADyaL2sXhtVSht7s%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=235&publication_year=1987&pages=177-182&author=D.+J.+Slamonauthor=G.+M+S.+Clarkauthor=G.+Wongauthor=W.+J.+Levinauthor=A.+Ullrichauthor=W.+L.+McGuire&title=Human+breast+cancer%3A+correlation+of+relapse+and+survival+with+amplification+of+the+HER-2%2Fneu+oncogene&doi=10.1126%2Fscience.3798106"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Human breast cancer:  correlation of relapse and survival with amplification of the HER-2/neu oncogene</span></div><div class="casAuthors">Slamon, Dennis J.; Clark, Gary M.; Wong, Steven G.; Levin, Wendy J.; Ullrich, Axel; McGuire, William L.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">1987</span>),
    <span class="NLM_cas:volume">235</span>
        (<span class="NLM_cas:issue">4785</span>),
    <span class="NLM_cas:pages">177-82</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    </div><div class="casAbstract">The HER-2/neu oncogene is a member of the erbB-like oncogene family, and is related to, but distinct from, the epidermal growth factor receptor.  This gene has been shown to be amplified in human breast cancer cell lines.  In the current study, alterations of the gene in 189 primary human breast cancers were investigated.  HER-2/neu was found to be amplified from 2- to >20-fold in 30% of the tumors.  Correlation of gene amplification with several disease parameters was evaluated.  Amplification of the HER-2neu gene was a significant predictor of both overall survival and time to relapse in patients with breast cancer.  It retained its significance even when adjustments were made for other known prognostic factors.  Moreover, HER-2/neu amplification had greater prognostic value than most currently used prognostic factors, including hormonal-receptor status, in lymph node-pos. disease.  These data indicate that this gene may play a role in the biol. behavior and(or) pathogenesis of human breast cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoWPpNbN8S_QrVg90H21EOLACvtfcHk0lgpHKOwJF9wIQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL2sXhtVSht7s%253D&md5=0889410d6e47651de4d8085e9bbd70d9</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1126%2Fscience.3798106&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.3798106%26sid%3Dliteratum%253Aachs%26aulast%3DSlamon%26aufirst%3DD.%2BJ.%26aulast%3DClark%26aufirst%3DG.%2BM%2BS.%26aulast%3DWong%26aufirst%3DG.%26aulast%3DLevin%26aufirst%3DW.%2BJ.%26aulast%3DUllrich%26aufirst%3DA.%26aulast%3DMcGuire%26aufirst%3DW.%2BL.%26atitle%3DHuman%2520breast%2520cancer%253A%2520correlation%2520of%2520relapse%2520and%2520survival%2520with%2520amplification%2520of%2520the%2520HER-2%252Fneu%2520oncogene%26jtitle%3DScience%26date%3D1987%26volume%3D235%26spage%3D177%26epage%3D182%26doi%3D10.1126%2Fscience.3798106" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Paik, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hazan, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fisher, E. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sass, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fisher, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Redmond, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schlessinger, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lippman, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">King, C. R.</span></span> <span> </span><span class="NLM_article-title">Pathologic findings from the national surgical adjuvant breast and bowel project: Prognostic significance of erbE-2 protein overexpression in primary breast cancer</span>. <i>J. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">1990</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">103</span>â <span class="NLM_lpage">112</span>, <span class="refDoi">Â DOI: 10.1200/JCO.1990.8.1.103</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01340&amp;key=10.1200%2FJCO.1990.8.1.103" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01340&amp;key=1967301" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01340&amp;key=1%3ACAS%3A280%3ADyaK3c7htFOktw%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=1990&pages=103-112&author=S.+Paikauthor=R.+Hazanauthor=E.+R.+Fisherauthor=R.+E.+Sassauthor=B.+Fisherauthor=C.+Redmondauthor=J.+Schlessingerauthor=M.+E.+Lippmanauthor=C.+R.+King&title=Pathologic+findings+from+the+national+surgical+adjuvant+breast+and+bowel+project%3A+Prognostic+significance+of+erbE-2+protein+overexpression+in+primary+breast+cancer&doi=10.1200%2FJCO.1990.8.1.103"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Pathologic findings from the National Surgical Adjuvant Breast and Bowel Project: prognostic significance of erbB-2 protein overexpression in primary breast cancer</span></div><div class="casAuthors">Paik S; Hazan R; Fisher E R; Sass R E; Fisher B; Redmond C; Schlessinger J; Lippman M E; King C R</div><div class="citationInfo"><span class="NLM_cas:title">Journal of clinical oncology : official journal of the American Society of Clinical Oncology</span>
        (<span class="NLM_cas:date">1990</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">103-12</span>
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    </div><div class="casAbstract">In order to investigate the prognostic significance of erbB-2 overexpression, immunohistochemical staining for the erbB-2 protein was performed on sections from paraffin blocks of 292 primary invasive breast cancers obtained from women enrolled in the National Surgical Adjuvant Breast and Bowel Project (NSABP) protocol B-06.  Positive reaction indicative of erbB-2 overexpression was observed on tumor cells in 62 (21%) samples.  Women whose cancers were judged to have erbB-2 overexpression had a significantly worse overall survival (P = .0012) with twice the mortality rate of women without detectable erbB-2 expression.  No statistically significant effect was evident for disease-free survival (P = .22).  In multivariate analysis, detection of erbB-2 overexpression was the second most predictive independent variable for survival after nodal status.  Overexpression of erbB-2 was more common among tumors of poor nuclear grade (29%) than those of good nuclear grade (12%).  The association of erbB-2 overexpression with decreased survival was evident only among women with tumors of good nuclear grade.  In this subgroup, erbB-2 overexpression was associated with an approximately fivefold increase in mortality rate (P = .00001).  The combined predictive value of erbB-2 overexpression and nuclear grade was evident regardless of their lymph node status.  These results provide evidence that detection of erbB-2 overexpression may be an independent prognostic variable for patient survival.  Moreover, when combined with evaluation of nuclear grade, it may be possible to use immunostaining for erbB-2 protein to identify patients at increased risk from within a relatively low-risk group.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcR2whjqgdBz2A5nADWVYHg1fW6udTcc2eYccB4T4h4_x7ntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK3c7htFOktw%253D%253D&md5=97590453275112f08f8ed2281ca2e485</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1200%2FJCO.1990.8.1.103&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.1990.8.1.103%26sid%3Dliteratum%253Aachs%26aulast%3DPaik%26aufirst%3DS.%26aulast%3DHazan%26aufirst%3DR.%26aulast%3DFisher%26aufirst%3DE.%2BR.%26aulast%3DSass%26aufirst%3DR.%2BE.%26aulast%3DFisher%26aufirst%3DB.%26aulast%3DRedmond%26aufirst%3DC.%26aulast%3DSchlessinger%26aufirst%3DJ.%26aulast%3DLippman%26aufirst%3DM.%2BE.%26aulast%3DKing%26aufirst%3DC.%2BR.%26atitle%3DPathologic%2520findings%2520from%2520the%2520national%2520surgical%2520adjuvant%2520breast%2520and%2520bowel%2520project%253A%2520Prognostic%2520significance%2520of%2520erbE-2%2520protein%2520overexpression%2520in%2520primary%2520breast%2520cancer%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D1990%26volume%3D8%26spage%3D103%26epage%3D112%26doi%3D10.1200%2FJCO.1990.8.1.103" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Garrett, T. P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McKern, N. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lou, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elleman, T. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adams, T. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lovrecz, G. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kofler, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jorissen, R. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nice, E. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burgess, A. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ward, C. W.</span></span> <span> </span><span class="NLM_article-title">The crystal structure of a truncated ErbB2 ectodomain reveals an active conformation, poised to interact with other ErbB receptors</span>. <i>Mol. Cell</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">495</span>â <span class="NLM_lpage">505</span>, <span class="refDoi">Â DOI: 10.1016/S1097-2765(03)00048-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01340&amp;key=10.1016%2FS1097-2765%2803%2900048-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01340&amp;key=12620236" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01340&amp;key=1%3ACAS%3A528%3ADC%252BD3sXit1WgsLo%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2003&pages=495-505&author=T.+P.+J.+Garrettauthor=N.+M.+McKernauthor=M.+Louauthor=T.+C.+Ellemanauthor=T.+E.+Adamsauthor=G.+O.+Lovreczauthor=M.+Koflerauthor=R.+N.+Jorissenauthor=E.+C.+Niceauthor=A.+W.+Burgessauthor=C.+W.+Ward&title=The+crystal+structure+of+a+truncated+ErbB2+ectodomain+reveals+an+active+conformation%2C+poised+to+interact+with+other+ErbB+receptors&doi=10.1016%2FS1097-2765%2803%2900048-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">The crystal structure of a truncated ErbB2 ectodomain reveals an active conformation, poised to interact with other ErbB receptors</span></div><div class="casAuthors">Garrett, Thomas P. J.; McKern, Neil M.; Lou, Meizhen; Elleman, Thomas C.; Adams, Timothy E.; Lovrecz, George O.; Kofler, Michael; Jorissen, Robert N.; Nice, Edouard C.; Burgess, Antony W.; Ward, Colin W.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cell</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">495-505</span>CODEN:
                <span class="NLM_cas:coden">MOCEFL</span>;
        ISSN:<span class="NLM_cas:issn">1097-2765</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">ErbB2 does not bind ligand, yet appears to be the major signaling partner for other ErbB receptors by forming heteromeric complexes with ErbB1, ErbB3, or ErbB4.  The crystal structure of residues 1-509 of ErbB2 at 2.5 Ã resoln. reveals an activated conformation similar to that of the EGFR when complexed with ligand and very different from that seen in the unactivated forms of ErbB3 or EGFR.  The structure explains the inability of ErbB2 to bind known ligands and suggests why ErbB2 fails to form homodimers.  Together, the data suggest a model in which ErbB2 is already in the activated conformation and ready to interact with other ligand-activated ErbB receptors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpKWPX-PxHzzbVg90H21EOLACvtfcHk0liJcYLQcI5t3g"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXit1WgsLo%253D&md5=117d9fe768aec8d63638724fb41ee14d</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1016%2FS1097-2765%2803%2900048-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1097-2765%252803%252900048-0%26sid%3Dliteratum%253Aachs%26aulast%3DGarrett%26aufirst%3DT.%2BP.%2BJ.%26aulast%3DMcKern%26aufirst%3DN.%2BM.%26aulast%3DLou%26aufirst%3DM.%26aulast%3DElleman%26aufirst%3DT.%2BC.%26aulast%3DAdams%26aufirst%3DT.%2BE.%26aulast%3DLovrecz%26aufirst%3DG.%2BO.%26aulast%3DKofler%26aufirst%3DM.%26aulast%3DJorissen%26aufirst%3DR.%2BN.%26aulast%3DNice%26aufirst%3DE.%2BC.%26aulast%3DBurgess%26aufirst%3DA.%2BW.%26aulast%3DWard%26aufirst%3DC.%2BW.%26atitle%3DThe%2520crystal%2520structure%2520of%2520a%2520truncated%2520ErbB2%2520ectodomain%2520reveals%2520an%2520active%2520conformation%252C%2520poised%2520to%2520interact%2520with%2520other%2520ErbB%2520receptors%26jtitle%3DMol.%2520Cell%26date%3D2003%26volume%3D11%26spage%3D495%26epage%3D505%26doi%3D10.1016%2FS1097-2765%2803%2900048-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Engel, R. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaklamani, V. G.</span></span> <span> </span><span class="NLM_article-title">HER2-positive breast cancer: Current and future treatment strategies</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>67</i></span>,  <span class="NLM_fpage">1329</span>â <span class="NLM_lpage">1341</span>, <span class="refDoi">Â DOI: 10.2165/00003495-200767090-00006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01340&amp;key=10.2165%2F00003495-200767090-00006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01340&amp;key=17547474" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01340&amp;key=1%3ACAS%3A528%3ADC%252BD2sXptVyku7s%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=67&publication_year=2007&pages=1329-1341&author=R.+H.+Engelauthor=V.+G.+Kaklamani&title=HER2-positive+breast+cancer%3A+Current+and+future+treatment+strategies&doi=10.2165%2F00003495-200767090-00006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">HER2-positive breast cancer: current and future treatment strategies</span></div><div class="casAuthors">Engel, Ryan H.; Kaklamani, Virginia G.</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">67</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1329-1341</span>CODEN:
                <span class="NLM_cas:coden">DRUGAY</span>;
        ISSN:<span class="NLM_cas:issn">0012-6667</span>.
    
            (<span class="NLM_cas:orgname">Wolters Kluwer Health</span>)
        </div><div class="casAbstract">A review.  In the year 2006, breast cancer was estd. to affect >200 000 American women and cause nearly 56 000 deaths.  Furthermore, breast cancer is the most common cancer diagnosed and second most common cause of cancer-related deaths in women.  The current treatment armamentarium for breast cancer includes chemotherapy, endocrine therapy and biol. therapy.  Treatment has become more individualized based on characteristics of the tumor including overexpression of the human epidermal growth factor receptor (HER)-2.  Between 20 and 30% of all breast cancers overexpress HER2, which means 40 000-60 000 patients will have this type of cancer.  Previously, overexpression of HER2 was a neg. prognostic and predictive risk factor for survival; however, with the advent of trastuzumab, patients' prognosis is improving in all treatment settings.  Much controversy exists in the use of trastuzumab, including (i) the sequence of adjuvant trastuzumab (concurrent with chemotherapy or sequential); (ii) the treatment duration (<1 yr, 1 yr or 2 years); and (iii) the treatment choice upon disease progression (whether to continue or not with trastuzumab and add another cytotoxic agent).  Current trials are ongoing to help answer these questions.  Furthermore, there has been interest in predicting which HER2-pos. patients would require anthracycline therapy, and which could avoid anthracycline therapy and its toxicities.  Novel therapeutics, such as lapatinib, an oral tyrosine kinase inhibitor, which blocks both the epidermal growth factor receptor and HER2 receptor has recently been approved by the US FDA.  Whereas pertuzumab, a humanized monoclonal antibody, directed against heterodimerization of HER2 and HER3 has entered phase II and III clin. trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrJgkiP3PQ-ZLVg90H21EOLACvtfcHk0liJcYLQcI5t3g"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXptVyku7s%253D&md5=28821ef69329052441a8b33e3d17daa2</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.2165%2F00003495-200767090-00006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2165%252F00003495-200767090-00006%26sid%3Dliteratum%253Aachs%26aulast%3DEngel%26aufirst%3DR.%2BH.%26aulast%3DKaklamani%26aufirst%3DV.%2BG.%26atitle%3DHER2-positive%2520breast%2520cancer%253A%2520Current%2520and%2520future%2520treatment%2520strategies%26jtitle%3DDrugs%26date%3D2007%26volume%3D67%26spage%3D1329%26epage%3D1341%26doi%3D10.2165%2F00003495-200767090-00006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Faltus, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zimmer, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kramer, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loibl, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaufmann, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strebhardt, K.</span></span> <span> </span><span class="NLM_article-title">Silencing of the HER2/neu gene by siRNA inhibits proliferation and induces apoptosis in HER2/neu-overexpressing breast cancer cells</span>. <i>Neoplasia</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">786</span>â <span class="NLM_lpage">795</span>, <span class="refDoi">Â DOI: 10.1593/neo.04313</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01340&amp;key=10.1593%2Fneo.04313" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01340&amp;key=15720805" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01340&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtFWnsb8%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2004&pages=786-795&author=T.+Faltusauthor=J.+Yuanauthor=B.+Zimmerauthor=A.+Kramerauthor=S.+Loiblauthor=M.+Kaufmannauthor=K.+Strebhardt&title=Silencing+of+the+HER2%2Fneu+gene+by+siRNA+inhibits+proliferation+and+induces+apoptosis+in+HER2%2Fneu-overexpressing+breast+cancer+cells&doi=10.1593%2Fneo.04313"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Silencing of the HER2/neu gene by siRNA inhibits proliferation and induces apoptosis in HER2/neu-overexpressing breast cancer cells</span></div><div class="casAuthors">Faltus, Timo; Yuan, Juping; Zimmer, Brigitte; Kraemer, Andrea; Loibl, Sibylle; Kaufmann, Manfred; Strebhardt, Klaus</div><div class="citationInfo"><span class="NLM_cas:title">Neoplasia (Ann Arbor, MI, United States)</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">786-795</span>CODEN:
                <span class="NLM_cas:coden">NEOPFL</span>;
        ISSN:<span class="NLM_cas:issn">1522-8002</span>.
    
            (<span class="NLM_cas:orgname">Neoplasia Press Inc.</span>)
        </div><div class="casAbstract">In eukaryotes, double-stranded (ds) RNA induces sequence-specific inhibition of gene expression referred to as RNA interference (RNAi).  We exploited RNAi to define the role of HER2/neu in the neoplastic proliferation of human breast cancer cells.  We transfected SK-BR-3, BT-474, MCF-7, and MDA-MB-468 breast cancer cells with short interfering RNA (siRNA) targeted against human HER2/neu and analyzed the specific inhibition of HER2/neu expression by Northern and Western blots.  Transfection with HER2/neu-specific siRNA resulted in a sequence-specific decrease in HER2/neu mRNA and protein levels.  Moreover, transfection with HER2/neu siRNA caused cell cycle arrest at G0/G1 in the breast cancer cell lines SK-BR-3 and BT-474, consistent with a powerful RNA silencing effect.  SiRNA treatment resulted in an antiproliferative and apoptotic response in cells overexpressing HER2/neu, but had no influence in cells with almost no expression of HER2/neu proteins like MDA-MB-468 cells.  These data indicate that HER2/neu function is essential for the proliferation of HER2/neu-overexpressing breast cancer cells.  Our observations suggest that siRNA targeted against human HER2/neu may be valuable tools as antiproliferative agents that display activity against neoplastic cells at very low doses.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpGk7M-n6brL7Vg90H21EOLACvtfcHk0lhOk7fmxaQMlw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtFWnsb8%253D&md5=8c682552394e1cf202e6f15580a44916</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1593%2Fneo.04313&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1593%252Fneo.04313%26sid%3Dliteratum%253Aachs%26aulast%3DFaltus%26aufirst%3DT.%26aulast%3DYuan%26aufirst%3DJ.%26aulast%3DZimmer%26aufirst%3DB.%26aulast%3DKramer%26aufirst%3DA.%26aulast%3DLoibl%26aufirst%3DS.%26aulast%3DKaufmann%26aufirst%3DM.%26aulast%3DStrebhardt%26aufirst%3DK.%26atitle%3DSilencing%2520of%2520the%2520HER2%252Fneu%2520gene%2520by%2520siRNA%2520inhibits%2520proliferation%2520and%2520induces%2520apoptosis%2520in%2520HER2%252Fneu-overexpressing%2520breast%2520cancer%2520cells%26jtitle%3DNeoplasia%26date%3D2004%26volume%3D6%26spage%3D786%26epage%3D795%26doi%3D10.1593%2Fneo.04313" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yang, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cai, K. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thompson-Lanza, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bast, R. C.,  Jr.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span> <span> </span><span class="NLM_article-title">Inhibition of breast and ovarian tumor growth through multiple signaling pathways by using retrovirus-mediated small interfering RNA against Her-2/neu gene expression</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>279</i></span>,  <span class="NLM_fpage">4339</span>â <span class="NLM_lpage">4345</span>, <span class="refDoi">Â DOI: 10.1074/jbc.M311153200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01340&amp;key=10.1074%2Fjbc.M311153200" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01340&amp;key=14625284" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01340&amp;key=1%3ACAS%3A528%3ADC%252BD2cXps12guw%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=279&publication_year=2004&pages=4339-4345&author=G.+Yangauthor=K.+Q.+Caiauthor=J.+A.+Thompson-Lanzaauthor=R.+C.+Bastauthor=J.+Liu&title=Inhibition+of+breast+and+ovarian+tumor+growth+through+multiple+signaling+pathways+by+using+retrovirus-mediated+small+interfering+RNA+against+Her-2%2Fneu+gene+expression&doi=10.1074%2Fjbc.M311153200"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of Breast and Ovarian Tumor Growth through Multiple Signaling Pathways by Using Retrovirus-mediated Small Interfering RNA against Her-2/neu Gene Expression</span></div><div class="casAuthors">Yang, Gong; Cai, Kathy Qi; Thompson-Lanza, Jennifer A.; Bast, Robert C., Jr.; Liu, Jinsong</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">279</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">4339-4345</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">The Her-2/neu oncogene is overexpressed in â¼30% of breast and ovarian cancer cases and often indicates a poor prognosis.  Therapeutic agents against Her-2/neu have been intensively sought over the past decade.  Here we show that small interfering RNA (siRNA) can silence the expression of Her-2/neu in models of human breast or ovarian cancer through retrovirus-mediated transfer of an siRNA against Her-2/neu.  Cells infected with retrovirus expressing anti-Her-2/neu siRNA exhibit slower proliferation, increased apoptosis, increased G0/G1 arrest, and decreased tumor growth.  Changes in cell cycle-assocd. factors included decreased levels of phosphatidylinositol 3-kinase, pAkt, and cyclin D1 and increased levels of p27 and phosphorylated retinoblastoma protein.  Knockdown of Her-2/neu expression by siRNA is also assocd. with increased expression of the anti-angiogenic factor thrombospondin-1 and decreased expression of the pro-angiogenic vascular endothelial growth factor, suggesting that Her-2/neu stimulates tumor growth at least in part by regulating angiogenesis.  SiRNA-mediated gene silencing of Her-2/neu and increasing the expression of thrombospondin-1 may be a useful therapeutic strategy for Her-2/neu-over-expressing breast or ovarian cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGohuyI7dYjoIbVg90H21EOLACvtfcHk0lhOk7fmxaQMlw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXps12guw%253D%253D&md5=bda2bf2120ef1725130173c2e084ac2d</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M311153200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M311153200%26sid%3Dliteratum%253Aachs%26aulast%3DYang%26aufirst%3DG.%26aulast%3DCai%26aufirst%3DK.%2BQ.%26aulast%3DThompson-Lanza%26aufirst%3DJ.%2BA.%26aulast%3DBast%26aufirst%3DR.%2BC.%26aulast%3DLiu%26aufirst%3DJ.%26atitle%3DInhibition%2520of%2520breast%2520and%2520ovarian%2520tumor%2520growth%2520through%2520multiple%2520signaling%2520pathways%2520by%2520using%2520retrovirus-mediated%2520small%2520interfering%2520RNA%2520against%2520Her-2%252Fneu%2520gene%2520expression%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2004%26volume%3D279%26spage%3D4339%26epage%3D4345%26doi%3D10.1074%2Fjbc.M311153200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pils, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pinter, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reibenwein, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alfanz, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Horak, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmid, B. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hefler, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Horvat, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reinthaller, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zeillinger, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krainer, M.</span></span> <span> </span><span class="NLM_article-title">In ovarian cancer the prognostic influence of HER2/neu is not dependent on the CXCR4/SDF-1 signalling pathway</span>. <i>Br. J. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>96</i></span>,  <span class="NLM_fpage">485</span>â <span class="NLM_lpage">491</span>, <span class="refDoi">Â DOI: 10.1038/sj.bjc.6603581</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01340&amp;key=10.1038%2Fsj.bjc.6603581" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01340&amp;key=17245339" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01340&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtlKjt70%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=96&publication_year=2007&pages=485-491&author=D.+Pilsauthor=A.+Pinterauthor=J.+Reibenweinauthor=A.+Alfanzauthor=P.+Horakauthor=B.+C.+Schmidauthor=L.+Heflerauthor=R.+Horvatauthor=A.+Reinthallerauthor=R.+Zeillingerauthor=M.+Krainer&title=In+ovarian+cancer+the+prognostic+influence+of+HER2%2Fneu+is+not+dependent+on+the+CXCR4%2FSDF-1+signalling+pathway&doi=10.1038%2Fsj.bjc.6603581"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">In ovarian cancer the prognostic influence of HER2/neu is not dependent on the CXCR4/SDF-1 signalling pathway</span></div><div class="casAuthors">Pils, D.; Pinter, A.; Reibenwein, J.; Alfanz, A.; Horak, P.; Schmid, B. C.; Hefler, L.; Horvat, R.; Reinthaller, A.; Zeillinger, R.; Krainer, M.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Cancer</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">96</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">485-491</span>CODEN:
                <span class="NLM_cas:coden">BJCAAI</span>;
        ISSN:<span class="NLM_cas:issn">0007-0920</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">HER2/neu overexpression is a driving force in the carcinogenesis of several human cancers.  In breast cancer the prognostic influence of HER2/neu was shown to be at least partly based on increased metastatic potential mediated by the chemokine-chemokine receptor pair SDF-1(CXCL12)/CXCR4.  We wanted to evaluate the influence of HER2/neu on ovarian cancer prognosis and to investigate whether compromised survival would correlate with CXCR4 expression and/or SDF-1 abundance.  Therefore, we analyzed HER2/neu, CXCR4, and SDF-1 in 148 ovarian tumor samples by means of immunohistochem. on tissue microarrays.  Overexpression of HER2/neu was found in 27.6% of ovarian cancer tissues and in 15% of ovarian borderline tumors.  In ovarian cancer patients, overexpression of HER2/neu correlated closely with overall survival (univariate hazard ratio (HR) 2.59, P=0.005; multiple cor. HR 1.92, P=0.074).  In contrast, CXCR4 expression and SDF-1 abundance had no impact on overall survival, and both parameters were not correlated with HER2/neu expression.  As expected, cytoplasmic CXCR4 expression and SDF-1 abundance correlated closely (P<0.0001).  Our results confirm a univariate influence of HER2/neu expression on overall survival, which was completely independent of the expression of CXCR4 and the abundance of SDF-1, implying significant differences between the HER2/neu downstream pathways in ovarian cancer compared with breast cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoExClqP7-BKrVg90H21EOLACvtfcHk0lhOk7fmxaQMlw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtlKjt70%253D&md5=59b5e993cc860bbad227a074a9763d1e</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1038%2Fsj.bjc.6603581&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.bjc.6603581%26sid%3Dliteratum%253Aachs%26aulast%3DPils%26aufirst%3DD.%26aulast%3DPinter%26aufirst%3DA.%26aulast%3DReibenwein%26aufirst%3DJ.%26aulast%3DAlfanz%26aufirst%3DA.%26aulast%3DHorak%26aufirst%3DP.%26aulast%3DSchmid%26aufirst%3DB.%2BC.%26aulast%3DHefler%26aufirst%3DL.%26aulast%3DHorvat%26aufirst%3DR.%26aulast%3DReinthaller%26aufirst%3DA.%26aulast%3DZeillinger%26aufirst%3DR.%26aulast%3DKrainer%26aufirst%3DM.%26atitle%3DIn%2520ovarian%2520cancer%2520the%2520prognostic%2520influence%2520of%2520HER2%252Fneu%2520is%2520not%2520dependent%2520on%2520the%2520CXCR4%252FSDF-1%2520signalling%2520pathway%26jtitle%3DBr.%2520J.%2520Cancer%26date%3D2007%26volume%3D96%26spage%3D485%26epage%3D491%26doi%3D10.1038%2Fsj.bjc.6603581" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Roh, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pippin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drebin, J. A.</span></span> <span> </span><span class="NLM_article-title">Down-regulation of HER2/neu expression induces apoptosis in human cancer cells that overexpress HER2/neu</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">560</span>â <span class="NLM_lpage">565</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01340&amp;key=10676637" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01340&amp;key=1%3ACAS%3A528%3ADC%252BD3cXht1Gmt7k%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2000&pages=560-565&author=H.+Rohauthor=J.+Pippinauthor=J.+A.+Drebin&title=Down-regulation+of+HER2%2Fneu+expression+induces+apoptosis+in+human+cancer+cells+that+overexpress+HER2%2Fneu"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Down-regulation of HER2/neu expression induces apoptosis in human cancer cells that overexpress HER2/neu</span></div><div class="casAuthors">Roh, Haeri; Pippin, James; Drebin, Jeffrey A.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">560-565</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">AACR Subscription Office</span>)
        </div><div class="casAbstract">The HER2/neu oncogene is overexpressed in a significant fraction of human tumors; such overexpression is thought to play a role in the aberrant proliferation of cancer cells.  The effects of HER2/neu-specific phosphorothioate antisense oligodeoxyribonucleotides on HER2/neu expression, tumor cell proliferation, and activation of apoptotic cell death pathways have been examd.  Antisense treatment down-regulates HER2/neu expression in a dose-dependent and sequence-specific manner.  HER2/neu antisense treatment specifically inhibits the growth of tumor lines that overexpress HER2/neu, but it has little effect on the growth of tumor cells that express low levels of HER2/neu.  Down-regulation of HER2/neu expression is not only cytostatic, but it also results in the activation of apoptotic cell death pathways in cells that overexpress HER2/neu.  These results suggest that, in addn. to stimulating tumor cell proliferation, HER2/neu overexpression in cancer cells acts as an antiapoptotic cell survival factor.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq01tOwwQSL_LVg90H21EOLACvtfcHk0lhOk7fmxaQMlw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXht1Gmt7k%253D&md5=3e3c538fe0df9db4890d93766c728f66</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DRoh%26aufirst%3DH.%26aulast%3DPippin%26aufirst%3DJ.%26aulast%3DDrebin%26aufirst%3DJ.%2BA.%26atitle%3DDown-regulation%2520of%2520HER2%252Fneu%2520expression%2520induces%2520apoptosis%2520in%2520human%2520cancer%2520cells%2520that%2520overexpress%2520HER2%252Fneu%26jtitle%3DCancer%2520Res.%26date%3D2000%26volume%3D60%26spage%3D560%26epage%3D565" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tai, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qin, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, K.</span></span> <span> </span><span class="NLM_article-title">Inhibition of breast cancer cell growth and invasiveness by dual silencing of HER2 and VEGF</span>. <i>Mol. Pharmaceutics</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">543</span>â <span class="NLM_lpage">556</span>, <span class="refDoi">Â DOI: 10.1021/mp9002514</span> </span><div class="citationLinks">[<a href="/doi/10.1021/mp9002514" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01340&amp;key=1%3ACAS%3A528%3ADC%252BC3cXptlGmsg%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2010&pages=543-556&author=W.+Taiauthor=B.+Qinauthor=K.+Cheng&title=Inhibition+of+breast+cancer+cell+growth+and+invasiveness+by+dual+silencing+of+HER2+and+VEGF&doi=10.1021%2Fmp9002514"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of Breast Cancer Cell Growth and Invasiveness by Dual Silencing of HER-2 and VEGF</span></div><div class="casAuthors">Tai, Wanyi; Qin, Bin; Cheng, Kun</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmaceutics</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">543-556</span>CODEN:
                <span class="NLM_cas:coden">MPOHBP</span>;
        ISSN:<span class="NLM_cas:issn">1543-8384</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Overexpression of HER-2 accounts for â¼25% of all breast cancer cases, while 87.7% of HER-2 pos. breast cancers are assocd. with upregulated VEGF.  The objective of this study is to explore the combination therapy of blocking HER-2 and VEGF expressions simultaneously using siRNA.  This is the first report to examine the effect of dual silencing of HER-2 and VEGF genes on tumor growth and invasiveness.  We have designed nine HER-2 siRNAs and ten VEGF siRNAs, and identified potent siRNA which can silence the target gene up to 75-83.5%.  The most potent HER-2 and VEGF siRNAs were used to conduct functional studies in HER-2 pos. breast cancer cells.  Tumor invasiveness properties including cell morphol. change, in vitro migration, cell spreading, and adhesion to ECM were evaluated.  In addn., cell proliferation and apoptosis were examd. after the siRNA treatment.  Our data demonstrated for the first time that HER-2 siRNA could inhibit cell migration and invasion abilities.  Combination of HER-2 and VEGF siRNAs exhibited synergistic silencing effect on VEGF.  Both HER-2 siRNA and VEGF siRNA showed significant inhibition on cell migration and proliferation.  HER-2 siRNA also demonstrated dramatic suppression on cell spreading and adhesion to ECM, as well as induction of apoptosis.  Dual silencing of HER-2 and VEGF exhibited significant cell morphol. change, and substantial suppression on migration, spreading, cell adhesion, and proliferation.  Our observations suggested that HER-2 pos. breast cancer may be more effectively treated by dual inhibition of HER-2 and VEGF gene expressions using siRNA.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr3G3Ku_S6O1rVg90H21EOLACvtfcHk0lgQLTZ8BMJZuA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXptlGmsg%253D%253D&md5=a719436c7474dfd4c60f33092e88698e</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1021%2Fmp9002514&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fmp9002514%26sid%3Dliteratum%253Aachs%26aulast%3DTai%26aufirst%3DW.%26aulast%3DQin%26aufirst%3DB.%26aulast%3DCheng%26aufirst%3DK.%26atitle%3DInhibition%2520of%2520breast%2520cancer%2520cell%2520growth%2520and%2520invasiveness%2520by%2520dual%2520silencing%2520of%2520HER2%2520and%2520VEGF%26jtitle%3DMol.%2520Pharmaceutics%26date%3D2010%26volume%3D7%26spage%3D543%26epage%3D556%26doi%3D10.1021%2Fmp9002514" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bookman, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Darcy, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clarke-Pearson, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boothby, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Horowitz, I. R.</span></span> <span> </span><span class="NLM_article-title">Evaluation of monoclonal humanized anti- HER2 antibody, trastuzumab, in patients with recurrent or refractory ovarian or primary peritoneal carcinoma with overexpression of HER2: a phase II trial of the Gynecologic Oncology Group</span>. <i>J. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">283</span>â <span class="NLM_lpage">290</span>, <span class="refDoi">Â DOI: 10.1200/JCO.2003.10.104</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01340&amp;key=10.1200%2FJCO.2003.10.104" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01340&amp;key=12525520" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01340&amp;key=1%3ACAS%3A528%3ADC%252BD2cXpsVWqs70%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2003&pages=283-290&author=M.+A.+Bookmanauthor=K.+M.+Darcyauthor=D.+Clarke-Pearsonauthor=R.+A.+Boothbyauthor=I.+R.+Horowitz&title=Evaluation+of+monoclonal+humanized+anti-+HER2+antibody%2C+trastuzumab%2C+in+patients+with+recurrent+or+refractory+ovarian+or+primary+peritoneal+carcinoma+with+overexpression+of+HER2%3A+a+phase+II+trial+of+the+Gynecologic+Oncology+Group&doi=10.1200%2FJCO.2003.10.104"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Evaluation of monoclonal humanized anti-HER2 antibody, trastuzumab, in patients with recurrent or refractory ovarian or primary peritoneal carcinoma with overexpression of HER2: a phase II trial of the gynecologic oncology group</span></div><div class="casAuthors">Bookman, Michael A.; Darcy, Kathleen M.; Clarke-Pearson, Daniel; Boothby, Richard A.; Horowitz, Ira R.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">283-290</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">Purpose: To evaluate the feasibility, toxicity, and efficacy of single-agent monoclonal antibody therapy targeting the human epidermal growth factor receptor 2 (HER2)/neu receptor in ovarian and primary peritoneal carcinoma.  Patients and Methods: Eligible patients had measurable persistent or recurrent epithelial ovarian or primary peritoneal carcinoma with 2+ or 3+ HER2 overexpression documented by immunohistochem.  I.v. trastuzumab was administered initially at a dose of 4 mg/kg, then weekly at 2 mg/kg.  Patients without progressive disease or excessive toxicity could continue treatment indefinitely.  Those with stable or responding disease at 8 wk were offered treatment at a higher weekly dose (4 mg/kg) at time of progression.  Patient sera were analyzed for the presence of the sol. extracellular domain of HER2, host antibodies against trastuzumab, and trastuzumab pharmacokinetics.  Results: A total of 837 tumor samples were screened for HER2 expression, and 95 patients (11.4%) exhibited the requisite 2+/3+ expression level.  Forty-five patients, all of whom received prior chemotherapy, were entered, and 41 were deemed eligible and assessable.  There were only mild expected toxicities and no treatment-related deaths.  Although an elevated level of the sol. extracellular domain of HER2 was detected in eight of 24 patients, serum HER2 was not assocd. with clin. outcome.  There was no evidence of host anti-trastuzumab antibody formation.  Serum concns. of trastuzumab gradually increased with continued therapy.  An overall response rate of 7.3% included one complete and two partial responses.  Median treatment duration was 8 wk (range, 2 to 104 wk), and median progression-free interval was 2.0 mo.  Conclusion: The clin. value of single-agent trastuzumab in recurrent ovarian cancer is limited by the low frequency of HER2 overexpression and low rate of objective response among patients with HER2 overexpression.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoBNR7aNbo9JLVg90H21EOLACvtfcHk0lgQLTZ8BMJZuA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXpsVWqs70%253D&md5=e8cb3031f12598014a99a2df6dc9a2cc</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1200%2FJCO.2003.10.104&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2003.10.104%26sid%3Dliteratum%253Aachs%26aulast%3DBookman%26aufirst%3DM.%2BA.%26aulast%3DDarcy%26aufirst%3DK.%2BM.%26aulast%3DClarke-Pearson%26aufirst%3DD.%26aulast%3DBoothby%26aufirst%3DR.%2BA.%26aulast%3DHorowitz%26aufirst%3DI.%2BR.%26atitle%3DEvaluation%2520of%2520monoclonal%2520humanized%2520anti-%2520HER2%2520antibody%252C%2520trastuzumab%252C%2520in%2520patients%2520with%2520recurrent%2520or%2520refractory%2520ovarian%2520or%2520primary%2520peritoneal%2520carcinoma%2520with%2520overexpression%2520of%2520HER2%253A%2520a%2520phase%2520II%2520trial%2520of%2520the%2520Gynecologic%2520Oncology%2520Group%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2003%26volume%3D21%26spage%3D283%26epage%3D290%26doi%3D10.1200%2FJCO.2003.10.104" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Steffensen, K. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">WaldstrÃ¸m, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jeppesen, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jakobsen, E. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brandslund, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jakobsen, A.</span></span> <span> </span><span class="NLM_article-title">The prognostic importance of cyclooxygenase 2 and HER2 expression in epithelial ovarian cancer</span>. <i>Int. J. Gynecol. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">798</span>â <span class="NLM_lpage">807</span>, <span class="refDoi">Â DOI: 10.1111/j.1525-1438.2006.00855.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01340&amp;key=10.1111%2Fj.1525-1438.2006.00855.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01340&amp;key=17309668" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01340&amp;key=1%3ACAS%3A280%3ADC%252BD2svhsFGhsA%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2007&pages=798-807&author=K.+D.+Steffensenauthor=M.+Waldstr%C3%B8mauthor=U.+Jeppesenauthor=E.+H.+Jakobsenauthor=I.+Brandslundauthor=A.+Jakobsen&title=The+prognostic+importance+of+cyclooxygenase+2+and+HER2+expression+in+epithelial+ovarian+cancer&doi=10.1111%2Fj.1525-1438.2006.00855.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">The prognostic importance of cyclooxygenase 2 and HER2 expression in epithelial ovarian cancer</span></div><div class="casAuthors">Steffensen K D; Waldstrom M; Jeppesen U; Jakobsen E; Brandslund I; Jakobsen A</div><div class="citationInfo"><span class="NLM_cas:title">International journal of gynecological cancer : official journal of the International Gynecological Cancer Society</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">798-807</span>
        ISSN:<span class="NLM_cas:issn">1048-891X</span>.
    </div><div class="casAbstract">Both cyclooxygenase 2 (COX2) and human epidermal growth factor receptor 2 (HER2, also called c-erbB-2) overexpression have been related to a worse prognosis in epithelial ovarian cancer (EOC), but the data are conflicting and the percentage of tumors with overexpression varies widely in different studies.  The aim of this study was to investigate the potential prognostic value of COX2 and HER2 expression in EOC.  A further purpose was to investigate a possible coexpression of the two markers, and finally, to elucidate the agreement between fluorescence in situ hybridization (FISH) and immunohistochemistry (IHC) for evaluation of the HER2 status in EOC.  Immunostaining was performed for COX2/HER2 together with FISH analysis for HER2 gene amplification in 160 patients with EOC, FIGO stages IIB-IV.  Follow-up was more than 10 years.  COX2 overexpression was found in 20.0% of the tumors.  With HER2 staining, 64.4% were scored as 0, 24.4% as 1+, 6.9% as 2+, and 4.4% as 3+.  Median survival time for COX2-negative tumors was 21.6 versus 36 months for COX2-positive tumors.  The longer survival for COX2 positive was significant by both univariate analysis (P= 0.015) and multivariate analysis (P= 0.025).  Positive immunostaining for HER2 was associated with poor overall survival (P= 0.03).  Agreement between IHC and FISH was seen in all cases (P < 0.0000001).  With long-term observation, patients with negative COX2 expression had significantly shorter survival compared to patients with COX2-positive tumors.  Positive HER2 expression also notified a grave prognosis, but the low rate of overexpression reduces its potential clinical application.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQjM0_gq9JboCnGiHuhFGv8fW6udTcc2eYFoQ9T4R3x3bntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2svhsFGhsA%253D%253D&md5=db09fd11518533e94fefd035f1a8d8d3</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1111%2Fj.1525-1438.2006.00855.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1525-1438.2006.00855.x%26sid%3Dliteratum%253Aachs%26aulast%3DSteffensen%26aufirst%3DK.%2BD.%26aulast%3DWaldstr%25C3%25B8m%26aufirst%3DM.%26aulast%3DJeppesen%26aufirst%3DU.%26aulast%3DJakobsen%26aufirst%3DE.%2BH.%26aulast%3DBrandslund%26aufirst%3DI.%26aulast%3DJakobsen%26aufirst%3DA.%26atitle%3DThe%2520prognostic%2520importance%2520of%2520cyclooxygenase%25202%2520and%2520HER2%2520expression%2520in%2520epithelial%2520ovarian%2520cancer%26jtitle%3DInt.%2520J.%2520Gynecol.%2520Cancer%26date%3D2007%26volume%3D17%26spage%3D798%26epage%3D807%26doi%3D10.1111%2Fj.1525-1438.2006.00855.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hellstrom, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goodman, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pullman, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">HellstrÃ¶m, K. E.</span></span> <span> </span><span class="NLM_article-title">Overexpression of HER2 in ovarian carcinomas</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">2420</span>â <span class="NLM_lpage">2423</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01340&amp;key=11289108" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01340&amp;key=1%3ACAS%3A528%3ADC%252BD3MXisVSlurk%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2001&pages=2420-2423&author=I.+Hellstromauthor=G.+Goodmanauthor=J.+Pullmanauthor=Y.+Yangauthor=K.+E.+Hellstr%C3%B6m&title=Overexpression+of+HER2+in+ovarian+carcinomas"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Overexpression of HER-2 in ovarian carcinomas</span></div><div class="casAuthors">Hellstrom, Ingegerd; Goodman, Gary; Pullman, Janice; Yang, Yi; Hellstrom, Karl Erik</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2420-2423</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The transmembrane receptor encoded by the HER-2 cellular oncogene is amplified in several types of human carcinomas and provides an attractive therapeutic target.  Shown by immunohistol., <25% of newly diagnosed ovarian carcinomas express the HER-2 protein.  However, now we report that this protein was expressed in all 20 tumor cell lines derived from stage III and IV ovarian cancers as well as in tumor cells harvested from patients with malignant ascites and in tumor samples taken at a second surgery, suggesting that cells with excess expression may have a selective growth advantage.  HER-2-pos. ovarian carcinoma cells were shown to be sensitive to antibody-dependent cellular cytotoxicity, and their in vitro proliferation was inhibited by anti-HER-2 MAb Herceptin.  We postulate, therefore, that therapy which targets HER-2 may be more efficacious in patients with ovarian carcinoma than indicated by the commonly low expression of HER-2 in tumors removed at the time of primary surgery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqxV_HyJmeAg7Vg90H21EOLACvtfcHk0lhS6zBYX-t_6w"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXisVSlurk%253D&md5=1d5ab010ed0cf05f26fecb722ae8fe45</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHellstrom%26aufirst%3DI.%26aulast%3DGoodman%26aufirst%3DG.%26aulast%3DPullman%26aufirst%3DJ.%26aulast%3DYang%26aufirst%3DY.%26aulast%3DHellstr%25C3%25B6m%26aufirst%3DK.%2BE.%26atitle%3DOverexpression%2520of%2520HER2%2520in%2520ovarian%2520carcinomas%26jtitle%3DCancer%2520Res.%26date%3D2001%26volume%3D61%26spage%3D2420%26epage%3D2423" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Calce, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Monfregola, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saviano, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Luca, S.</span></span> <span> </span><span class="NLM_article-title">HER2-mediated anticancer drug delivery: strategies to prepare targeting ligands highly specific for the receptor</span>. <i>Curr. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">2525</span>â <span class="NLM_lpage">2538</span>, <span class="refDoi">Â DOI: 10.2174/0929867322666150521091103</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01340&amp;key=10.2174%2F0929867322666150521091103" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01340&amp;key=25994863" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01340&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhsFWms73I" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2015&pages=2525-2538&author=E.+Calceauthor=L.+Monfregolaauthor=M.+Savianoauthor=S.+De+Luca&title=HER2-mediated+anticancer+drug+delivery%3A+strategies+to+prepare+targeting+ligands+highly+specific+for+the+receptor&doi=10.2174%2F0929867322666150521091103"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">HER2-Mediated Anticancer Drug Delivery: Strategies to Prepare Targeting Ligands Highly Specific for the Receptor</span></div><div class="casAuthors">Calce, Enrica; Monfregola, Luca; Saviano, Michele; De Luca, Stefania</div><div class="citationInfo"><span class="NLM_cas:title">Current Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">2525-2538</span>CODEN:
                <span class="NLM_cas:coden">CMCHE7</span>;
        ISSN:<span class="NLM_cas:issn">0929-8673</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">HER2 receptor, for its involvement in tumorigenesis, has been largely studied as topic in cancer research.  In particular, the employment of trastuzumab (Herceptin), a humanized anti-HER2 antibody, showed several clin. benefits in the therapy against the breast cancer.  Moreover, for its accessible extracellular domain, this receptor is considered an ideal target to deliver anticancer drugs for the receptor-mediated anticancer therapy.  By now, monoclonal antibody and its fragments, affibody, and some peptides have been employed as targeting agents in order to deliver various drugs to HER2 pos. tumor cells.  In particular, the ability to perform a fast and reliable screening of a large no. of peptide mols. would make possible the selection of highly specific compds. to the receptor target.  In this regard, the availability of prepg. a simplified synthetic model which is a good mimetic of the receptor target and can be used in a reliable screening method of ligands would be of a strategic importance for the development of selective HER2-targeting peptide mols.  Herein, we illustrate the importance of HER2-targeted anticancer therapies.  We also report on a synthetic and effective mimetic of the receptor, which revealed to be a useful tool for the selection of specific HER2 ligands.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrKaNiUZMNR8bVg90H21EOLACvtfcHk0lhS6zBYX-t_6w"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhsFWms73I&md5=04161c731108f43a5c6fa4663d8e5f63</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.2174%2F0929867322666150521091103&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F0929867322666150521091103%26sid%3Dliteratum%253Aachs%26aulast%3DCalce%26aufirst%3DE.%26aulast%3DMonfregola%26aufirst%3DL.%26aulast%3DSaviano%26aufirst%3DM.%26aulast%3DDe%2BLuca%26aufirst%3DS.%26atitle%3DHER2-mediated%2520anticancer%2520drug%2520delivery%253A%2520strategies%2520to%2520prepare%2520targeting%2520ligands%2520highly%2520specific%2520for%2520the%2520receptor%26jtitle%3DCurr.%2520Med.%2520Chem.%26date%3D2015%26volume%3D22%26spage%3D2525%26epage%3D2538%26doi%3D10.2174%2F0929867322666150521091103" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Monfregola, L.</span>; <span class="NLM_string-name">De Luca, S.</span></span> <span> </span><span class="NLM_article-title">The Role of HER2 in Targeted Cancer Therapy and Hypothesized Future Perspectives</span>. In  <i>HER2 and Cancer: Mechanism, Testing and Targeted Therapy</i>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, S. I.</span>, <span class="NLM_string-name">Rogers, C. E.</span></span>, Ed.; <span class="NLM_publisher-name">Nova Science Publishers</span> <span class="NLM_year">2011</span>; pp  <span class="NLM_fpage">101</span>â <span class="NLM_lpage">122</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2011&pages=101-122&author=L.+Monfregola&author=S.+De+Lucaauthor=S.+I.+Williams&author=C.+E.+Rogers&title=HER2+and+Cancer%3A+Mechanism%2C+Testing+and+Targeted+Therapy"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DMonfregola%26aufirst%3DL.%26atitle%3DThe%2520Role%2520of%2520HER2%2520in%2520Targeted%2520Cancer%2520Therapy%2520and%2520Hypothesized%2520Future%2520Perspectives%26btitle%3DHER2%2520and%2520Cancer%253A%2520Mechanism%252C%2520Testing%2520and%2520Targeted%2520Therapy%26aulast%3DWilliams%26aufirst%3DS.%2BI.%26pub%3DNova%2520Science%2520Publishers%26date%3D2011%26spage%3D101%26epage%3D122" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tan, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Swain, S. M.</span></span> <span> </span><span class="NLM_article-title">Ongoing adjuvant trials with trastuzumab in breast cancer</span>. <i>Semin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>30</i></span>,  <span class="NLM_fpage">54</span>â <span class="NLM_lpage">64</span>, <span class="refDoi">Â DOI: 10.1053/j.seminoncol.2003.08.008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01340&amp;key=10.1053%2Fj.seminoncol.2003.08.008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01340&amp;key=14613027" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01340&amp;key=1%3ACAS%3A528%3ADC%252BD3sXhtVSjtrrL" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2003&pages=54-64&author=A.+R.+Tanauthor=S.+M.+Swain&title=Ongoing+adjuvant+trials+with+trastuzumab+in+breast+cancer&doi=10.1053%2Fj.seminoncol.2003.08.008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Ongoing adjuvant trials with trastuzumab in breast cancer</span></div><div class="casAuthors">Tan, Antoinette R.; Swain, Sandra M.</div><div class="citationInfo"><span class="NLM_cas:title">Seminars in Oncology</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">5, Suppl. 16</span>),
    <span class="NLM_cas:pages">54-64</span>CODEN:
                <span class="NLM_cas:coden">SOLGAV</span>;
        ISSN:<span class="NLM_cas:issn">0093-7754</span>.
    
            (<span class="NLM_cas:orgname">W. B. Saunders Co.</span>)
        </div><div class="casAbstract">A review.  Trastuzumab has had a major impact in the treatment of HER2-pos. metastatic breast cancer.  In combination with chemotherapy, trastuzumab provides significant clin. benefit in terms of increased response rate and extended survival compared with chemotherapy alone in patients with HER2-pos. advanced breast cancer.  Trastuzumab also has therapeutic activity as monotherapy in the front-line management of HER2-overexpressed or HER2-amplified metastatic breast cancer.  Given its proven efficacy in the metastatic setting, the combination and sequential use of trastuzumab with adjuvant and neoadjuvant chemotherapy are the focus of several ongoing clin. studies.  In this review, the design of the four major phase III multicenter adjuvant trastuzumab trials will be described and their major differences highlighted.  Because therapy with trastuzumab has been assocd. with cardiac toxicity, esp. with prior or concurrent anthracyclines, the evaluation of cardiac dysfunction in the adjuvant trial setting is also a priority.  For now, the use of trastuzumab as adjuvant therapy is still investigational, but its integration has tremendous potential to improve treatment outcomes in patients with primary breast cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrHj06sZbd9HbVg90H21EOLACvtfcHk0lj7fIeztfkSfw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXhtVSjtrrL&md5=7b4c2ef6d0587ce8584ed01cfcfd1659</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1053%2Fj.seminoncol.2003.08.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1053%252Fj.seminoncol.2003.08.008%26sid%3Dliteratum%253Aachs%26aulast%3DTan%26aufirst%3DA.%2BR.%26aulast%3DSwain%26aufirst%3DS.%2BM.%26atitle%3DOngoing%2520adjuvant%2520trials%2520with%2520trastuzumab%2520in%2520breast%2520cancer%26jtitle%3DSemin.%2520Oncol.%26date%3D2003%26volume%3D30%26spage%3D54%26epage%3D64%26doi%3D10.1053%2Fj.seminoncol.2003.08.008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Leonard, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hill, A. D. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kelly, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dijkstra, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McDermott, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">OâHiggins, N. J.</span></span> <span> </span><span class="NLM_article-title">Anti-human epidermal growth factor receptor 2 monoclonal antibody therapy for breast cancer</span>. <i>Br. J. Surg.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>89</i></span>,  <span class="NLM_fpage">262</span>â <span class="NLM_lpage">271</span>, <span class="refDoi">Â DOI: 10.1046/j.0007-1323.2001.02022.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01340&amp;key=10.1046%2Fj.0007-1323.2001.02022.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01340&amp;key=11872048" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01340&amp;key=1%3ACAS%3A280%3ADC%252BD387jsleqsg%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=89&publication_year=2002&pages=262-271&author=D.+S.+Leonardauthor=A.+D.+K.+Hillauthor=L.+Kellyauthor=B.+Dijkstraauthor=E.+McDermottauthor=N.+J.+O%E2%80%99Higgins&title=Anti-human+epidermal+growth+factor+receptor+2+monoclonal+antibody+therapy+for+breast+cancer&doi=10.1046%2Fj.0007-1323.2001.02022.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Anti-human epidermal growth factor receptor 2 monoclonal antibody therapy for breast cancer</span></div><div class="casAuthors">Leonard D S; Hill A D K; Kelly L; Dijkstra B; McDermott E; O'Higgins N J</div><div class="citationInfo"><span class="NLM_cas:title">The British journal of surgery</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">89</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">262-71</span>
        ISSN:<span class="NLM_cas:issn">0007-1323</span>.
    </div><div class="casAbstract">BACKGROUND:  Advances in molecular biology and improved understanding of tumour biology have led to the development of novel treatments for cancer.  Trastuzumab (Herceptin; Genentech, San Francisco, California, USA) is a monoclonal antibody directed against human epidermal growth factor receptor (HER) 2 protein, which is overexpressed in a wide variety of human cancers, including 20-30 per cent of human breast cancers.  HER-2 plays an important role in oncogenic transformation, tumorigenesis and metastatic spread.  Overexpression is associated with a poor prognosis and predicts a poor response to several treatment modalities.  METHOD:  Literature relating to the monoclonal antibody was identified by a Medline literature search and by cross-referencing from the references of seminal articles on the subject.  Four major clinical trials were identified and reviewed.  RESULTS AND CONCLUSION:  In clinical trials approximately 15-20 per cent of patients with HER-2-overexpressing tumours benefited from treatment with trastuzumab.  In sensitive patients the antibody appeared to have intrinsic anticancer activity when given as a single agent.  In combination chemotherapy it appeared to act synergistically with other agents.  Ongoing research is evaluating trastuzumab in combination with numerous standard chemotherapy regimens and with other novel chemotherapeutic agents.  Clinical trials have also revealed several serious side-effects of monoclonal antibody therapy.  Most notable is an unpredictable cardiotoxicity, especially when used in combination with anthracycline-based chemotherapy regimens.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcT9i8Gw8a-zse_Q9URG6Dx8fW6udTcc2ebZXwJLdQrh4Lntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD387jsleqsg%253D%253D&md5=f420c49f4f58285d83c345a663444863</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1046%2Fj.0007-1323.2001.02022.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1046%252Fj.0007-1323.2001.02022.x%26sid%3Dliteratum%253Aachs%26aulast%3DLeonard%26aufirst%3DD.%2BS.%26aulast%3DHill%26aufirst%3DA.%2BD.%2BK.%26aulast%3DKelly%26aufirst%3DL.%26aulast%3DDijkstra%26aufirst%3DB.%26aulast%3DMcDermott%26aufirst%3DE.%26aulast%3DO%25E2%2580%2599Higgins%26aufirst%3DN.%2BJ.%26atitle%3DAnti-human%2520epidermal%2520growth%2520factor%2520receptor%25202%2520monoclonal%2520antibody%2520therapy%2520for%2520breast%2520cancer%26jtitle%3DBr.%2520J.%2520Surg.%26date%3D2002%26volume%3D89%26spage%3D262%26epage%3D271%26doi%3D10.1046%2Fj.0007-1323.2001.02022.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Behr, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">BÃ©hÃ©, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">WÃ¶rmann, B.</span></span> <span> </span><span class="NLM_article-title">Trastuzumab and breast cancer</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>345</i></span>,  <span class="NLM_fpage">995</span>â <span class="NLM_lpage">998</span>, <span class="refDoi">Â DOI: 10.1056/NEJM200109273451312</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01340&amp;key=10.1056%2FNEJM200109273451312" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01340&amp;key=11575295" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01340&amp;key=1%3ACAS%3A528%3ADC%252BD3MXntlehtbk%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=345&publication_year=2001&pages=995-998&author=T.+M.+Behrauthor=M.+B%C3%A9h%C3%A9author=B.+W%C3%B6rmann&title=Trastuzumab+and+breast+cancer&doi=10.1056%2FNEJM200109273451312"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Trastuzumab and breast cancer.Comments</span></div><div class="casAuthors">Behr, Thomas M.; Behe, Martin; Woermann, Bernhard</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">345</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">995-996</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">A polemic in response to Slamon et al. (2001).  In the study by Slamon et al. (2001), better responses and longer survival was attained in the use of trastuzumab in combination with chemotherapy compared with a chemotherapy alone.  However, cardiotoxicity is the most serious complication of the use of trastuzumab, esp. when combined with anthracyclines.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpnsBDMDXJKjrVg90H21EOLACvtfcHk0lj7fIeztfkSfw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXntlehtbk%253D&md5=4c3c59f7a3645def4a2c884e4bf5684f</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1056%2FNEJM200109273451312&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJM200109273451312%26sid%3Dliteratum%253Aachs%26aulast%3DBehr%26aufirst%3DT.%2BM.%26aulast%3DB%25C3%25A9h%25C3%25A9%26aufirst%3DM.%26aulast%3DW%25C3%25B6rmann%26aufirst%3DB.%26atitle%3DTrastuzumab%2520and%2520breast%2520cancer%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2001%26volume%3D345%26spage%3D995%26epage%3D998%26doi%3D10.1056%2FNEJM200109273451312" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cai, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bembas, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drebin, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greene, M. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H.</span></span> <span> </span><span class="NLM_article-title">Differential binding patterns of monoclonal antibody 2C4 to the ErbB3-p185her2/neu and the EGFR-p185her2/neu complexes</span>. <i>Oncogene</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>27</i></span>,  <span class="NLM_fpage">3870</span>â <span class="NLM_lpage">3874</span>, <span class="refDoi">Â DOI: 10.1038/onc.2008.13</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01340&amp;key=10.1038%2Fonc.2008.13" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01340&amp;key=18264138" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01340&amp;key=1%3ACAS%3A528%3ADC%252BD1cXntlCqu74%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2008&pages=3870-3874&author=Z.+Caiauthor=G.+Zhangauthor=Z.+Zhouauthor=K.+Bembasauthor=J.+A.+Drebinauthor=M.+I.+Greeneauthor=H.+Zhang&title=Differential+binding+patterns+of+monoclonal+antibody+2C4+to+the+ErbB3-p185her2%2Fneu+and+the+EGFR-p185her2%2Fneu+complexes&doi=10.1038%2Fonc.2008.13"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Differential binding patterns of monoclonal antibody 2C4 to the ErbB3-p185her2/neu and the EGFR-p185her2/neu complexes</span></div><div class="casAuthors">Cai, Z.; Zhang, G.; Zhou, Z.; Bembas, K.; Drebin, J. A.; Greene, M. I.; Zhang, H.</div><div class="citationInfo"><span class="NLM_cas:title">Oncogene</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">27</span>),
    <span class="NLM_cas:pages">3870-3874</span>CODEN:
                <span class="NLM_cas:coden">ONCNES</span>;
        ISSN:<span class="NLM_cas:issn">0950-9232</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">2C4 (Pertuzumab, Omnitarg) is a monoclonal antibody targeting p185her2/neu, which is overexpressed in 30% of invasive breast cancer.  2C4 is currently in phase II clin. trials for several types of cancers.  This antibody has been reported to disrupt the assocn. between p185her2/neu and ErbB3.  In the authors' studies of epidermal growth factor receptor (EGFR)-p185her2/neu heterodimerization, the authors noted that 2C4 formed assocns. with the EGFR-p185her2/neu receptor complex.  The data argue against 2C4 as a universal heterodimerization blocker for p185her2/neu, but indicate that cocktails of monoclonal antibodies binding distinct interaction surfaces of p185her2/neu will emerge as the most potent targeted therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqclMPFoGCulLVg90H21EOLACvtfcHk0liSw3dxU-PQqw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXntlCqu74%253D&md5=44053ba75986641e5049b10a3af12fc7</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1038%2Fonc.2008.13&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fonc.2008.13%26sid%3Dliteratum%253Aachs%26aulast%3DCai%26aufirst%3DZ.%26aulast%3DZhang%26aufirst%3DG.%26aulast%3DZhou%26aufirst%3DZ.%26aulast%3DBembas%26aufirst%3DK.%26aulast%3DDrebin%26aufirst%3DJ.%2BA.%26aulast%3DGreene%26aufirst%3DM.%2BI.%26aulast%3DZhang%26aufirst%3DH.%26atitle%3DDifferential%2520binding%2520patterns%2520of%2520monoclonal%2520antibody%25202C4%2520to%2520the%2520ErbB3-p185her2%252Fneu%2520and%2520the%2520EGFR-p185her2%252Fneu%2520complexes%26jtitle%3DOncogene%26date%3D2008%26volume%3D27%26spage%3D3870%26epage%3D3874%26doi%3D10.1038%2Fonc.2008.13" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Scheuer, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Friess, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burtscher, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bossenmaier, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Endl, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hasmann, M.</span></span> <span> </span><span class="NLM_article-title">Strongly enhanced antitumor activity of trastuzumab and pertuzumab combination treatment on HER2-positive human xenograft tumor models</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>69</i></span>,  <span class="NLM_fpage">9330</span>â <span class="NLM_lpage">9336</span>, <span class="refDoi">Â DOI: 10.1158/0008-5472.CAN-08-4597</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01340&amp;key=10.1158%2F0008-5472.CAN-08-4597" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01340&amp;key=19934333" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01340&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhsFGrtbnM" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=69&publication_year=2009&pages=9330-9336&author=W.+Scheuerauthor=T.+Friessauthor=H.+Burtscherauthor=B.+Bossenmaierauthor=J.+Endlauthor=M.+Hasmann&title=Strongly+enhanced+antitumor+activity+of+trastuzumab+and+pertuzumab+combination+treatment+on+HER2-positive+human+xenograft+tumor+models&doi=10.1158%2F0008-5472.CAN-08-4597"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Strongly Enhanced Antitumor Activity of Trastuzumab and Pertuzumab Combination Treatment on HER2-Positive Human Xenograft Tumor Models</span></div><div class="casAuthors">Scheuer, Werner; Friess, Thomas; Burtscher, Helmut; Bossenmaier, Birgit; Endl, Josef; Hasmann, Max</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">69</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">9330-9336</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The human epidermal growth factor receptor (HER) family plays an important role in cell survival and proliferation, and is implicated in oncogenesis.  Overexpression of HER2 is assocd. with aggressive disease and poor prognosis.  Trastuzumab is a humanized monoclonal antibody targeting HER2 and has proven survival benefit for women with HER2-pos. early and metastatic breast cancer.  Pertuzumab, another monoclonal antibody, is a HER2 dimerization inhibitor that binds to a different epitope on HER2 than trastuzumab and inhibits HER2 dimer formation with other HER family members such as HER3 and HER1.  We investigated the antitumor activity of these agents alone and in combination in HER2-pos. breast and non-small cell lung cancer xenografts.  Our data show that the combination of trastuzumab and pertuzumab has a strongly enhanced antitumor effect and induces tumor regression in both xenograft models, something that cannot be achieved by either monotherapy.  The enhanced efficacy of the combination was also obsd. after tumor progression during trastuzumab monotherapy.  Near-IR fluorescence imaging expts. confirm that pertuzumab binding to tumors is not impaired by trastuzumab pretreatment.  Furthermore, we show by in vitro assay that both trastuzumab and pertuzumab potently activate antibody-dependent cellular cytotoxicity.  However, our data suggest that the strongly enhanced antitumor activity is mainly due to the differing but complementary mechanisms of action of trastuzumab and pertuzumab, namely inhibition of HER2 dimerization and prevention of p95HER2 formation. [Cancer Res 2009;69(24):9330-6].</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrgmVfUweob2rVg90H21EOLACvtfcHk0liSw3dxU-PQqw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhsFGrtbnM&md5=ff2eb6dcf98d5d8ce7b2978f34113de4</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-08-4597&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-08-4597%26sid%3Dliteratum%253Aachs%26aulast%3DScheuer%26aufirst%3DW.%26aulast%3DFriess%26aufirst%3DT.%26aulast%3DBurtscher%26aufirst%3DH.%26aulast%3DBossenmaier%26aufirst%3DB.%26aulast%3DEndl%26aufirst%3DJ.%26aulast%3DHasmann%26aufirst%3DM.%26atitle%3DStrongly%2520enhanced%2520antitumor%2520activity%2520of%2520trastuzumab%2520and%2520pertuzumab%2520combination%2520treatment%2520on%2520HER2-positive%2520human%2520xenograft%2520tumor%2520models%26jtitle%3DCancer%2520Res.%26date%3D2009%26volume%3D69%26spage%3D9330%26epage%3D9336%26doi%3D10.1158%2F0008-5472.CAN-08-4597" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Brockhoff, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heckel, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmidt-Bruecken, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Plander, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hofstaedter, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vollmann, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diermeier, S.</span></span> <span> </span><span class="NLM_article-title">Differential impact of cetuximab, pertuzumab and trastuzumab on BT474 and SK-BR-3 breast cancer cell proliferation</span>. <i>Cell Proliferation</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>40</i></span>,  <span class="NLM_fpage">488</span>â <span class="NLM_lpage">507</span>, <span class="refDoi">Â DOI: 10.1111/j.1365-2184.2007.00449.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01340&amp;key=10.1111%2Fj.1365-2184.2007.00449.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01340&amp;key=17635517" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01340&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtVSksLnF" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=2007&pages=488-507&author=G.+Brockhoffauthor=B.+Heckelauthor=E.+Schmidt-Brueckenauthor=M.+Planderauthor=F.+Hofstaedterauthor=A.+Vollmannauthor=S.+Diermeier&title=Differential+impact+of+cetuximab%2C+pertuzumab+and+trastuzumab+on+BT474+and+SK-BR-3+breast+cancer+cell+proliferation&doi=10.1111%2Fj.1365-2184.2007.00449.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Differential impact of cetuximab, pertuzumab and trastuzumab on BT474 and SK-BR-3 breast cancer cell proliferation</span></div><div class="casAuthors">Brockhoff, G.; Heckel, B.; Schmidt-Bruecken, E.; Plander, M.; Hofstaedter, F.; Vollmann, A.; Diermeier, S.</div><div class="citationInfo"><span class="NLM_cas:title">Cell Proliferation</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">40</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">488-507</span>CODEN:
                <span class="NLM_cas:coden">CPROEM</span>;
        ISSN:<span class="NLM_cas:issn">0960-7722</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Publishing Ltd.</span>)
        </div><div class="casAbstract">The potential of epidermal growth factor receptor (EGFR)- and Her2-targeted antibodies Cetuximab, Pertuzumab and Trastuzumab, used in combination to inhibit cell proliferation of breast cancer cells in vitro, has not been extensively investigated.  It is anticipated that there would be differences between specific erbB receptor co-expression profiles that would affect tumor cell growth.  We have examd. the effects of Cetuximab, Pertuzumab and Trastuzumab, applied sep. or in combination, on cell proliferation of BT474 and SK-BR-3 breast cancer cell lines.  Cell cycle progression of BT474 and SK-BR-3 cells was statically and dynamically assessed using flow cytometry.  In order to discover a potential influence of differential EGFR co-expression on sensitivity to antibody treatment, EGFR was down-regulated by siRNA in SK-BR-3.  An annexinV/propidium iodide assay was used to identify potential induction of apoptosis.  Treatment with Pertuzumab and Trastuzumab, both targeted to Her2, resulted in a reduced fraction of proliferating cells, prolongation of G1 phase and a great increase in quiescent BT474 cells.  Cetuximab had no addnl. contribution to the effect of either Pertuzumab or Trastuzumab when administered simultaneously.  Treatment with the antibodies did not induce an appreciable amt. of apoptosis in either BT474 or SK-BR-3 cells.  In contrast to SK-BR-3, the BT474 cell line appears to be more sensitive to antibody treatment due to low EGFR content besides Her2 overexpression.  The extent of decelerated or blocked cell proliferation after antibody treatment that is targeted to EGFR and to Her2 depends both on EGFR and Her2 co-expression and on antibody combination used in the treatment setting.  Cetuximab did not enhance any inhibitory effect of Trastuzumab or Pertuzumab, most probably due to the dominant overexpression of Her2.  Cell susceptibility to Trastuzumab/Pertuzumab, both targeted to Her2, was defined by the ratio of EGFR/Her2 co-expression.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGomagxMuC5_U7Vg90H21EOLACvtfcHk0liSw3dxU-PQqw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtVSksLnF&md5=9b32ea25b7228c5c73b69726ed40a59a</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1111%2Fj.1365-2184.2007.00449.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1365-2184.2007.00449.x%26sid%3Dliteratum%253Aachs%26aulast%3DBrockhoff%26aufirst%3DG.%26aulast%3DHeckel%26aufirst%3DB.%26aulast%3DSchmidt-Bruecken%26aufirst%3DE.%26aulast%3DPlander%26aufirst%3DM.%26aulast%3DHofstaedter%26aufirst%3DF.%26aulast%3DVollmann%26aufirst%3DA.%26aulast%3DDiermeier%26aufirst%3DS.%26atitle%3DDifferential%2520impact%2520of%2520cetuximab%252C%2520pertuzumab%2520and%2520trastuzumab%2520on%2520BT474%2520and%2520SK-BR-3%2520breast%2520cancer%2520cell%2520proliferation%26jtitle%3DCell%2520Proliferation%26date%3D2007%26volume%3D40%26spage%3D488%26epage%3D507%26doi%3D10.1111%2Fj.1365-2184.2007.00449.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Franklin, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carey, K. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vajdos, F. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leahy, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Vos, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sliwkowski, M. X.</span></span> <span> </span><span class="NLM_article-title">Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex</span>. <i>Cancer Cell</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>5</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">317</span>â <span class="NLM_lpage">328</span>, <span class="refDoi">Â DOI: 10.1016/S1535-6108(04)00083-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01340&amp;key=10.1016%2FS1535-6108%2804%2900083-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01340&amp;key=15093539" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01340&amp;key=1%3ACAS%3A528%3ADC%252BD2cXjvVaqtLc%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2004&pages=317-328&issue=4&author=M.+C.+Franklinauthor=K.+D.+Careyauthor=F.+F.+Vajdosauthor=D.+J.+Leahyauthor=A.+M.+de+Vosauthor=M.+X.+Sliwkowski&title=Insights+into+ErbB+signaling+from+the+structure+of+the+ErbB2-pertuzumab+complex&doi=10.1016%2FS1535-6108%2804%2900083-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex</span></div><div class="casAuthors">Franklin, Matthew C.; Carey, Kendall D.; Vajdos, Felix F.; Leahy, Daniel J.; De Vos, Abraham M.; Sliwkowski, Mark X.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Cell</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">317-328</span>CODEN:
                <span class="NLM_cas:coden">CCAECI</span>;
        ISSN:<span class="NLM_cas:issn">1535-6108</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">The authors have detd. the 3.2 Ã x-ray crystal structure of the extracellular domain of the human epidermal growth factor receptor 2 (ErbB2 or HER2) in a complex with the antigen binding fragment of pertuzumab, an anti-ErbB2 monoclonal antibody also known as 2C4 or Omnitarg.  Pertuzumab binds to ErbB2 near the center of domain II, sterically blocking a binding pocket necessary for receptor dimerization and signaling.  The ErbB2-pertuzumab structure, combined with earlier mutagenesis data, defines the pertuzumab residues essential for ErbB2 interaction.  To analyze the ErbB2 side of the interface, the authors have mutated a no. of residues contacting pertuzumab and examd. the effects of these mutations on pertuzumab binding and ErbB2-ErbB3 heterodimerization.  The authors have also shown that conserved residues previously shown to be necessary for EGF receptor homodimerization may be dispensable for ErbB2-ErbB3 heterodimerization.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoU3tqrjPCfoLVg90H21EOLACvtfcHk0lhwIaNnpuNWnQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXjvVaqtLc%253D&md5=91f40410383328240e1f2ec67d147e89</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1016%2FS1535-6108%2804%2900083-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1535-6108%252804%252900083-2%26sid%3Dliteratum%253Aachs%26aulast%3DFranklin%26aufirst%3DM.%2BC.%26aulast%3DCarey%26aufirst%3DK.%2BD.%26aulast%3DVajdos%26aufirst%3DF.%2BF.%26aulast%3DLeahy%26aufirst%3DD.%2BJ.%26aulast%3Dde%2BVos%26aufirst%3DA.%2BM.%26aulast%3DSliwkowski%26aufirst%3DM.%2BX.%26atitle%3DInsights%2520into%2520ErbB%2520signaling%2520from%2520the%2520structure%2520of%2520the%2520ErbB2-pertuzumab%2520complex%26jtitle%3DCancer%2520Cell%26date%3D2004%26volume%3D5%26issue%3D4%26spage%3D317%26epage%3D328%26doi%3D10.1016%2FS1535-6108%2804%2900083-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marks, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheung, L. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hittelman, W. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosenblum, M. G.</span></span> <span> </span><span class="NLM_article-title">Design optimization and characterization of HER2/neu-targeted immunotoxins: comparative in vitro and in vivo efficacy studies</span>. <i>Oncogene</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>33</i></span>,  <span class="NLM_fpage">429</span>â <span class="NLM_lpage">439</span>, <span class="refDoi">Â DOI: 10.1038/onc.2012.612</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01340&amp;key=10.1038%2Fonc.2012.612" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01340&amp;key=23376850" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01340&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhvFWkt7s%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2014&pages=429-439&author=Y.+Caoauthor=J.+W.+Marksauthor=Z.+Liuauthor=L.+H.+Cheungauthor=W.+N.+Hittelmanauthor=M.+G.+Rosenblum&title=Design+optimization+and+characterization+of+HER2%2Fneu-targeted+immunotoxins%3A+comparative+in+vitro+and+in+vivo+efficacy+studies&doi=10.1038%2Fonc.2012.612"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Design optimization and characterization of Her2/neu-targeted immunotoxins: comparative in vitro and in vivo efficacy studies</span></div><div class="casAuthors">Cao, Y.; Marks, J. W.; Liu, Z.; Cheung, L. H.; Hittelman, W. N.; Rosenblum, M. G.</div><div class="citationInfo"><span class="NLM_cas:title">Oncogene</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">33</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">429-439</span>CODEN:
                <span class="NLM_cas:coden">ONCNES</span>;
        ISSN:<span class="NLM_cas:issn">0950-9232</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Targeted therapeutics are potential therapeutic agents because of their selectivity and efficacy against tumors resistant to conventional therapy.  The goal of this study was to det. the comparative activity of monovalent, engineered anti-Her2/neu immunotoxins fused to recombinant gelonin (rGel) to the activity of bivalent IgG-contg. immunoconjugates.  Utilizing Herceptin and its derived humanized single-chain antibody (single-chain fragment variable, designated 4D5), we generated bivalent chem. Herceptin/rGel conjugate, and the corresponding monovalent recombinant immunotoxins in two orientations, 4D5/rGel and rGel/4D5.  All the constructs showed similar affinity to Her2/neu-overexpressing cancer cells, but significantly different antitumor activities.  The rGel/4D5 orientation construct and Herceptin/rGel conjugate were superior to 4D5/rGel construct in in vitro and in vivo efficacy.  The enhanced activity was attributed to improved intracellular toxin uptake into target cells and efficient downregulation of Her2/neu-related signaling pathways.  The Her2/neu-targeted immunotoxins effectively targeted cells with Her2/neu expression level >1.5Ã105 sites per cell.  Cells resistant to Herceptin or chemotherapeutic agents were not cross-resistant to rGel-based immunotoxins.  Against SK-OV-3 tumor xenografts, the rGel/4D5 construct with excellent tumor penetration showed impressive tumor inhibition.  Although Herceptin/rGel conjugate demonstrated comparatively longer serum half-life, the in vivo efficacy of the conjugate was similar to the rGel/4D5 fusion.  These comparative studies demonstrate that the monovalent, engineered rGel/4D5 construct displayed comparable in vitro and in vivo antitumor efficacy as bivalent Herceptin/rGel conjugate.  Immunotoxin orientation can significantly impact the overall functionality and performance of these agents.  The recombinant rGel/4D5 construct with excellent tumor penetration and rapid blood clearance may reduce the unwanted toxicity when administering to patients, and warrants consideration for further clin. evaluation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpS045nkCnvu7Vg90H21EOLACvtfcHk0lhwIaNnpuNWnQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhvFWkt7s%253D&md5=4f615c80e0aa130c1ad7f42cd05c6c9e</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1038%2Fonc.2012.612&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fonc.2012.612%26sid%3Dliteratum%253Aachs%26aulast%3DCao%26aufirst%3DY.%26aulast%3DMarks%26aufirst%3DJ.%2BW.%26aulast%3DLiu%26aufirst%3DZ.%26aulast%3DCheung%26aufirst%3DL.%2BH.%26aulast%3DHittelman%26aufirst%3DW.%2BN.%26aulast%3DRosenblum%26aufirst%3DM.%2BG.%26atitle%3DDesign%2520optimization%2520and%2520characterization%2520of%2520HER2%252Fneu-targeted%2520immunotoxins%253A%2520comparative%2520in%2520vitro%2520and%2520in%2520vivo%2520efficacy%2520studies%26jtitle%3DOncogene%26date%3D2014%26volume%3D33%26spage%3D429%26epage%3D439%26doi%3D10.1038%2Fonc.2012.612" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zielinski, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lyakhov, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hassan, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuban, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shafer-Weaver, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gandjbakhche, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Capala, J.</span></span> <span> </span><span class="NLM_article-title">HER2-affitoxin: a potent therapeutic agent for the treatment of HER2-overexpressing tumors</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">5071</span>â <span class="NLM_lpage">5081</span>, <span class="refDoi">Â DOI: 10.1158/1078-0432.CCR-10-2887</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01340&amp;key=10.1158%2F1078-0432.CCR-10-2887" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01340&amp;key=21791637" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01340&amp;key=1%3ACAS%3A528%3ADC%252BC3MXpsFSks7k%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2011&pages=5071-5081&author=R.+Zielinskiauthor=I.+Lyakhovauthor=M.+Hassanauthor=M.+Kubanauthor=K.+Shafer-Weaverauthor=A.+Gandjbakhcheauthor=J.+Capala&title=HER2-affitoxin%3A+a+potent+therapeutic+agent+for+the+treatment+of+HER2-overexpressing+tumors&doi=10.1158%2F1078-0432.CCR-10-2887"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">HER2-Affitoxin: A Potent Therapeutic Agent for the Treatment of HER2-Overexpressing Tumors</span></div><div class="casAuthors">Zielinski, Rafal; Lyakhov, Ilya; Hassan, Moinuddin; Kuban, Monika; Shafer-Weaver, Kimberly; Gandjbakhche, Amir; Capala, Jacek</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">5071-5081</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">PURPOSE: Cancers overexpressing the HER2/neu gene are usually more aggressive and are assocd. with poor prognosis.  Although trastuzumab has significantly improved the outcome, many tumors do not respond or acquire resistance to current therapies.  To provide an alternative HER2-targeted therapy, we have developed and characterized a novel recombinant protein combining an HER2-specific Affibody and modified Pseudomonas aeruginosa exotoxin A (PE 38), which, after binding to HER2, is internalized and delivered to the cytosol of the tumor cell, where it blocks protein synthesis by ADP ribosylation of eEF-2.  Exptl. Design: The effect of the Affitoxin on cell viability was assessed using CellTiter-Glo (Promega).  To assess HER2-specific efficacy, athymic nude mice bearing BT-474 breast cancer, SK-OV-3 ovarian cancer, and NCI-N87 gastric carcinoma xenografts were treated with the Affitoxin (HER2- or Tag-specific), which was injected every third day.  Affitoxin immunogenicity in female BALB/c mice was investigated using std. antibody prodn. and splenocyte proliferation assays.  RESULTS:In vitro expts. proved that HER2-Affitoxin is a potent agent that eliminates HER2-overexpressing cells at low picomolar concns.  Therapeutic efficacy studies showed complete eradication of relatively large BT-474 tumors and significant effects on SK-OV-3 and NCI-N87 tumors.  HER2-Affitoxin cleared quickly from circulation (T1/2 < 10 min) and was well tolerated by mice at doses of 0.5 mg/kg and below.  Immunogenicity studies indicated that HER2-Affitoxin induced antibody development after the third injected dose.  CONCLUSIONS: Our findings showed that HER2-Affitoxin is an effective anticancer agent and a potential candidate for clin. studies.  Clin Cancer Res; 17(15); 5071-81.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqBgt3YcIcDPLVg90H21EOLACvtfcHk0lhwIaNnpuNWnQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXpsFSks7k%253D&md5=2ab40e5fa2a4a33b519667ef974a4f11</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-10-2887&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-10-2887%26sid%3Dliteratum%253Aachs%26aulast%3DZielinski%26aufirst%3DR.%26aulast%3DLyakhov%26aufirst%3DI.%26aulast%3DHassan%26aufirst%3DM.%26aulast%3DKuban%26aufirst%3DM.%26aulast%3DShafer-Weaver%26aufirst%3DK.%26aulast%3DGandjbakhche%26aufirst%3DA.%26aulast%3DCapala%26aufirst%3DJ.%26atitle%3DHER2-affitoxin%253A%2520a%2520potent%2520therapeutic%2520agent%2520for%2520the%2520treatment%2520of%2520HER2-overexpressing%2520tumors%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2011%26volume%3D17%26spage%3D5071%26epage%3D5081%26doi%3D10.1158%2F1078-0432.CCR-10-2887" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Altai, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Orlova, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tolmachev, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">GrÃ¤slund, T.</span></span> <span> </span><span class="NLM_article-title">Influence of molecular design on biodistribution and targeting properties of an Affibody-fused HER2-recognising anticancer toxin</span>. <i>Int. J. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>49</i></span>,  <span class="NLM_fpage">1185</span>â <span class="NLM_lpage">1194</span>, <span class="refDoi">Â DOI: 10.3892/ijo.2016.3614</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01340&amp;key=10.3892%2Fijo.2016.3614" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01340&amp;key=27573289" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01340&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsFOqu7nK" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2016&pages=1185-1194&author=M.+Altaiauthor=H.+Liuauthor=A.+Orlovaauthor=V.+Tolmachevauthor=T.+Gr%C3%A4slund&title=Influence+of+molecular+design+on+biodistribution+and+targeting+properties+of+an+Affibody-fused+HER2-recognising+anticancer+toxin&doi=10.3892%2Fijo.2016.3614"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Influence of molecular design on biodistribution and targeting properties of an Affibody-fused HER2-recognising anticancer toxin</span></div><div class="casAuthors">Altai, Mohamed; Liu, Hao; Orlova, Anna; Tolmachev, Vladimir; Graeslund, Torbjoern</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Oncology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1185-1194</span>CODEN:
                <span class="NLM_cas:coden">IJONES</span>;
        ISSN:<span class="NLM_cas:issn">1791-2423</span>.
    
            (<span class="NLM_cas:orgname">Spandidos Publications Ltd.</span>)
        </div><div class="casAbstract">Targeted delivery of toxins is a promising way to treat disseminated cancer.  The use of monoclonal antibodies as targeting moiety has provided proof-of-principle for this approach.  However, extravasation and tissue penetration rates of antibody-based immunotoxins are limited due to antibody bulkiness.  The use of a novel class of targeting probes, Affibody mols., provides smaller toxin-conjugated constructs, which may improve targeting.  Earlier, we have demonstrated that affitoxins contg. a HER2-targeting Affibody moiety and a deimmunized and truncated exotoxin A from Pseudomonas aeruginosa, PE38X8, provide highly selective toxicity to HER2-expressing cancer cells.  To evaluate the influence of mol. design on targeting and biodistribution properties, a series of novel affitoxins were labeled with the residualizing radionuclide 111In.  In this study, we have shown that the novel conjugates are more rapidly internalized compared with the parental affitoxin.  The use of a (HE)3 purifn. tag instead of a hexahistidine tag enabled significant (p<0.05) redn. of the hepatic uptake of the affitoxin in a murine model.  Fusion of the affitoxin with an albumin-binding domain (ABD) caused appreciable extension of the residence time in circulation and several-fold redn. of the renal uptake.  The best variant, 111In-(HE)3-ZHER2-ABD-PE38X8, demonstrated receptor-specific accumulation in HER2-expressing SKOV-3 xenografts.  In conclusion, a careful mol. design of scaffold protein based anticancer targeted toxins can appreciably improve their biodistribution and targeting properties.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpfPlbKZ7YJJLVg90H21EOLACvtfcHk0ljHjzXF7whKJA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsFOqu7nK&md5=0f9b572e3d9d7351f71ce97bddc374e4</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.3892%2Fijo.2016.3614&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3892%252Fijo.2016.3614%26sid%3Dliteratum%253Aachs%26aulast%3DAltai%26aufirst%3DM.%26aulast%3DLiu%26aufirst%3DH.%26aulast%3DOrlova%26aufirst%3DA.%26aulast%3DTolmachev%26aufirst%3DV.%26aulast%3DGr%25C3%25A4slund%26aufirst%3DT.%26atitle%3DInfluence%2520of%2520molecular%2520design%2520on%2520biodistribution%2520and%2520targeting%2520properties%2520of%2520an%2520Affibody-fused%2520HER2-recognising%2520anticancer%2520toxin%26jtitle%3DInt.%2520J.%2520Oncol.%26date%3D2016%26volume%3D49%26spage%3D1185%26epage%3D1194%26doi%3D10.3892%2Fijo.2016.3614" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Burris, H. A.,  3rd</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tibbitts, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holden, S. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sliwkowski, M. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lewis Phillips, G. D.</span></span> <span> </span><span class="NLM_article-title">Trastuzumab emtansine (T-DM1): a novel agent for targeting HER2+ breast cancer</span>. <i>Clin. Breast Cancer</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">275</span>â <span class="NLM_lpage">282</span>, <span class="refDoi">Â DOI: 10.1016/j.clbc.2011.03.018</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01340&amp;key=10.1016%2Fj.clbc.2011.03.018" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01340&amp;key=21729661" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01340&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhsVOhtL%252FF" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2011&pages=275-282&author=H.+A.+Burrisauthor=J.+Tibbittsauthor=S.+N.+Holdenauthor=M.+X.+Sliwkowskiauthor=G.+D.+Lewis+Phillips&title=Trastuzumab+emtansine+%28T-DM1%29%3A+a+novel+agent+for+targeting+HER2%2B+breast+cancer&doi=10.1016%2Fj.clbc.2011.03.018"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Trastuzumab emtansine (T-DM1): a novel agent for targeting HER2+ breast cancer</span></div><div class="casAuthors">Burris, Howard A.; Tibbitts, Jay; Holden, Scott N.; Sliwkowski, Mark X.; Phillips, Gail D. Lewis</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Breast Cancer</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">275-282</span>CODEN:
                <span class="NLM_cas:coden">CBCLB7</span>;
        ISSN:<span class="NLM_cas:issn">1526-8209</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A review.  Increased understanding of the mol. mechanisms of tumorigenesis has led to the development of novel agents that target tumor cells with minimal effects on normal cells.  The success of this approach is exemplified by the development of monoclonal antibodies directed toward antigens expressed selectively by tumor cells.  The conjugation of these monoclonal antibodies with potent cytotoxic drugs has the potential to further improve efficacy while retaining a favorable safety profile.  Trastuzumab emtansine (T-DM1) is an antibody-drug conjugate (ADC) currently in clin. development.  It combines the humanized antibody trastuzumab, which targets the human epidermal growth factor receptor 2 (HER2) receptor on cancer cells, and the potent antimicrotubule agent DM1 using a unique highly stable linker.  When T-DM1 binds to HER2, a proportion of the receptors are thought to be internalized by the process of receptor endocytosis, followed by the intracellular release of an active form of DM1, which in turn kills the tumor cell.  This review presents the rationale for the development of T-DM1 and summarizes the preclin. and clin. data for this novel agent for the treatment of breast cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo7ZQT0-dTJK7Vg90H21EOLACvtfcHk0ljHjzXF7whKJA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhsVOhtL%252FF&md5=797b6cc51cf2cd37e70fcf8aba68d0be</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1016%2Fj.clbc.2011.03.018&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.clbc.2011.03.018%26sid%3Dliteratum%253Aachs%26aulast%3DBurris%26aufirst%3DH.%2BA.%26aulast%3DTibbitts%26aufirst%3DJ.%26aulast%3DHolden%26aufirst%3DS.%2BN.%26aulast%3DSliwkowski%26aufirst%3DM.%2BX.%26aulast%3DLewis%2BPhillips%26aufirst%3DG.%2BD.%26atitle%3DTrastuzumab%2520emtansine%2520%2528T-DM1%2529%253A%2520a%2520novel%2520agent%2520for%2520targeting%2520HER2%252B%2520breast%2520cancer%26jtitle%3DClin.%2520Breast%2520Cancer%26date%3D2011%26volume%3D11%26spage%3D275%26epage%3D282%26doi%3D10.1016%2Fj.clbc.2011.03.018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Spector, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xia, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">El-Hariry, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yarden, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bacus, S.</span></span> <span> </span><span class="NLM_article-title">HER2 therapy. Small molecule HER-2 tyrosine kinase inhibitors</span>. <i>Breast Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">205</span>, <span class="refDoi">Â DOI: 10.1186/bcr1652</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01340&amp;key=10.1186%2Fbcr1652" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01340&amp;key=17338834" title="">PubMed</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2007&pages=205&author=N.+Spectorauthor=W.+Xiaauthor=I.+El-Hariryauthor=Y.+Yardenauthor=S.+Bacus&title=HER2+therapy.+Small+molecule+HER-2+tyrosine+kinase+inhibitors&doi=10.1186%2Fbcr1652"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1186%2Fbcr1652&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fbcr1652%26sid%3Dliteratum%253Aachs%26aulast%3DSpector%26aufirst%3DN.%26aulast%3DXia%26aufirst%3DW.%26aulast%3DEl-Hariry%26aufirst%3DI.%26aulast%3DYarden%26aufirst%3DY.%26aulast%3DBacus%26aufirst%3DS.%26atitle%3DHER2%2520therapy.%2520Small%2520molecule%2520HER-2%2520tyrosine%2520kinase%2520inhibitors%26jtitle%3DBreast%2520Cancer%2520Res.%26date%3D2007%26volume%3D9%26spage%3D205%26doi%3D10.1186%2Fbcr1652" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Eberle, A. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mild, G.</span></span> <span> </span><span class="NLM_article-title">Receptor-mediated tumor targeting with radiopeptides. Part 1. General principles and methods</span>. <i>J. Recept. Signal Transduction Res.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>29</i></span>,  <span class="NLM_fpage">1</span>â <span class="NLM_lpage">37</span>, <span class="refDoi">Â DOI: 10.1080/10799890902732823</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01340&amp;key=10.1080%2F10799890902732823" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01340&amp;key=19519167" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01340&amp;key=1%3ACAS%3A280%3ADC%252BD1MvhtlGmsw%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2009&pages=1-37&author=A.+N.+Eberleauthor=G.+Mild&title=Receptor-mediated+tumor+targeting+with+radiopeptides.+Part+1.+General+principles+and+methods&doi=10.1080%2F10799890902732823"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Receptor-mediated tumor targeting with radiopeptides. Part 1. General principles and methods</span></div><div class="casAuthors">Eberle Alex N; Mild Gabriele</div><div class="citationInfo"><span class="NLM_cas:title">Journal of receptor and signal transduction research</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">1-37</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Radiolabeled peptides have become important tools for preclinical cancer research, and in nuclear oncology they serve as diagnostic and more recently also as therapeutic agents.  In the latter application, radiolabeled peptides represent a distinct sector of the molecular targeting approach, which in many areas of therapy implements the old "magic bullet" concept by specifically directing the therapeutic agent to the site of action.  Although in the past few years the development of receptor-mediated targeting for therapy has been confined to some radiolabeled antibodies and to somatostatin/SRIF, research into an increasing number of radiolabeled peptides and their receptors expressed by different tumors will soon lead to a wider use of peptide radiopharmaceuticals.  In a consecutive series of six reviews we present a comprehensive overview of the literature on receptor-mediated tumor targeting with the different radiopeptides currently studied.  Part 1 summarizes the concepts and methods of radiopeptide targeting, the selection of radioisotopes, chelators, the criteria of peptide ligand development and some general aspects of diagnostic and therapeutic application of peptide radiopharmaceuticals.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTFA4lUC0UN4kPI-fCgwosgfW6udTcc2eY00BJ_vGfdIrntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1MvhtlGmsw%253D%253D&md5=411e64994bece3cca7f24363531f7c7a</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1080%2F10799890902732823&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F10799890902732823%26sid%3Dliteratum%253Aachs%26aulast%3DEberle%26aufirst%3DA.%2BN.%26aulast%3DMild%26aufirst%3DG.%26atitle%3DReceptor-mediated%2520tumor%2520targeting%2520with%2520radiopeptides.%2520Part%25201.%2520General%2520principles%2520and%2520methods%26jtitle%3DJ.%2520Recept.%2520Signal%2520Transduction%2520Res.%26date%3D2009%26volume%3D29%26spage%3D1%26epage%3D37%26doi%3D10.1080%2F10799890902732823" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Reilly, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kiarash, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sandhu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, Y. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cameron, R. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hendler, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vallis, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">GariÃ¨py, J.</span></span> <span> </span><span class="NLM_article-title">A comparison of EGF and MAb 528 labeled with 111In for imaging human breast cancer</span>. <i>J. Nucl. Med.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>41</i></span>,  <span class="NLM_fpage">903</span>â <span class="NLM_lpage">911</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01340&amp;key=10809207" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01340&amp;key=1%3ACAS%3A528%3ADC%252BD3cXjslSlsr8%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=41&publication_year=2000&pages=903-911&author=R.+M.+Reillyauthor=R.+Kiarashauthor=J.+Sandhuauthor=Y.+W.+Leeauthor=R.+G.+Cameronauthor=A.+Hendlerauthor=K.+Vallisauthor=J.+Gari%C3%A8py&title=A+comparison+of+EGF+and+MAb+528+labeled+with+111In+for+imaging+human+breast+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">A comparison of EGF and MAb 528 labeled with 111In for imaging human breast cancer</span></div><div class="casAuthors">Reilly, Raymond M.; Kiarash, Reza; Sandhu, Jasbir; Lee, Ying Wai; Cameron, Ross G.; Hendler, Aaron; Vallis, Katherine; Gariepy, Jean</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Nuclear Medicine</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">41</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">903-911</span>CODEN:
                <span class="NLM_cas:coden">JNMEAQ</span>;
        ISSN:<span class="NLM_cas:issn">0161-5505</span>.
    
            (<span class="NLM_cas:orgname">Society of Nuclear Medicine, Inc.</span>)
        </div><div class="casAbstract">Our objective was to compare 111In-labeled human epidermal growth factor (hEGF), a 53-amino acid peptide with anti-epidermal growth factor receptor (EGFR) monoclonal antibody (MAb) 528 (IgG2a) for imaging EGFR-pos. breast cancer.  Methods: hEGF and MAb 528 were derivatized with diethylenetriamine pentaacetic acid (DTPA) and labeled with 111In acetate.  Receptor binding assays were conducted in vitro against MDA-MB-468 human breast cancer cells.  Biodistribution and tumor imaging studies were conducted after i.v. injection of the radiopharmaceuticals in athymic mice bearing s.c. MCF-7, MDA-MB-231, or MDA-MB-468 human breast cancer xenografts or in severe combined immunodeficiency mice implanted with a breast cancer metastasis (JW-97 cells).  MCF-7, MDA-MB-231, JW-97, and MDA-MB-468 cells expressed 1.5 Ã 104, 1.3 Ã 105, 2.7 Ã 105, and 1.3 Ã 106 EGFR/cell, resp. in vitro.  Results: 111In-DTPA-hEGF and 111In-DTPA-MAb 528 bound with high affinity to MDA-MB-468 cells (Ka of 7.5 Ã 108 and 1.2 Ã 108 L/mol, resp.).  111In-DTPA-hEGF was eliminated rapidly from the blood with < 0.2% injected dose/g (%ID/g) circulating at 72 h after injection, whereas 111In-DTPA-MAb 528 was cleared more slowly (3%ID/g in the blood at 72 h).  Maximum localization of 111In-DTPA-hEGF in MDA-MB-468 tumors (2.2 %ID/g) was 10-fold lower than with 111In-DTPA-MAb 528 (21.6 %ID/g).  There was high uptake in the liver and kidneys for both radiopharmaceuticals.  Tumor-to-blood ratios were greater for 111In-labeled hEGF than for MAb 528 (12:1 vs. 6:1), but all other tumor-to-normal tissue ratios were higher for MAb 528.  MDA-MB-468 and JW-97 tumors were imaged successfully with both radiopharmaceuticals, but tumors were more easily visualized using 111In-labeled MAb 528.  There was no direct quant. relationship between EGFR expression on breast cancer cell lines in vitro, and tumor uptake of the radiopharmaceuticals in vivo, but control studies showed that tumor uptake was receptor mediated.  Conclusion: Our results suggest that the tumor uptake in vivo of receptor-binding radiopharmaceuticals is controlled to a greater extent by their elimination rate from the blood than by the level of receptor expression on the cancer cells.  Radiolabeled anti-EGFRMAbs would be more effective for tumor imaging in cancer patients than peptide-based radiopharmaceuticals such as hEGF, because they exhibit higher tumor uptake at only moderately lower tumor-to-blood ratios.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqSri3SUsFXPLVg90H21EOLACvtfcHk0lieLmx02x86ig"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXjslSlsr8%253D&md5=8d4ce22249ecd06e65dcdf411bc670ab</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DReilly%26aufirst%3DR.%2BM.%26aulast%3DKiarash%26aufirst%3DR.%26aulast%3DSandhu%26aufirst%3DJ.%26aulast%3DLee%26aufirst%3DY.%2BW.%26aulast%3DCameron%26aufirst%3DR.%2BG.%26aulast%3DHendler%26aufirst%3DA.%26aulast%3DVallis%26aufirst%3DK.%26aulast%3DGari%25C3%25A8py%26aufirst%3DJ.%26atitle%3DA%2520comparison%2520of%2520EGF%2520and%2520MAb%2520528%2520labeled%2520with%2520111In%2520for%2520imaging%2520human%2520breast%2520cancer%26jtitle%3DJ.%2520Nucl.%2520Med.%26date%3D2000%26volume%3D41%26spage%3D903%26epage%3D911" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Orlova, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">WÃ¥llberg, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stone-Elander, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tolmachev, V.</span></span> <span> </span><span class="NLM_article-title">On the selection of a tracer for PET imaging of HER2-expressing tumors: direct comparison of a 124I-labeled affibody molecule and trastuzumab in a murine xenograft model</span>. <i>J. Nucl. Med.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>50</i></span>,  <span class="NLM_fpage">417</span>â <span class="NLM_lpage">425</span>, <span class="refDoi">Â DOI: 10.2967/jnumed.108.057919</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01340&amp;key=10.2967%2Fjnumed.108.057919" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01340&amp;key=19223403" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01340&amp;key=1%3ACAS%3A528%3ADC%252BD1MXktVynsro%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2009&pages=417-425&author=A.+Orlovaauthor=H.+W%C3%A5llbergauthor=S.+Stone-Elanderauthor=V.+Tolmachev&title=On+the+selection+of+a+tracer+for+PET+imaging+of+HER2-expressing+tumors%3A+direct+comparison+of+a+124I-labeled+affibody+molecule+and+trastuzumab+in+a+murine+xenograft+model&doi=10.2967%2Fjnumed.108.057919"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">On the selection of a tracer for PET imaging of HER2-expressing tumours: direct comparison of a 124I-labeled affibody molecule and trastuzumab in a murine xenograft model</span></div><div class="casAuthors">Orlova, Anna; Waallberg, Helena; Stone-Elander, Sharon; Tolmachev, Vladimir</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Nuclear Medicine</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">50</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">417-425</span>CODEN:
                <span class="NLM_cas:coden">JNMEAQ</span>;
        ISSN:<span class="NLM_cas:issn">0161-5505</span>.
    
            (<span class="NLM_cas:orgname">Society of Nuclear Medicine</span>)
        </div><div class="casAbstract">Human epidermal growth factor receptor type 2 (HER2) is a tyrosine kinase, which is often overexpressed in many carcinomas.  Imaging HER2 expression in malignant tumors can provide important prognostic and predictive diagnostic information.  The use of anti-HER2 tracers labeled with positron-emitting radionuclides may increase the sensitivity of HER2 imaging.  The goal of this study was to compare directly 2 approaches for developing anti-HER2 PET tracers: a 124I-labeled monoclonal antibody and a small (7-kDa) scaffold protein, the Affibody mol.  The anti-HER2 Affibody ZHER2:342 and humanized monoclonal antibody trastuzumab were labeled with 124/125I using p-iodo-benzoate (PIB) as a linker.  Cellular processing of both tracers by HER2-expressing cells was investigated.  The biodistributions of 124I-PIB-ZHER2:342 and 125I-PIB-trastuzumab were compared in BALB/C nu/nu mice bearing HER2-expressing NCI-N87 xenografts using paired labels.  Small-animal PET of 124I-PIB-ZHER2:342 and 124I-PIB-trastuzumab in tumor-bearing mice was performed at 6, 24, and 72 h after injection.  Both radioiodinated ZHER2:342 and trastuzumab bound specifically to HER2-expressing cells in vitro and specifically targeted HER2-expressing xenografts in vivo.  Radioiodinated trastuzumab was more rapidly internalized and degraded, which resulted in better retention of radioactivity delivered by ZHER2:342.  Total uptake of trastuzumab in tumors was higher than that of 124I-PIB-ZHER2:342.  However, tumor-to-organ ratios were appreciably higher for 124I-PIB-ZHER2:342 due to the more rapid clearance of radioactivity from blood and normal organs.  The ex vivo results were confirmed by small-animal PET.  The use of the small scaffold targeting Affibody provides better contrast in HER2 imaging than does the monoclonal antibody.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpAfr9P8kFP6bVg90H21EOLACvtfcHk0lieLmx02x86ig"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXktVynsro%253D&md5=028d50e7db64a308728979b3e1c1c7a3</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.2967%2Fjnumed.108.057919&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2967%252Fjnumed.108.057919%26sid%3Dliteratum%253Aachs%26aulast%3DOrlova%26aufirst%3DA.%26aulast%3DW%25C3%25A5llberg%26aufirst%3DH.%26aulast%3DStone-Elander%26aufirst%3DS.%26aulast%3DTolmachev%26aufirst%3DV.%26atitle%3DOn%2520the%2520selection%2520of%2520a%2520tracer%2520for%2520PET%2520imaging%2520of%2520HER2-expressing%2520tumors%253A%2520direct%2520comparison%2520of%2520a%2520124I-labeled%2520affibody%2520molecule%2520and%2520trastuzumab%2520in%2520a%2520murine%2520xenograft%2520model%26jtitle%3DJ.%2520Nucl.%2520Med.%26date%3D2009%26volume%3D50%26spage%3D417%26epage%3D425%26doi%3D10.2967%2Fjnumed.108.057919" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Calce, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Monfregola, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sandomenico, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saviano, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Luca, S.</span></span> <span> </span><span class="NLM_article-title">Fluorescence study for selecting specific ligands toward HER2 receptor: an example of receptor fragment approach</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">116</span>â <span class="NLM_lpage">121</span>, <span class="refDoi">Â DOI: 10.1016/j.ejmech.2012.09.024</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01340&amp;key=10.1016%2Fj.ejmech.2012.09.024" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01340&amp;key=23107515" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01340&amp;key=1%3ACAS%3A528%3ADC%252BC38XhsFynur7F" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2013&pages=116-121&author=E.+Calceauthor=L.+Monfregolaauthor=A.+Sandomenicoauthor=M.+Savianoauthor=S.+De+Luca&title=Fluorescence+study+for+selecting+specific+ligands+toward+HER2+receptor%3A+an+example+of+receptor+fragment+approach&doi=10.1016%2Fj.ejmech.2012.09.024"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Fluorescence study for selecting specific ligands toward HER2 receptor: An example of receptor fragment approach</span></div><div class="casAuthors">Calce, Enrica; Monfregola, Luca; Sandomenico, Annamaria; Saviano, Michele; De Luca, Stefania</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">116-121</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Fluorescence titrns. allowed the authors to study the interaction process between Herceptin (Fab)-derived peptides and a synthetic peptide mimicking a subdomain IV of the receptor HER2 (HER2-DIVMP).  For some of the investigated peptide/HER2-DIVMP complexes a nanomolar dissocn. const. was found.  The performed interaction studies were completely immune from interferences of other receptor domains not covered by the design, thus decreasing the possibilities of selecting potential ligands able to bind other subtypes of HER2 receptor family.  The authors' results demonstrate that the adopted receptor fragment approach represents an efficient methodol. for selecting new mols. as lead structures specific for the receptor target.  For these reasons the optimized compds. could be employed as delivery agents for the receptor-mediated anticancer therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqvvVP961zzwrVg90H21EOLACvtfcHk0li_jFmsdwZsVA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhsFynur7F&md5=4e80f6f4f156905c00a785bb2415d572</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2012.09.024&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2012.09.024%26sid%3Dliteratum%253Aachs%26aulast%3DCalce%26aufirst%3DE.%26aulast%3DMonfregola%26aufirst%3DL.%26aulast%3DSandomenico%26aufirst%3DA.%26aulast%3DSaviano%26aufirst%3DM.%26aulast%3DDe%2BLuca%26aufirst%3DS.%26atitle%3DFluorescence%2520study%2520for%2520selecting%2520specific%2520ligands%2520toward%2520HER2%2520receptor%253A%2520an%2520example%2520of%2520receptor%2520fragment%2520approach%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2013%26volume%3D61%26spage%3D116%26epage%3D121%26doi%3D10.1016%2Fj.ejmech.2012.09.024" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Monfregola, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vitale, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amodeo, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Luca, S.</span></span> <span> </span><span class="NLM_article-title">A SPR strategy for high-throughput ligand screenings based on synthetic peptides mimicking a selected subdomain of the target protein: a proof of concept on HER2 receptor</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">7015</span>â <span class="NLM_lpage">7020</span>, <span class="refDoi">Â DOI: 10.1016/j.bmc.2009.08.004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01340&amp;key=10.1016%2Fj.bmc.2009.08.004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01340&amp;key=19733086" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01340&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtFamsbnM" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2009&pages=7015-7020&author=L.+Monfregolaauthor=R.+M.+Vitaleauthor=P.+Amodeoauthor=S.+De+Luca&title=A+SPR+strategy+for+high-throughput+ligand+screenings+based+on+synthetic+peptides+mimicking+a+selected+subdomain+of+the+target+protein%3A+a+proof+of+concept+on+HER2+receptor&doi=10.1016%2Fj.bmc.2009.08.004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">A SPR strategy for high-throughput ligand screenings based on synthetic peptides mimicking a selected subdomain of the target protein: A proof of concept on HER2 receptor</span></div><div class="casAuthors">Monfregola, Luca; Vitale, Rosa Maria; Amodeo, Pietro; De Luca, Stefania</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">7015-7020</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The discovery of pharmaceutical agents is a complex, lengthy and costly process, critically depending on the availability of rapid and efficient screening methods.  In particular, when targets are large, multidomain proteins, their complexity may affect unfavorably tech. feasibility, costs and unambiguity of binding test interpretation.  A possible strategy to overcome these problems relies on mol. design of receptor fragments that are: sensible targets for ligand screenings, conformationally stable also as standalone domains, easily synthesized and immobilized on chip for Biacore expts.  An addnl. desirable feature for new ligands is the ability of selectively targeting alternative conformational states typical of many proteins.  To test the feasibility of such approach on a case with potential applicative interest, we developed a surface plasmon resonance (SPR)-based screening method for drug candidates toward HER2, a Tyr-kinase receptor targeted in anticancer therapies.  HER2 was mimicked by HER2-DIVMP, a modified fragment of it immobilized onto the sensor surface specifically modeling HER2 domain IV in its bounded form, designed by structural comparison of HER2 alone and in complex with Herceptin, a monoclonal therapeutic anti-HER2 antibody.  This design and its implementation in SPR devices was validated by investigating Herceptin- HER2-DIVMP affinity, measuring its dissocn. const. (K D = 19.2 nM).  An efficient synthetic procedure to prep. the HER2-DIVMP peptide was also developed.  The HER2-DIVMP conformational stability suggested by exptl. and computational results, makes it also a valuable candidate as a mold to design new mols. selectively targeting domain IV of HER2.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGopaFRdelSg8rVg90H21EOLACvtfcHk0li_jFmsdwZsVA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtFamsbnM&md5=f1d4612facfaff1b8e21ea51a3defb46</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2009.08.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2009.08.004%26sid%3Dliteratum%253Aachs%26aulast%3DMonfregola%26aufirst%3DL.%26aulast%3DVitale%26aufirst%3DR.%2BM.%26aulast%3DAmodeo%26aufirst%3DP.%26aulast%3DDe%2BLuca%26aufirst%3DS.%26atitle%3DA%2520SPR%2520strategy%2520for%2520high-throughput%2520ligand%2520screenings%2520based%2520on%2520synthetic%2520peptides%2520mimicking%2520a%2520selected%2520subdomain%2520of%2520the%2520target%2520protein%253A%2520a%2520proof%2520of%2520concept%2520on%2520HER2%2520receptor%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2009%26volume%3D17%26spage%3D7015%26epage%3D7020%26doi%3D10.1016%2Fj.bmc.2009.08.004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Calce, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leone, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Monfregola, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Luca, S.</span></span> <span> </span><span class="NLM_article-title">Lipidated peptides via post-synthetic thioalkylation promoted by molecular sieves</span>. <i>Amino Acids</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>46</i></span>,  <span class="NLM_fpage">1899</span>â <span class="NLM_lpage">1905</span>, <span class="refDoi">Â DOI: 10.1007/s00726-014-1742-y</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01340&amp;key=10.1007%2Fs00726-014-1742-y" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01340&amp;key=24748120" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01340&amp;key=1%3ACAS%3A528%3ADC%252BC2cXmsVKnt74%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2014&pages=1899-1905&author=E.+Calceauthor=M.+Leoneauthor=L.+Monfregolaauthor=S.+De+Luca&title=Lipidated+peptides+via+post-synthetic+thioalkylation+promoted+by+molecular+sieves&doi=10.1007%2Fs00726-014-1742-y"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Lipidated peptides via post-synthetic thioalkylation promoted by molecular sieves</span></div><div class="casAuthors">Calce, Enrica; Leone, Marilisa; Monfregola, Luca; De Luca, Stefania</div><div class="citationInfo"><span class="NLM_cas:title">Amino Acids</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">46</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1899-1905</span>CODEN:
                <span class="NLM_cas:coden">AACIE6</span>;
        ISSN:<span class="NLM_cas:issn">0939-4451</span>.
    
            (<span class="NLM_cas:orgname">Springer-Verlag GmbH</span>)
        </div><div class="casAbstract">A thioalkylation procedure, which uses mol. sieves to promote the reaction, was exploited to provide peptides with useful functional groups (lipidic moieties), naturally occurring on proteins as post-translational modifications.  The procedure was further implemented to synthesize tailor-made lipidated peptides, interesting tools to investigate biol. processes involving their Ras parent proteins.  Moreover, the one-pot prepn. of multi-alkylated peptides confirms the versatility and flexibility of the employed methodol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp-Px105u1SCbVg90H21EOLACvtfcHk0lgHzClXrhglHw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXmsVKnt74%253D&md5=3a887e98bd0f0358fb279e8f6536c073</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1007%2Fs00726-014-1742-y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00726-014-1742-y%26sid%3Dliteratum%253Aachs%26aulast%3DCalce%26aufirst%3DE.%26aulast%3DLeone%26aufirst%3DM.%26aulast%3DMonfregola%26aufirst%3DL.%26aulast%3DDe%2BLuca%26aufirst%3DS.%26atitle%3DLipidated%2520peptides%2520via%2520post-synthetic%2520thioalkylation%2520promoted%2520by%2520molecular%2520sieves%26jtitle%3DAmino%2520Acids%26date%3D2014%26volume%3D46%26spage%3D1899%26epage%3D1905%26doi%3D10.1007%2Fs00726-014-1742-y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Langella, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Calce, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saviano, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Luca, S.</span></span> <span> </span><span class="NLM_article-title">Structural identification of HER2 receptor model binding pocket to optimize lead compounds: a combined experimental and computational approach</span>. <i>Mol. BioSyst.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">2159</span>â <span class="NLM_lpage">2167</span>, <span class="refDoi">Â DOI: 10.1039/C6MB00158K</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01340&amp;key=10.1039%2FC6MB00158K" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01340&amp;key=27113673" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01340&amp;key=1%3ACAS%3A528%3ADC%252BC28XmsF2ksr8%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2016&pages=2159-2167&author=E.+Langellaauthor=E.+Calceauthor=M.+Savianoauthor=S.+De+Luca&title=Structural+identification+of+HER2+receptor+model+binding+pocket+to+optimize+lead+compounds%3A+a+combined+experimental+and+computational+approach&doi=10.1039%2FC6MB00158K"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Structural identification of an HER2 receptor model binding pocket to optimize lead compounds: a combined experimental and computational approach</span></div><div class="casAuthors">Langella, Emma; Calce, Enrica; Saviano, Michele; De Luca, Stefania</div><div class="citationInfo"><span class="NLM_cas:title">Molecular BioSystems</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2159-2167</span>CODEN:
                <span class="NLM_cas:coden">MBOIBW</span>;
        ISSN:<span class="NLM_cas:issn">1742-2051</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">The structural investigation of the ligand/target interactions represents a challenging task in the field of drug discovery or lead compd. optimization.  In the present study, a computational approach allowed the identification of the binding site of A9 peptide, within a synthetic model of HER2 receptor (HER2-DIVMP).  To this aim, mol. docking calcns. and mol. dynamics simulations were employed, taking into account exptl. data obtained by fluorescence studies.  The computational model was further validated by performing fluorescence binding studies between the ligand A9 and HER2-DIVMP mutants, prepd. by replacing key amino acid residues.  A new binding pocket of HER2-DIVMP was identified, which could be fruitfully exploited for future lead-optimization studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrPRXJyoMKRM7Vg90H21EOLACvtfcHk0lgHzClXrhglHw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XmsF2ksr8%253D&md5=4bac610eb075316e37378f00848ca132</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1039%2FC6MB00158K&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC6MB00158K%26sid%3Dliteratum%253Aachs%26aulast%3DLangella%26aufirst%3DE.%26aulast%3DCalce%26aufirst%3DE.%26aulast%3DSaviano%26aufirst%3DM.%26aulast%3DDe%2BLuca%26aufirst%3DS.%26atitle%3DStructural%2520identification%2520of%2520HER2%2520receptor%2520model%2520binding%2520pocket%2520to%2520optimize%2520lead%2520compounds%253A%2520a%2520combined%2520experimental%2520and%2520computational%2520approach%26jtitle%3DMol.%2520BioSyst.%26date%3D2016%26volume%3D12%26spage%3D2159%26epage%3D2167%26doi%3D10.1039%2FC6MB00158K" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Honarvar, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Calce, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doti, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Langella, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Orlova, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buijs, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DâAmato, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bianco, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saviano, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tolmachev, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Luca, S.</span></span> <span> </span><span class="NLM_article-title">Evaluation of HER2-specific peptide ligand for its employment as radiolabeled imaging probe</span>. <i>Sci. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">2998</span>, <span class="refDoi">Â DOI: 10.1038/s41598-018-21283-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01340&amp;key=10.1038%2Fs41598-018-21283-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01340&amp;key=29445216" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01340&amp;key=1%3ACAS%3A280%3ADC%252BC1Mrhsl2muw%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2018&pages=2998&author=H.+Honarvarauthor=E.+Calceauthor=N.+Dotiauthor=E.+Langellaauthor=A.+Orlovaauthor=J.+Buijsauthor=V.+D%E2%80%99Amatoauthor=R.+Biancoauthor=M.+Savianoauthor=V.+Tolmachevauthor=S.+De+Luca&title=Evaluation+of+HER2-specific+peptide+ligand+for+its+employment+as+radiolabeled+imaging+probe&doi=10.1038%2Fs41598-018-21283-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Evaluation of HER2-specific peptide ligand for its employment as radiolabeled imaging probe</span></div><div class="casAuthors">Honarvar Hadis; Calce Enrica; Doti Nunzianna; Langella Emma; De Luca Stefania; Orlova Anna; Buijs Jos; D'Amato Valentina; Bianco Roberto; Saviano Michele; Tolmachev Vladimir</div><div class="citationInfo"><span class="NLM_cas:title">Scientific reports</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">2998</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">HER2 transmembrane receptor is an important target in immunotherapy treatment of breast and gastroesophageal cancer.  Molecular imaging of HER2 expression may provide essential prognostic and predictive information concerning disseminated cancer and aid in selection of an optimal therapy.  Radiolabeled low molecular weight peptide ligands are particularly attractive as probes for molecular imaging, since they reach and bind to the target and clear from non-target organs and blood stream faster than bulky antibodies.  In this study, we evaluated a potential HER2-imaging probe, an A9 nonapeptide, derived from the trastuzumab-Fab portion.  Its cellular uptake was investigated by mass spectrometry analysis of the cytoplasmic cellular extracts.  Moreover, based on in-silico modeling, DTPA chelator was conjugated to N-terminus of A9. (111)In-labeled A9 demonstrated nanomolar affinity to HER2-expressing BT474 cells and favorable biodistribution profile in NMRI mice.  This study suggests that the peptide A9 represents a good lead candidate for development of molecular probe, to be used for imaging purposes and for the delivery of cytotoxic agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcT4X4RisZQBEPIW7hznt0zpfW6udTcc2eYJ0huL0rJKe7ntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1Mrhsl2muw%253D%253D&md5=a9b49d6cec0048c5e63468be3fe800cd</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1038%2Fs41598-018-21283-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41598-018-21283-3%26sid%3Dliteratum%253Aachs%26aulast%3DHonarvar%26aufirst%3DH.%26aulast%3DCalce%26aufirst%3DE.%26aulast%3DDoti%26aufirst%3DN.%26aulast%3DLangella%26aufirst%3DE.%26aulast%3DOrlova%26aufirst%3DA.%26aulast%3DBuijs%26aufirst%3DJ.%26aulast%3DD%25E2%2580%2599Amato%26aufirst%3DV.%26aulast%3DBianco%26aufirst%3DR.%26aulast%3DSaviano%26aufirst%3DM.%26aulast%3DTolmachev%26aufirst%3DV.%26aulast%3DDe%2BLuca%26aufirst%3DS.%26atitle%3DEvaluation%2520of%2520HER2-specific%2520peptide%2520ligand%2520for%2520its%2520employment%2520as%2520radiolabeled%2520imaging%2520probe%26jtitle%3DSci.%2520Rep.%26date%3D2018%26volume%3D8%26spage%3D2998%26doi%3D10.1038%2Fs41598-018-21283-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cho, H. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mason, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramyar, K. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stanley, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gabelli, S. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Denney, D. W.,  Jr.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leahy, D. J.</span></span> <span> </span><span class="NLM_article-title">Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>421</i></span>,  <span class="NLM_fpage">756</span>â <span class="NLM_lpage">760</span>, <span class="refDoi">Â DOI: 10.1038/nature01392</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01340&amp;key=10.1038%2Fnature01392" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01340&amp;key=12610629" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01340&amp;key=1%3ACAS%3A528%3ADC%252BD3sXhsV2rtrw%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=421&publication_year=2003&pages=756-760&author=H.+S.+Choauthor=K.+Masonauthor=K.+X.+Ramyarauthor=A.+M.+Stanleyauthor=S.+B.+Gabelliauthor=D.+W.+Denneyauthor=D.+J.+Leahy&title=Structure+of+the+extracellular+region+of+HER2+alone+and+in+complex+with+the+Herceptin+Fab&doi=10.1038%2Fnature01392"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab</span></div><div class="casAuthors">Cho, Hyun-Soo; Mason, Karen; Ramyar, Kasra X.; Stanley, Ann Marie; Gabelli, Sandra B.; Denney, Dan W.; Leahy, Daniel J.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">421</span>
        (<span class="NLM_cas:issue">6924</span>),
    <span class="NLM_cas:pages">756-760</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">HER2 (also known as Neu, ErbB2) is a member of the epidermal growth factor receptor (EGFR; also known as ErbB) family of receptor tyrosine kinases, which in humans includes HER1 (EGFR, ERBB1), HER2, HER3 (ERBB3) and HER4 (ERBB4).  ErbB receptors are essential mediators of cell proliferation and differentiation in the developing embryo and in adult tissues, and their inappropriate activation is assocd. with the development and severity of many cancers.  Overexpression of HER2 is found in 20-30% of human breast cancers, and correlates with more aggressive tumors and a poorer prognosis.  Anticancer therapies targeting ErbB receptors have shown promise, and a monoclonal antibody against HER2, Herceptin (also known as trastuzumab), is currently in use as a treatment for breast cancer.  Here we report crystal structures of the entire extracellular regions of rat HER2 at 2.4 Ã and human HER2 complexed with the Herceptin antigen-binding fragment (Fab) at 2.5 Ã.  These structures reveal a fixed conformation for HER2 that resembles a ligand-activated state, and show HER2 poised to interact with other ErbB receptors in the absence of direct ligand binding.  Herceptin binds to the juxtamembrane region of HER2, identifying this site as a target for anticancer therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrE9_6F4odgzLVg90H21EOLACvtfcHk0lhA34vZgf6YIw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXhsV2rtrw%253D&md5=cfbf5e782ca461ce28c60ad688afe682</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1038%2Fnature01392&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature01392%26sid%3Dliteratum%253Aachs%26aulast%3DCho%26aufirst%3DH.%2BS.%26aulast%3DMason%26aufirst%3DK.%26aulast%3DRamyar%26aufirst%3DK.%2BX.%26aulast%3DStanley%26aufirst%3DA.%2BM.%26aulast%3DGabelli%26aufirst%3DS.%2BB.%26aulast%3DDenney%26aufirst%3DD.%2BW.%26aulast%3DLeahy%26aufirst%3DD.%2BJ.%26atitle%3DStructure%2520of%2520the%2520extracellular%2520region%2520of%2520HER2%2520alone%2520and%2520in%2520complex%2520with%2520the%2520Herceptin%2520Fab%26jtitle%3DNature%26date%3D2003%26volume%3D421%26spage%3D756%26epage%3D760%26doi%3D10.1038%2Fnature01392" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref39"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref39'); return false;" data-citation="" class="refNumLink">39</a></strong><div class="NLM_citation" id="cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Calce, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sandomenico, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saviano, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruvo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Luca, S.</span></span> <span> </span><span class="NLM_article-title">Cysteine co-oxidation process driven by native peptide folding: on example of HER2 receptor model system</span>. <i>Amino Acids</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>46</i></span>,  <span class="NLM_fpage">1197</span>â <span class="NLM_lpage">1206</span>, <span class="refDoi">Â DOI: 10.1007/s00726-014-1681-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01340&amp;key=10.1007%2Fs00726-014-1681-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01340&amp;key=24493095" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01340&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhs1Kjsrg%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2014&pages=1197-1206&author=E.+Calceauthor=A.+Sandomenicoauthor=M.+Savianoauthor=M.+Ruvoauthor=S.+De+Luca&title=Cysteine+co-oxidation+process+driven+by+native+peptide+folding%3A+on+example+of+HER2+receptor+model+system&doi=10.1007%2Fs00726-014-1681-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Cysteine co-oxidation process driven by native peptide folding: an example on HER2 receptor model system</span></div><div class="casAuthors">Calce, Enrica; Sandomenico, Annamaria; Saviano, Michele; Ruvo, Menotti; De Luca, Stefania</div><div class="citationInfo"><span class="NLM_cas:title">Amino Acids</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">46</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1197-1206</span>CODEN:
                <span class="NLM_cas:coden">AACIE6</span>;
        ISSN:<span class="NLM_cas:issn">0939-4451</span>.
    
            (<span class="NLM_cas:orgname">Springer-Verlag GmbH</span>)
        </div><div class="casAbstract">Synthetic models of receptors that have relevant biol. roles are valuable tools for studying receptors itself and the corresponding ligands.  Their properties can be validated at first by their capacity to fold in soln. under native-like conditions and to assume conformations structurally and functionally equiv. to those in the native receptor.  In this context, a new strategy to prep. the two-fragments synthetic receptor model HER2-DIVMP, an independent structural and functional motif of HER2, has been developed and the folding properties have been investigated.  The strategy is based on a one-step cysteine co-oxidn. procedure in slightly alk. aq. buffers, whereby the two sep. peptide chains are allowed to self-assemble in soln.  Under these conditions, the two chains spontaneously form the expected heterodimer with the correct pattern of disulfide bridges.  To gain insights on the folding mechanism, we investigated the folding of two scrambled variants of the constituent peptide chains.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqEIpYhqc_Tj7Vg90H21EOLACvtfcHk0lhA34vZgf6YIw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhs1Kjsrg%253D&md5=81c9ec130e4b3c413f7413f000a2440c</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1007%2Fs00726-014-1681-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00726-014-1681-7%26sid%3Dliteratum%253Aachs%26aulast%3DCalce%26aufirst%3DE.%26aulast%3DSandomenico%26aufirst%3DA.%26aulast%3DSaviano%26aufirst%3DM.%26aulast%3DRuvo%26aufirst%3DM.%26aulast%3DDe%2BLuca%26aufirst%3DS.%26atitle%3DCysteine%2520co-oxidation%2520process%2520driven%2520by%2520native%2520peptide%2520folding%253A%2520on%2520example%2520of%2520HER2%2520receptor%2520model%2520system%26jtitle%3DAmino%2520Acids%26date%3D2014%26volume%3D46%26spage%3D1197%26epage%3D1206%26doi%3D10.1007%2Fs00726-014-1681-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref40"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref40'); return false;" data-citation="" class="refNumLink">40</a></strong><div class="NLM_citation" id="cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">De
Luca, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verdoliva, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saviano, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fattorusso, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diana, D.</span></span> <span> </span><span class="NLM_article-title">SPR and NMR characterization of the molecular interaction between A9 peptide and a model system of HER2 receptor: A fragment approach for selecting peptide structures specific for their target</span>. <i>J. Pept. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>26</i></span>, <span class="NLM_elocation-id">e3231</span> <span class="refDoi">Â DOI: 10.1002/psc.3231</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01340&amp;key=10.1002%2Fpsc.3231" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01340&amp;key=31749266" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01340&amp;key=1%3ACAS%3A528%3ADC%252BC1MXitFyqsLnF" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2020&author=S.+De%0ALucaauthor=V.+Verdolivaauthor=M.+Savianoauthor=R.+Fattorussoauthor=D.+Diana&title=SPR+and+NMR+characterization+of+the+molecular+interaction+between+A9+peptide+and+a+model+system+of+HER2+receptor%3A+A+fragment+approach+for+selecting+peptide+structures+specific+for+their+target&doi=10.1002%2Fpsc.3231"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">SPR and NMR characterization of the molecular interaction between A9 peptide and a model system of HER2 receptor: A fragment approach for selecting peptide structures specific for their target</span></div><div class="casAuthors">De Luca, Stefania; Verdoliva, Valentina; Saviano, Michele; Fattorusso, Roberto; Diana, Donatella</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Peptide Science</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">e3231</span>CODEN:
                <span class="NLM_cas:coden">JPSIEI</span>;
        ISSN:<span class="NLM_cas:issn">1075-2617</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons Ltd.</span>)
        </div><div class="casAbstract">The binding process of A9 peptide toward HER2-DIVMP, a synthetic model of the receptor domain IV, was studied by using the surface plasmon resonance (SPR) technique, with the aim of validating it as a fast and reliable screening method for selecting peptide ligands specifically targeting a domain of their target.  To investigate the structural basis of A9 binding to the model of HER2-DIVMP, multiple ligand-based NMR (NMR) methods were applied.  The use of satn. transfer difference (STD) and WaterLOGSY NMR expts. identified key residues in the peptide for the receptor binding.  Moreover, the bound conformation of the A9 peptide was obtained using transferred nuclear Overhauser effect spectroscopy (trNOESY) expts.  The NMR data revealed an extended binding surface that confirms an in silico model previously reported.  These structural findings could provide good starting points for future lead structures optimization specific for the receptor target.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo08rwjOqzqqrVg90H21EOLACvtfcHk0lhA34vZgf6YIw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXitFyqsLnF&md5=ba53040e1c423f07696ba5277212ca4a</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1002%2Fpsc.3231&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fpsc.3231%26sid%3Dliteratum%253Aachs%26aulast%3DDe%2BLuca%26aufirst%3DS.%26aulast%3DVerdoliva%26aufirst%3DV.%26aulast%3DSaviano%26aufirst%3DM.%26aulast%3DFattorusso%26aufirst%3DR.%26aulast%3DDiana%26aufirst%3DD.%26atitle%3DSPR%2520and%2520NMR%2520characterization%2520of%2520the%2520molecular%2520interaction%2520between%2520A9%2520peptide%2520and%2520a%2520model%2520system%2520of%2520HER2%2520receptor%253A%2520A%2520fragment%2520approach%2520for%2520selecting%2520peptide%2520structures%2520specific%2520for%2520their%2520target%26jtitle%3DJ.%2520Pept.%2520Sci.%26date%3D2020%26volume%3D26%26doi%3D10.1002%2Fpsc.3231" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref41"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref41'); return false;" data-citation="" class="refNumLink">41</a></strong><div class="NLM_citation" id="cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span><span class="NLM_etal"></span> <span> </span><span class="NLM_article-title">Synthesis and structure determination of seven coordinate KInIII(Hdtpa)Â·3.5H<sub>2</sub>O</span>. <i>Chem. J. Chin. Univ. Chinese Ed.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">1468</span>â <span class="NLM_lpage">1470</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2000&pages=1468-1470&author=J.+Wang&title=Synthesis+and+structure+determination+of+seven+coordinate+KInIII%28Hdtpa%29%C2%B73.5H2O"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DJ.%26atitle%3DSynthesis%2520and%2520structure%2520determination%2520of%2520seven%2520coordinate%2520KInIII%2528Hdtpa%2529%25C2%25B73.5H2O%26jtitle%3DChem.%2520J.%2520Chin.%2520Univ.%2520Chinese%2520Ed.%26date%3D2000%26volume%3D21%26spage%3D1468%26epage%3D1470" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref42"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref42'); return false;" data-citation="" class="refNumLink">42</a></strong><div class="NLM_citation" id="cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hnatowich, D. J.</span></span> <span> </span><span class="NLM_article-title">Label stability in serum of four radionuclides on DTPA-coupled antibodies-an evaluation</span>. <i>Int. J. Rad. Appl. Instrum. B</i> <span class="NLM_year" style="font-weight: bold;">1986</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">353</span>â <span class="NLM_lpage">358</span>, <span class="refDoi">Â DOI: 10.1016/0883-2897(86)90009-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01340&amp;key=10.1016%2F0883-2897%2886%2990009-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01340&amp;key=3793489" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01340&amp;key=1%3ACAS%3A280%3ADyaL2s%252Fot1ynuw%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=1986&pages=353-358&author=D.+J.+Hnatowich&title=Label+stability+in+serum+of+four+radionuclides+on+DTPA-coupled+antibodies-an+evaluation&doi=10.1016%2F0883-2897%2886%2990009-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Label stability in serum of four radionuclides on DTPA-coupled antibodies--an evaluation</span></div><div class="casAuthors">Hnatowich D J</div><div class="citationInfo"><span class="NLM_cas:title">International journal of radiation applications and instrumentation. Part B, Nuclear medicine and biology</span>
        (<span class="NLM_cas:date">1986</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">353-8</span>
        ISSN:<span class="NLM_cas:issn">0883-2897</span>.
    </div><div class="casAbstract">Although DTPA forms strong chelates with many metals, the harsh chemical environment of the serum may nevertheless dissociate metallic radionuclides from DTPA attached to proteins.  We have investigated the stability in 37 degrees C serum of 111In, 99mTc, 90Y and 153Gd chelated to DTPA-coupled antibodies.  Stability was evaluated primarily by affinity chromatography and HPLC analysis of serum incubates; however, the stability of 111In was determined in vivo in patient studies.  Analysis of patient urine showed no evidence for dissociation of DTPA from antibody whereas analysis of serum demonstrated exchange rates of 111In to transferrin of about 9%/day.  When labeled by the described method, 99mTc on DTPA coupled antibodies shows instability in serum but superior stability than 99mTc on antibodies without the attached DTPA.  Both 90Y and 153Gd dissociate in serum at rates which are comparable to that of 111In.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQezmyNaFLJ86cY7HFp97qMfW6udTcc2eb9u2kjHASZiLntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaL2s%252Fot1ynuw%253D%253D&md5=2a42d54626143bba9a685ad75f53814b</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1016%2F0883-2897%2886%2990009-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0883-2897%252886%252990009-7%26sid%3Dliteratum%253Aachs%26aulast%3DHnatowich%26aufirst%3DD.%2BJ.%26atitle%3DLabel%2520stability%2520in%2520serum%2520of%2520four%2520radionuclides%2520on%2520DTPA-coupled%2520antibodies-an%2520evaluation%26jtitle%3DInt.%2520J.%2520Rad.%2520Appl.%2520Instrum.%2520B%26date%3D1986%26volume%3D13%26spage%3D353%26epage%3D358%26doi%3D10.1016%2F0883-2897%2886%2990009-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref43"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref43'); return false;" data-citation="" class="refNumLink">43</a></strong><div class="NLM_citation" id="cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Groom, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bruno, I. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lightfoot, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ward, S. C.</span></span> <span> </span><span class="NLM_article-title">The cambridge structural database</span>. <i>Acta Crystallogr., Sect. B: Struct. Sci., Cryst. Eng. Mater.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>B72</i></span>,  <span class="NLM_fpage">171</span>â <span class="NLM_lpage">179</span>, <span class="refDoi">Â DOI: 10.1107/S2052520616003954</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01340&amp;key=10.1107%2FS2052520616003954" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=B72&publication_year=2016&pages=171-179&author=C.+R.+Groomauthor=I.+J.+Brunoauthor=M.+P.+Lightfootauthor=S.+C.+Ward&title=The+cambridge+structural+database&doi=10.1107%2FS2052520616003954"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1107%2FS2052520616003954&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1107%252FS2052520616003954%26sid%3Dliteratum%253Aachs%26aulast%3DGroom%26aufirst%3DC.%2BR.%26aulast%3DBruno%26aufirst%3DI.%2BJ.%26aulast%3DLightfoot%26aufirst%3DM.%2BP.%26aulast%3DWard%26aufirst%3DS.%2BC.%26atitle%3DThe%2520cambridge%2520structural%2520database%26jtitle%3DActa%2520Crystallogr.%252C%2520Sect.%2520B%253A%2520Struct.%2520Sci.%252C%2520Cryst.%2520Eng.%2520Mater.%26date%3D2016%26volume%3DB72%26spage%3D171%26epage%3D179%26doi%3D10.1107%2FS2052520616003954" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref44"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref44'); return false;" data-citation="" class="refNumLink">44</a></strong><div class="NLM_citation" id="cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Barta, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Malmberg, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Melicharova, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">StrandgÃ¥rd, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Orlova, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tolmachev, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laznicek, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andersson, K.</span></span> <span> </span><span class="NLM_article-title">Protein interactions with HER-family receptors can have different characteristics depending on the hosting cell line</span>. <i>Int. J. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>40</i></span>,  <span class="NLM_fpage">1677</span>â <span class="NLM_lpage">1682</span>, <span class="refDoi">Â DOI: 10.3892/ijo.2011.1307</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01340&amp;key=10.3892%2Fijo.2011.1307" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01340&amp;key=22200885" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01340&amp;key=1%3ACAS%3A528%3ADC%252BC38XmtlGlurk%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=2012&pages=1677-1682&author=P.+Bartaauthor=J.+Malmbergauthor=L.+Melicharovaauthor=J.+Strandg%C3%A5rdauthor=A.+Orlovaauthor=V.+Tolmachevauthor=M.+Laznicekauthor=K.+Andersson&title=Protein+interactions+with+HER-family+receptors+can+have+different+characteristics+depending+on+the+hosting+cell+line&doi=10.3892%2Fijo.2011.1307"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">Protein interactions with HER-family receptors can have different characteristics depending on the hosting cell line</span></div><div class="casAuthors">Barta, Pavel; Malmberg, Jennie; Melicharova, Ludmila; Strandgard, John; Orlova, Anna; Tolmachev, Vladimir; Laznicek, Milan; Andersson, Karl</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Oncology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">40</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1677-1682</span>CODEN:
                <span class="NLM_cas:coden">IJONES</span>;
        ISSN:<span class="NLM_cas:issn">1019-6439</span>.
    
            (<span class="NLM_cas:orgname">International Journal of Oncology</span>)
        </div><div class="casAbstract">Cell lines are common model systems in the development of therapeutic proteins and in the research on cellular functions and dysfunctions.  In this field, the protein interaction assay is a frequently used tool for assessing the adequacy of a protein for diagnostic and therapeutic purposes.  In this study, we investigated the extent to which the interaction characteristics depend on the choice of cell line for HER-family receptors.  The interaction characteristics of two therapeutic antibodies (trastuzumab and cetuximab) and one Affibody mol. (ZHER2:342), interacting with the intended receptor were characterized with high precision using an automated real-time interaction method, in different cell lines (HaCaT, A431, HEP-G2, SKOV3, PC3, DU-145).  Clear differences in binding affinity and kinetics, up to one order of magnitude, were found for the interaction of the same protein binding to the same receptor on different cells for all three proteins.  For HER-family receptors, it is therefore important to refer to the measured affinity for a protein-receptor interaction together with the hosting cell line.  The ability to accurately measure affinity and kinetics of a protein-receptor interaction on cell lines of different origins may increase the understanding of underlying receptor biol., and impact the selection of candidates in the development of therapeutic or diagnostic agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpYbr3x9EoXh7Vg90H21EOLACvtfcHk0lgPzKWDOaNtFA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XmtlGlurk%253D&md5=9099fa83ce7504c323df188e7df470cf</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.3892%2Fijo.2011.1307&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3892%252Fijo.2011.1307%26sid%3Dliteratum%253Aachs%26aulast%3DBarta%26aufirst%3DP.%26aulast%3DMalmberg%26aufirst%3DJ.%26aulast%3DMelicharova%26aufirst%3DL.%26aulast%3DStrandg%25C3%25A5rd%26aufirst%3DJ.%26aulast%3DOrlova%26aufirst%3DA.%26aulast%3DTolmachev%26aufirst%3DV.%26aulast%3DLaznicek%26aufirst%3DM.%26aulast%3DAndersson%26aufirst%3DK.%26atitle%3DProtein%2520interactions%2520with%2520HER-family%2520receptors%2520can%2520have%2520different%2520characteristics%2520depending%2520on%2520the%2520hosting%2520cell%2520line%26jtitle%3DInt.%2520J.%2520Oncol.%26date%3D2012%26volume%3D40%26spage%3D1677%26epage%3D1682%26doi%3D10.3892%2Fijo.2011.1307" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref45"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref45'); return false;" data-citation="" class="refNumLink">45</a></strong><div class="NLM_citation" id="cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">BjÃ¶rkelund, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gedda, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barta, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Malmqvist, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andersson, K.</span></span> <span> </span><span class="NLM_article-title">Gefitinib induces epidermal growth factor receptor dimers which alters the interaction characteristics with 125I-EGF</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>6</i></span>, <span class="NLM_elocation-id">e24739</span> <span class="refDoi">Â DOI: 10.1371/journal.pone.0024739</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01340&amp;key=10.1371%2Fjournal.pone.0024739" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01340&amp;key=21931838" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01340&amp;key=1%3ACAS%3A280%3ADC%252BC3MfkvFajsQ%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2011&author=H.+Bj%C3%B6rkelundauthor=L.+Geddaauthor=P.+Bartaauthor=M.+Malmqvistauthor=K.+Andersson&title=Gefitinib+induces+epidermal+growth+factor+receptor+dimers+which+alters+the+interaction+characteristics+with+125I-EGF&doi=10.1371%2Fjournal.pone.0024739"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">Gefitinib induces epidermal growth factor receptor dimers which alters the interaction characteristics with 125I-EGF</span></div><div class="casAuthors">Bjorkelund Hanna; Gedda Lars; Barta Pavel; Malmqvist Magnus; Andersson Karl</div><div class="citationInfo"><span class="NLM_cas:title">PloS one</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">e24739</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The tyrosine kinase inhibitor gefitinib inhibits growth in some tumor types by targeting the epidermal growth factor receptor (EGFR).  Previous studies show that the affinity of the EGF-EGFR interaction varies between hosting cell line, and that gefitinib increases the affinity for some cell lines.  In this paper, we investigate possible mechanisms behind these observations.  Real-time interaction analysis in LigandTracerÂ® Grey revealed that the HER2 dimerization preventing antibody pertuzumab clearly modified the binding of 125I-EGF to EGFR on HER2 overexpressing SKOV3 cells in the presence of gefitinib.  Pertuzumab did not affect the binding on A431 cells, which express low levels of HER2.  Cross-linking measurements showed that gefitinib increased the amount of EGFR dimers 3.0-3.8 times in A431 cells in the absence of EGF.  In EGF stimulated SKOV3 cells the amount of EGFR dimers increased 1.8-2.2 times by gefitinib, but this effect was cancelled by pertuzumab.  Gefitinib treatment did not alter the number of EGFR or HER2 expressed in tumor cell lines A431, U343, SKOV3 and SKBR3.  Real-time binding traces were further analyzed in a novel tool, Interaction Map, which deciphered the different components of the measured interaction and supports EGF binding to multiple binding sites.  EGFR and HER2 expression affect the levels of EGFR monomers, homodimers and heterodimers and EGF binds to the various monomeric/dimeric forms of EGFR with unique binding properties.  Taken together, we conclude that dimerization explains the varying affinity of EGF-EGFR in different cells, and we propose that gefitinib induces EGFR dimmers, which alters the interaction characteristics with 125I-EGF.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQmKCzaldFZyMyail4HZd-ifW6udTcc2eb9u2kjHASZiLntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3MfkvFajsQ%253D%253D&md5=c2bfe5fe03d421cf313e4c2cac0a23b2</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0024739&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0024739%26sid%3Dliteratum%253Aachs%26aulast%3DBj%25C3%25B6rkelund%26aufirst%3DH.%26aulast%3DGedda%26aufirst%3DL.%26aulast%3DBarta%26aufirst%3DP.%26aulast%3DMalmqvist%26aufirst%3DM.%26aulast%3DAndersson%26aufirst%3DK.%26atitle%3DGefitinib%2520induces%2520epidermal%2520growth%2520factor%2520receptor%2520dimers%2520which%2520alters%2520the%2520interaction%2520characteristics%2520with%2520125I-EGF%26jtitle%3DPLoS%2520One%26date%3D2011%26volume%3D6%26doi%3D10.1371%2Fjournal.pone.0024739" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref46"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref46'); return false;" data-citation="" class="refNumLink">46</a></strong><div class="NLM_citation" id="cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tran, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosik, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">AbrahmsÃ©n, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">SandstrÃ¶m, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">SjÃ¶berg, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">WÃ¥llberg, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahlgren, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Orlova, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tolmachev, V.</span></span> <span> </span><span class="NLM_article-title">Design, synthesis and biological evaluation of a multifunctional HER2-specific affibody molecule for molecular imaging</span>. <i>Eur. J. Nucl. Med. Mol. Imaging</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>36</i></span>,  <span class="NLM_fpage">1864</span>â <span class="NLM_lpage">1873</span>, <span class="refDoi">Â DOI: 10.1007/s00259-009-1176-z</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01340&amp;key=10.1007%2Fs00259-009-1176-z" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01340&amp;key=19504093" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01340&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtlSlu7zJ" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2009&pages=1864-1873&author=T.+A.+Tranauthor=D.+Rosikauthor=L.+Abrahms%C3%A9nauthor=M.+Sandstr%C3%B6mauthor=A.+Sj%C3%B6bergauthor=H.+W%C3%A5llbergauthor=S.+Ahlgrenauthor=A.+Orlovaauthor=V.+Tolmachev&title=Design%2C+synthesis+and+biological+evaluation+of+a+multifunctional+HER2-specific+affibody+molecule+for+molecular+imaging&doi=10.1007%2Fs00259-009-1176-z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">Design, synthesis and biological evaluation of a multifunctional HER2-specific Affibody molecule for molecular imaging</span></div><div class="casAuthors">Tran, Thuy A.; Rosik, Daniel; Abrahmsen, Lars; Sandstroem, Mattias; Sjoeberg, Anna; Wallberg, Helena; Ahlgren, Sara; Orlova, Anna; Tolmachev, Vladimir</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Nuclear Medicine and Molecular Imaging</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">36</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1864-1873</span>CODEN:
                <span class="NLM_cas:coden">EJNMA6</span>;
        ISSN:<span class="NLM_cas:issn">1619-7070</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Purpose. The purpose of this study was to design and evaluate a novel platform for labeling of Affibody mols., enabling both recombinant and synthetic prodn. and site-specific labeling with 99mTc or trivalent radiometals.  Methods. The HER2-specific Affibody mol. PEP05352 was made by peptide synthesis.  The chelator sequence SECG (serine-glutamic acid-cysteine-glycine) was anchored on the C-terminal to allow 99mTc labeling.  The cysteine can alternatively serve as a conjugation site of the chelator DOTA for indium labeling.  The resulting 99mTc- and 111In-labeled Affibody mols. were evaluated both in vitro and in vivo.  Results. Both conjugates retained their capacity to bind to HER2 receptors in vitro and in vivo.  The tumor to blood ratio in LS174T xenografts was 30 at 4 h post-injection for both conjugates.  Biodistribution data showed that the 99mTc-labeled Affibody mol. had a fourfold lower kidney accumulation compared with the 111In-labeled Affibody mol. while the accumulation in other organs was similar.  Gamma camera imaging of the conjugates could clearly visualize the tumors 4 h after injection.  Conclusion. Incorporation of the C-terminal SECG sequence in Affibody mols. provides a general multifunctional platform for site-specific labeling with different nuclides (technetium, indium, gallium, cobalt or yttrium) and for a flexible prodn. (chem. synthesis or recombinant).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqzFLblUMuT1bVg90H21EOLACvtfcHk0lguSho9MG9EmA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtlSlu7zJ&md5=1e422a4037468bb6fe505a6afdec92bb</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1007%2Fs00259-009-1176-z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00259-009-1176-z%26sid%3Dliteratum%253Aachs%26aulast%3DTran%26aufirst%3DT.%2BA.%26aulast%3DRosik%26aufirst%3DD.%26aulast%3DAbrahms%25C3%25A9n%26aufirst%3DL.%26aulast%3DSandstr%25C3%25B6m%26aufirst%3DM.%26aulast%3DSj%25C3%25B6berg%26aufirst%3DA.%26aulast%3DW%25C3%25A5llberg%26aufirst%3DH.%26aulast%3DAhlgren%26aufirst%3DS.%26aulast%3DOrlova%26aufirst%3DA.%26aulast%3DTolmachev%26aufirst%3DV.%26atitle%3DDesign%252C%2520synthesis%2520and%2520biological%2520evaluation%2520of%2520a%2520multifunctional%2520HER2-specific%2520affibody%2520molecule%2520for%2520molecular%2520imaging%26jtitle%3DEur.%2520J.%2520Nucl.%2520Med.%2520Mol.%2520Imaging%26date%3D2009%26volume%3D36%26spage%3D1864%26epage%3D1873%26doi%3D10.1007%2Fs00259-009-1176-z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref47"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref47'); return false;" data-citation="" class="refNumLink">47</a></strong><div class="NLM_citation" id="cit47"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nock, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maina, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krenning, E. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Jong, M.</span></span> <span> </span><span class="NLM_article-title">To serve and protectâ: enzyme inhibitors as radiopeptide escorts promote tumor targeting</span>. <i>J. Nucl. Med.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">121</span>â <span class="NLM_lpage">127</span>, <span class="refDoi">Â DOI: 10.2967/jnumed.113.129411</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01340&amp;key=10.2967%2Fjnumed.113.129411" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01340&amp;key=24287321" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01340&amp;key=1%3ACAS%3A528%3ADC%252BC2cXjtlCkur0%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2014&pages=121-127&author=B.+A.+Nockauthor=T.+Mainaauthor=E.+P.+Krenningauthor=M.+de+Jong&title=To+serve+and+protect%E2%80%9D%3A+enzyme+inhibitors+as+radiopeptide+escorts+promote+tumor+targeting&doi=10.2967%2Fjnumed.113.129411"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">"To serve and protect": enzyme inhibitors as radiopeptide escorts promote tumor targeting</span></div><div class="casAuthors">Nock, Berthold A.; Maina, Theodosia; Krenning, Eric P.; de Jong, Marion</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Nuclear Medicine</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">121-127</span>CODEN:
                <span class="NLM_cas:coden">JNMEAQ</span>;
        ISSN:<span class="NLM_cas:issn">0161-5505</span>.
    
            (<span class="NLM_cas:orgname">Society of Nuclear Medicine and Molecular Imaging</span>)
        </div><div class="casAbstract">Radiolabeled octreotide analogs are most successfully being applied today in clin. cancer imaging and treatment.  Propagation of this paradigm to other radiopeptide families has been greatly hampered by the inherent poor metabolic stability of systemically administered peptide analogs.  We hypothesized that the in vivo coadministration of specific enzyme inhibitors would improve peptide bioavailability and hence tumor uptake.  Through single coinjection of the neutral endopeptidase inhibitor phosphoramidon (PA), we were able to provoke remarkable rises in the percentages of circulating intact somatostatin, gastrin, and bombesin radiopeptides in mouse models, resulting in a remarkable increase in uptake in tumor xenografts in mice.  Methods: The peptide conjugates [DOTA-Ala1]SS14 (DOTA-Ala-Gly-c[Cys-Lys-Asn-Phe-Phe-Trp-Lys-Thr-Phe-Thr-Ser-Cys]-OH), PanSB1 (DOTA-PEG2-DTyr-Gln-Trp-Ala-Val-Î²Ala-His-Phe-Nle-NH2), and DOTA-MG11 (DOTA-DGlu-Ala-Tyr-Gly-Trp-Met-Asp-Phe-NH2) were labeled with 111In by 20 min of heating at an acidic pH.  Metabolic stability was studied with high-performance liq. chromatog. anal. of blood samples collected 5 min after the injection of the test radiopeptide alone or with PA into mice.  Biodistribution was studied after injection of each 111In-labeled radiopeptide alone or after coinjection of PA in tumor-bearing severe combined immunodeficient (SCID) mice.  Results: The amt. of intact [111In-DOTA-Ala1] SS14 detected in the mouse circulation at 5 min after the injection of PA increased impressively-from less than 2% to 86%-whereas the uptake in AR4-2J xenografts rose from less than 1 percentage injected dose per g of tissue (%ID/g) to 14 %ID/g at 4 h after injection.  Likewise, the coadministration of PA resulted in a marked increase in the amt. of circulating intact 111In-PanSB1-from 12% to 80%-at 5 min after injection, and radioligand uptake in human PC-3 xenografts in SCID mice escalated from less than 4 %ID/g to greater than 21 %ID/g at 4 h after injection.  In a similar manner, the coadministration of PA resulted in an equally impressive increase in intact [111In-DOTA]MG11 levels in the mouse bloodstream-from less than 5% to 70%-at 5 min after injection, leading to a remarkable increase in radiotracer uptake-from 2 %ID/g to greater than 15 %ID/g-in both AR4-2J tumors and A431(CCKR+) tumors (i.e., tumors induced by A431 cells transfected to stably express the human cholecystokinin subtype 2 receptor) in mice at 4 h after injection.  This effect was well visualized by SPECT/CT imaging of AR4-2J tumor-bearing mice at 4 h after injection.  Conclusion: The results of this study clearly demonstrate that the coadministration of key enzyme inhibitors can effectively prolong the survival of radiolabeled peptides in the circulation, securing their safe transit to the target.  This strategy clearly provoked an unprecedented increase in radiolabel accumulation in tumor xenografts in mice; this increase might translate into higher diagnostic sensitivity or improved therapeutic efficacy of radiopeptide drugs in cancer patients.  Hence, our findings provide exciting new opportunities for the application of biodegradable (radio)peptide drugs of either natural or synthetic origin as well as for the rationale design of analogs that are stable in vivo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqTBCeCpf9QNLVg90H21EOLACvtfcHk0lguSho9MG9EmA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXjtlCkur0%253D&md5=f0a71739c53837fa71c2ce9863cbf668</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.2967%2Fjnumed.113.129411&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2967%252Fjnumed.113.129411%26sid%3Dliteratum%253Aachs%26aulast%3DNock%26aufirst%3DB.%2BA.%26aulast%3DMaina%26aufirst%3DT.%26aulast%3DKrenning%26aufirst%3DE.%2BP.%26aulast%3Dde%2BJong%26aufirst%3DM.%26atitle%3DTo%2520serve%2520and%2520protect%25E2%2580%259D%253A%2520enzyme%2520inhibitors%2520as%2520radiopeptide%2520escorts%2520promote%2520tumor%2520targeting%26jtitle%3DJ.%2520Nucl.%2520Med.%26date%3D2014%26volume%3D55%26spage%3D121%26epage%3D127%26doi%3D10.2967%2Fjnumed.113.129411" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref48"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref48'); return false;" data-citation="" class="refNumLink">48</a></strong><div class="NLM_citation" id="cit48"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chatalic, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Konijnenberg, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nonnekens, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Blois, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoeben, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Ridder, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brunel, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fehrentz, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martinez, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Gent, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nock, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maina, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Weerden, W. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Jong, M.</span></span> <span> </span><span class="NLM_article-title">In vivo stabilization of a gastrin-releasing peptide receptor antagonist enhances PET imaging and radionuclide therapy of prostate cancer in preclinical studies</span>. <i>Theranostics</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">104</span>â <span class="NLM_lpage">117</span>, <span class="refDoi">Â DOI: 10.7150/thno.13580</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01340&amp;key=10.7150%2Fthno.13580" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01340&amp;key=26722377" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01340&amp;key=1%3ACAS%3A528%3ADC%252BC28XntV2msrw%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2016&pages=104-117&author=K.+L.+Chatalicauthor=M.+Konijnenbergauthor=J.+Nonnekensauthor=E.+de+Bloisauthor=S.+Hoebenauthor=C.+de+Ridderauthor=L.+Brunelauthor=J.+A.+Fehrentzauthor=J.+Martinezauthor=D.+C.+van+Gentauthor=B.+A.+Nockauthor=T.+Mainaauthor=W.+M.+van+Weerdenauthor=M.+de+Jong&title=In+vivo+stabilization+of+a+gastrin-releasing+peptide+receptor+antagonist+enhances+PET+imaging+and+radionuclide+therapy+of+prostate+cancer+in+preclinical+studies&doi=10.7150%2Fthno.13580"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">In vivo stabilization of a gastrin-releasing peptide receptor antagonist enhances PET imaging and radionuclide therapy of prostate cancer in preclinical studies</span></div><div class="casAuthors">Chatalic, Kristell L. S.; Konijnenberg, Mark; Nonnekens, Julie; de Blois, Erik; Hoeben, Sander; de Ridder, Corrina; Brunel, Luc; Fehrentz, Jean-Alain; Martinez, Jean; van Gent, Dik C.; Nock, Berthold A.; Maina, Theodosia; van Weerden, Wytske M.; de Jong, Marion</div><div class="citationInfo"><span class="NLM_cas:title">Theranostics</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">104-117</span>CODEN:
                <span class="NLM_cas:coden">THERDS</span>;
        ISSN:<span class="NLM_cas:issn">1838-7640</span>.
    
            (<span class="NLM_cas:orgname">Ivyspring International Publisher</span>)
        </div><div class="casAbstract">A single tool for early detection, accurate staging, and personalized treatment of prostate cancer (PCa) would be a major breakthrough in the field of PCa.  Gastrin-releasing peptide receptor (GRPR) targeting peptides are promising probes for a theranostic approach for PCa overexpressing GRPR.  However, the successful application of small peptides in a theranostic approach is often hampered by their fast in vivo degrdn. by proteolytic enzymes, such as neutral endopeptidase (NEP).  Here we show for the first time that co-injection of a NEP inhibitor (phosphoramidon (PA)) can lead to an impressive enhancement of diagnostic sensitivity and therapeutic efficacy of the theranostic 68Ga-/177Lu-JMV4168 GRPR-antagonist.  Co-injection of PA (300 Î¼g) led to stabilization of 177Lu-JMV4168 in murine peripheral blood.  In PC-3 tumor-bearing mice, PA co-injection led to a two-fold increase in tumor uptake of 68Ga-/177Lu-JMV4168, 1 h after injection.  In positron emission tomog. (PET) imaging with 68Ga-JMV4168, PA co-injection substantially enhanced PC-3 tumor signal intensity.  Radionuclide therapy with 177Lu-JMV4168 resulted in significant regression of PC-3 tumor size.  Radionuclide therapy efficacy was confirmed by prodn. of DNA double strand breaks, decreased cell proliferation and increased apoptosis.  Increased survival rates were obsd. in mice treated with 177Lu-JMV4168 plus PA as compared to those without PA.  This data shows that co-injection of the enzyme inhibitor PA greatly enhances the theranostic potential of GRPR-radioantagonists for future application in PCa patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoIJYrjL-c5s7Vg90H21EOLACvtfcHk0lguSho9MG9EmA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XntV2msrw%253D&md5=094e700a40c22abd81a44d20d63345b9</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.7150%2Fthno.13580&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.7150%252Fthno.13580%26sid%3Dliteratum%253Aachs%26aulast%3DChatalic%26aufirst%3DK.%2BL.%26aulast%3DKonijnenberg%26aufirst%3DM.%26aulast%3DNonnekens%26aufirst%3DJ.%26aulast%3Dde%2BBlois%26aufirst%3DE.%26aulast%3DHoeben%26aufirst%3DS.%26aulast%3Dde%2BRidder%26aufirst%3DC.%26aulast%3DBrunel%26aufirst%3DL.%26aulast%3DFehrentz%26aufirst%3DJ.%2BA.%26aulast%3DMartinez%26aufirst%3DJ.%26aulast%3Dvan%2BGent%26aufirst%3DD.%2BC.%26aulast%3DNock%26aufirst%3DB.%2BA.%26aulast%3DMaina%26aufirst%3DT.%26aulast%3Dvan%2BWeerden%26aufirst%3DW.%2BM.%26aulast%3Dde%2BJong%26aufirst%3DM.%26atitle%3DIn%2520vivo%2520stabilization%2520of%2520a%2520gastrin-releasing%2520peptide%2520receptor%2520antagonist%2520enhances%2520PET%2520imaging%2520and%2520radionuclide%2520therapy%2520of%2520prostate%2520cancer%2520in%2520preclinical%2520studies%26jtitle%3DTheranostics%26date%3D2016%26volume%3D6%26spage%3D104%26epage%3D117%26doi%3D10.7150%2Fthno.13580" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref49"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref49'); return false;" data-citation="" class="refNumLink">49</a></strong><div class="NLM_citation" id="cit49"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dong, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cui, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhong, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jin, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jia, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, F.</span></span> <span> </span><span class="NLM_article-title"><sup>99m</sup>Tc-Labeled Dimeric Octreotide Peptide: A radiotracer with high tumor uptake for single-photon emission computed tomography imaging of somatostatin receptor subtype 2-positive tumors</span>. <i>Mol. Pharmaceutics</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">2925</span>â <span class="NLM_lpage">2933</span>, <span class="refDoi">Â DOI: 10.1021/mp400040z</span> </span><div class="citationLinks">[<a href="/doi/10.1021/mp400040z" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01340&amp;key=1%3ACAS%3A528%3ADC%252BC3sXpsVGmt74%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2013&pages=2925-2933&author=C.+Dongauthor=H.+Zhaoauthor=S.+Yangauthor=J.+Shiauthor=J.+Huangauthor=L.+Cuiauthor=L.+Zhongauthor=X.+Jinauthor=F.+Liauthor=Z.+Liuauthor=B.+Jiaauthor=F.+Wang&title=99mTc-Labeled+Dimeric+Octreotide+Peptide%3A+A+radiotracer+with+high+tumor+uptake+for+single-photon+emission+computed+tomography+imaging+of+somatostatin+receptor+subtype+2-positive+tumors&doi=10.1021%2Fmp400040z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">99mTc-Labeled Dimeric Octreotide Peptide: A Radiotracer with High Tumor Uptake for Single-Photon Emission Computed Tomography Imaging of Somatostatin Receptor Subtype 2-Positive Tumors</span></div><div class="casAuthors">Dong, Chengyan; Zhao, Huiyun; Yang, Sujuan; Shi, Jiyun; Huang, Jinming; Cui, Liyang; Zhong, Lijun; Jin, Xiaona; Li, Fang; Liu, Zhaofei; Jia, Bing; Wang, Fan</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmaceutics</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2925-2933</span>CODEN:
                <span class="NLM_cas:coden">MPOHBP</span>;
        ISSN:<span class="NLM_cas:issn">1543-8384</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">There is growing interest in the development of radiolabeled multivalent ligands because of their higher tumor uptake vs. that of the corresponding monomer.  This report presents the synthesis of a [Tyr3]octreotide dimer conjugate, HYNIC-E([Tyr3]octreotide)2 {HYNIC-TOC2, HYNIC = 6-[2-(2-sulfonatobenzaldehyde)hydrazono]nicotinyl}, and its biol. evaluation in the AR42J tumor model.  The binding affinity of HYNIC-TOC2 for somatostatin receptor subtype 2 (SSTR2) was detd. in AR42J rat pancreatic cancer cells, using 125I-[Tyr3]octreotide as the radiotracer. 99mTc-HYNIC-TOC2 was prepd. by using tricine and EDDA as coligands (EDDA = ethylenediamine-N,N'-diacetic acid).  Biodistribution and Î³ imaging were performed in nude mice bearing AR42J tumors. 99mTc-HYNIC-TOC2 was obtained in >95% labeling yield with favorable stability.  Compared with those of HYNIC-TOC (IC50 = 3.74 Â± 0.82 nM), HYNIC-TOC2 showed significantly increased SSTR2 binding affinity (IC50 = 0.74 Â± 0.19 nM), and 99mTc-HYNIC-TOC2 showed significantly increased tumor uptake [13.31 Â± 3.14%ID/g vs 5.32 Â± 0.94%ID/g 1 h postinjection (p.i.) and 12.05 Â± 2.92%ID/g vs 5.87 Â± 1.96%ID/g 4 h p.i.].  Although the level of accumulation of 99mTc-HYNIC-TOC2 in kidneys was significantly increased (94.40 Â± 6.51%ID/g vs 32.27 Â± 4.51%ID/g 1 h p.i.), this high uptake was inhibited by the injection of l-lysine before the administration of 99mTc-HYNIC-TOC2 (30.99 Â± 5.05%ID/g 1 h p.i.) while tumor uptake decreased only slightly.  Consistent with biodistribution data, in vivo planar Î³ imaging showed that the tumors were clearly visualized, while the background signal was much weaker except for that of the kidneys and bladder.  The new radiotracer 99mTc-HYNIC-TOC2 with a higher binding affinity and good stability was designed and evaluated.  The higher tumor uptake of 99mTc-HYNIC-TOC2 suggests that 90Y/177Lu-labeled TOC2 might have an advantage for the radiotherapy of SSTR2-pos. tumors.  These data merit the translation of 99mTc-HYNIC-TOC2 to a clin. setting.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpwMXJ8r89uFLVg90H21EOLACvtfcHk0lgRbayGhE_z4w"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXpsVGmt74%253D&md5=fb5eb21c0d7bfef7251c71f2927be088</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1021%2Fmp400040z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fmp400040z%26sid%3Dliteratum%253Aachs%26aulast%3DDong%26aufirst%3DC.%26aulast%3DZhao%26aufirst%3DH.%26aulast%3DYang%26aufirst%3DS.%26aulast%3DShi%26aufirst%3DJ.%26aulast%3DHuang%26aufirst%3DJ.%26aulast%3DCui%26aufirst%3DL.%26aulast%3DZhong%26aufirst%3DL.%26aulast%3DJin%26aufirst%3DX.%26aulast%3DLi%26aufirst%3DF.%26aulast%3DLiu%26aufirst%3DZ.%26aulast%3DJia%26aufirst%3DB.%26aulast%3DWang%26aufirst%3DF.%26atitle%3D99mTc-Labeled%2520Dimeric%2520Octreotide%2520Peptide%253A%2520A%2520radiotracer%2520with%2520high%2520tumor%2520uptake%2520for%2520single-photon%2520emission%2520computed%2520tomography%2520imaging%2520of%2520somatostatin%2520receptor%2520subtype%25202-positive%2520tumors%26jtitle%3DMol.%2520Pharmaceutics%26date%3D2013%26volume%3D10%26spage%3D2925%26epage%3D2933%26doi%3D10.1021%2Fmp400040z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref50"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref50'); return false;" data-citation="" class="refNumLink">50</a></strong><div class="NLM_citation" id="cit50"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Maina, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Konijnenberg, M. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">KolencPeitl, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garnuszek, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nock, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaloudi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kroselj, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zaletel, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maecke, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mansi, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Erba, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">von Guggenberg, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hubalewska-Dydejczyk, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mikolajczak, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Decristoforo, C.</span></span> <span> </span><span class="NLM_article-title">Preclinical pharmacokinetics, biodistribution, radiation dosimetry and toxicity studies required for regulatory approval of a phase I clinical trial with (111)In-CP04 in medullary thyroid carcinoma patients</span>. <i>Eur. J. Pharm. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>91</i></span>,  <span class="NLM_fpage">236</span>â <span class="NLM_lpage">242</span>, <span class="refDoi">Â DOI: 10.1016/j.ejps.2016.05.011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01340&amp;key=10.1016%2Fj.ejps.2016.05.011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01340&amp;key=27185299" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01340&amp;key=1%3ACAS%3A528%3ADC%252BC28Xos1Wmt7w%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=91&publication_year=2016&pages=236-242&author=T.+Mainaauthor=M.+W.+Konijnenbergauthor=P.+KolencPeitlauthor=P.+Garnuszekauthor=B.+A.+Nockauthor=A.+Kaloudiauthor=M.+Kroseljauthor=K.+Zaletelauthor=H.+Maeckeauthor=R.+Mansiauthor=P.+Erbaauthor=E.+von+Guggenbergauthor=A.+Hubalewska-Dydejczykauthor=R.+Mikolajczakauthor=C.+Decristoforo&title=Preclinical+pharmacokinetics%2C+biodistribution%2C+radiation+dosimetry+and+toxicity+studies+required+for+regulatory+approval+of+a+phase+I+clinical+trial+with+%28111%29In-CP04+in+medullary+thyroid+carcinoma+patients&doi=10.1016%2Fj.ejps.2016.05.011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">Preclinical pharmacokinetics, biodistribution, radiation dosimetry and toxicity studies required for regulatory approval of a phase I clinical trial with 111In-CP04 in medullary thyroid carcinoma patients</span></div><div class="casAuthors">Maina, Theodosia; Konijnenberg, Mark W.; KolencPeitl, Petra; Garnuszek, Piotr; Nock, Berthold A.; Kaloudi, Aikaterini; Kroselj, Marko; Zaletel, Katja; Maecke, Helmut; Mansi, Rosalba; Erba, Paola; von Guggenberg, Elisabeth; Hubalewska-Dydejczyk, Alicja; Mikolajczak, Renata; Decristoforo, Clemens</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Pharmaceutical Sciences</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">91</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">236-242</span>CODEN:
                <span class="NLM_cas:coden">EPSCED</span>;
        ISSN:<span class="NLM_cas:issn">0928-0987</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">From a series of radiolabeled cholecystokinin (CCK) and gastrin analogs, 111In-CP04 (111In-DOTA-(DGlu)6-Ala-Tyr-Gly-Trp-Met-Asp-Phe-NH2) was selected for further translation as a diagnostic radiopharmaceutical towards a first-in-man study in patients with medullary thyroid carcinoma (MTC).  We herein report on biosafety, in vivo stability, biodistribution and dosimetry aspects of 111In-CP04 in animal models, essential for the regulatory approval of the clin. trial.  Acute and extended single dose toxicity of CP04 was tested in rodents, while the in vivo stability of 111In-CP04 was assessed by HPLC anal. of mouse blood samples.  CP04 was well-tolerated by both mice and rats, with an LD50 > 178.5 Î¼g/kg body wt. for mice and a NOAEL (no-obsd.-adverse-effect-level) of 89 Î¼g/kg body wt. for rats.  After labeling, 111In-CP04 remained > 70% intact in peripheral mouse blood at 5 min pi.  The uptake of 111In-CP04 prepd. from the freeze-dried kit and by wet-labeling were comparable in the A431-CCK2R(+)-xenografts (9.24 Â± 1.35%ID/g and 8.49 Â± 0.39%ID/g, resp.; P > 0.05).  The present study has provided convincing toxicol., biodistribution and dosimetry data for prompt implementation of the freeze-dried kit formulation without or with gelofusine administration in a multicentre clin. trial in MTC patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr2W-Fn82biTLVg90H21EOLACvtfcHk0lgRbayGhE_z4w"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xos1Wmt7w%253D&md5=718e368b781ca88f0ab914bf0f0847c9</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1016%2Fj.ejps.2016.05.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejps.2016.05.011%26sid%3Dliteratum%253Aachs%26aulast%3DMaina%26aufirst%3DT.%26aulast%3DKonijnenberg%26aufirst%3DM.%2BW.%26aulast%3DKolencPeitl%26aufirst%3DP.%26aulast%3DGarnuszek%26aufirst%3DP.%26aulast%3DNock%26aufirst%3DB.%2BA.%26aulast%3DKaloudi%26aufirst%3DA.%26aulast%3DKroselj%26aufirst%3DM.%26aulast%3DZaletel%26aufirst%3DK.%26aulast%3DMaecke%26aufirst%3DH.%26aulast%3DMansi%26aufirst%3DR.%26aulast%3DErba%26aufirst%3DP.%26aulast%3Dvon%2BGuggenberg%26aufirst%3DE.%26aulast%3DHubalewska-Dydejczyk%26aufirst%3DA.%26aulast%3DMikolajczak%26aufirst%3DR.%26aulast%3DDecristoforo%26aufirst%3DC.%26atitle%3DPreclinical%2520pharmacokinetics%252C%2520biodistribution%252C%2520radiation%2520dosimetry%2520and%2520toxicity%2520studies%2520required%2520for%2520regulatory%2520approval%2520of%2520a%2520phase%2520I%2520clinical%2520trial%2520with%2520%2528111%2529In-CP04%2520in%2520medullary%2520thyroid%2520carcinoma%2520patients%26jtitle%3DEur.%2520J.%2520Pharm.%2520Sci.%26date%3D2016%26volume%3D91%26spage%3D236%26epage%3D242%26doi%3D10.1016%2Fj.ejps.2016.05.011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref51"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref51'); return false;" data-citation="" class="refNumLink">51</a></strong><div class="NLM_citation" id="cit51"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Duggineni, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mitra, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lamberto, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">An, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pasquale, E. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Z.</span></span> <span> </span><span class="NLM_article-title">Design and synthesis of potent bivalent peptide agonists targeting the ephA2 receptor</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">344</span>â <span class="NLM_lpage">348</span>, <span class="refDoi">Â DOI: 10.1021/ml3004523</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ml3004523" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01340&amp;key=1%3ACAS%3A528%3ADC%252BC3sXitFajur4%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2013&pages=344-348&author=S.+Duggineniauthor=S.+Mitraauthor=I.+Lambertoauthor=X.+Hanauthor=Y.+Xuauthor=J.+Anauthor=E.+B.+Pasqualeauthor=Z.+Huang&title=Design+and+synthesis+of+potent+bivalent+peptide+agonists+targeting+the+ephA2+receptor&doi=10.1021%2Fml3004523"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit51R"><div class="casContent"><span class="casTitleNuber">51</span><div class="casTitle"><span class="NLM_cas:atitle">Design and Synthesis of Potent Bivalent Peptide Agonists Targeting the EphA2 Receptor</span></div><div class="casAuthors">Duggineni, Srinivas; Mitra, Sayantan; Lamberto, Ilaria; Han, Xiaofeng; Xu, Yan; An, Jing; Pasquale, Elena B.; Huang, Ziwei</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">344-348</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Designing potent and selective peptides and small mols. that target Eph receptor tyrosine kinases remains a challenge, and new strategies are needed for developing novel and potent ligands for these receptors.  In this study, we performed a structure-activity relationship study of a previously identified 12 amino acid-long peptide, SWL, by alanine scanning to identify residues important for receptor binding.  To further enhance and optimize the receptor binding affinity of the SWL peptide, we applied the concept of bivalent ligand design to synthesize several SWL-derived dimeric peptides as novel ligands capable of binding simultaneously to two EphA2 receptor mols.  The dimeric peptides possess higher receptor binding affinity than the original monomeric SWL peptide, consistent with bivalent binding.  The most potent dimeric peptide, a SWL dimer with a six-carbon linker, has about 13-fold increased potency as compared to SWL.  Furthermore, similar to SWL, the dimeric peptide is an agonist and can promote EphA2 tyrosine phosphorylation (activation) in cultured cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp5CfG69V9xzLVg90H21EOLACvtfcHk0ljiAGEKPyqVfA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXitFajur4%253D&md5=cfde81669466bc1ce0733c0816baf7c9</span></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1021%2Fml3004523&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fml3004523%26sid%3Dliteratum%253Aachs%26aulast%3DDuggineni%26aufirst%3DS.%26aulast%3DMitra%26aufirst%3DS.%26aulast%3DLamberto%26aufirst%3DI.%26aulast%3DHan%26aufirst%3DX.%26aulast%3DXu%26aufirst%3DY.%26aulast%3DAn%26aufirst%3DJ.%26aulast%3DPasquale%26aufirst%3DE.%2BB.%26aulast%3DHuang%26aufirst%3DZ.%26atitle%3DDesign%2520and%2520synthesis%2520of%2520potent%2520bivalent%2520peptide%2520agonists%2520targeting%2520the%2520ephA2%2520receptor%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2013%26volume%3D4%26spage%3D344%26epage%3D348%26doi%3D10.1021%2Fml3004523" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref52"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref52'); return false;" data-citation="" class="refNumLink">52</a></strong><div class="NLM_citation" id="cit52"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Digilio, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barbero, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bracco, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Corpillo, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Esposito, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Piquet, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Traversa, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aime, S.</span></span> <span> </span><span class="NLM_article-title">NMR structure of two novel polyethylene glycol conjugates of the human growth hormone-releasing factor, hGRF (1- 29)- NH<sub>2</sub></span>. <i>J. Am. Chem. Soc.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>125</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">3458</span>â <span class="NLM_lpage">3470</span>, <span class="refDoi">Â DOI: 10.1021/ja021264j</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ja021264j" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01340&amp;key=1%3ACAS%3A528%3ADC%252BD3sXhsVyntrk%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=125&publication_year=2003&pages=3458-3470&issue=12&author=G.+Digilioauthor=L.+Barberoauthor=C.+Braccoauthor=D.+Corpilloauthor=P.+Espositoauthor=G.+Piquetauthor=S.+Traversaauthor=S.+Aime&title=NMR+structure+of+two+novel+polyethylene+glycol+conjugates+of+the+human+growth+hormone-releasing+factor%2C+hGRF+%281-+29%29-+NH2&doi=10.1021%2Fja021264j"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit52R"><div class="casContent"><span class="casTitleNuber">52</span><div class="casTitle"><span class="NLM_cas:atitle">NMR structure of two novel PEG conjugates of the human Growth Hormone-Releasing Factor, hGRF(1-29)-NH2</span></div><div class="casAuthors">Digilio, Giuseppe; Barbero, Luca; Bracco, Chiara; Corpillo, Davide; Esposito, Pierandrea; Piquet, Gilles; Traversa, Silvio; Aime, Silvio</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">125</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">3458-3470</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Two novel mono-PEGylated derivs. of hGRF(1-29)-NH2 [human growth hormone-releasing factor, fragment 1-29] have been synthesized by regio-specific conjugation of Lys12 or Lys21 to a monomethoxy-PEG5000 chain (compds. Lys12PEG-GRF and Lys21PEG-GRF).  The PEG moiety has been covalently linked at the amino group of a norleucine residue via a carbamate bond.  The Lys12PEG-GRF regioisomer was found to be slightly less active in vitro than both the unmodified peptide and Lys21PEG-GRF.  To assess whether the differences in the biol. activity of the PEGylated analogs could be related to conformational rearrangements induced by the PEG moiety, the structure of these PEGylated derivs. has been worked out (TFE soln.) by means of NMR spectroscopy and mol. dynamics.  Secondary structure shifts, hydrogen/deuterium exchange kinetics, temp. coeffs. of amide protons, and NOE-based mol. models point out that hGRF(1-29)-NH2, Lys21PEG-GRF and Lys12PEG-GRF share a remarkably similar pattern of secondary structure.  All three compds. adopt an Î±-helix conformation which spans the whole length of the mol., and which becomes increasingly rigid on going from the N-terminus to the C-terminus.  Residues Lys12 and Lys21 are enclosed in all the compds. considered into well-defined Î±-helical domains, indicating that PEGylation either at Lys12 or Lys21 does not alter the tendency of the peptide to adopt a stable Î±-helix conformation, nor does it induce appreciable conformational mobility in the proximity of the PEGylation sites.  No significant variation of the amphiphilic organization of the Î±-helix is obsd. among the three peptides. Therefore, the different biol. activities obsd. for the PEGylated analogs are not due to conformational effects, but are rather due to steric hindrance effects.  The relationship between the biol. activity of the mono-PEGylated derivs. and steric hindrance is discussed in terms of the topol. of interaction between hGRF(1-29)-NH2 and its receptor.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGojknXc4DDxNLVg90H21EOLACvtfcHk0ljiAGEKPyqVfA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXhsVyntrk%253D&md5=1ad044f8f9e383ddd68238c71df5cab8</span></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1021%2Fja021264j&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja021264j%26sid%3Dliteratum%253Aachs%26aulast%3DDigilio%26aufirst%3DG.%26aulast%3DBarbero%26aufirst%3DL.%26aulast%3DBracco%26aufirst%3DC.%26aulast%3DCorpillo%26aufirst%3DD.%26aulast%3DEsposito%26aufirst%3DP.%26aulast%3DPiquet%26aufirst%3DG.%26aulast%3DTraversa%26aufirst%3DS.%26aulast%3DAime%26aufirst%3DS.%26atitle%3DNMR%2520structure%2520of%2520two%2520novel%2520polyethylene%2520glycol%2520conjugates%2520of%2520the%2520human%2520growth%2520hormone-releasing%2520factor%252C%2520hGRF%2520%25281-%252029%2529-%2520NH2%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D2003%26volume%3D125%26issue%3D12%26spage%3D3458%26epage%3D3470%26doi%3D10.1021%2Fja021264j" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref53"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref53'); return false;" data-citation="" class="refNumLink">53</a></strong><div class="NLM_citation" id="cit53"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gioux, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choi, H. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frangioni, J. V.</span></span> <span> </span><span class="NLM_article-title">Image-guided surgery using invisible near-infrared light: fundamentals of clinical translation</span>. <i>Mol. Imaging</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">00034</span>, <span class="refDoi">Â DOI: 10.2310/7290.2010.00034</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01340&amp;key=10.2310%2F7290.2010.00034" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2010&pages=00034&author=S.+Giouxauthor=H.+S.+Choiauthor=J.+V.+Frangioni&title=Image-guided+surgery+using+invisible+near-infrared+light%3A+fundamentals+of+clinical+translation&doi=10.2310%2F7290.2010.00034"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.2310%2F7290.2010.00034&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2310%252F7290.2010.00034%26sid%3Dliteratum%253Aachs%26aulast%3DGioux%26aufirst%3DS.%26aulast%3DChoi%26aufirst%3DH.%2BS.%26aulast%3DFrangioni%26aufirst%3DJ.%2BV.%26atitle%3DImage-guided%2520surgery%2520using%2520invisible%2520near-infrared%2520light%253A%2520fundamentals%2520of%2520clinical%2520translation%26jtitle%3DMol.%2520Imaging%26date%3D2010%26volume%3D9%26spage%3D00034%26doi%3D10.2310%2F7290.2010.00034" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref54"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref54'); return false;" data-citation="" class="refNumLink">54</a></strong><div class="NLM_citation" id="cit54"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Quaglino, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mastini, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Forni, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cavallo, F.</span></span> <span> </span><span class="NLM_article-title">ErbB2 transgenic mice: a tool for investigation of the immune prevention and treatment of mammary carcinomas</span>. <i>Curr. Protoc. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>82</i></span>,  <span class="NLM_fpage">20</span>â <span class="NLM_lpage">29</span>, <span class="refDoi">Â DOI: 10.1002/0471142735.im2009s82</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01340&amp;key=10.1002%2F0471142735.im2009s82" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=82&publication_year=2008&pages=20-29&author=E.+Quaglinoauthor=C.+Mastiniauthor=G.+Forniauthor=F.+Cavallo&title=ErbB2+transgenic+mice%3A+a+tool+for+investigation+of+the+immune+prevention+and+treatment+of+mammary+carcinomas&doi=10.1002%2F0471142735.im2009s82"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.1002%2F0471142735.im2009s82&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252F0471142735.im2009s82%26sid%3Dliteratum%253Aachs%26aulast%3DQuaglino%26aufirst%3DE.%26aulast%3DMastini%26aufirst%3DC.%26aulast%3DForni%26aufirst%3DG.%26aulast%3DCavallo%26aufirst%3DF.%26atitle%3DErbB2%2520transgenic%2520mice%253A%2520a%2520tool%2520for%2520investigation%2520of%2520the%2520immune%2520prevention%2520and%2520treatment%2520of%2520mammary%2520carcinomas%26jtitle%3DCurr.%2520Protoc.%2520Immunol.%26date%3D2008%26volume%3D82%26spage%3D20%26epage%3D29%26doi%3D10.1002%2F0471142735.im2009s82" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref55"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref55'); return false;" data-citation="" class="refNumLink">55</a></strong><div class="NLM_citation" id="cit55"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Aime, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Calabi, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cavallotti, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gianolio, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giovenzana, G. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Losi, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maiocchi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palmisano, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sisti, M.</span></span> <span> </span><span class="NLM_article-title">Gd-AAZTA-: a new structural entry for an improved generation of MRI contrast agents</span>. <i>Inorg. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>43</i></span> (<span class="NLM_issue">24</span>),  <span class="NLM_fpage">7588</span>â <span class="NLM_lpage">7590</span>, <span class="refDoi">Â DOI: 10.1021/ic0489692</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ic0489692" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01340&amp;key=1%3ACAS%3A528%3ADC%252BD2cXptValsb4%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=2004&pages=7588-7590&issue=24&author=S.+Aimeauthor=L.+Calabiauthor=C.+Cavallottiauthor=E.+Gianolioauthor=G.+B.+Giovenzanaauthor=P.+Losiauthor=A.+Maiocchiauthor=G.+Palmisanoauthor=M.+Sisti&title=Gd-AAZTA-%3A+a+new+structural+entry+for+an+improved+generation+of+MRI+contrast+agents&doi=10.1021%2Fic0489692"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit55R"><div class="casContent"><span class="casTitleNuber">55</span><div class="casTitle"><span class="NLM_cas:atitle">[Gd-AAZTA]-: A New Structural Entry for an Improved Generation of MRI Contrast Agents</span></div><div class="casAuthors">Aime, Silvio; Calabi, Luisella; Cavallotti, Camilla; Gianolio, Eliana; Giovenzana, Giovanni B.; Losi, Pietro; Maiocchi, Alessandro; Palmisano, Giovanni; Sisti, Massimo</div><div class="citationInfo"><span class="NLM_cas:title">Inorganic Chemistry</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">43</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">7588-7590</span>CODEN:
                <span class="NLM_cas:coden">INOCAJ</span>;
        ISSN:<span class="NLM_cas:issn">0020-1669</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">An innovative MRI contrast agent based on the unprecedented and easily obtained ligand AAZTA (I) is described.  The simple and straightforward synthesis of the ligand, together with the potentiometric and relaxometric behavior of the corresponding Gd(III) chelate, is reported.  [Gd(AAZTA-4H)]- shows outstanding magnetic properties connected with high thermodn. stability in aq. soln. and a nearly complete inertness toward the influence of bidentate endogenous anions, placing this compd. as one of the most promising candidates for the development of high performance MRI contrast agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpPgrD7a1RlrLVg90H21EOLACvtfcHk0lhbAFoUCCy2ng"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXptValsb4%253D&md5=321b4e8c6eaee06eb3eed6e6d0d2583a</span></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.1021%2Fic0489692&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fic0489692%26sid%3Dliteratum%253Aachs%26aulast%3DAime%26aufirst%3DS.%26aulast%3DCalabi%26aufirst%3DL.%26aulast%3DCavallotti%26aufirst%3DC.%26aulast%3DGianolio%26aufirst%3DE.%26aulast%3DGiovenzana%26aufirst%3DG.%2BB.%26aulast%3DLosi%26aufirst%3DP.%26aulast%3DMaiocchi%26aufirst%3DA.%26aulast%3DPalmisano%26aufirst%3DG.%26aulast%3DSisti%26aufirst%3DM.%26atitle%3DGd-AAZTA-%253A%2520a%2520new%2520structural%2520entry%2520for%2520an%2520improved%2520generation%2520of%2520MRI%2520contrast%2520agents%26jtitle%3DInorg.%2520Chem.%26date%3D2004%26volume%3D43%26issue%3D24%26spage%3D7588%26epage%3D7590%26doi%3D10.1021%2Fic0489692" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref56"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref56'); return false;" data-citation="" class="refNumLink">56</a></strong><div class="NLM_citation" id="cit56"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Waldron, B. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parker, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burchardt, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yufit, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zimny, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roesch, F.</span></span> <span> </span><span class="NLM_article-title">Structure and stability of hexadentate complexes of ligands based on AAZTA for efficient PET labelling with gallium-68</span>. <i>Chem. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>49</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">579</span>â <span class="NLM_lpage">581</span>, <span class="refDoi">Â DOI: 10.1039/C2CC37544C</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01340&amp;key=10.1039%2FC2CC37544C" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01340&amp;key=23212712" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01340&amp;key=1%3ACAS%3A528%3ADC%252BC38XhvVCju7fN" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2013&pages=579-581&issue=6&author=B.+P.+Waldronauthor=D.+Parkerauthor=C.+Burchardtauthor=D.+S.+Yufitauthor=M.+Zimnyauthor=F.+Roesch&title=Structure+and+stability+of+hexadentate+complexes+of+ligands+based+on+AAZTA+for+efficient+PET+labelling+with+gallium-68&doi=10.1039%2FC2CC37544C"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit56R"><div class="casContent"><span class="casTitleNuber">56</span><div class="casTitle"><span class="NLM_cas:atitle">Structure and stability of hexadentate complexes of ligands based on AAZTA for efficient PET labelling with gallium-68</span></div><div class="casAuthors">Waldron, Bradley P.; Parker, David; Burchardt, Carsten; Yufit, Dmitry S.; Zimny, Melanie; Roesch, Frank</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Communications (Cambridge, United Kingdom)</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">579-581</span>CODEN:
                <span class="NLM_cas:coden">CHCOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-7345</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">Pre-organised tricarboxylate ligands based on 6-amino-perhydro-1,4-diazepine bind 68Ga rapidly and selectively in acetate buffer at pH 4 to 7, forming kinetically stable complexes suitable for use in PET imaging.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp8sLogoR3UOrVg90H21EOLACvtfcHk0lhbAFoUCCy2ng"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhvVCju7fN&md5=7059a4137fe7abb2a7b0f366b5dd8d61</span></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=10.1039%2FC2CC37544C&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC2CC37544C%26sid%3Dliteratum%253Aachs%26aulast%3DWaldron%26aufirst%3DB.%2BP.%26aulast%3DParker%26aufirst%3DD.%26aulast%3DBurchardt%26aufirst%3DC.%26aulast%3DYufit%26aufirst%3DD.%2BS.%26aulast%3DZimny%26aufirst%3DM.%26aulast%3DRoesch%26aufirst%3DF.%26atitle%3DStructure%2520and%2520stability%2520of%2520hexadentate%2520complexes%2520of%2520ligands%2520based%2520on%2520AAZTA%2520for%2520efficient%2520PET%2520labelling%2520with%2520gallium-68%26jtitle%3DChem.%2520Commun.%26date%3D2013%26volume%3D49%26issue%3D6%26spage%3D579%26epage%3D581%26doi%3D10.1039%2FC2CC37544C" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref57"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref57'); return false;" data-citation="" class="refNumLink">57</a></strong><div class="NLM_citation" id="cit57"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Baranyai, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uggeri, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maiocchi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giovenzana, G. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cavallotti, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">TakÃ¡cs, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">TÃ³th, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">BÃ¡nyai, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">BÃ©nyei, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brucher, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aime, S.</span></span> <span> </span><span class="NLM_article-title">Equilibrium, kinetic and structural studies of AAZTA complexes with Ga3+, In3+ and Cu2+</span>. <i>Eur. J. Inorg. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>2013</i></span>,  <span class="NLM_fpage">147</span>â <span class="NLM_lpage">162</span>, <span class="refDoi">Â DOI: 10.1002/ejic.201201108</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01340&amp;key=10.1002%2Fejic.201201108" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01340&amp;key=1%3ACAS%3A528%3ADC%252BC38XhslSmtLnK" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2013&publication_year=2013&pages=147-162&author=Z.+Baranyaiauthor=F.+Uggeriauthor=A.+Maiocchiauthor=G.+B.+Giovenzanaauthor=C.+Cavallottiauthor=A.+Tak%C3%A1csauthor=I.+T%C3%B3thauthor=I.+B%C3%A1nyaiauthor=A.+B%C3%A9nyeiauthor=E.+Brucherauthor=S.+Aime&title=Equilibrium%2C+kinetic+and+structural+studies+of+AAZTA+complexes+with+Ga3%2B%2C+In3%2B+and+Cu2%2B&doi=10.1002%2Fejic.201201108"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit57R"><div class="casContent"><span class="casTitleNuber">57</span><div class="casTitle"><span class="NLM_cas:atitle">Equilibrium, Kinetic and Structural Studies of AAZTA Complexes with Ga3+, In3+ and Cu2+</span></div><div class="casAuthors">Baranyai, Zsolt; Uggeri, Fulvio; Maiocchi, Alessandro; Giovenzana, Giovanni B.; Cavallotti, Camilla; Takacs, Anett; Toth, Imre; Banyai, Istvan; Benyei, Attila; Brucher, Erno; Aime, Silvio</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Inorganic Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">2013</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">147-162</span>CODEN:
                <span class="NLM_cas:coden">EJICFO</span>;
        ISSN:<span class="NLM_cas:issn">1434-1948</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">A detailed study of the structures, thermodn. stabilities and kinetics of the dissocn. of Ga3+, In3+ and Cu2+ complexes formed with the heptadentate ligand AAZTA is reported (AAZTA is 6-[bis(hydroxycarbonylmethyl)amino]1,4-bis(hydroxycarbonylmethyl)-6-methylperhydro-1,4-diazepine).  The stability consts. (log KML) of the AAZTA complexes of Ga3+, In3+ and Cu2+ are 22.18, 29.58 and 22.27, resp., which suggests that the seven-membered-ring skeleton is suited to the accommodation of these metal ions.  The solid-state structure of [Cu(H2AAZTA)]Â·H2O shows a distorted octahedral coordination.  The equatorial coordination sites of Cu2+ are occupied by one of the ring N atoms, a water O atom, one of the carboxylate O atoms and the N atom of the iminodiacetate moiety.  The other ring N atom and the carboxylate O atom of the iminodiacetate moiety coordinate to the Cu2+ in the axial positions.  In the pH range 4.5-8.5, Ga3+ is present in the form of the highly stable [Ga(AAZTA)OH]2- (log Î²GaLH-1 = 17.69).  The exchange reactions of [Ga(AAZTA)OH]2- with Cu2+ and transferrin are very slow and mainly occur through the spontaneous dissocn. of the complex close to physiol. conditions.  The half-life for the dissocn. of [Ga(AAZTA)OH]2- is t1/2 = 23 h at pH = 7.5 and 25 Â°C in 0.025 M NaHCO3 and 0.15 M NaCl.  The high conditional stability, fast formation and sufficiently slow dissocn. of [Ga(AAZTA)OH]2- represent promising properties for the complexation and diagnostic applications of radioactive Ga isotopes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrwmyH2ohQABLVg90H21EOLACvtfcHk0lhbAFoUCCy2ng"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhslSmtLnK&md5=df01a7ffcd93fae02bee97621c2ed9ca</span></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=10.1002%2Fejic.201201108&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fejic.201201108%26sid%3Dliteratum%253Aachs%26aulast%3DBaranyai%26aufirst%3DZ.%26aulast%3DUggeri%26aufirst%3DF.%26aulast%3DMaiocchi%26aufirst%3DA.%26aulast%3DGiovenzana%26aufirst%3DG.%2BB.%26aulast%3DCavallotti%26aufirst%3DC.%26aulast%3DTak%25C3%25A1cs%26aufirst%3DA.%26aulast%3DT%25C3%25B3th%26aufirst%3DI.%26aulast%3DB%25C3%25A1nyai%26aufirst%3DI.%26aulast%3DB%25C3%25A9nyei%26aufirst%3DA.%26aulast%3DBrucher%26aufirst%3DE.%26aulast%3DAime%26aufirst%3DS.%26atitle%3DEquilibrium%252C%2520kinetic%2520and%2520structural%2520studies%2520of%2520AAZTA%2520complexes%2520with%2520Ga3%252B%252C%2520In3%252B%2520and%2520Cu2%252B%26jtitle%3DEur.%2520J.%2520Inorg.%2520Chem.%26date%3D2013%26volume%3D2013%26spage%3D147%26epage%3D162%26doi%3D10.1002%2Fejic.201201108" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref58"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref58'); return false;" data-citation="" class="refNumLink">58</a></strong><div class="NLM_citation" id="cit58"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Biggin, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harris, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hedt, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jeffery, C.</span></span> <span> </span><span class="NLM_article-title">Radiological properties of next generation theranostics (Cu-64/Cu-67)</span>. <i>J. Nucl. Med.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">1014</span>â <span class="NLM_lpage">1014</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2017&pages=1014-1014&author=C.+Bigginauthor=M.+Harrisauthor=A.+Hedtauthor=C.+Jeffery&title=Radiological+properties+of+next+generation+theranostics+%28Cu-64%2FCu-67%29"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBiggin%26aufirst%3DC.%26aulast%3DHarris%26aufirst%3DM.%26aulast%3DHedt%26aufirst%3DA.%26aulast%3DJeffery%26aufirst%3DC.%26atitle%3DRadiological%2520properties%2520of%2520next%2520generation%2520theranostics%2520%2528Cu-64%252FCu-67%2529%26jtitle%3DJ.%2520Nucl.%2520Med.%26date%3D2017%26volume%3D58%26spage%3D1014%26epage%3D1014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref59"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref59'); return false;" data-citation="" class="refNumLink">59</a></strong><div class="NLM_citation" id="cit59"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Panikar, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">RamÃ­rez-GarcÃ­a, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vallejo-Cardona, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Banu, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">PatrÃ³n-Soberano, O. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cialla-May, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Camacho-Villegas, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de la Rosa, E.</span></span> <span> </span><span class="NLM_article-title">Novel anti-HER2 peptide-conjugated theranostic nanoliposomes combining NaYF4:Yb,Er nanoparticles for NIR-activated bioimaging and chemo-photodynamic therapy against breast cancer</span>. <i>Nanoscale</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">20598</span>â <span class="NLM_lpage">20613</span>, <span class="refDoi">Â DOI: 10.1039/C9NR06535K</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01340&amp;key=10.1039%2FC9NR06535K" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01340&amp;key=31641713" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01340&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhvFeqsrrM" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2019&pages=20598-20613&author=S.+S.+Panikarauthor=G.+Ram%C3%ADrez-Garc%C3%ADaauthor=A.+A.+Vallejo-Cardonaauthor=N.+Banuauthor=O.+A.+Patr%C3%B3n-Soberanoauthor=D.+Cialla-Mayauthor=T.+A.+Camacho-Villegasauthor=E.+de+la+Rosa&title=Novel+anti-HER2+peptide-conjugated+theranostic+nanoliposomes+combining+NaYF4%3AYb%2CEr+nanoparticles+for+NIR-activated+bioimaging+and+chemo-photodynamic+therapy+against+breast+cancer&doi=10.1039%2FC9NR06535K"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit59R"><div class="casContent"><span class="casTitleNuber">59</span><div class="casTitle"><span class="NLM_cas:atitle">Novel anti-HER2 peptide-conjugated theranostic nanoliposomes combining NaYF4:Yb,Er nanoparticles for NIR-activated bioimaging and chemo-photodynamic therapy against breast cancer</span></div><div class="casAuthors">Panikar, Sandeep Surendra; Ramirez-Garcia, Gonzalo; Vallejo-Cardona, Alba A.; Banu, Nehla; Patron-Soberano, Olga A.; Cialla-May, Dana; Camacho-Villegas, Tanya A.; de la Rosa, Elder</div><div class="citationInfo"><span class="NLM_cas:title">Nanoscale</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">43</span>),
    <span class="NLM_cas:pages">20598-20613</span>CODEN:
                <span class="NLM_cas:coden">NANOHL</span>;
        ISSN:<span class="NLM_cas:issn">2040-3372</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">Herein, we reported the fabrication of novel peptide-conjugated ligand-targeted nanoliposomes (LTLs) for chemo-photodynamic therapy against HER2-pos. breast cancer.  The LTL core was utilized for encapsulating doxorubicin (DOX) for chemotherapy, and methylene blue (MB) attached NaYF4:Yb,Er upconversion nanoparticles (UCNPs) for NIR-activated bioimaging and leveraging its visible emission for photoexciting MB for enhanced photodynamic therapy (PDT).  The specificity of our LTLs was achieved by conjugating a newly discovered anti-HER2 peptide screened from a phage display peptide library.  The high selectivity of the peptide-conjugated LTLs was confirmed by confocal imaging of SKBR-3 (HER2-pos.) and MCF-7 (HER2-neg.) breast cancer cell lines, illustrating its target-specific nature.  The energy transfer from UCNPs to MB was verified, thus enabling the generation of reactive oxygen species upon activation with a 975 nm laser source (0.60 W cm-2) under 5 min continuous excitation.  A significant decline in the cell viability by 95% was obsd. using chemo-photodynamic combinational therapy, whereas for chemo-drug alone and PDT alone, the cell proliferation declined by 77% and 84%, resp.  Furthermore, we demonstrated an improved uptake of the LTLs inside a 3D model of SKBR-3 tumor spheroids, where the spheroid cell viability was suppressed by 66% after the use of combinational therapy.  Thus, our results suggest great prospective use of theranostic LTLs for breast cancer management.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoTNV2_Ty2IxrVg90H21EOLACvtfcHk0lhiSKOtlNNeUw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhvFeqsrrM&md5=718bf25079fd24ff5158803f7edc1938</span></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=10.1039%2FC9NR06535K&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC9NR06535K%26sid%3Dliteratum%253Aachs%26aulast%3DPanikar%26aufirst%3DS.%2BS.%26aulast%3DRam%25C3%25ADrez-Garc%25C3%25ADa%26aufirst%3DG.%26aulast%3DVallejo-Cardona%26aufirst%3DA.%2BA.%26aulast%3DBanu%26aufirst%3DN.%26aulast%3DPatr%25C3%25B3n-Soberano%26aufirst%3DO.%2BA.%26aulast%3DCialla-May%26aufirst%3DD.%26aulast%3DCamacho-Villegas%26aufirst%3DT.%2BA.%26aulast%3Dde%2Bla%2BRosa%26aufirst%3DE.%26atitle%3DNovel%2520anti-HER2%2520peptide-conjugated%2520theranostic%2520nanoliposomes%2520combining%2520NaYF4%253AYb%252CEr%2520nanoparticles%2520for%2520NIR-activated%2520bioimaging%2520and%2520chemo-photodynamic%2520therapy%2520against%2520breast%2520cancer%26jtitle%3DNanoscale%26date%3D2019%26volume%3D11%26spage%3D20598%26epage%3D20613%26doi%3D10.1039%2FC9NR06535K" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref60"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref60'); return false;" data-citation="" class="refNumLink">60</a></strong><div class="NLM_citation" id="cit60"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tripepi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Capuana, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gianolio, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kock, F. V. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pagoto, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stefania, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Digilio, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aime, S.</span></span> <span> </span><span class="NLM_article-title">Synthesis of high relaxivity gadolinium AAZTA tetramers as building blocks for bioconjugation</span>. <i>Bioconjugate Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>29</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">1428</span>â <span class="NLM_lpage">1437</span>, <span class="refDoi">Â DOI: 10.1021/acs.bioconjchem.8b00120</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.bioconjchem.8b00120" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01340&amp;key=1%3ACAS%3A528%3ADC%252BC1cXjtFCitbc%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2018&pages=1428-1437&issue=4&author=M.+Tripepiauthor=F.+Capuanaauthor=E.+Gianolioauthor=F.+V.+C.+Kockauthor=A.+Pagotoauthor=R.+Stefaniaauthor=G.+Digilioauthor=S.+Aime&title=Synthesis+of+high+relaxivity+gadolinium+AAZTA+tetramers+as+building+blocks+for+bioconjugation&doi=10.1021%2Facs.bioconjchem.8b00120"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit60R"><div class="casContent"><span class="casTitleNuber">60</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis of High Relaxivity Gadolinium AAZTA Tetramers as Building Blocks for Bioconjugation</span></div><div class="casAuthors">Tripepi, Martina; Capuana, Federico; Gianolio, Eliana; Kock, Flavio Vinicius Crizostomo; Pagoto, Amerigo; Stefania, Rachele; Digilio, Giuseppe; Aime, Silvio</div><div class="citationInfo"><span class="NLM_cas:title">Bioconjugate Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1428-1437</span>CODEN:
                <span class="NLM_cas:coden">BCCHES</span>;
        ISSN:<span class="NLM_cas:issn">1043-1802</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Mol. imaging requires the specific accumulation of contrast agents at the target.  To exploit the superb resoln. of MRI for applications in mol. imaging, gadolinium chelates, as the MRI contrast agents (CA), have to be conjugated to a specific vector able to recognize the epitope of interest.  Several Gd(III)-chelates can be chem. linked to the same binding vector in order to deliver multiple copies of the CA (multimers) in a single targeting event thus increasing the sensitivity of the mol. probe.  Herein three novel bifunctional agents, carrying one functional group for the bioconjugation to targeting vectors and four Gd(III)-AAZTA chelate functions for MRI contrast enhancement (AAZTA = 6-amino-6-methylperhydro-1,4-diazepinetetraacetic acid), are reported.  The relaxivity in the tetrameric derivs. is 16.4 Â± 0.2 mMGd-1 s-1 at 21.5 MHz and 25 Â°C, being 2.4-fold higher than that of parent, monomeric Gd(III)-AAZTA.  These compds. can be used as versatile building blocks to insert preformed, high relaxivity, and high d. Gd-centers to biol. targeting vectors.  As an example, we describe the use of these bifunctional Gd(III)-chelates to label a fibrin-targeting peptide.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpCFBseuEdWkLVg90H21EOLACvtfcHk0lhiSKOtlNNeUw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXjtFCitbc%253D&md5=db2799a8f2d32521ad7447a33c28dc25</span></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=10.1021%2Facs.bioconjchem.8b00120&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.bioconjchem.8b00120%26sid%3Dliteratum%253Aachs%26aulast%3DTripepi%26aufirst%3DM.%26aulast%3DCapuana%26aufirst%3DF.%26aulast%3DGianolio%26aufirst%3DE.%26aulast%3DKock%26aufirst%3DF.%2BV.%2BC.%26aulast%3DPagoto%26aufirst%3DA.%26aulast%3DStefania%26aufirst%3DR.%26aulast%3DDigilio%26aufirst%3DG.%26aulast%3DAime%26aufirst%3DS.%26atitle%3DSynthesis%2520of%2520high%2520relaxivity%2520gadolinium%2520AAZTA%2520tetramers%2520as%2520building%2520blocks%2520for%2520bioconjugation%26jtitle%3DBioconjugate%2520Chem.%26date%3D2018%26volume%3D29%26issue%3D4%26spage%3D1428%26epage%3D1437%26doi%3D10.1021%2Facs.bioconjchem.8b00120" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref61"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref61'); return false;" data-citation="" class="refNumLink">61</a></strong><div class="NLM_citation" id="cit61"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pagoto, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stefania, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garello, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arena, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Digilio, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aime, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Terreno, E.</span></span> <span> </span><span class="NLM_article-title">Paramagnetic phospholipid-based micelles targeting VCAM-1 receptors for MRI visualization of inflammation</span>. <i>Bioconjugate Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>27</i></span> (<span class="NLM_issue">8</span>),  <span class="NLM_fpage">1921</span>â <span class="NLM_lpage">1930</span>, <span class="refDoi">Â DOI: 10.1021/acs.bioconjchem.6b00308</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.bioconjchem.6b00308" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01340&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtVSrsrzL" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2016&pages=1921-1930&issue=8&author=A.+Pagotoauthor=R.+Stefaniaauthor=F.+Garelloauthor=F.+Arenaauthor=G.+Digilioauthor=S.+Aimeauthor=E.+Terreno&title=Paramagnetic+phospholipid-based+micelles+targeting+VCAM-1+receptors+for+MRI+visualization+of+inflammation&doi=10.1021%2Facs.bioconjchem.6b00308"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit61R"><div class="casContent"><span class="casTitleNuber">61</span><div class="casTitle"><span class="NLM_cas:atitle">Paramagnetic Phospholipid-Based Micelles Targeting VCAM-1 Receptors for MRI Visualization of Inflammation</span></div><div class="casAuthors">Pagoto, Amerigo; Stefania, Rachele; Garello, Francesca; Arena, Francesca; Digilio, Giuseppe; Aime, Silvio; Terreno, Enzo</div><div class="citationInfo"><span class="NLM_cas:title">Bioconjugate Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1921-1930</span>CODEN:
                <span class="NLM_cas:coden">BCCHES</span>;
        ISSN:<span class="NLM_cas:issn">1043-1802</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Inflammation is signaled by the overexpression of epitopes on the vascular endothelium that primarily aim at recruiting immune cells into the inflamed area.  The intravascular localization of these biomarkers makes them suitable targets for the MRI visualization of inflammation.  Phospholipid-based nanosystems appear excellent candidates in virtue of their good biocompatibility, ability to deliver a high no. of imaging units at the target site, and for the easy functionalization with targeting vectors.  In this work, phospholipid-based micelles (hydrodynamic diam. of 20 nm) loaded with the amphiphilic Gd(III)-complex Gd-DOTAMA(C18)2 were vectorized with a small peptide able to specifically bind VCAM-1 receptors.  The micelles displayed a high longitudinal relaxivity (36.4 s-1mmolGd-1 at 25 Â°C and 0.7 T).  A 1H- and 17O-water relaxometry study indicated that the paramagnetic complex embedded in the nanoparticles adopted two isomeric conformations, likely reflecting the well-known square antiprismatic (SAP) and twisted square antiprismatic (TSAP) configurations typically obsd. in DOTA-like lanthanide complexes.  Interestingly, the TSAP structure, showing a much faster exchange rate for the water mol. coordinated to the metal ion, was the most abundant, thus explaining the high relaxivity of the micellar agent.  The systemic administration of the micelles into a lipopolysaccharide-induced murine model of acute inflammation successfully demonstrated the ability of the targeting agents to detect the diseased area by T1 contrast enhanced MRI.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrKIdHNK-378LVg90H21EOLACvtfcHk0lhiSKOtlNNeUw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtVSrsrzL&md5=590c29f60527d3687303058968644696</span></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=10.1021%2Facs.bioconjchem.6b00308&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.bioconjchem.6b00308%26sid%3Dliteratum%253Aachs%26aulast%3DPagoto%26aufirst%3DA.%26aulast%3DStefania%26aufirst%3DR.%26aulast%3DGarello%26aufirst%3DF.%26aulast%3DArena%26aufirst%3DF.%26aulast%3DDigilio%26aufirst%3DG.%26aulast%3DAime%26aufirst%3DS.%26aulast%3DTerreno%26aufirst%3DE.%26atitle%3DParamagnetic%2520phospholipid-based%2520micelles%2520targeting%2520VCAM-1%2520receptors%2520for%2520MRI%2520visualization%2520of%2520inflammation%26jtitle%3DBioconjugate%2520Chem.%26date%3D2016%26volume%3D27%26issue%3D8%26spage%3D1921%26epage%3D1930%26doi%3D10.1021%2Facs.bioconjchem.6b00308" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref62"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref62'); return false;" data-citation="" class="refNumLink">62</a></strong><div class="NLM_citation" id="cit62"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Slaga, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ellerman, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lombana, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vij, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hristopoulos, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clark, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnston, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shelton, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mai, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gadkar, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lo, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koerber, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Totpal, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prell, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spiess, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Junttila, T. T.</span></span> <span> </span><span class="NLM_article-title">Avidity-based binding to HER2 results in selective killing of HER2-overexpressing cells by anti-HER2/CD3</span>. <i>Sci. Transl. Med.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>10</i></span>, <span class="NLM_elocation-id">eaat5775</span> <span class="refDoi">Â DOI: 10.1126/scitranslmed.aat5775</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01340&amp;key=10.1126%2Fscitranslmed.aat5775" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01340&amp;key=30333240" title="">PubMed</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2018&author=D.+Slagaauthor=D.+Ellermanauthor=N.+Lombanaauthor=R.+Vijauthor=J.+Liauthor=M.+Hristopoulosauthor=R.+Clarkauthor=J.+Johnstonauthor=A.+Sheltonauthor=E.+Maiauthor=K.+Gadkarauthor=A.+A.+Loauthor=J.+T.+Koerberauthor=K.+Totpalauthor=R.+Prellauthor=G.+Leeauthor=C.+Spiessauthor=T.+T.+Junttila&title=Avidity-based+binding+to+HER2+results+in+selective+killing+of+HER2-overexpressing+cells+by+anti-HER2%2FCD3&doi=10.1126%2Fscitranslmed.aat5775"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit62&amp;dbid=16384&amp;doi=10.1126%2Fscitranslmed.aat5775&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscitranslmed.aat5775%26sid%3Dliteratum%253Aachs%26aulast%3DSlaga%26aufirst%3DD.%26aulast%3DEllerman%26aufirst%3DD.%26aulast%3DLombana%26aufirst%3DN.%26aulast%3DVij%26aufirst%3DR.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DHristopoulos%26aufirst%3DM.%26aulast%3DClark%26aufirst%3DR.%26aulast%3DJohnston%26aufirst%3DJ.%26aulast%3DShelton%26aufirst%3DA.%26aulast%3DMai%26aufirst%3DE.%26aulast%3DGadkar%26aufirst%3DK.%26aulast%3DLo%26aufirst%3DA.%2BA.%26aulast%3DKoerber%26aufirst%3DJ.%2BT.%26aulast%3DTotpal%26aufirst%3DK.%26aulast%3DPrell%26aufirst%3DR.%26aulast%3DLee%26aufirst%3DG.%26aulast%3DSpiess%26aufirst%3DC.%26aulast%3DJunttila%26aufirst%3DT.%2BT.%26atitle%3DAvidity-based%2520binding%2520to%2520HER2%2520results%2520in%2520selective%2520killing%2520of%2520HER2-overexpressing%2520cells%2520by%2520anti-HER2%252FCD3%26jtitle%3DSci.%2520Transl.%2520Med.%26date%3D2018%26volume%3D10%26doi%3D10.1126%2Fscitranslmed.aat5775" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref63"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref63'); return false;" data-citation="" class="refNumLink">63</a></strong><div class="NLM_citation" id="cit63"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quinn, T. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deutscher, S. L.</span></span> <span> </span><span class="NLM_article-title">Evaluation of an <sup>111</sup>In-Radiolabeled peptide as a targeting and imaging agent for ErbB-2 receptor-expressing breast carcinomas</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>13</i></span> (<span class="NLM_issue">20</span>),  <span class="NLM_fpage">6070</span>â <span class="NLM_lpage">6079</span>, <span class="refDoi">Â DOI: 10.1158/1078-0432.CCR-07-0160</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01340&amp;key=10.1158%2F1078-0432.CCR-07-0160" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01340&amp;key=17947470" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01340&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtFygs7bM" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2007&pages=6070-6079&issue=20&author=S.+R.+Kumarauthor=T.+P.+Quinnauthor=S.+L.+Deutscher&title=Evaluation+of+an+111In-Radiolabeled+peptide+as+a+targeting+and+imaging+agent+for+ErbB-2+receptor-expressing+breast+carcinomas&doi=10.1158%2F1078-0432.CCR-07-0160"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit63R"><div class="casContent"><span class="casTitleNuber">63</span><div class="casTitle"><span class="NLM_cas:atitle">Evaluation of an 111In-Radiolabeled Peptide as a Targeting and Imaging Agent for ErbB-2 Receptor-Expressing Breast Carcinomas</span></div><div class="casAuthors">Kumar, Senthil R.; Quinn, Thomas P.; Deutscher, Susan L.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">6070-6079</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">PURPOSE: The cellular targeting and tumor imaging properties of a novel ErbB-2-avid peptide, discovered from bacteriophage display, were evaluated in human breast carcinoma cells and in breast carcinoma-xenografted mice.  Exptl. Design: The affinity of the ErbB-2 targeting peptide KCCYSL and its alanine substituted counterparts for the extracellular domain (ECD) of purified recombinant ErbB-2 (ErbB-2-ECD) was assessed by fluorescence titrn.  Binding of the KCCYSL peptide to breast and prostate carcinoma cells was analyzed by confocal microscopy.  A DOTA(GSG)-KCCYSL peptide conjugate was radiolabeled with 111In, and stability, target binding, and internalization were analyzed in vitro.  In vivo biodistribution and single-photon emission computed tomog. imaging studies were done with the radiolabeled peptide in MDA-MB-435 human breast tumor-bearing severe combined immunodeficient mice.  RESULTS: KCCYSL peptide exhibited high affinity (295 Â± 56 nmol/L) to ErbB-2-ECD.  Substitution of alanine for lysine, tryptophan, and cysteine reduced the peptide affinity â¼ 1- to 2.4-fold, whereas replacing leucine completely abolished binding.  Both biotin-KCCYSL and 111In-DOTA(GSG)-KCCYSL were capable of binding ErbB-2-expressing human breast carcinoma cells in vitro.  Approx. 11% of the total bound radioactivity was internalized in the carcinoma cells.  Competitive binding studies indicated that the radiolabeled peptide exhibited an IC50 value of 42.5 Â± 2.76 nmol/L for the breast carcinoma cells.  111In-DOTA(GSG)-KCCYSL was stable in serum and exhibited rapid tumor uptake (2.12 Â± 0.32 %ID/g) at 15 min postinjection and extended retention coupled with rapid whole body disappearance, as obsd. by biodistribution and single-photon emission computed tomog. imaging studies, resp.  The DOTA(GSG)-KCCYSL peptide has the potential to be used as a tumor-imaging agent and a vehicle for specific delivery of radionuclide or cytotoxic agents for tumors overexpressing ErbB-2.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr6amYMOtE6XLVg90H21EOLACvtfcHk0lhooE7EX2yFsQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtFygs7bM&md5=2d6f047acc7c4c14e8edbc981b3c78d4</span></div><a href="/servlet/linkout?suffix=cit63&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-07-0160&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-07-0160%26sid%3Dliteratum%253Aachs%26aulast%3DKumar%26aufirst%3DS.%2BR.%26aulast%3DQuinn%26aufirst%3DT.%2BP.%26aulast%3DDeutscher%26aufirst%3DS.%2BL.%26atitle%3DEvaluation%2520of%2520an%2520111In-Radiolabeled%2520peptide%2520as%2520a%2520targeting%2520and%2520imaging%2520agent%2520for%2520ErbB-2%2520receptor-expressing%2520breast%2520carcinomas%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2007%26volume%3D13%26issue%3D20%26spage%3D6070%26epage%3D6079%26doi%3D10.1158%2F1078-0432.CCR-07-0160" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref64"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref64'); return false;" data-citation="" class="refNumLink">64</a></strong><div class="NLM_citation" id="cit64"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yimchuen, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kadonosono, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ota, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sato, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kitazawa, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shiozawa, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuchimaru, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taki, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ito, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakamura, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kizaka-Kondoh, S.</span></span> <span> </span><span class="NLM_article-title">Strategic design to create HER2-targeting proteins with target-binding peptides immobilized on a fibronectin type III domain scaffold</span>. <i>RSC Adv.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">15154</span>â <span class="NLM_lpage">15162</span>, <span class="refDoi">Â DOI: 10.1039/D0RA00427H</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01340&amp;key=10.1039%2FD0RA00427H" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01340&amp;key=1%3ACAS%3A528%3ADC%252BB3cXntlegu78%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2020&pages=15154-15162&author=W.+Yimchuenauthor=T.+Kadonosonoauthor=Y.+Otaauthor=S.+Satoauthor=M.+Kitazawaauthor=T.+Shiozawaauthor=T.+Kuchimaruauthor=M.+Takiauthor=Y.+Itoauthor=H.+Nakamuraauthor=S.+Kizaka-Kondoh&title=Strategic+design+to+create+HER2-targeting+proteins+with+target-binding+peptides+immobilized+on+a+fibronectin+type+III+domain+scaffold&doi=10.1039%2FD0RA00427H"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit64R"><div class="casContent"><span class="casTitleNuber">64</span><div class="casTitle"><span class="NLM_cas:atitle">Strategic design to create HER2-targeting proteins with target-binding peptides immobilized on a fibronectin type III domain scaffold</span></div><div class="casAuthors">Yimchuen, Wanaporn; Kadonosono, Tetsuya; Ota, Yumi; Sato, Shinichi; Kitazawa, Maika; Shiozawa, Tadashi; Kuchimaru, Takahiro; Taki, Masumi; Ito, Yuji; Nakamura, Hiroyuki; Kizaka-Kondoh, Shinae</div><div class="citationInfo"><span class="NLM_cas:title">RSC Advances</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">26</span>),
    <span class="NLM_cas:pages">15154-15162</span>CODEN:
                <span class="NLM_cas:coden">RSCACL</span>;
        ISSN:<span class="NLM_cas:issn">2046-2069</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">Tumor-binding peptides such as human epidermal growth factor receptor 2 (HER2)-binding peptides are attractive therapeutic and diagnostic options for cancer.  However, the HER2-binding peptides (HBPs) developed thus far are susceptible to proteolysis and lose their affinity to HER2 in vivo.  In this report, a method to create a HER2-binding fluctuation-regulated affinity protein (HBP-FLAP) consisting of a fibronectin type III domain (FN3) scaffold with a structurally immobilized HBP is presented.  HBPs were selected by phage-library screening and grafted onto FN3 to create FN3-HBPs, and the HBP-FLAP with the highest affinity (HBP sequence: YCAHNM) was identified after affinity maturation of the grafted HBP.  HBP-FLAP contg. the YCAHNM peptide showed increased proteolysis-resistance, binding to HER2 with a dissocn. const. (KD) of 58 nM in ELISA and 287 nM in biolayer interferometry and specifically detects HER2-expressing cancer cells.  In addn., HBP-FLAP clearly delineated HER2-expressing tumors with a half-life of 6 h after i.v. injection into tumor-bearing mice.  FN3-based FLAP is an excellent platform for developing target-binding small proteins for clin. applications.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpcOXJCjvCC17Vg90H21EOLACvtfcHk0lhooE7EX2yFsQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXntlegu78%253D&md5=563e1822c2f0108bcf9ee5be7283c163</span></div><a href="/servlet/linkout?suffix=cit64&amp;dbid=16384&amp;doi=10.1039%2FD0RA00427H&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FD0RA00427H%26sid%3Dliteratum%253Aachs%26aulast%3DYimchuen%26aufirst%3DW.%26aulast%3DKadonosono%26aufirst%3DT.%26aulast%3DOta%26aufirst%3DY.%26aulast%3DSato%26aufirst%3DS.%26aulast%3DKitazawa%26aufirst%3DM.%26aulast%3DShiozawa%26aufirst%3DT.%26aulast%3DKuchimaru%26aufirst%3DT.%26aulast%3DTaki%26aufirst%3DM.%26aulast%3DIto%26aufirst%3DY.%26aulast%3DNakamura%26aufirst%3DH.%26aulast%3DKizaka-Kondoh%26aufirst%3DS.%26atitle%3DStrategic%2520design%2520to%2520create%2520HER2-targeting%2520proteins%2520with%2520target-binding%2520peptides%2520immobilized%2520on%2520a%2520fibronectin%2520type%2520III%2520domain%2520scaffold%26jtitle%3DRSC%2520Adv.%26date%3D2020%26volume%3D10%26spage%3D15154%26epage%3D15162%26doi%3D10.1039%2FD0RA00427H" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref65"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref65'); return false;" data-citation="" class="refNumLink">65</a></strong><div class="NLM_citation" id="cit65"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cui, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Geng, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fang, Q.</span></span> <span> </span><span class="NLM_article-title">Peptide probes derived from pertuzumab by molecular dynamics modeling for HER2 positive tumor imaging</span>. <i>PLoS Comput. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>13</i></span> (<span class="NLM_issue">4</span>), <span class="NLM_elocation-id">e1005441</span> <span class="refDoi">Â DOI: 10.1371/journal.pcbi.1005441</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01340&amp;key=10.1371%2Fjournal.pcbi.1005441" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01340&amp;key=28406988" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01340&amp;key=1%3ACAS%3A528%3ADC%252BC2sXht1aisb3O" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2017&issue=4&author=X.+Yangauthor=Z.+Wangauthor=Z.+Xiangauthor=D.+Liauthor=Z.+Huauthor=W.+Cuiauthor=L.+Gengauthor=Q.+Fang&title=Peptide+probes+derived+from+pertuzumab+by+molecular+dynamics+modeling+for+HER2+positive+tumor+imaging&doi=10.1371%2Fjournal.pcbi.1005441"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit65R"><div class="casContent"><span class="casTitleNuber">65</span><div class="casTitle"><span class="NLM_cas:atitle">Peptide probes derived from pertuzumab by molecular dynamics modeling for HER2 positive tumor imaging</span></div><div class="casAuthors">Yang, Xiaoliang; Wang, Zihua; Xiang, Zhichu; Li, Dan; Hu, Zhiyuan; Cui, Wei; Geng, Lingling; Fang, Qiaojun</div><div class="citationInfo"><span class="NLM_cas:title">PLoS Computational Biology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">e1005441/1-e1005441/22</span>CODEN:
                <span class="NLM_cas:coden">PCBLBG</span>;
        ISSN:<span class="NLM_cas:issn">1553-7358</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">A high level of HER2 expression in breast cancer correlates with a higher tumor growth rate, high metastatic potential, and a poor long-term patient survival rate.  Pertuzumab, a human monoclonal antibody, can reduce the effect of HER2 overexpression by preventing HER2 dimerization.  In this study, a combination protocol of mol. dynamics modeling and MM/GBSA binding free energy calcns. was applied to design peptides that interact with HER2 based on the HER2-pertuzumab crystal structure.  Based on a Î² hairpin in pertuzumab from Glu46 to Lys65-which plays a key role in interacting with HER2-mutations were carried out in silico to improve the binding free energy of the hairpin that interacts with the Phe256-Lys314 of the HER2 protein.  Combined the use of one-bead-one-compd. library screening, among all the mutations, a peptide (58F63Y) with the lowest binding free energy was confirmed exptl. to have the highest affinity, and it may be used as a new probe in diagnosing and treating HER2-pos. breast cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqmXWRFsjEjD7Vg90H21EOLACvtfcHk0liZSjSiJlk8kA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXht1aisb3O&md5=d05751e1806c42e2ebc91c5dafad5d5b</span></div><a href="/servlet/linkout?suffix=cit65&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pcbi.1005441&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pcbi.1005441%26sid%3Dliteratum%253Aachs%26aulast%3DYang%26aufirst%3DX.%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DXiang%26aufirst%3DZ.%26aulast%3DLi%26aufirst%3DD.%26aulast%3DHu%26aufirst%3DZ.%26aulast%3DCui%26aufirst%3DW.%26aulast%3DGeng%26aufirst%3DL.%26aulast%3DFang%26aufirst%3DQ.%26atitle%3DPeptide%2520probes%2520derived%2520from%2520pertuzumab%2520by%2520molecular%2520dynamics%2520modeling%2520for%2520HER2%2520positive%2520tumor%2520imaging%26jtitle%3DPLoS%2520Comput.%2520Biol.%26date%3D2017%26volume%3D13%26issue%3D4%26doi%3D10.1371%2Fjournal.pcbi.1005441" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36'],'ref37':['cit37'],'ref38':['cit38'],'ref39':['cit39'],'ref40':['cit40'],'ref41':['cit41'],'ref42':['cit42'],'ref43':['cit43'],'ref44':['cit44'],'ref45':['cit45'],'ref46':['cit46'],'ref47':['cit47'],'ref48':['cit48'],'ref49':['cit49'],'ref50':['cit50'],'ref51':['cit51'],'ref52':['cit52'],'ref53':['cit53'],'ref54':['cit54'],'ref55':['cit55'],'ref56':['cit56'],'ref57':['cit57'],'ref58':['cit58'],'ref59':['cit59'],'ref60':['cit60'],'ref61':['cit61'],'ref62':['cit62'],'ref63':['cit63'],'ref64':['cit64'],'ref65':['cit65']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article has not yet been cited by other publications.</p></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="_i1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01340/20201218/images/medium/jm0c01340_0016.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01340/20201218/images/large/jm0c01340_0016.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01340&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01340/20201218/images/medium/jm0c01340_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01340/20201218/images/large/jm0c01340_0001.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Superimposition of the crystal structure of pertuzumab (yellow) in complex with human HER2 ECD (green), and trastuzumab (pink) bound in complex with human HER2 ECD (blue).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01340/20201218/images/large/jm0c01340_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01340&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01340/20201218/images/medium/jm0c01340_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01340/20201218/images/large/jm0c01340_0002.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Structure of of T-DM1.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01340/20201218/images/large/jm0c01340_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01340&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01340/20201218/images/medium/jm0c01340_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01340/20201218/images/large/jm0c01340_0003.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. A9 peptide in stick representation (blue) selected from the Fab-heavy chain of trastuzumab (in green ribbon representation) and its amino acids sequences.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01340/20201218/images/large/jm0c01340_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01340&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01340/20201218/images/medium/jm0c01340_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01340/20201218/images/large/jm0c01340_0004.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. (A) Stick representation of HER2 557â607 segment in complex with Fab of trastuzumab. (B) Crystal structure of rat HER2 ECD.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01340/20201218/images/large/jm0c01340_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01340&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01340/20201218/images/medium/jm0c01340_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01340/20201218/images/large/jm0c01340_0005.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Stick representation (pink and green) (A) of HER2-DIVMP and its amino acid sequence (B).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01340/20201218/images/large/jm0c01340_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01340&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01340/20201218/images/medium/jm0c01340_0015.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01340/20201218/images/large/jm0c01340_0015.jpeg" id="rightTab-gr15" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of Peptide HER2-DIVMP</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01340/20201218/images/large/jm0c01340_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01340&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig6" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01340/20201218/images/medium/jm0c01340_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01340/20201218/images/large/jm0c01340_0006.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Sensorgrams (best fit) of kinetic interaction of Biot-HER2-DIVMP with trastuzumab (A). Sensorgrams (best fit) of kinetic interaction of Biot-HER2-DIVMP with A9 peptide.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01340/20201218/images/large/jm0c01340_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01340&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig7" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01340/20201218/images/medium/jm0c01340_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01340/20201218/images/large/jm0c01340_0007.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Titration curve of HER2-DIVMP with A9 peptide.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01340/20201218/images/large/jm0c01340_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01340&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig8" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01340/20201218/images/medium/jm0c01340_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01340/20201218/images/large/jm0c01340_0008.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Fluorescence signals of HER2-DIVMP alone (A) and interacting with A9 (B); Æ<sub>ex</sub> = 280 nm (1 and 4) and pÆ<sub>ex</sub> = 295 nm (2 and 5). The difference spectra, 3 and 6, express the contribution of the Tyr residue.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01340/20201218/images/large/jm0c01340_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01340&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig9" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01340/20201218/images/medium/jm0c01340_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01340/20201218/images/large/jm0c01340_0009.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. MD structure of the complex between HER2-DIVMP (orange ribbon with green amino acid residues involvend in the interaction) and A9 (purple stick representation).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01340/20201218/images/large/jm0c01340_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01340&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig10" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01340/20201218/images/medium/jm0c01340_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01340/20201218/images/large/jm0c01340_0010.jpeg" id="rightTab-gr10" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 10. MD model of the complex between HER2-DIVMP (blue ribbon) and A9 (green stick). The amino acid sequence of A9 is shown interacting with amino acid residues of HER2-DIVMP.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01340/20201218/images/large/jm0c01340_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01340&amp;id=fig10"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig11" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Figure 11</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01340/20201218/images/medium/jm0c01340_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01340/20201218/images/large/jm0c01340_0011.jpeg" id="rightTab-gr11" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 11. NMR resolution structure of A9 peptide obtaned in complex with HER2-DIVMP (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6SON">6SON</a>) (A). Superimposition of A9 NMR structure (pink) and A9MD structure (blue); the side chain of the residues responsible of the interaction with HER2-DIVMP are labeled (B).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01340/20201218/images/large/jm0c01340_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01340&amp;id=fig11"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig12" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Figure 12</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01340/20201218/images/medium/jm0c01340_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01340/20201218/images/large/jm0c01340_0012.jpeg" id="rightTab-gr12" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 12. Schematic view of the crucial stemps of the affinity tag experiments and mass spectrometry analysis: (a) MS/MS spectra of the [M + 2H]<sup>2+</sup> precursor of biotinylated A9 at 615.2m/z. (b) SRM plot of the selected transition at <i>m</i>/<i>z</i> 615.2â477.8.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01340/20201218/images/large/jm0c01340_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01340&amp;id=fig12"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig13" data-index="14" class="article__inlineFigure"><h2 class="fig-label">Figure 13</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01340/20201218/images/medium/jm0c01340_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01340/20201218/images/large/jm0c01340_0013.jpeg" id="rightTab-gr13" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 13. Chemical structure of DTPA-A9 conjugate and MD structure of the conjugate <sup>111</sup>In-DTPA-A9.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01340/20201218/images/large/jm0c01340_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01340&amp;id=fig13"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig14" data-index="15" class="article__inlineFigure"><h2 class="fig-label">Figure 14</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01340/20201218/images/medium/jm0c01340_0014.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01340/20201218/images/large/jm0c01340_0014.jpeg" id="rightTab-gr14" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 14. Interaction Maps of <sup>111</sup>In-DTPA-A9 interaction with HER2-expressing BT474 cells. Concentrations of <sup>111</sup>In-DTPA-A9 were 4, 12, and 36 nM. Fitting binding LigandTracer curves to 1:2 interaction models suggest the presence of two interactions, one stronger (4.9 nM) and one weaker but predominant (103 nM).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01340/20201218/images/large/jm0c01340_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01340&amp;id=fig14"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i22">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_00085" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_00085" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 65 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yarden, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sliwkowski, M. X.</span></span> <span> </span><span class="NLM_article-title">Untangling the ErbB signalling network</span>. <i>Nat. Rev. Mol. Cell Biol.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">127</span>â <span class="NLM_lpage">137</span>, <span class="refDoi">Â DOI: 10.1038/35052073</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01340&amp;key=10.1038%2F35052073" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01340&amp;key=11252954" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01340&amp;key=1%3ACAS%3A528%3ADC%252BD3MXivVWnt7k%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2001&pages=127-137&author=Y.+Yardenauthor=M.+X.+Sliwkowski&title=Untangling+the+ErbB+signalling+network&doi=10.1038%2F35052073"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Untangling the ErbB signalling network</span></div><div class="casAuthors">Yarden, Yosef; Sliwkowski, Mark X.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Molecular Cell Biology</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">127-137</span>CODEN:
                <span class="NLM_cas:coden">NRMCBP</span>;
        ISSN:<span class="NLM_cas:issn">1471-0072</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review, with 112 refs.  When epidermal growth factor and its relatives bind the ErbB family of receptors, they trigger a rich network of signaling pathways, culminating in responses ranging from cell division to death, motility to adhesion.  The network is often dysregulated in cancer and lends credence to the mantra that mol. understanding yields clin. benefit: over 25,000 women with breast cancer have now been treated with Herceptin, a recombinant antibody designed to block the receptor ErbB2.  Likewise, small-mol. enzyme inhibitors and monoclonal antibodies to ErbB1 are in advanced phases of clin. testing.  What can this pathway teach us about translating basic science into clin. use.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGovhWL1HObvNrVg90H21EOLACvtfcHk0lg2rMhy4S2xjA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXivVWnt7k%253D&md5=1561a9666f77fce888be821399870cd6</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1038%2F35052073&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F35052073%26sid%3Dliteratum%253Aachs%26aulast%3DYarden%26aufirst%3DY.%26aulast%3DSliwkowski%26aufirst%3DM.%2BX.%26atitle%3DUntangling%2520the%2520ErbB%2520signalling%2520network%26jtitle%3DNat.%2520Rev.%2520Mol.%2520Cell%2520Biol.%26date%3D2001%26volume%3D2%26spage%3D127%26epage%3D137%26doi%3D10.1038%2F35052073" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Niehans, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singleton, T. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dykoski, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kiang, D. T.</span></span> <span> </span><span class="NLM_article-title">Stability of HER-2/neu expression over time and at multiple metastatic sites</span>. <i>J. Natl. Cancer Inst.</i> <span class="NLM_year" style="font-weight: bold;">1993</span>,  <span class="NLM_volume"><i>85</i></span>,  <span class="NLM_fpage">1230</span>â <span class="NLM_lpage">1235</span>, <span class="refDoi">Â DOI: 10.1093/jnci/85.15.1230</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01340&amp;key=10.1093%2Fjnci%2F85.15.1230" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01340&amp;key=8101229" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01340&amp;key=1%3ACAS%3A280%3ADyaK3szitlWntw%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=85&publication_year=1993&pages=1230-1235&author=G.+A.+Niehansauthor=T.+P.+Singletonauthor=D.+Dykoskiauthor=D.+T.+Kiang&title=Stability+of+HER-2%2Fneu+expression+over+time+and+at+multiple+metastatic+sites&doi=10.1093%2Fjnci%2F85.15.1230"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Stability of HER-2/neu expression over time and at multiple metastatic sites</span></div><div class="casAuthors">Niehans G A; Singleton T P; Dykoski D; Kiang D T</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the National Cancer Institute</span>
        (<span class="NLM_cas:date">1993</span>),
    <span class="NLM_cas:volume">85</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">1230-5</span>
        ISSN:<span class="NLM_cas:issn">0027-8874</span>.
    </div><div class="casAbstract">BACKGROUND:  Amplification and over-expression of the HER-2/neu oncogene (also known as c-erbB-2) occurs in 20%-30% of invasive breast carcinomas.  The extent to which HER-2/neu expression changes over time in association with tumor progression or is heterogeneous at different metastatic sites has received only limited study.  PURPOSE:  Our purpose was to determine whether primary tumors differ from metastases in HER-2/neu protein content or whether metastases are heterogeneous in regard to HER-2/neu expression.  METHODS:  In a retrospective study, we examined tumor tissue obtained at autopsy from two to five metastatic organ sites in each of 30 patients who died with metastatic breast carcinoma.  Using an immunoperoxidase technique, we stained archival formalin-fixed, paraffin-embedded tissue sections with a monoclonal antibody to the 185-kilodalton protein product (p185) of the HER-2/neu gene.  RESULTS:  The tissue from eight of 30 patients showed strong diffuse reactivity for p185 at all metastatic sites examined.  Tissues from six patients showed faint staining and tissues from 15 were negative, again with a congruent staining pattern.  A single case showed discordant staining, in that two of four metastases showed faint staining, whereas the other two showed strong immunoreactivity.  In 14 cases, we were able to obtain paraffin blocks from the original biopsy or surgical resection of the primary breast lesion.  For these 14 patients, the average length of time between initial diagnosis and death was 4 years (range, 2-9).  There was good correlation between results from autopsy and original surgical tissues.  CONCLUSIONS:  Expression of HER-2/neu appears to be relatively stable over time and is generally congruent at different metastatic sites.  IMPLICATIONS:  The fact that p185 immunoreactivity is rarely heterogeneous is encouraging, both for the potential use of HER-2/neu-related proteins as serum tumor markers and for innovative therapies targeted at p185 expression.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTvT3ZMfUDd95agfuraLLzSfW6udTcc2eZv1cyhbCZPC7ntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK3szitlWntw%253D%253D&md5=012292a70380d2aa4905099741b03916</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1093%2Fjnci%2F85.15.1230&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fjnci%252F85.15.1230%26sid%3Dliteratum%253Aachs%26aulast%3DNiehans%26aufirst%3DG.%2BA.%26aulast%3DSingleton%26aufirst%3DT.%2BP.%26aulast%3DDykoski%26aufirst%3DD.%26aulast%3DKiang%26aufirst%3DD.%2BT.%26atitle%3DStability%2520of%2520HER-2%252Fneu%2520expression%2520over%2520time%2520and%2520at%2520multiple%2520metastatic%2520sites%26jtitle%3DJ.%2520Natl.%2520Cancer%2520Inst.%26date%3D1993%26volume%3D85%26spage%3D1230%26epage%3D1235%26doi%3D10.1093%2Fjnci%2F85.15.1230" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Neve, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lane, H. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hynes, N. E.</span></span> <span> </span><span class="NLM_article-title">The role of overexpressed HER2 in transformation</span>. <i>Ann. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">S9</span>â <span class="NLM_lpage">S13</span>, <span class="refDoi">Â DOI: 10.1093/annonc/12.suppl_1.S9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01340&amp;key=10.1093%2Fannonc%2F12.suppl_1.S9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01340&amp;key=11521729" title="">PubMed</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2001&pages=S9-S13&author=R.+M.+Neveauthor=H.+A.+Laneauthor=N.+E.+Hynes&title=The+role+of+overexpressed+HER2+in+transformation&doi=10.1093%2Fannonc%2F12.suppl_1.S9"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1093%2Fannonc%2F12.suppl_1.S9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fannonc%252F12.suppl_1.S9%26sid%3Dliteratum%253Aachs%26aulast%3DNeve%26aufirst%3DR.%2BM.%26aulast%3DLane%26aufirst%3DH.%2BA.%26aulast%3DHynes%26aufirst%3DN.%2BE.%26atitle%3DThe%2520role%2520of%2520overexpressed%2520HER2%2520in%2520transformation%26jtitle%3DAnn.%2520Oncol.%26date%3D2001%26volume%3D12%26spage%3DS9%26epage%3DS13%26doi%3D10.1093%2Fannonc%2F12.suppl_1.S9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Slamon, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clark, G. M S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levin, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ullrich, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McGuire, W. L.</span></span> <span> </span><span class="NLM_article-title">Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">1987</span>,  <span class="NLM_volume"><i>235</i></span>,  <span class="NLM_fpage">177</span>â <span class="NLM_lpage">182</span>, <span class="refDoi">Â DOI: 10.1126/science.3798106</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01340&amp;key=10.1126%2Fscience.3798106" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01340&amp;key=3798106" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01340&amp;key=1%3ACAS%3A528%3ADyaL2sXhtVSht7s%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=235&publication_year=1987&pages=177-182&author=D.+J.+Slamonauthor=G.+M+S.+Clarkauthor=G.+Wongauthor=W.+J.+Levinauthor=A.+Ullrichauthor=W.+L.+McGuire&title=Human+breast+cancer%3A+correlation+of+relapse+and+survival+with+amplification+of+the+HER-2%2Fneu+oncogene&doi=10.1126%2Fscience.3798106"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Human breast cancer:  correlation of relapse and survival with amplification of the HER-2/neu oncogene</span></div><div class="casAuthors">Slamon, Dennis J.; Clark, Gary M.; Wong, Steven G.; Levin, Wendy J.; Ullrich, Axel; McGuire, William L.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">1987</span>),
    <span class="NLM_cas:volume">235</span>
        (<span class="NLM_cas:issue">4785</span>),
    <span class="NLM_cas:pages">177-82</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    </div><div class="casAbstract">The HER-2/neu oncogene is a member of the erbB-like oncogene family, and is related to, but distinct from, the epidermal growth factor receptor.  This gene has been shown to be amplified in human breast cancer cell lines.  In the current study, alterations of the gene in 189 primary human breast cancers were investigated.  HER-2/neu was found to be amplified from 2- to >20-fold in 30% of the tumors.  Correlation of gene amplification with several disease parameters was evaluated.  Amplification of the HER-2neu gene was a significant predictor of both overall survival and time to relapse in patients with breast cancer.  It retained its significance even when adjustments were made for other known prognostic factors.  Moreover, HER-2/neu amplification had greater prognostic value than most currently used prognostic factors, including hormonal-receptor status, in lymph node-pos. disease.  These data indicate that this gene may play a role in the biol. behavior and(or) pathogenesis of human breast cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoWPpNbN8S_QrVg90H21EOLACvtfcHk0li93DE1PGcKsQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL2sXhtVSht7s%253D&md5=0889410d6e47651de4d8085e9bbd70d9</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1126%2Fscience.3798106&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.3798106%26sid%3Dliteratum%253Aachs%26aulast%3DSlamon%26aufirst%3DD.%2BJ.%26aulast%3DClark%26aufirst%3DG.%2BM%2BS.%26aulast%3DWong%26aufirst%3DG.%26aulast%3DLevin%26aufirst%3DW.%2BJ.%26aulast%3DUllrich%26aufirst%3DA.%26aulast%3DMcGuire%26aufirst%3DW.%2BL.%26atitle%3DHuman%2520breast%2520cancer%253A%2520correlation%2520of%2520relapse%2520and%2520survival%2520with%2520amplification%2520of%2520the%2520HER-2%252Fneu%2520oncogene%26jtitle%3DScience%26date%3D1987%26volume%3D235%26spage%3D177%26epage%3D182%26doi%3D10.1126%2Fscience.3798106" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Paik, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hazan, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fisher, E. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sass, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fisher, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Redmond, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schlessinger, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lippman, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">King, C. R.</span></span> <span> </span><span class="NLM_article-title">Pathologic findings from the national surgical adjuvant breast and bowel project: Prognostic significance of erbE-2 protein overexpression in primary breast cancer</span>. <i>J. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">1990</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">103</span>â <span class="NLM_lpage">112</span>, <span class="refDoi">Â DOI: 10.1200/JCO.1990.8.1.103</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01340&amp;key=10.1200%2FJCO.1990.8.1.103" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01340&amp;key=1967301" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01340&amp;key=1%3ACAS%3A280%3ADyaK3c7htFOktw%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=1990&pages=103-112&author=S.+Paikauthor=R.+Hazanauthor=E.+R.+Fisherauthor=R.+E.+Sassauthor=B.+Fisherauthor=C.+Redmondauthor=J.+Schlessingerauthor=M.+E.+Lippmanauthor=C.+R.+King&title=Pathologic+findings+from+the+national+surgical+adjuvant+breast+and+bowel+project%3A+Prognostic+significance+of+erbE-2+protein+overexpression+in+primary+breast+cancer&doi=10.1200%2FJCO.1990.8.1.103"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Pathologic findings from the National Surgical Adjuvant Breast and Bowel Project: prognostic significance of erbB-2 protein overexpression in primary breast cancer</span></div><div class="casAuthors">Paik S; Hazan R; Fisher E R; Sass R E; Fisher B; Redmond C; Schlessinger J; Lippman M E; King C R</div><div class="citationInfo"><span class="NLM_cas:title">Journal of clinical oncology : official journal of the American Society of Clinical Oncology</span>
        (<span class="NLM_cas:date">1990</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">103-12</span>
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    </div><div class="casAbstract">In order to investigate the prognostic significance of erbB-2 overexpression, immunohistochemical staining for the erbB-2 protein was performed on sections from paraffin blocks of 292 primary invasive breast cancers obtained from women enrolled in the National Surgical Adjuvant Breast and Bowel Project (NSABP) protocol B-06.  Positive reaction indicative of erbB-2 overexpression was observed on tumor cells in 62 (21%) samples.  Women whose cancers were judged to have erbB-2 overexpression had a significantly worse overall survival (P = .0012) with twice the mortality rate of women without detectable erbB-2 expression.  No statistically significant effect was evident for disease-free survival (P = .22).  In multivariate analysis, detection of erbB-2 overexpression was the second most predictive independent variable for survival after nodal status.  Overexpression of erbB-2 was more common among tumors of poor nuclear grade (29%) than those of good nuclear grade (12%).  The association of erbB-2 overexpression with decreased survival was evident only among women with tumors of good nuclear grade.  In this subgroup, erbB-2 overexpression was associated with an approximately fivefold increase in mortality rate (P = .00001).  The combined predictive value of erbB-2 overexpression and nuclear grade was evident regardless of their lymph node status.  These results provide evidence that detection of erbB-2 overexpression may be an independent prognostic variable for patient survival.  Moreover, when combined with evaluation of nuclear grade, it may be possible to use immunostaining for erbB-2 protein to identify patients at increased risk from within a relatively low-risk group.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcR2whjqgdBz2A5nADWVYHg1fW6udTcc2eZUC7Kk9ykUCrntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK3c7htFOktw%253D%253D&md5=97590453275112f08f8ed2281ca2e485</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1200%2FJCO.1990.8.1.103&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.1990.8.1.103%26sid%3Dliteratum%253Aachs%26aulast%3DPaik%26aufirst%3DS.%26aulast%3DHazan%26aufirst%3DR.%26aulast%3DFisher%26aufirst%3DE.%2BR.%26aulast%3DSass%26aufirst%3DR.%2BE.%26aulast%3DFisher%26aufirst%3DB.%26aulast%3DRedmond%26aufirst%3DC.%26aulast%3DSchlessinger%26aufirst%3DJ.%26aulast%3DLippman%26aufirst%3DM.%2BE.%26aulast%3DKing%26aufirst%3DC.%2BR.%26atitle%3DPathologic%2520findings%2520from%2520the%2520national%2520surgical%2520adjuvant%2520breast%2520and%2520bowel%2520project%253A%2520Prognostic%2520significance%2520of%2520erbE-2%2520protein%2520overexpression%2520in%2520primary%2520breast%2520cancer%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D1990%26volume%3D8%26spage%3D103%26epage%3D112%26doi%3D10.1200%2FJCO.1990.8.1.103" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Garrett, T. P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McKern, N. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lou, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elleman, T. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adams, T. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lovrecz, G. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kofler, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jorissen, R. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nice, E. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burgess, A. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ward, C. W.</span></span> <span> </span><span class="NLM_article-title">The crystal structure of a truncated ErbB2 ectodomain reveals an active conformation, poised to interact with other ErbB receptors</span>. <i>Mol. Cell</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">495</span>â <span class="NLM_lpage">505</span>, <span class="refDoi">Â DOI: 10.1016/S1097-2765(03)00048-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01340&amp;key=10.1016%2FS1097-2765%2803%2900048-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01340&amp;key=12620236" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01340&amp;key=1%3ACAS%3A528%3ADC%252BD3sXit1WgsLo%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2003&pages=495-505&author=T.+P.+J.+Garrettauthor=N.+M.+McKernauthor=M.+Louauthor=T.+C.+Ellemanauthor=T.+E.+Adamsauthor=G.+O.+Lovreczauthor=M.+Koflerauthor=R.+N.+Jorissenauthor=E.+C.+Niceauthor=A.+W.+Burgessauthor=C.+W.+Ward&title=The+crystal+structure+of+a+truncated+ErbB2+ectodomain+reveals+an+active+conformation%2C+poised+to+interact+with+other+ErbB+receptors&doi=10.1016%2FS1097-2765%2803%2900048-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">The crystal structure of a truncated ErbB2 ectodomain reveals an active conformation, poised to interact with other ErbB receptors</span></div><div class="casAuthors">Garrett, Thomas P. J.; McKern, Neil M.; Lou, Meizhen; Elleman, Thomas C.; Adams, Timothy E.; Lovrecz, George O.; Kofler, Michael; Jorissen, Robert N.; Nice, Edouard C.; Burgess, Antony W.; Ward, Colin W.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cell</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">495-505</span>CODEN:
                <span class="NLM_cas:coden">MOCEFL</span>;
        ISSN:<span class="NLM_cas:issn">1097-2765</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">ErbB2 does not bind ligand, yet appears to be the major signaling partner for other ErbB receptors by forming heteromeric complexes with ErbB1, ErbB3, or ErbB4.  The crystal structure of residues 1-509 of ErbB2 at 2.5 Ã resoln. reveals an activated conformation similar to that of the EGFR when complexed with ligand and very different from that seen in the unactivated forms of ErbB3 or EGFR.  The structure explains the inability of ErbB2 to bind known ligands and suggests why ErbB2 fails to form homodimers.  Together, the data suggest a model in which ErbB2 is already in the activated conformation and ready to interact with other ligand-activated ErbB receptors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpKWPX-PxHzzbVg90H21EOLACvtfcHk0lhLA1YWGGC8rA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXit1WgsLo%253D&md5=117d9fe768aec8d63638724fb41ee14d</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1016%2FS1097-2765%2803%2900048-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1097-2765%252803%252900048-0%26sid%3Dliteratum%253Aachs%26aulast%3DGarrett%26aufirst%3DT.%2BP.%2BJ.%26aulast%3DMcKern%26aufirst%3DN.%2BM.%26aulast%3DLou%26aufirst%3DM.%26aulast%3DElleman%26aufirst%3DT.%2BC.%26aulast%3DAdams%26aufirst%3DT.%2BE.%26aulast%3DLovrecz%26aufirst%3DG.%2BO.%26aulast%3DKofler%26aufirst%3DM.%26aulast%3DJorissen%26aufirst%3DR.%2BN.%26aulast%3DNice%26aufirst%3DE.%2BC.%26aulast%3DBurgess%26aufirst%3DA.%2BW.%26aulast%3DWard%26aufirst%3DC.%2BW.%26atitle%3DThe%2520crystal%2520structure%2520of%2520a%2520truncated%2520ErbB2%2520ectodomain%2520reveals%2520an%2520active%2520conformation%252C%2520poised%2520to%2520interact%2520with%2520other%2520ErbB%2520receptors%26jtitle%3DMol.%2520Cell%26date%3D2003%26volume%3D11%26spage%3D495%26epage%3D505%26doi%3D10.1016%2FS1097-2765%2803%2900048-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Engel, R. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaklamani, V. G.</span></span> <span> </span><span class="NLM_article-title">HER2-positive breast cancer: Current and future treatment strategies</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>67</i></span>,  <span class="NLM_fpage">1329</span>â <span class="NLM_lpage">1341</span>, <span class="refDoi">Â DOI: 10.2165/00003495-200767090-00006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01340&amp;key=10.2165%2F00003495-200767090-00006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01340&amp;key=17547474" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01340&amp;key=1%3ACAS%3A528%3ADC%252BD2sXptVyku7s%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=67&publication_year=2007&pages=1329-1341&author=R.+H.+Engelauthor=V.+G.+Kaklamani&title=HER2-positive+breast+cancer%3A+Current+and+future+treatment+strategies&doi=10.2165%2F00003495-200767090-00006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">HER2-positive breast cancer: current and future treatment strategies</span></div><div class="casAuthors">Engel, Ryan H.; Kaklamani, Virginia G.</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">67</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1329-1341</span>CODEN:
                <span class="NLM_cas:coden">DRUGAY</span>;
        ISSN:<span class="NLM_cas:issn">0012-6667</span>.
    
            (<span class="NLM_cas:orgname">Wolters Kluwer Health</span>)
        </div><div class="casAbstract">A review.  In the year 2006, breast cancer was estd. to affect >200 000 American women and cause nearly 56 000 deaths.  Furthermore, breast cancer is the most common cancer diagnosed and second most common cause of cancer-related deaths in women.  The current treatment armamentarium for breast cancer includes chemotherapy, endocrine therapy and biol. therapy.  Treatment has become more individualized based on characteristics of the tumor including overexpression of the human epidermal growth factor receptor (HER)-2.  Between 20 and 30% of all breast cancers overexpress HER2, which means 40 000-60 000 patients will have this type of cancer.  Previously, overexpression of HER2 was a neg. prognostic and predictive risk factor for survival; however, with the advent of trastuzumab, patients' prognosis is improving in all treatment settings.  Much controversy exists in the use of trastuzumab, including (i) the sequence of adjuvant trastuzumab (concurrent with chemotherapy or sequential); (ii) the treatment duration (<1 yr, 1 yr or 2 years); and (iii) the treatment choice upon disease progression (whether to continue or not with trastuzumab and add another cytotoxic agent).  Current trials are ongoing to help answer these questions.  Furthermore, there has been interest in predicting which HER2-pos. patients would require anthracycline therapy, and which could avoid anthracycline therapy and its toxicities.  Novel therapeutics, such as lapatinib, an oral tyrosine kinase inhibitor, which blocks both the epidermal growth factor receptor and HER2 receptor has recently been approved by the US FDA.  Whereas pertuzumab, a humanized monoclonal antibody, directed against heterodimerization of HER2 and HER3 has entered phase II and III clin. trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrJgkiP3PQ-ZLVg90H21EOLACvtfcHk0lhLA1YWGGC8rA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXptVyku7s%253D&md5=28821ef69329052441a8b33e3d17daa2</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.2165%2F00003495-200767090-00006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2165%252F00003495-200767090-00006%26sid%3Dliteratum%253Aachs%26aulast%3DEngel%26aufirst%3DR.%2BH.%26aulast%3DKaklamani%26aufirst%3DV.%2BG.%26atitle%3DHER2-positive%2520breast%2520cancer%253A%2520Current%2520and%2520future%2520treatment%2520strategies%26jtitle%3DDrugs%26date%3D2007%26volume%3D67%26spage%3D1329%26epage%3D1341%26doi%3D10.2165%2F00003495-200767090-00006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Faltus, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zimmer, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kramer, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loibl, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaufmann, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strebhardt, K.</span></span> <span> </span><span class="NLM_article-title">Silencing of the HER2/neu gene by siRNA inhibits proliferation and induces apoptosis in HER2/neu-overexpressing breast cancer cells</span>. <i>Neoplasia</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">786</span>â <span class="NLM_lpage">795</span>, <span class="refDoi">Â DOI: 10.1593/neo.04313</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01340&amp;key=10.1593%2Fneo.04313" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01340&amp;key=15720805" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01340&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtFWnsb8%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2004&pages=786-795&author=T.+Faltusauthor=J.+Yuanauthor=B.+Zimmerauthor=A.+Kramerauthor=S.+Loiblauthor=M.+Kaufmannauthor=K.+Strebhardt&title=Silencing+of+the+HER2%2Fneu+gene+by+siRNA+inhibits+proliferation+and+induces+apoptosis+in+HER2%2Fneu-overexpressing+breast+cancer+cells&doi=10.1593%2Fneo.04313"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Silencing of the HER2/neu gene by siRNA inhibits proliferation and induces apoptosis in HER2/neu-overexpressing breast cancer cells</span></div><div class="casAuthors">Faltus, Timo; Yuan, Juping; Zimmer, Brigitte; Kraemer, Andrea; Loibl, Sibylle; Kaufmann, Manfred; Strebhardt, Klaus</div><div class="citationInfo"><span class="NLM_cas:title">Neoplasia (Ann Arbor, MI, United States)</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">786-795</span>CODEN:
                <span class="NLM_cas:coden">NEOPFL</span>;
        ISSN:<span class="NLM_cas:issn">1522-8002</span>.
    
            (<span class="NLM_cas:orgname">Neoplasia Press Inc.</span>)
        </div><div class="casAbstract">In eukaryotes, double-stranded (ds) RNA induces sequence-specific inhibition of gene expression referred to as RNA interference (RNAi).  We exploited RNAi to define the role of HER2/neu in the neoplastic proliferation of human breast cancer cells.  We transfected SK-BR-3, BT-474, MCF-7, and MDA-MB-468 breast cancer cells with short interfering RNA (siRNA) targeted against human HER2/neu and analyzed the specific inhibition of HER2/neu expression by Northern and Western blots.  Transfection with HER2/neu-specific siRNA resulted in a sequence-specific decrease in HER2/neu mRNA and protein levels.  Moreover, transfection with HER2/neu siRNA caused cell cycle arrest at G0/G1 in the breast cancer cell lines SK-BR-3 and BT-474, consistent with a powerful RNA silencing effect.  SiRNA treatment resulted in an antiproliferative and apoptotic response in cells overexpressing HER2/neu, but had no influence in cells with almost no expression of HER2/neu proteins like MDA-MB-468 cells.  These data indicate that HER2/neu function is essential for the proliferation of HER2/neu-overexpressing breast cancer cells.  Our observations suggest that siRNA targeted against human HER2/neu may be valuable tools as antiproliferative agents that display activity against neoplastic cells at very low doses.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpGk7M-n6brL7Vg90H21EOLACvtfcHk0lhLA1YWGGC8rA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtFWnsb8%253D&md5=8c682552394e1cf202e6f15580a44916</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1593%2Fneo.04313&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1593%252Fneo.04313%26sid%3Dliteratum%253Aachs%26aulast%3DFaltus%26aufirst%3DT.%26aulast%3DYuan%26aufirst%3DJ.%26aulast%3DZimmer%26aufirst%3DB.%26aulast%3DKramer%26aufirst%3DA.%26aulast%3DLoibl%26aufirst%3DS.%26aulast%3DKaufmann%26aufirst%3DM.%26aulast%3DStrebhardt%26aufirst%3DK.%26atitle%3DSilencing%2520of%2520the%2520HER2%252Fneu%2520gene%2520by%2520siRNA%2520inhibits%2520proliferation%2520and%2520induces%2520apoptosis%2520in%2520HER2%252Fneu-overexpressing%2520breast%2520cancer%2520cells%26jtitle%3DNeoplasia%26date%3D2004%26volume%3D6%26spage%3D786%26epage%3D795%26doi%3D10.1593%2Fneo.04313" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yang, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cai, K. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thompson-Lanza, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bast, R. C.,  Jr.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span> <span> </span><span class="NLM_article-title">Inhibition of breast and ovarian tumor growth through multiple signaling pathways by using retrovirus-mediated small interfering RNA against Her-2/neu gene expression</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>279</i></span>,  <span class="NLM_fpage">4339</span>â <span class="NLM_lpage">4345</span>, <span class="refDoi">Â DOI: 10.1074/jbc.M311153200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01340&amp;key=10.1074%2Fjbc.M311153200" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01340&amp;key=14625284" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01340&amp;key=1%3ACAS%3A528%3ADC%252BD2cXps12guw%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=279&publication_year=2004&pages=4339-4345&author=G.+Yangauthor=K.+Q.+Caiauthor=J.+A.+Thompson-Lanzaauthor=R.+C.+Bastauthor=J.+Liu&title=Inhibition+of+breast+and+ovarian+tumor+growth+through+multiple+signaling+pathways+by+using+retrovirus-mediated+small+interfering+RNA+against+Her-2%2Fneu+gene+expression&doi=10.1074%2Fjbc.M311153200"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of Breast and Ovarian Tumor Growth through Multiple Signaling Pathways by Using Retrovirus-mediated Small Interfering RNA against Her-2/neu Gene Expression</span></div><div class="casAuthors">Yang, Gong; Cai, Kathy Qi; Thompson-Lanza, Jennifer A.; Bast, Robert C., Jr.; Liu, Jinsong</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">279</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">4339-4345</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">The Her-2/neu oncogene is overexpressed in â¼30% of breast and ovarian cancer cases and often indicates a poor prognosis.  Therapeutic agents against Her-2/neu have been intensively sought over the past decade.  Here we show that small interfering RNA (siRNA) can silence the expression of Her-2/neu in models of human breast or ovarian cancer through retrovirus-mediated transfer of an siRNA against Her-2/neu.  Cells infected with retrovirus expressing anti-Her-2/neu siRNA exhibit slower proliferation, increased apoptosis, increased G0/G1 arrest, and decreased tumor growth.  Changes in cell cycle-assocd. factors included decreased levels of phosphatidylinositol 3-kinase, pAkt, and cyclin D1 and increased levels of p27 and phosphorylated retinoblastoma protein.  Knockdown of Her-2/neu expression by siRNA is also assocd. with increased expression of the anti-angiogenic factor thrombospondin-1 and decreased expression of the pro-angiogenic vascular endothelial growth factor, suggesting that Her-2/neu stimulates tumor growth at least in part by regulating angiogenesis.  SiRNA-mediated gene silencing of Her-2/neu and increasing the expression of thrombospondin-1 may be a useful therapeutic strategy for Her-2/neu-over-expressing breast or ovarian cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGohuyI7dYjoIbVg90H21EOLACvtfcHk0lhNJWplKnWVQA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXps12guw%253D%253D&md5=bda2bf2120ef1725130173c2e084ac2d</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M311153200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M311153200%26sid%3Dliteratum%253Aachs%26aulast%3DYang%26aufirst%3DG.%26aulast%3DCai%26aufirst%3DK.%2BQ.%26aulast%3DThompson-Lanza%26aufirst%3DJ.%2BA.%26aulast%3DBast%26aufirst%3DR.%2BC.%26aulast%3DLiu%26aufirst%3DJ.%26atitle%3DInhibition%2520of%2520breast%2520and%2520ovarian%2520tumor%2520growth%2520through%2520multiple%2520signaling%2520pathways%2520by%2520using%2520retrovirus-mediated%2520small%2520interfering%2520RNA%2520against%2520Her-2%252Fneu%2520gene%2520expression%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2004%26volume%3D279%26spage%3D4339%26epage%3D4345%26doi%3D10.1074%2Fjbc.M311153200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pils, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pinter, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reibenwein, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alfanz, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Horak, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmid, B. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hefler, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Horvat, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reinthaller, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zeillinger, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krainer, M.</span></span> <span> </span><span class="NLM_article-title">In ovarian cancer the prognostic influence of HER2/neu is not dependent on the CXCR4/SDF-1 signalling pathway</span>. <i>Br. J. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>96</i></span>,  <span class="NLM_fpage">485</span>â <span class="NLM_lpage">491</span>, <span class="refDoi">Â DOI: 10.1038/sj.bjc.6603581</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01340&amp;key=10.1038%2Fsj.bjc.6603581" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01340&amp;key=17245339" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01340&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtlKjt70%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=96&publication_year=2007&pages=485-491&author=D.+Pilsauthor=A.+Pinterauthor=J.+Reibenweinauthor=A.+Alfanzauthor=P.+Horakauthor=B.+C.+Schmidauthor=L.+Heflerauthor=R.+Horvatauthor=A.+Reinthallerauthor=R.+Zeillingerauthor=M.+Krainer&title=In+ovarian+cancer+the+prognostic+influence+of+HER2%2Fneu+is+not+dependent+on+the+CXCR4%2FSDF-1+signalling+pathway&doi=10.1038%2Fsj.bjc.6603581"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">In ovarian cancer the prognostic influence of HER2/neu is not dependent on the CXCR4/SDF-1 signalling pathway</span></div><div class="casAuthors">Pils, D.; Pinter, A.; Reibenwein, J.; Alfanz, A.; Horak, P.; Schmid, B. C.; Hefler, L.; Horvat, R.; Reinthaller, A.; Zeillinger, R.; Krainer, M.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Cancer</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">96</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">485-491</span>CODEN:
                <span class="NLM_cas:coden">BJCAAI</span>;
        ISSN:<span class="NLM_cas:issn">0007-0920</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">HER2/neu overexpression is a driving force in the carcinogenesis of several human cancers.  In breast cancer the prognostic influence of HER2/neu was shown to be at least partly based on increased metastatic potential mediated by the chemokine-chemokine receptor pair SDF-1(CXCL12)/CXCR4.  We wanted to evaluate the influence of HER2/neu on ovarian cancer prognosis and to investigate whether compromised survival would correlate with CXCR4 expression and/or SDF-1 abundance.  Therefore, we analyzed HER2/neu, CXCR4, and SDF-1 in 148 ovarian tumor samples by means of immunohistochem. on tissue microarrays.  Overexpression of HER2/neu was found in 27.6% of ovarian cancer tissues and in 15% of ovarian borderline tumors.  In ovarian cancer patients, overexpression of HER2/neu correlated closely with overall survival (univariate hazard ratio (HR) 2.59, P=0.005; multiple cor. HR 1.92, P=0.074).  In contrast, CXCR4 expression and SDF-1 abundance had no impact on overall survival, and both parameters were not correlated with HER2/neu expression.  As expected, cytoplasmic CXCR4 expression and SDF-1 abundance correlated closely (P<0.0001).  Our results confirm a univariate influence of HER2/neu expression on overall survival, which was completely independent of the expression of CXCR4 and the abundance of SDF-1, implying significant differences between the HER2/neu downstream pathways in ovarian cancer compared with breast cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoExClqP7-BKrVg90H21EOLACvtfcHk0lhNJWplKnWVQA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtlKjt70%253D&md5=59b5e993cc860bbad227a074a9763d1e</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1038%2Fsj.bjc.6603581&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.bjc.6603581%26sid%3Dliteratum%253Aachs%26aulast%3DPils%26aufirst%3DD.%26aulast%3DPinter%26aufirst%3DA.%26aulast%3DReibenwein%26aufirst%3DJ.%26aulast%3DAlfanz%26aufirst%3DA.%26aulast%3DHorak%26aufirst%3DP.%26aulast%3DSchmid%26aufirst%3DB.%2BC.%26aulast%3DHefler%26aufirst%3DL.%26aulast%3DHorvat%26aufirst%3DR.%26aulast%3DReinthaller%26aufirst%3DA.%26aulast%3DZeillinger%26aufirst%3DR.%26aulast%3DKrainer%26aufirst%3DM.%26atitle%3DIn%2520ovarian%2520cancer%2520the%2520prognostic%2520influence%2520of%2520HER2%252Fneu%2520is%2520not%2520dependent%2520on%2520the%2520CXCR4%252FSDF-1%2520signalling%2520pathway%26jtitle%3DBr.%2520J.%2520Cancer%26date%3D2007%26volume%3D96%26spage%3D485%26epage%3D491%26doi%3D10.1038%2Fsj.bjc.6603581" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Roh, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pippin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drebin, J. A.</span></span> <span> </span><span class="NLM_article-title">Down-regulation of HER2/neu expression induces apoptosis in human cancer cells that overexpress HER2/neu</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">560</span>â <span class="NLM_lpage">565</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01340&amp;key=10676637" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01340&amp;key=1%3ACAS%3A528%3ADC%252BD3cXht1Gmt7k%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2000&pages=560-565&author=H.+Rohauthor=J.+Pippinauthor=J.+A.+Drebin&title=Down-regulation+of+HER2%2Fneu+expression+induces+apoptosis+in+human+cancer+cells+that+overexpress+HER2%2Fneu"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Down-regulation of HER2/neu expression induces apoptosis in human cancer cells that overexpress HER2/neu</span></div><div class="casAuthors">Roh, Haeri; Pippin, James; Drebin, Jeffrey A.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">560-565</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">AACR Subscription Office</span>)
        </div><div class="casAbstract">The HER2/neu oncogene is overexpressed in a significant fraction of human tumors; such overexpression is thought to play a role in the aberrant proliferation of cancer cells.  The effects of HER2/neu-specific phosphorothioate antisense oligodeoxyribonucleotides on HER2/neu expression, tumor cell proliferation, and activation of apoptotic cell death pathways have been examd.  Antisense treatment down-regulates HER2/neu expression in a dose-dependent and sequence-specific manner.  HER2/neu antisense treatment specifically inhibits the growth of tumor lines that overexpress HER2/neu, but it has little effect on the growth of tumor cells that express low levels of HER2/neu.  Down-regulation of HER2/neu expression is not only cytostatic, but it also results in the activation of apoptotic cell death pathways in cells that overexpress HER2/neu.  These results suggest that, in addn. to stimulating tumor cell proliferation, HER2/neu overexpression in cancer cells acts as an antiapoptotic cell survival factor.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq01tOwwQSL_LVg90H21EOLACvtfcHk0lhNJWplKnWVQA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXht1Gmt7k%253D&md5=3e3c538fe0df9db4890d93766c728f66</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DRoh%26aufirst%3DH.%26aulast%3DPippin%26aufirst%3DJ.%26aulast%3DDrebin%26aufirst%3DJ.%2BA.%26atitle%3DDown-regulation%2520of%2520HER2%252Fneu%2520expression%2520induces%2520apoptosis%2520in%2520human%2520cancer%2520cells%2520that%2520overexpress%2520HER2%252Fneu%26jtitle%3DCancer%2520Res.%26date%3D2000%26volume%3D60%26spage%3D560%26epage%3D565" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tai, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qin, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, K.</span></span> <span> </span><span class="NLM_article-title">Inhibition of breast cancer cell growth and invasiveness by dual silencing of HER2 and VEGF</span>. <i>Mol. Pharmaceutics</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">543</span>â <span class="NLM_lpage">556</span>, <span class="refDoi">Â DOI: 10.1021/mp9002514</span> </span><div class="citationLinks">[<a href="/doi/10.1021/mp9002514" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01340&amp;key=1%3ACAS%3A528%3ADC%252BC3cXptlGmsg%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2010&pages=543-556&author=W.+Taiauthor=B.+Qinauthor=K.+Cheng&title=Inhibition+of+breast+cancer+cell+growth+and+invasiveness+by+dual+silencing+of+HER2+and+VEGF&doi=10.1021%2Fmp9002514"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of Breast Cancer Cell Growth and Invasiveness by Dual Silencing of HER-2 and VEGF</span></div><div class="casAuthors">Tai, Wanyi; Qin, Bin; Cheng, Kun</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmaceutics</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">543-556</span>CODEN:
                <span class="NLM_cas:coden">MPOHBP</span>;
        ISSN:<span class="NLM_cas:issn">1543-8384</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Overexpression of HER-2 accounts for â¼25% of all breast cancer cases, while 87.7% of HER-2 pos. breast cancers are assocd. with upregulated VEGF.  The objective of this study is to explore the combination therapy of blocking HER-2 and VEGF expressions simultaneously using siRNA.  This is the first report to examine the effect of dual silencing of HER-2 and VEGF genes on tumor growth and invasiveness.  We have designed nine HER-2 siRNAs and ten VEGF siRNAs, and identified potent siRNA which can silence the target gene up to 75-83.5%.  The most potent HER-2 and VEGF siRNAs were used to conduct functional studies in HER-2 pos. breast cancer cells.  Tumor invasiveness properties including cell morphol. change, in vitro migration, cell spreading, and adhesion to ECM were evaluated.  In addn., cell proliferation and apoptosis were examd. after the siRNA treatment.  Our data demonstrated for the first time that HER-2 siRNA could inhibit cell migration and invasion abilities.  Combination of HER-2 and VEGF siRNAs exhibited synergistic silencing effect on VEGF.  Both HER-2 siRNA and VEGF siRNA showed significant inhibition on cell migration and proliferation.  HER-2 siRNA also demonstrated dramatic suppression on cell spreading and adhesion to ECM, as well as induction of apoptosis.  Dual silencing of HER-2 and VEGF exhibited significant cell morphol. change, and substantial suppression on migration, spreading, cell adhesion, and proliferation.  Our observations suggested that HER-2 pos. breast cancer may be more effectively treated by dual inhibition of HER-2 and VEGF gene expressions using siRNA.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr3G3Ku_S6O1rVg90H21EOLACvtfcHk0lg6rP-VANZ_gA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXptlGmsg%253D%253D&md5=a719436c7474dfd4c60f33092e88698e</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1021%2Fmp9002514&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fmp9002514%26sid%3Dliteratum%253Aachs%26aulast%3DTai%26aufirst%3DW.%26aulast%3DQin%26aufirst%3DB.%26aulast%3DCheng%26aufirst%3DK.%26atitle%3DInhibition%2520of%2520breast%2520cancer%2520cell%2520growth%2520and%2520invasiveness%2520by%2520dual%2520silencing%2520of%2520HER2%2520and%2520VEGF%26jtitle%3DMol.%2520Pharmaceutics%26date%3D2010%26volume%3D7%26spage%3D543%26epage%3D556%26doi%3D10.1021%2Fmp9002514" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bookman, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Darcy, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clarke-Pearson, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boothby, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Horowitz, I. R.</span></span> <span> </span><span class="NLM_article-title">Evaluation of monoclonal humanized anti- HER2 antibody, trastuzumab, in patients with recurrent or refractory ovarian or primary peritoneal carcinoma with overexpression of HER2: a phase II trial of the Gynecologic Oncology Group</span>. <i>J. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">283</span>â <span class="NLM_lpage">290</span>, <span class="refDoi">Â DOI: 10.1200/JCO.2003.10.104</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01340&amp;key=10.1200%2FJCO.2003.10.104" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01340&amp;key=12525520" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01340&amp;key=1%3ACAS%3A528%3ADC%252BD2cXpsVWqs70%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2003&pages=283-290&author=M.+A.+Bookmanauthor=K.+M.+Darcyauthor=D.+Clarke-Pearsonauthor=R.+A.+Boothbyauthor=I.+R.+Horowitz&title=Evaluation+of+monoclonal+humanized+anti-+HER2+antibody%2C+trastuzumab%2C+in+patients+with+recurrent+or+refractory+ovarian+or+primary+peritoneal+carcinoma+with+overexpression+of+HER2%3A+a+phase+II+trial+of+the+Gynecologic+Oncology+Group&doi=10.1200%2FJCO.2003.10.104"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Evaluation of monoclonal humanized anti-HER2 antibody, trastuzumab, in patients with recurrent or refractory ovarian or primary peritoneal carcinoma with overexpression of HER2: a phase II trial of the gynecologic oncology group</span></div><div class="casAuthors">Bookman, Michael A.; Darcy, Kathleen M.; Clarke-Pearson, Daniel; Boothby, Richard A.; Horowitz, Ira R.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">283-290</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">Purpose: To evaluate the feasibility, toxicity, and efficacy of single-agent monoclonal antibody therapy targeting the human epidermal growth factor receptor 2 (HER2)/neu receptor in ovarian and primary peritoneal carcinoma.  Patients and Methods: Eligible patients had measurable persistent or recurrent epithelial ovarian or primary peritoneal carcinoma with 2+ or 3+ HER2 overexpression documented by immunohistochem.  I.v. trastuzumab was administered initially at a dose of 4 mg/kg, then weekly at 2 mg/kg.  Patients without progressive disease or excessive toxicity could continue treatment indefinitely.  Those with stable or responding disease at 8 wk were offered treatment at a higher weekly dose (4 mg/kg) at time of progression.  Patient sera were analyzed for the presence of the sol. extracellular domain of HER2, host antibodies against trastuzumab, and trastuzumab pharmacokinetics.  Results: A total of 837 tumor samples were screened for HER2 expression, and 95 patients (11.4%) exhibited the requisite 2+/3+ expression level.  Forty-five patients, all of whom received prior chemotherapy, were entered, and 41 were deemed eligible and assessable.  There were only mild expected toxicities and no treatment-related deaths.  Although an elevated level of the sol. extracellular domain of HER2 was detected in eight of 24 patients, serum HER2 was not assocd. with clin. outcome.  There was no evidence of host anti-trastuzumab antibody formation.  Serum concns. of trastuzumab gradually increased with continued therapy.  An overall response rate of 7.3% included one complete and two partial responses.  Median treatment duration was 8 wk (range, 2 to 104 wk), and median progression-free interval was 2.0 mo.  Conclusion: The clin. value of single-agent trastuzumab in recurrent ovarian cancer is limited by the low frequency of HER2 overexpression and low rate of objective response among patients with HER2 overexpression.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoBNR7aNbo9JLVg90H21EOLACvtfcHk0lg6rP-VANZ_gA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXpsVWqs70%253D&md5=e8cb3031f12598014a99a2df6dc9a2cc</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1200%2FJCO.2003.10.104&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2003.10.104%26sid%3Dliteratum%253Aachs%26aulast%3DBookman%26aufirst%3DM.%2BA.%26aulast%3DDarcy%26aufirst%3DK.%2BM.%26aulast%3DClarke-Pearson%26aufirst%3DD.%26aulast%3DBoothby%26aufirst%3DR.%2BA.%26aulast%3DHorowitz%26aufirst%3DI.%2BR.%26atitle%3DEvaluation%2520of%2520monoclonal%2520humanized%2520anti-%2520HER2%2520antibody%252C%2520trastuzumab%252C%2520in%2520patients%2520with%2520recurrent%2520or%2520refractory%2520ovarian%2520or%2520primary%2520peritoneal%2520carcinoma%2520with%2520overexpression%2520of%2520HER2%253A%2520a%2520phase%2520II%2520trial%2520of%2520the%2520Gynecologic%2520Oncology%2520Group%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2003%26volume%3D21%26spage%3D283%26epage%3D290%26doi%3D10.1200%2FJCO.2003.10.104" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Steffensen, K. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">WaldstrÃ¸m, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jeppesen, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jakobsen, E. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brandslund, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jakobsen, A.</span></span> <span> </span><span class="NLM_article-title">The prognostic importance of cyclooxygenase 2 and HER2 expression in epithelial ovarian cancer</span>. <i>Int. J. Gynecol. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">798</span>â <span class="NLM_lpage">807</span>, <span class="refDoi">Â DOI: 10.1111/j.1525-1438.2006.00855.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01340&amp;key=10.1111%2Fj.1525-1438.2006.00855.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01340&amp;key=17309668" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01340&amp;key=1%3ACAS%3A280%3ADC%252BD2svhsFGhsA%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2007&pages=798-807&author=K.+D.+Steffensenauthor=M.+Waldstr%C3%B8mauthor=U.+Jeppesenauthor=E.+H.+Jakobsenauthor=I.+Brandslundauthor=A.+Jakobsen&title=The+prognostic+importance+of+cyclooxygenase+2+and+HER2+expression+in+epithelial+ovarian+cancer&doi=10.1111%2Fj.1525-1438.2006.00855.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">The prognostic importance of cyclooxygenase 2 and HER2 expression in epithelial ovarian cancer</span></div><div class="casAuthors">Steffensen K D; Waldstrom M; Jeppesen U; Jakobsen E; Brandslund I; Jakobsen A</div><div class="citationInfo"><span class="NLM_cas:title">International journal of gynecological cancer : official journal of the International Gynecological Cancer Society</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">798-807</span>
        ISSN:<span class="NLM_cas:issn">1048-891X</span>.
    </div><div class="casAbstract">Both cyclooxygenase 2 (COX2) and human epidermal growth factor receptor 2 (HER2, also called c-erbB-2) overexpression have been related to a worse prognosis in epithelial ovarian cancer (EOC), but the data are conflicting and the percentage of tumors with overexpression varies widely in different studies.  The aim of this study was to investigate the potential prognostic value of COX2 and HER2 expression in EOC.  A further purpose was to investigate a possible coexpression of the two markers, and finally, to elucidate the agreement between fluorescence in situ hybridization (FISH) and immunohistochemistry (IHC) for evaluation of the HER2 status in EOC.  Immunostaining was performed for COX2/HER2 together with FISH analysis for HER2 gene amplification in 160 patients with EOC, FIGO stages IIB-IV.  Follow-up was more than 10 years.  COX2 overexpression was found in 20.0% of the tumors.  With HER2 staining, 64.4% were scored as 0, 24.4% as 1+, 6.9% as 2+, and 4.4% as 3+.  Median survival time for COX2-negative tumors was 21.6 versus 36 months for COX2-positive tumors.  The longer survival for COX2 positive was significant by both univariate analysis (P= 0.015) and multivariate analysis (P= 0.025).  Positive immunostaining for HER2 was associated with poor overall survival (P= 0.03).  Agreement between IHC and FISH was seen in all cases (P < 0.0000001).  With long-term observation, patients with negative COX2 expression had significantly shorter survival compared to patients with COX2-positive tumors.  Positive HER2 expression also notified a grave prognosis, but the low rate of overexpression reduces its potential clinical application.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQjM0_gq9JboCnGiHuhFGv8fW6udTcc2ebQWd4pIxSeYrntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2svhsFGhsA%253D%253D&md5=db09fd11518533e94fefd035f1a8d8d3</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1111%2Fj.1525-1438.2006.00855.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1525-1438.2006.00855.x%26sid%3Dliteratum%253Aachs%26aulast%3DSteffensen%26aufirst%3DK.%2BD.%26aulast%3DWaldstr%25C3%25B8m%26aufirst%3DM.%26aulast%3DJeppesen%26aufirst%3DU.%26aulast%3DJakobsen%26aufirst%3DE.%2BH.%26aulast%3DBrandslund%26aufirst%3DI.%26aulast%3DJakobsen%26aufirst%3DA.%26atitle%3DThe%2520prognostic%2520importance%2520of%2520cyclooxygenase%25202%2520and%2520HER2%2520expression%2520in%2520epithelial%2520ovarian%2520cancer%26jtitle%3DInt.%2520J.%2520Gynecol.%2520Cancer%26date%3D2007%26volume%3D17%26spage%3D798%26epage%3D807%26doi%3D10.1111%2Fj.1525-1438.2006.00855.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hellstrom, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goodman, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pullman, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">HellstrÃ¶m, K. E.</span></span> <span> </span><span class="NLM_article-title">Overexpression of HER2 in ovarian carcinomas</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">2420</span>â <span class="NLM_lpage">2423</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01340&amp;key=11289108" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01340&amp;key=1%3ACAS%3A528%3ADC%252BD3MXisVSlurk%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2001&pages=2420-2423&author=I.+Hellstromauthor=G.+Goodmanauthor=J.+Pullmanauthor=Y.+Yangauthor=K.+E.+Hellstr%C3%B6m&title=Overexpression+of+HER2+in+ovarian+carcinomas"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Overexpression of HER-2 in ovarian carcinomas</span></div><div class="casAuthors">Hellstrom, Ingegerd; Goodman, Gary; Pullman, Janice; Yang, Yi; Hellstrom, Karl Erik</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2420-2423</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The transmembrane receptor encoded by the HER-2 cellular oncogene is amplified in several types of human carcinomas and provides an attractive therapeutic target.  Shown by immunohistol., <25% of newly diagnosed ovarian carcinomas express the HER-2 protein.  However, now we report that this protein was expressed in all 20 tumor cell lines derived from stage III and IV ovarian cancers as well as in tumor cells harvested from patients with malignant ascites and in tumor samples taken at a second surgery, suggesting that cells with excess expression may have a selective growth advantage.  HER-2-pos. ovarian carcinoma cells were shown to be sensitive to antibody-dependent cellular cytotoxicity, and their in vitro proliferation was inhibited by anti-HER-2 MAb Herceptin.  We postulate, therefore, that therapy which targets HER-2 may be more efficacious in patients with ovarian carcinoma than indicated by the commonly low expression of HER-2 in tumors removed at the time of primary surgery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqxV_HyJmeAg7Vg90H21EOLACvtfcHk0lhhAQUT73ZZLQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXisVSlurk%253D&md5=1d5ab010ed0cf05f26fecb722ae8fe45</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHellstrom%26aufirst%3DI.%26aulast%3DGoodman%26aufirst%3DG.%26aulast%3DPullman%26aufirst%3DJ.%26aulast%3DYang%26aufirst%3DY.%26aulast%3DHellstr%25C3%25B6m%26aufirst%3DK.%2BE.%26atitle%3DOverexpression%2520of%2520HER2%2520in%2520ovarian%2520carcinomas%26jtitle%3DCancer%2520Res.%26date%3D2001%26volume%3D61%26spage%3D2420%26epage%3D2423" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Calce, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Monfregola, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saviano, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Luca, S.</span></span> <span> </span><span class="NLM_article-title">HER2-mediated anticancer drug delivery: strategies to prepare targeting ligands highly specific for the receptor</span>. <i>Curr. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">2525</span>â <span class="NLM_lpage">2538</span>, <span class="refDoi">Â DOI: 10.2174/0929867322666150521091103</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01340&amp;key=10.2174%2F0929867322666150521091103" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01340&amp;key=25994863" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01340&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhsFWms73I" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2015&pages=2525-2538&author=E.+Calceauthor=L.+Monfregolaauthor=M.+Savianoauthor=S.+De+Luca&title=HER2-mediated+anticancer+drug+delivery%3A+strategies+to+prepare+targeting+ligands+highly+specific+for+the+receptor&doi=10.2174%2F0929867322666150521091103"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">HER2-Mediated Anticancer Drug Delivery: Strategies to Prepare Targeting Ligands Highly Specific for the Receptor</span></div><div class="casAuthors">Calce, Enrica; Monfregola, Luca; Saviano, Michele; De Luca, Stefania</div><div class="citationInfo"><span class="NLM_cas:title">Current Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">2525-2538</span>CODEN:
                <span class="NLM_cas:coden">CMCHE7</span>;
        ISSN:<span class="NLM_cas:issn">0929-8673</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">HER2 receptor, for its involvement in tumorigenesis, has been largely studied as topic in cancer research.  In particular, the employment of trastuzumab (Herceptin), a humanized anti-HER2 antibody, showed several clin. benefits in the therapy against the breast cancer.  Moreover, for its accessible extracellular domain, this receptor is considered an ideal target to deliver anticancer drugs for the receptor-mediated anticancer therapy.  By now, monoclonal antibody and its fragments, affibody, and some peptides have been employed as targeting agents in order to deliver various drugs to HER2 pos. tumor cells.  In particular, the ability to perform a fast and reliable screening of a large no. of peptide mols. would make possible the selection of highly specific compds. to the receptor target.  In this regard, the availability of prepg. a simplified synthetic model which is a good mimetic of the receptor target and can be used in a reliable screening method of ligands would be of a strategic importance for the development of selective HER2-targeting peptide mols.  Herein, we illustrate the importance of HER2-targeted anticancer therapies.  We also report on a synthetic and effective mimetic of the receptor, which revealed to be a useful tool for the selection of specific HER2 ligands.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrKaNiUZMNR8bVg90H21EOLACvtfcHk0lhhAQUT73ZZLQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhsFWms73I&md5=04161c731108f43a5c6fa4663d8e5f63</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.2174%2F0929867322666150521091103&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F0929867322666150521091103%26sid%3Dliteratum%253Aachs%26aulast%3DCalce%26aufirst%3DE.%26aulast%3DMonfregola%26aufirst%3DL.%26aulast%3DSaviano%26aufirst%3DM.%26aulast%3DDe%2BLuca%26aufirst%3DS.%26atitle%3DHER2-mediated%2520anticancer%2520drug%2520delivery%253A%2520strategies%2520to%2520prepare%2520targeting%2520ligands%2520highly%2520specific%2520for%2520the%2520receptor%26jtitle%3DCurr.%2520Med.%2520Chem.%26date%3D2015%26volume%3D22%26spage%3D2525%26epage%3D2538%26doi%3D10.2174%2F0929867322666150521091103" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Monfregola, L.</span>; <span class="NLM_string-name">De Luca, S.</span></span> <span> </span><span class="NLM_article-title">The Role of HER2 in Targeted Cancer Therapy and Hypothesized Future Perspectives</span>. In  <i>HER2 and Cancer: Mechanism, Testing and Targeted Therapy</i>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, S. I.</span>, <span class="NLM_string-name">Rogers, C. E.</span></span>, Ed.; <span class="NLM_publisher-name">Nova Science Publishers</span> <span class="NLM_year">2011</span>; pp  <span class="NLM_fpage">101</span>â <span class="NLM_lpage">122</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2011&pages=101-122&author=L.+Monfregola&author=S.+De+Lucaauthor=S.+I.+Williams&author=C.+E.+Rogers&title=HER2+and+Cancer%3A+Mechanism%2C+Testing+and+Targeted+Therapy"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DMonfregola%26aufirst%3DL.%26atitle%3DThe%2520Role%2520of%2520HER2%2520in%2520Targeted%2520Cancer%2520Therapy%2520and%2520Hypothesized%2520Future%2520Perspectives%26btitle%3DHER2%2520and%2520Cancer%253A%2520Mechanism%252C%2520Testing%2520and%2520Targeted%2520Therapy%26aulast%3DWilliams%26aufirst%3DS.%2BI.%26pub%3DNova%2520Science%2520Publishers%26date%3D2011%26spage%3D101%26epage%3D122" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tan, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Swain, S. M.</span></span> <span> </span><span class="NLM_article-title">Ongoing adjuvant trials with trastuzumab in breast cancer</span>. <i>Semin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>30</i></span>,  <span class="NLM_fpage">54</span>â <span class="NLM_lpage">64</span>, <span class="refDoi">Â DOI: 10.1053/j.seminoncol.2003.08.008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01340&amp;key=10.1053%2Fj.seminoncol.2003.08.008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01340&amp;key=14613027" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01340&amp;key=1%3ACAS%3A528%3ADC%252BD3sXhtVSjtrrL" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2003&pages=54-64&author=A.+R.+Tanauthor=S.+M.+Swain&title=Ongoing+adjuvant+trials+with+trastuzumab+in+breast+cancer&doi=10.1053%2Fj.seminoncol.2003.08.008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Ongoing adjuvant trials with trastuzumab in breast cancer</span></div><div class="casAuthors">Tan, Antoinette R.; Swain, Sandra M.</div><div class="citationInfo"><span class="NLM_cas:title">Seminars in Oncology</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">5, Suppl. 16</span>),
    <span class="NLM_cas:pages">54-64</span>CODEN:
                <span class="NLM_cas:coden">SOLGAV</span>;
        ISSN:<span class="NLM_cas:issn">0093-7754</span>.
    
            (<span class="NLM_cas:orgname">W. B. Saunders Co.</span>)
        </div><div class="casAbstract">A review.  Trastuzumab has had a major impact in the treatment of HER2-pos. metastatic breast cancer.  In combination with chemotherapy, trastuzumab provides significant clin. benefit in terms of increased response rate and extended survival compared with chemotherapy alone in patients with HER2-pos. advanced breast cancer.  Trastuzumab also has therapeutic activity as monotherapy in the front-line management of HER2-overexpressed or HER2-amplified metastatic breast cancer.  Given its proven efficacy in the metastatic setting, the combination and sequential use of trastuzumab with adjuvant and neoadjuvant chemotherapy are the focus of several ongoing clin. studies.  In this review, the design of the four major phase III multicenter adjuvant trastuzumab trials will be described and their major differences highlighted.  Because therapy with trastuzumab has been assocd. with cardiac toxicity, esp. with prior or concurrent anthracyclines, the evaluation of cardiac dysfunction in the adjuvant trial setting is also a priority.  For now, the use of trastuzumab as adjuvant therapy is still investigational, but its integration has tremendous potential to improve treatment outcomes in patients with primary breast cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrHj06sZbd9HbVg90H21EOLACvtfcHk0lhez6cXn-vYvQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXhtVSjtrrL&md5=7b4c2ef6d0587ce8584ed01cfcfd1659</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1053%2Fj.seminoncol.2003.08.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1053%252Fj.seminoncol.2003.08.008%26sid%3Dliteratum%253Aachs%26aulast%3DTan%26aufirst%3DA.%2BR.%26aulast%3DSwain%26aufirst%3DS.%2BM.%26atitle%3DOngoing%2520adjuvant%2520trials%2520with%2520trastuzumab%2520in%2520breast%2520cancer%26jtitle%3DSemin.%2520Oncol.%26date%3D2003%26volume%3D30%26spage%3D54%26epage%3D64%26doi%3D10.1053%2Fj.seminoncol.2003.08.008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Leonard, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hill, A. D. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kelly, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dijkstra, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McDermott, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">OâHiggins, N. J.</span></span> <span> </span><span class="NLM_article-title">Anti-human epidermal growth factor receptor 2 monoclonal antibody therapy for breast cancer</span>. <i>Br. J. Surg.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>89</i></span>,  <span class="NLM_fpage">262</span>â <span class="NLM_lpage">271</span>, <span class="refDoi">Â DOI: 10.1046/j.0007-1323.2001.02022.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01340&amp;key=10.1046%2Fj.0007-1323.2001.02022.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01340&amp;key=11872048" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01340&amp;key=1%3ACAS%3A280%3ADC%252BD387jsleqsg%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=89&publication_year=2002&pages=262-271&author=D.+S.+Leonardauthor=A.+D.+K.+Hillauthor=L.+Kellyauthor=B.+Dijkstraauthor=E.+McDermottauthor=N.+J.+O%E2%80%99Higgins&title=Anti-human+epidermal+growth+factor+receptor+2+monoclonal+antibody+therapy+for+breast+cancer&doi=10.1046%2Fj.0007-1323.2001.02022.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Anti-human epidermal growth factor receptor 2 monoclonal antibody therapy for breast cancer</span></div><div class="casAuthors">Leonard D S; Hill A D K; Kelly L; Dijkstra B; McDermott E; O'Higgins N J</div><div class="citationInfo"><span class="NLM_cas:title">The British journal of surgery</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">89</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">262-71</span>
        ISSN:<span class="NLM_cas:issn">0007-1323</span>.
    </div><div class="casAbstract">BACKGROUND:  Advances in molecular biology and improved understanding of tumour biology have led to the development of novel treatments for cancer.  Trastuzumab (Herceptin; Genentech, San Francisco, California, USA) is a monoclonal antibody directed against human epidermal growth factor receptor (HER) 2 protein, which is overexpressed in a wide variety of human cancers, including 20-30 per cent of human breast cancers.  HER-2 plays an important role in oncogenic transformation, tumorigenesis and metastatic spread.  Overexpression is associated with a poor prognosis and predicts a poor response to several treatment modalities.  METHOD:  Literature relating to the monoclonal antibody was identified by a Medline literature search and by cross-referencing from the references of seminal articles on the subject.  Four major clinical trials were identified and reviewed.  RESULTS AND CONCLUSION:  In clinical trials approximately 15-20 per cent of patients with HER-2-overexpressing tumours benefited from treatment with trastuzumab.  In sensitive patients the antibody appeared to have intrinsic anticancer activity when given as a single agent.  In combination chemotherapy it appeared to act synergistically with other agents.  Ongoing research is evaluating trastuzumab in combination with numerous standard chemotherapy regimens and with other novel chemotherapeutic agents.  Clinical trials have also revealed several serious side-effects of monoclonal antibody therapy.  Most notable is an unpredictable cardiotoxicity, especially when used in combination with anthracycline-based chemotherapy regimens.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcT9i8Gw8a-zse_Q9URG6Dx8fW6udTcc2eZs6nr9kmGh5bntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD387jsleqsg%253D%253D&md5=f420c49f4f58285d83c345a663444863</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1046%2Fj.0007-1323.2001.02022.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1046%252Fj.0007-1323.2001.02022.x%26sid%3Dliteratum%253Aachs%26aulast%3DLeonard%26aufirst%3DD.%2BS.%26aulast%3DHill%26aufirst%3DA.%2BD.%2BK.%26aulast%3DKelly%26aufirst%3DL.%26aulast%3DDijkstra%26aufirst%3DB.%26aulast%3DMcDermott%26aufirst%3DE.%26aulast%3DO%25E2%2580%2599Higgins%26aufirst%3DN.%2BJ.%26atitle%3DAnti-human%2520epidermal%2520growth%2520factor%2520receptor%25202%2520monoclonal%2520antibody%2520therapy%2520for%2520breast%2520cancer%26jtitle%3DBr.%2520J.%2520Surg.%26date%3D2002%26volume%3D89%26spage%3D262%26epage%3D271%26doi%3D10.1046%2Fj.0007-1323.2001.02022.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Behr, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">BÃ©hÃ©, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">WÃ¶rmann, B.</span></span> <span> </span><span class="NLM_article-title">Trastuzumab and breast cancer</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>345</i></span>,  <span class="NLM_fpage">995</span>â <span class="NLM_lpage">998</span>, <span class="refDoi">Â DOI: 10.1056/NEJM200109273451312</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01340&amp;key=10.1056%2FNEJM200109273451312" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01340&amp;key=11575295" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01340&amp;key=1%3ACAS%3A528%3ADC%252BD3MXntlehtbk%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=345&publication_year=2001&pages=995-998&author=T.+M.+Behrauthor=M.+B%C3%A9h%C3%A9author=B.+W%C3%B6rmann&title=Trastuzumab+and+breast+cancer&doi=10.1056%2FNEJM200109273451312"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Trastuzumab and breast cancer.Comments</span></div><div class="casAuthors">Behr, Thomas M.; Behe, Martin; Woermann, Bernhard</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">345</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">995-996</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">A polemic in response to Slamon et al. (2001).  In the study by Slamon et al. (2001), better responses and longer survival was attained in the use of trastuzumab in combination with chemotherapy compared with a chemotherapy alone.  However, cardiotoxicity is the most serious complication of the use of trastuzumab, esp. when combined with anthracyclines.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpnsBDMDXJKjrVg90H21EOLACvtfcHk0lhez6cXn-vYvQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXntlehtbk%253D&md5=4c3c59f7a3645def4a2c884e4bf5684f</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1056%2FNEJM200109273451312&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJM200109273451312%26sid%3Dliteratum%253Aachs%26aulast%3DBehr%26aufirst%3DT.%2BM.%26aulast%3DB%25C3%25A9h%25C3%25A9%26aufirst%3DM.%26aulast%3DW%25C3%25B6rmann%26aufirst%3DB.%26atitle%3DTrastuzumab%2520and%2520breast%2520cancer%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2001%26volume%3D345%26spage%3D995%26epage%3D998%26doi%3D10.1056%2FNEJM200109273451312" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cai, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bembas, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drebin, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greene, M. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H.</span></span> <span> </span><span class="NLM_article-title">Differential binding patterns of monoclonal antibody 2C4 to the ErbB3-p185her2/neu and the EGFR-p185her2/neu complexes</span>. <i>Oncogene</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>27</i></span>,  <span class="NLM_fpage">3870</span>â <span class="NLM_lpage">3874</span>, <span class="refDoi">Â DOI: 10.1038/onc.2008.13</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01340&amp;key=10.1038%2Fonc.2008.13" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01340&amp;key=18264138" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01340&amp;key=1%3ACAS%3A528%3ADC%252BD1cXntlCqu74%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2008&pages=3870-3874&author=Z.+Caiauthor=G.+Zhangauthor=Z.+Zhouauthor=K.+Bembasauthor=J.+A.+Drebinauthor=M.+I.+Greeneauthor=H.+Zhang&title=Differential+binding+patterns+of+monoclonal+antibody+2C4+to+the+ErbB3-p185her2%2Fneu+and+the+EGFR-p185her2%2Fneu+complexes&doi=10.1038%2Fonc.2008.13"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Differential binding patterns of monoclonal antibody 2C4 to the ErbB3-p185her2/neu and the EGFR-p185her2/neu complexes</span></div><div class="casAuthors">Cai, Z.; Zhang, G.; Zhou, Z.; Bembas, K.; Drebin, J. A.; Greene, M. I.; Zhang, H.</div><div class="citationInfo"><span class="NLM_cas:title">Oncogene</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">27</span>),
    <span class="NLM_cas:pages">3870-3874</span>CODEN:
                <span class="NLM_cas:coden">ONCNES</span>;
        ISSN:<span class="NLM_cas:issn">0950-9232</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">2C4 (Pertuzumab, Omnitarg) is a monoclonal antibody targeting p185her2/neu, which is overexpressed in 30% of invasive breast cancer.  2C4 is currently in phase II clin. trials for several types of cancers.  This antibody has been reported to disrupt the assocn. between p185her2/neu and ErbB3.  In the authors' studies of epidermal growth factor receptor (EGFR)-p185her2/neu heterodimerization, the authors noted that 2C4 formed assocns. with the EGFR-p185her2/neu receptor complex.  The data argue against 2C4 as a universal heterodimerization blocker for p185her2/neu, but indicate that cocktails of monoclonal antibodies binding distinct interaction surfaces of p185her2/neu will emerge as the most potent targeted therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqclMPFoGCulLVg90H21EOLACvtfcHk0lgdgK6AdMjU1Q"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXntlCqu74%253D&md5=44053ba75986641e5049b10a3af12fc7</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1038%2Fonc.2008.13&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fonc.2008.13%26sid%3Dliteratum%253Aachs%26aulast%3DCai%26aufirst%3DZ.%26aulast%3DZhang%26aufirst%3DG.%26aulast%3DZhou%26aufirst%3DZ.%26aulast%3DBembas%26aufirst%3DK.%26aulast%3DDrebin%26aufirst%3DJ.%2BA.%26aulast%3DGreene%26aufirst%3DM.%2BI.%26aulast%3DZhang%26aufirst%3DH.%26atitle%3DDifferential%2520binding%2520patterns%2520of%2520monoclonal%2520antibody%25202C4%2520to%2520the%2520ErbB3-p185her2%252Fneu%2520and%2520the%2520EGFR-p185her2%252Fneu%2520complexes%26jtitle%3DOncogene%26date%3D2008%26volume%3D27%26spage%3D3870%26epage%3D3874%26doi%3D10.1038%2Fonc.2008.13" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Scheuer, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Friess, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burtscher, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bossenmaier, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Endl, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hasmann, M.</span></span> <span> </span><span class="NLM_article-title">Strongly enhanced antitumor activity of trastuzumab and pertuzumab combination treatment on HER2-positive human xenograft tumor models</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>69</i></span>,  <span class="NLM_fpage">9330</span>â <span class="NLM_lpage">9336</span>, <span class="refDoi">Â DOI: 10.1158/0008-5472.CAN-08-4597</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01340&amp;key=10.1158%2F0008-5472.CAN-08-4597" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01340&amp;key=19934333" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01340&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhsFGrtbnM" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=69&publication_year=2009&pages=9330-9336&author=W.+Scheuerauthor=T.+Friessauthor=H.+Burtscherauthor=B.+Bossenmaierauthor=J.+Endlauthor=M.+Hasmann&title=Strongly+enhanced+antitumor+activity+of+trastuzumab+and+pertuzumab+combination+treatment+on+HER2-positive+human+xenograft+tumor+models&doi=10.1158%2F0008-5472.CAN-08-4597"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Strongly Enhanced Antitumor Activity of Trastuzumab and Pertuzumab Combination Treatment on HER2-Positive Human Xenograft Tumor Models</span></div><div class="casAuthors">Scheuer, Werner; Friess, Thomas; Burtscher, Helmut; Bossenmaier, Birgit; Endl, Josef; Hasmann, Max</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">69</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">9330-9336</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The human epidermal growth factor receptor (HER) family plays an important role in cell survival and proliferation, and is implicated in oncogenesis.  Overexpression of HER2 is assocd. with aggressive disease and poor prognosis.  Trastuzumab is a humanized monoclonal antibody targeting HER2 and has proven survival benefit for women with HER2-pos. early and metastatic breast cancer.  Pertuzumab, another monoclonal antibody, is a HER2 dimerization inhibitor that binds to a different epitope on HER2 than trastuzumab and inhibits HER2 dimer formation with other HER family members such as HER3 and HER1.  We investigated the antitumor activity of these agents alone and in combination in HER2-pos. breast and non-small cell lung cancer xenografts.  Our data show that the combination of trastuzumab and pertuzumab has a strongly enhanced antitumor effect and induces tumor regression in both xenograft models, something that cannot be achieved by either monotherapy.  The enhanced efficacy of the combination was also obsd. after tumor progression during trastuzumab monotherapy.  Near-IR fluorescence imaging expts. confirm that pertuzumab binding to tumors is not impaired by trastuzumab pretreatment.  Furthermore, we show by in vitro assay that both trastuzumab and pertuzumab potently activate antibody-dependent cellular cytotoxicity.  However, our data suggest that the strongly enhanced antitumor activity is mainly due to the differing but complementary mechanisms of action of trastuzumab and pertuzumab, namely inhibition of HER2 dimerization and prevention of p95HER2 formation. [Cancer Res 2009;69(24):9330-6].</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrgmVfUweob2rVg90H21EOLACvtfcHk0lgdgK6AdMjU1Q"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhsFGrtbnM&md5=ff2eb6dcf98d5d8ce7b2978f34113de4</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-08-4597&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-08-4597%26sid%3Dliteratum%253Aachs%26aulast%3DScheuer%26aufirst%3DW.%26aulast%3DFriess%26aufirst%3DT.%26aulast%3DBurtscher%26aufirst%3DH.%26aulast%3DBossenmaier%26aufirst%3DB.%26aulast%3DEndl%26aufirst%3DJ.%26aulast%3DHasmann%26aufirst%3DM.%26atitle%3DStrongly%2520enhanced%2520antitumor%2520activity%2520of%2520trastuzumab%2520and%2520pertuzumab%2520combination%2520treatment%2520on%2520HER2-positive%2520human%2520xenograft%2520tumor%2520models%26jtitle%3DCancer%2520Res.%26date%3D2009%26volume%3D69%26spage%3D9330%26epage%3D9336%26doi%3D10.1158%2F0008-5472.CAN-08-4597" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Brockhoff, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heckel, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmidt-Bruecken, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Plander, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hofstaedter, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vollmann, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diermeier, S.</span></span> <span> </span><span class="NLM_article-title">Differential impact of cetuximab, pertuzumab and trastuzumab on BT474 and SK-BR-3 breast cancer cell proliferation</span>. <i>Cell Proliferation</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>40</i></span>,  <span class="NLM_fpage">488</span>â <span class="NLM_lpage">507</span>, <span class="refDoi">Â DOI: 10.1111/j.1365-2184.2007.00449.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01340&amp;key=10.1111%2Fj.1365-2184.2007.00449.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01340&amp;key=17635517" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01340&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtVSksLnF" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=2007&pages=488-507&author=G.+Brockhoffauthor=B.+Heckelauthor=E.+Schmidt-Brueckenauthor=M.+Planderauthor=F.+Hofstaedterauthor=A.+Vollmannauthor=S.+Diermeier&title=Differential+impact+of+cetuximab%2C+pertuzumab+and+trastuzumab+on+BT474+and+SK-BR-3+breast+cancer+cell+proliferation&doi=10.1111%2Fj.1365-2184.2007.00449.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Differential impact of cetuximab, pertuzumab and trastuzumab on BT474 and SK-BR-3 breast cancer cell proliferation</span></div><div class="casAuthors">Brockhoff, G.; Heckel, B.; Schmidt-Bruecken, E.; Plander, M.; Hofstaedter, F.; Vollmann, A.; Diermeier, S.</div><div class="citationInfo"><span class="NLM_cas:title">Cell Proliferation</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">40</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">488-507</span>CODEN:
                <span class="NLM_cas:coden">CPROEM</span>;
        ISSN:<span class="NLM_cas:issn">0960-7722</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Publishing Ltd.</span>)
        </div><div class="casAbstract">The potential of epidermal growth factor receptor (EGFR)- and Her2-targeted antibodies Cetuximab, Pertuzumab and Trastuzumab, used in combination to inhibit cell proliferation of breast cancer cells in vitro, has not been extensively investigated.  It is anticipated that there would be differences between specific erbB receptor co-expression profiles that would affect tumor cell growth.  We have examd. the effects of Cetuximab, Pertuzumab and Trastuzumab, applied sep. or in combination, on cell proliferation of BT474 and SK-BR-3 breast cancer cell lines.  Cell cycle progression of BT474 and SK-BR-3 cells was statically and dynamically assessed using flow cytometry.  In order to discover a potential influence of differential EGFR co-expression on sensitivity to antibody treatment, EGFR was down-regulated by siRNA in SK-BR-3.  An annexinV/propidium iodide assay was used to identify potential induction of apoptosis.  Treatment with Pertuzumab and Trastuzumab, both targeted to Her2, resulted in a reduced fraction of proliferating cells, prolongation of G1 phase and a great increase in quiescent BT474 cells.  Cetuximab had no addnl. contribution to the effect of either Pertuzumab or Trastuzumab when administered simultaneously.  Treatment with the antibodies did not induce an appreciable amt. of apoptosis in either BT474 or SK-BR-3 cells.  In contrast to SK-BR-3, the BT474 cell line appears to be more sensitive to antibody treatment due to low EGFR content besides Her2 overexpression.  The extent of decelerated or blocked cell proliferation after antibody treatment that is targeted to EGFR and to Her2 depends both on EGFR and Her2 co-expression and on antibody combination used in the treatment setting.  Cetuximab did not enhance any inhibitory effect of Trastuzumab or Pertuzumab, most probably due to the dominant overexpression of Her2.  Cell susceptibility to Trastuzumab/Pertuzumab, both targeted to Her2, was defined by the ratio of EGFR/Her2 co-expression.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGomagxMuC5_U7Vg90H21EOLACvtfcHk0lgdgK6AdMjU1Q"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtVSksLnF&md5=9b32ea25b7228c5c73b69726ed40a59a</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1111%2Fj.1365-2184.2007.00449.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1365-2184.2007.00449.x%26sid%3Dliteratum%253Aachs%26aulast%3DBrockhoff%26aufirst%3DG.%26aulast%3DHeckel%26aufirst%3DB.%26aulast%3DSchmidt-Bruecken%26aufirst%3DE.%26aulast%3DPlander%26aufirst%3DM.%26aulast%3DHofstaedter%26aufirst%3DF.%26aulast%3DVollmann%26aufirst%3DA.%26aulast%3DDiermeier%26aufirst%3DS.%26atitle%3DDifferential%2520impact%2520of%2520cetuximab%252C%2520pertuzumab%2520and%2520trastuzumab%2520on%2520BT474%2520and%2520SK-BR-3%2520breast%2520cancer%2520cell%2520proliferation%26jtitle%3DCell%2520Proliferation%26date%3D2007%26volume%3D40%26spage%3D488%26epage%3D507%26doi%3D10.1111%2Fj.1365-2184.2007.00449.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Franklin, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carey, K. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vajdos, F. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leahy, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Vos, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sliwkowski, M. X.</span></span> <span> </span><span class="NLM_article-title">Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex</span>. <i>Cancer Cell</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>5</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">317</span>â <span class="NLM_lpage">328</span>, <span class="refDoi">Â DOI: 10.1016/S1535-6108(04)00083-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01340&amp;key=10.1016%2FS1535-6108%2804%2900083-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01340&amp;key=15093539" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01340&amp;key=1%3ACAS%3A528%3ADC%252BD2cXjvVaqtLc%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2004&pages=317-328&issue=4&author=M.+C.+Franklinauthor=K.+D.+Careyauthor=F.+F.+Vajdosauthor=D.+J.+Leahyauthor=A.+M.+de+Vosauthor=M.+X.+Sliwkowski&title=Insights+into+ErbB+signaling+from+the+structure+of+the+ErbB2-pertuzumab+complex&doi=10.1016%2FS1535-6108%2804%2900083-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex</span></div><div class="casAuthors">Franklin, Matthew C.; Carey, Kendall D.; Vajdos, Felix F.; Leahy, Daniel J.; De Vos, Abraham M.; Sliwkowski, Mark X.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Cell</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">317-328</span>CODEN:
                <span class="NLM_cas:coden">CCAECI</span>;
        ISSN:<span class="NLM_cas:issn">1535-6108</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">The authors have detd. the 3.2 Ã x-ray crystal structure of the extracellular domain of the human epidermal growth factor receptor 2 (ErbB2 or HER2) in a complex with the antigen binding fragment of pertuzumab, an anti-ErbB2 monoclonal antibody also known as 2C4 or Omnitarg.  Pertuzumab binds to ErbB2 near the center of domain II, sterically blocking a binding pocket necessary for receptor dimerization and signaling.  The ErbB2-pertuzumab structure, combined with earlier mutagenesis data, defines the pertuzumab residues essential for ErbB2 interaction.  To analyze the ErbB2 side of the interface, the authors have mutated a no. of residues contacting pertuzumab and examd. the effects of these mutations on pertuzumab binding and ErbB2-ErbB3 heterodimerization.  The authors have also shown that conserved residues previously shown to be necessary for EGF receptor homodimerization may be dispensable for ErbB2-ErbB3 heterodimerization.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoU3tqrjPCfoLVg90H21EOLACvtfcHk0lj4OODNl0nIAA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXjvVaqtLc%253D&md5=91f40410383328240e1f2ec67d147e89</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1016%2FS1535-6108%2804%2900083-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1535-6108%252804%252900083-2%26sid%3Dliteratum%253Aachs%26aulast%3DFranklin%26aufirst%3DM.%2BC.%26aulast%3DCarey%26aufirst%3DK.%2BD.%26aulast%3DVajdos%26aufirst%3DF.%2BF.%26aulast%3DLeahy%26aufirst%3DD.%2BJ.%26aulast%3Dde%2BVos%26aufirst%3DA.%2BM.%26aulast%3DSliwkowski%26aufirst%3DM.%2BX.%26atitle%3DInsights%2520into%2520ErbB%2520signaling%2520from%2520the%2520structure%2520of%2520the%2520ErbB2-pertuzumab%2520complex%26jtitle%3DCancer%2520Cell%26date%3D2004%26volume%3D5%26issue%3D4%26spage%3D317%26epage%3D328%26doi%3D10.1016%2FS1535-6108%2804%2900083-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marks, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheung, L. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hittelman, W. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosenblum, M. G.</span></span> <span> </span><span class="NLM_article-title">Design optimization and characterization of HER2/neu-targeted immunotoxins: comparative in vitro and in vivo efficacy studies</span>. <i>Oncogene</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>33</i></span>,  <span class="NLM_fpage">429</span>â <span class="NLM_lpage">439</span>, <span class="refDoi">Â DOI: 10.1038/onc.2012.612</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01340&amp;key=10.1038%2Fonc.2012.612" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01340&amp;key=23376850" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01340&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhvFWkt7s%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2014&pages=429-439&author=Y.+Caoauthor=J.+W.+Marksauthor=Z.+Liuauthor=L.+H.+Cheungauthor=W.+N.+Hittelmanauthor=M.+G.+Rosenblum&title=Design+optimization+and+characterization+of+HER2%2Fneu-targeted+immunotoxins%3A+comparative+in+vitro+and+in+vivo+efficacy+studies&doi=10.1038%2Fonc.2012.612"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Design optimization and characterization of Her2/neu-targeted immunotoxins: comparative in vitro and in vivo efficacy studies</span></div><div class="casAuthors">Cao, Y.; Marks, J. W.; Liu, Z.; Cheung, L. H.; Hittelman, W. N.; Rosenblum, M. G.</div><div class="citationInfo"><span class="NLM_cas:title">Oncogene</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">33</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">429-439</span>CODEN:
                <span class="NLM_cas:coden">ONCNES</span>;
        ISSN:<span class="NLM_cas:issn">0950-9232</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Targeted therapeutics are potential therapeutic agents because of their selectivity and efficacy against tumors resistant to conventional therapy.  The goal of this study was to det. the comparative activity of monovalent, engineered anti-Her2/neu immunotoxins fused to recombinant gelonin (rGel) to the activity of bivalent IgG-contg. immunoconjugates.  Utilizing Herceptin and its derived humanized single-chain antibody (single-chain fragment variable, designated 4D5), we generated bivalent chem. Herceptin/rGel conjugate, and the corresponding monovalent recombinant immunotoxins in two orientations, 4D5/rGel and rGel/4D5.  All the constructs showed similar affinity to Her2/neu-overexpressing cancer cells, but significantly different antitumor activities.  The rGel/4D5 orientation construct and Herceptin/rGel conjugate were superior to 4D5/rGel construct in in vitro and in vivo efficacy.  The enhanced activity was attributed to improved intracellular toxin uptake into target cells and efficient downregulation of Her2/neu-related signaling pathways.  The Her2/neu-targeted immunotoxins effectively targeted cells with Her2/neu expression level >1.5Ã105 sites per cell.  Cells resistant to Herceptin or chemotherapeutic agents were not cross-resistant to rGel-based immunotoxins.  Against SK-OV-3 tumor xenografts, the rGel/4D5 construct with excellent tumor penetration showed impressive tumor inhibition.  Although Herceptin/rGel conjugate demonstrated comparatively longer serum half-life, the in vivo efficacy of the conjugate was similar to the rGel/4D5 fusion.  These comparative studies demonstrate that the monovalent, engineered rGel/4D5 construct displayed comparable in vitro and in vivo antitumor efficacy as bivalent Herceptin/rGel conjugate.  Immunotoxin orientation can significantly impact the overall functionality and performance of these agents.  The recombinant rGel/4D5 construct with excellent tumor penetration and rapid blood clearance may reduce the unwanted toxicity when administering to patients, and warrants consideration for further clin. evaluation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpS045nkCnvu7Vg90H21EOLACvtfcHk0lj4OODNl0nIAA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhvFWkt7s%253D&md5=4f615c80e0aa130c1ad7f42cd05c6c9e</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1038%2Fonc.2012.612&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fonc.2012.612%26sid%3Dliteratum%253Aachs%26aulast%3DCao%26aufirst%3DY.%26aulast%3DMarks%26aufirst%3DJ.%2BW.%26aulast%3DLiu%26aufirst%3DZ.%26aulast%3DCheung%26aufirst%3DL.%2BH.%26aulast%3DHittelman%26aufirst%3DW.%2BN.%26aulast%3DRosenblum%26aufirst%3DM.%2BG.%26atitle%3DDesign%2520optimization%2520and%2520characterization%2520of%2520HER2%252Fneu-targeted%2520immunotoxins%253A%2520comparative%2520in%2520vitro%2520and%2520in%2520vivo%2520efficacy%2520studies%26jtitle%3DOncogene%26date%3D2014%26volume%3D33%26spage%3D429%26epage%3D439%26doi%3D10.1038%2Fonc.2012.612" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zielinski, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lyakhov, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hassan, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuban, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shafer-Weaver, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gandjbakhche, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Capala, J.</span></span> <span> </span><span class="NLM_article-title">HER2-affitoxin: a potent therapeutic agent for the treatment of HER2-overexpressing tumors</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">5071</span>â <span class="NLM_lpage">5081</span>, <span class="refDoi">Â DOI: 10.1158/1078-0432.CCR-10-2887</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01340&amp;key=10.1158%2F1078-0432.CCR-10-2887" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01340&amp;key=21791637" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01340&amp;key=1%3ACAS%3A528%3ADC%252BC3MXpsFSks7k%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2011&pages=5071-5081&author=R.+Zielinskiauthor=I.+Lyakhovauthor=M.+Hassanauthor=M.+Kubanauthor=K.+Shafer-Weaverauthor=A.+Gandjbakhcheauthor=J.+Capala&title=HER2-affitoxin%3A+a+potent+therapeutic+agent+for+the+treatment+of+HER2-overexpressing+tumors&doi=10.1158%2F1078-0432.CCR-10-2887"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">HER2-Affitoxin: A Potent Therapeutic Agent for the Treatment of HER2-Overexpressing Tumors</span></div><div class="casAuthors">Zielinski, Rafal; Lyakhov, Ilya; Hassan, Moinuddin; Kuban, Monika; Shafer-Weaver, Kimberly; Gandjbakhche, Amir; Capala, Jacek</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">5071-5081</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">PURPOSE: Cancers overexpressing the HER2/neu gene are usually more aggressive and are assocd. with poor prognosis.  Although trastuzumab has significantly improved the outcome, many tumors do not respond or acquire resistance to current therapies.  To provide an alternative HER2-targeted therapy, we have developed and characterized a novel recombinant protein combining an HER2-specific Affibody and modified Pseudomonas aeruginosa exotoxin A (PE 38), which, after binding to HER2, is internalized and delivered to the cytosol of the tumor cell, where it blocks protein synthesis by ADP ribosylation of eEF-2.  Exptl. Design: The effect of the Affitoxin on cell viability was assessed using CellTiter-Glo (Promega).  To assess HER2-specific efficacy, athymic nude mice bearing BT-474 breast cancer, SK-OV-3 ovarian cancer, and NCI-N87 gastric carcinoma xenografts were treated with the Affitoxin (HER2- or Tag-specific), which was injected every third day.  Affitoxin immunogenicity in female BALB/c mice was investigated using std. antibody prodn. and splenocyte proliferation assays.  RESULTS:In vitro expts. proved that HER2-Affitoxin is a potent agent that eliminates HER2-overexpressing cells at low picomolar concns.  Therapeutic efficacy studies showed complete eradication of relatively large BT-474 tumors and significant effects on SK-OV-3 and NCI-N87 tumors.  HER2-Affitoxin cleared quickly from circulation (T1/2 < 10 min) and was well tolerated by mice at doses of 0.5 mg/kg and below.  Immunogenicity studies indicated that HER2-Affitoxin induced antibody development after the third injected dose.  CONCLUSIONS: Our findings showed that HER2-Affitoxin is an effective anticancer agent and a potential candidate for clin. studies.  Clin Cancer Res; 17(15); 5071-81.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqBgt3YcIcDPLVg90H21EOLACvtfcHk0lj4OODNl0nIAA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXpsFSks7k%253D&md5=2ab40e5fa2a4a33b519667ef974a4f11</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-10-2887&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-10-2887%26sid%3Dliteratum%253Aachs%26aulast%3DZielinski%26aufirst%3DR.%26aulast%3DLyakhov%26aufirst%3DI.%26aulast%3DHassan%26aufirst%3DM.%26aulast%3DKuban%26aufirst%3DM.%26aulast%3DShafer-Weaver%26aufirst%3DK.%26aulast%3DGandjbakhche%26aufirst%3DA.%26aulast%3DCapala%26aufirst%3DJ.%26atitle%3DHER2-affitoxin%253A%2520a%2520potent%2520therapeutic%2520agent%2520for%2520the%2520treatment%2520of%2520HER2-overexpressing%2520tumors%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2011%26volume%3D17%26spage%3D5071%26epage%3D5081%26doi%3D10.1158%2F1078-0432.CCR-10-2887" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Altai, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Orlova, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tolmachev, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">GrÃ¤slund, T.</span></span> <span> </span><span class="NLM_article-title">Influence of molecular design on biodistribution and targeting properties of an Affibody-fused HER2-recognising anticancer toxin</span>. <i>Int. J. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>49</i></span>,  <span class="NLM_fpage">1185</span>â <span class="NLM_lpage">1194</span>, <span class="refDoi">Â DOI: 10.3892/ijo.2016.3614</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01340&amp;key=10.3892%2Fijo.2016.3614" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01340&amp;key=27573289" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01340&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsFOqu7nK" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2016&pages=1185-1194&author=M.+Altaiauthor=H.+Liuauthor=A.+Orlovaauthor=V.+Tolmachevauthor=T.+Gr%C3%A4slund&title=Influence+of+molecular+design+on+biodistribution+and+targeting+properties+of+an+Affibody-fused+HER2-recognising+anticancer+toxin&doi=10.3892%2Fijo.2016.3614"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Influence of molecular design on biodistribution and targeting properties of an Affibody-fused HER2-recognising anticancer toxin</span></div><div class="casAuthors">Altai, Mohamed; Liu, Hao; Orlova, Anna; Tolmachev, Vladimir; Graeslund, Torbjoern</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Oncology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1185-1194</span>CODEN:
                <span class="NLM_cas:coden">IJONES</span>;
        ISSN:<span class="NLM_cas:issn">1791-2423</span>.
    
            (<span class="NLM_cas:orgname">Spandidos Publications Ltd.</span>)
        </div><div class="casAbstract">Targeted delivery of toxins is a promising way to treat disseminated cancer.  The use of monoclonal antibodies as targeting moiety has provided proof-of-principle for this approach.  However, extravasation and tissue penetration rates of antibody-based immunotoxins are limited due to antibody bulkiness.  The use of a novel class of targeting probes, Affibody mols., provides smaller toxin-conjugated constructs, which may improve targeting.  Earlier, we have demonstrated that affitoxins contg. a HER2-targeting Affibody moiety and a deimmunized and truncated exotoxin A from Pseudomonas aeruginosa, PE38X8, provide highly selective toxicity to HER2-expressing cancer cells.  To evaluate the influence of mol. design on targeting and biodistribution properties, a series of novel affitoxins were labeled with the residualizing radionuclide 111In.  In this study, we have shown that the novel conjugates are more rapidly internalized compared with the parental affitoxin.  The use of a (HE)3 purifn. tag instead of a hexahistidine tag enabled significant (p<0.05) redn. of the hepatic uptake of the affitoxin in a murine model.  Fusion of the affitoxin with an albumin-binding domain (ABD) caused appreciable extension of the residence time in circulation and several-fold redn. of the renal uptake.  The best variant, 111In-(HE)3-ZHER2-ABD-PE38X8, demonstrated receptor-specific accumulation in HER2-expressing SKOV-3 xenografts.  In conclusion, a careful mol. design of scaffold protein based anticancer targeted toxins can appreciably improve their biodistribution and targeting properties.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpfPlbKZ7YJJLVg90H21EOLACvtfcHk0lg_7OY1QEuJ5g"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsFOqu7nK&md5=0f9b572e3d9d7351f71ce97bddc374e4</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.3892%2Fijo.2016.3614&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3892%252Fijo.2016.3614%26sid%3Dliteratum%253Aachs%26aulast%3DAltai%26aufirst%3DM.%26aulast%3DLiu%26aufirst%3DH.%26aulast%3DOrlova%26aufirst%3DA.%26aulast%3DTolmachev%26aufirst%3DV.%26aulast%3DGr%25C3%25A4slund%26aufirst%3DT.%26atitle%3DInfluence%2520of%2520molecular%2520design%2520on%2520biodistribution%2520and%2520targeting%2520properties%2520of%2520an%2520Affibody-fused%2520HER2-recognising%2520anticancer%2520toxin%26jtitle%3DInt.%2520J.%2520Oncol.%26date%3D2016%26volume%3D49%26spage%3D1185%26epage%3D1194%26doi%3D10.3892%2Fijo.2016.3614" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Burris, H. A.,  3rd</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tibbitts, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holden, S. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sliwkowski, M. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lewis Phillips, G. D.</span></span> <span> </span><span class="NLM_article-title">Trastuzumab emtansine (T-DM1): a novel agent for targeting HER2+ breast cancer</span>. <i>Clin. Breast Cancer</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">275</span>â <span class="NLM_lpage">282</span>, <span class="refDoi">Â DOI: 10.1016/j.clbc.2011.03.018</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01340&amp;key=10.1016%2Fj.clbc.2011.03.018" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01340&amp;key=21729661" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01340&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhsVOhtL%252FF" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2011&pages=275-282&author=H.+A.+Burrisauthor=J.+Tibbittsauthor=S.+N.+Holdenauthor=M.+X.+Sliwkowskiauthor=G.+D.+Lewis+Phillips&title=Trastuzumab+emtansine+%28T-DM1%29%3A+a+novel+agent+for+targeting+HER2%2B+breast+cancer&doi=10.1016%2Fj.clbc.2011.03.018"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Trastuzumab emtansine (T-DM1): a novel agent for targeting HER2+ breast cancer</span></div><div class="casAuthors">Burris, Howard A.; Tibbitts, Jay; Holden, Scott N.; Sliwkowski, Mark X.; Phillips, Gail D. Lewis</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Breast Cancer</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">275-282</span>CODEN:
                <span class="NLM_cas:coden">CBCLB7</span>;
        ISSN:<span class="NLM_cas:issn">1526-8209</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A review.  Increased understanding of the mol. mechanisms of tumorigenesis has led to the development of novel agents that target tumor cells with minimal effects on normal cells.  The success of this approach is exemplified by the development of monoclonal antibodies directed toward antigens expressed selectively by tumor cells.  The conjugation of these monoclonal antibodies with potent cytotoxic drugs has the potential to further improve efficacy while retaining a favorable safety profile.  Trastuzumab emtansine (T-DM1) is an antibody-drug conjugate (ADC) currently in clin. development.  It combines the humanized antibody trastuzumab, which targets the human epidermal growth factor receptor 2 (HER2) receptor on cancer cells, and the potent antimicrotubule agent DM1 using a unique highly stable linker.  When T-DM1 binds to HER2, a proportion of the receptors are thought to be internalized by the process of receptor endocytosis, followed by the intracellular release of an active form of DM1, which in turn kills the tumor cell.  This review presents the rationale for the development of T-DM1 and summarizes the preclin. and clin. data for this novel agent for the treatment of breast cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo7ZQT0-dTJK7Vg90H21EOLACvtfcHk0lg_7OY1QEuJ5g"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhsVOhtL%252FF&md5=797b6cc51cf2cd37e70fcf8aba68d0be</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1016%2Fj.clbc.2011.03.018&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.clbc.2011.03.018%26sid%3Dliteratum%253Aachs%26aulast%3DBurris%26aufirst%3DH.%2BA.%26aulast%3DTibbitts%26aufirst%3DJ.%26aulast%3DHolden%26aufirst%3DS.%2BN.%26aulast%3DSliwkowski%26aufirst%3DM.%2BX.%26aulast%3DLewis%2BPhillips%26aufirst%3DG.%2BD.%26atitle%3DTrastuzumab%2520emtansine%2520%2528T-DM1%2529%253A%2520a%2520novel%2520agent%2520for%2520targeting%2520HER2%252B%2520breast%2520cancer%26jtitle%3DClin.%2520Breast%2520Cancer%26date%3D2011%26volume%3D11%26spage%3D275%26epage%3D282%26doi%3D10.1016%2Fj.clbc.2011.03.018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Spector, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xia, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">El-Hariry, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yarden, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bacus, S.</span></span> <span> </span><span class="NLM_article-title">HER2 therapy. Small molecule HER-2 tyrosine kinase inhibitors</span>. <i>Breast Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">205</span>, <span class="refDoi">Â DOI: 10.1186/bcr1652</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01340&amp;key=10.1186%2Fbcr1652" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01340&amp;key=17338834" title="">PubMed</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2007&pages=205&author=N.+Spectorauthor=W.+Xiaauthor=I.+El-Hariryauthor=Y.+Yardenauthor=S.+Bacus&title=HER2+therapy.+Small+molecule+HER-2+tyrosine+kinase+inhibitors&doi=10.1186%2Fbcr1652"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1186%2Fbcr1652&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fbcr1652%26sid%3Dliteratum%253Aachs%26aulast%3DSpector%26aufirst%3DN.%26aulast%3DXia%26aufirst%3DW.%26aulast%3DEl-Hariry%26aufirst%3DI.%26aulast%3DYarden%26aufirst%3DY.%26aulast%3DBacus%26aufirst%3DS.%26atitle%3DHER2%2520therapy.%2520Small%2520molecule%2520HER-2%2520tyrosine%2520kinase%2520inhibitors%26jtitle%3DBreast%2520Cancer%2520Res.%26date%3D2007%26volume%3D9%26spage%3D205%26doi%3D10.1186%2Fbcr1652" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Eberle, A. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mild, G.</span></span> <span> </span><span class="NLM_article-title">Receptor-mediated tumor targeting with radiopeptides. Part 1. General principles and methods</span>. <i>J. Recept. Signal Transduction Res.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>29</i></span>,  <span class="NLM_fpage">1</span>â <span class="NLM_lpage">37</span>, <span class="refDoi">Â DOI: 10.1080/10799890902732823</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01340&amp;key=10.1080%2F10799890902732823" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01340&amp;key=19519167" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01340&amp;key=1%3ACAS%3A280%3ADC%252BD1MvhtlGmsw%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2009&pages=1-37&author=A.+N.+Eberleauthor=G.+Mild&title=Receptor-mediated+tumor+targeting+with+radiopeptides.+Part+1.+General+principles+and+methods&doi=10.1080%2F10799890902732823"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Receptor-mediated tumor targeting with radiopeptides. Part 1. General principles and methods</span></div><div class="casAuthors">Eberle Alex N; Mild Gabriele</div><div class="citationInfo"><span class="NLM_cas:title">Journal of receptor and signal transduction research</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">1-37</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Radiolabeled peptides have become important tools for preclinical cancer research, and in nuclear oncology they serve as diagnostic and more recently also as therapeutic agents.  In the latter application, radiolabeled peptides represent a distinct sector of the molecular targeting approach, which in many areas of therapy implements the old "magic bullet" concept by specifically directing the therapeutic agent to the site of action.  Although in the past few years the development of receptor-mediated targeting for therapy has been confined to some radiolabeled antibodies and to somatostatin/SRIF, research into an increasing number of radiolabeled peptides and their receptors expressed by different tumors will soon lead to a wider use of peptide radiopharmaceuticals.  In a consecutive series of six reviews we present a comprehensive overview of the literature on receptor-mediated tumor targeting with the different radiopeptides currently studied.  Part 1 summarizes the concepts and methods of radiopeptide targeting, the selection of radioisotopes, chelators, the criteria of peptide ligand development and some general aspects of diagnostic and therapeutic application of peptide radiopharmaceuticals.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTFA4lUC0UN4kPI-fCgwosgfW6udTcc2ebHNQgS9oItjLntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1MvhtlGmsw%253D%253D&md5=411e64994bece3cca7f24363531f7c7a</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1080%2F10799890902732823&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F10799890902732823%26sid%3Dliteratum%253Aachs%26aulast%3DEberle%26aufirst%3DA.%2BN.%26aulast%3DMild%26aufirst%3DG.%26atitle%3DReceptor-mediated%2520tumor%2520targeting%2520with%2520radiopeptides.%2520Part%25201.%2520General%2520principles%2520and%2520methods%26jtitle%3DJ.%2520Recept.%2520Signal%2520Transduction%2520Res.%26date%3D2009%26volume%3D29%26spage%3D1%26epage%3D37%26doi%3D10.1080%2F10799890902732823" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Reilly, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kiarash, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sandhu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, Y. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cameron, R. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hendler, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vallis, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">GariÃ¨py, J.</span></span> <span> </span><span class="NLM_article-title">A comparison of EGF and MAb 528 labeled with 111In for imaging human breast cancer</span>. <i>J. Nucl. Med.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>41</i></span>,  <span class="NLM_fpage">903</span>â <span class="NLM_lpage">911</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01340&amp;key=10809207" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01340&amp;key=1%3ACAS%3A528%3ADC%252BD3cXjslSlsr8%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=41&publication_year=2000&pages=903-911&author=R.+M.+Reillyauthor=R.+Kiarashauthor=J.+Sandhuauthor=Y.+W.+Leeauthor=R.+G.+Cameronauthor=A.+Hendlerauthor=K.+Vallisauthor=J.+Gari%C3%A8py&title=A+comparison+of+EGF+and+MAb+528+labeled+with+111In+for+imaging+human+breast+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">A comparison of EGF and MAb 528 labeled with 111In for imaging human breast cancer</span></div><div class="casAuthors">Reilly, Raymond M.; Kiarash, Reza; Sandhu, Jasbir; Lee, Ying Wai; Cameron, Ross G.; Hendler, Aaron; Vallis, Katherine; Gariepy, Jean</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Nuclear Medicine</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">41</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">903-911</span>CODEN:
                <span class="NLM_cas:coden">JNMEAQ</span>;
        ISSN:<span class="NLM_cas:issn">0161-5505</span>.
    
            (<span class="NLM_cas:orgname">Society of Nuclear Medicine, Inc.</span>)
        </div><div class="casAbstract">Our objective was to compare 111In-labeled human epidermal growth factor (hEGF), a 53-amino acid peptide with anti-epidermal growth factor receptor (EGFR) monoclonal antibody (MAb) 528 (IgG2a) for imaging EGFR-pos. breast cancer.  Methods: hEGF and MAb 528 were derivatized with diethylenetriamine pentaacetic acid (DTPA) and labeled with 111In acetate.  Receptor binding assays were conducted in vitro against MDA-MB-468 human breast cancer cells.  Biodistribution and tumor imaging studies were conducted after i.v. injection of the radiopharmaceuticals in athymic mice bearing s.c. MCF-7, MDA-MB-231, or MDA-MB-468 human breast cancer xenografts or in severe combined immunodeficiency mice implanted with a breast cancer metastasis (JW-97 cells).  MCF-7, MDA-MB-231, JW-97, and MDA-MB-468 cells expressed 1.5 Ã 104, 1.3 Ã 105, 2.7 Ã 105, and 1.3 Ã 106 EGFR/cell, resp. in vitro.  Results: 111In-DTPA-hEGF and 111In-DTPA-MAb 528 bound with high affinity to MDA-MB-468 cells (Ka of 7.5 Ã 108 and 1.2 Ã 108 L/mol, resp.).  111In-DTPA-hEGF was eliminated rapidly from the blood with < 0.2% injected dose/g (%ID/g) circulating at 72 h after injection, whereas 111In-DTPA-MAb 528 was cleared more slowly (3%ID/g in the blood at 72 h).  Maximum localization of 111In-DTPA-hEGF in MDA-MB-468 tumors (2.2 %ID/g) was 10-fold lower than with 111In-DTPA-MAb 528 (21.6 %ID/g).  There was high uptake in the liver and kidneys for both radiopharmaceuticals.  Tumor-to-blood ratios were greater for 111In-labeled hEGF than for MAb 528 (12:1 vs. 6:1), but all other tumor-to-normal tissue ratios were higher for MAb 528.  MDA-MB-468 and JW-97 tumors were imaged successfully with both radiopharmaceuticals, but tumors were more easily visualized using 111In-labeled MAb 528.  There was no direct quant. relationship between EGFR expression on breast cancer cell lines in vitro, and tumor uptake of the radiopharmaceuticals in vivo, but control studies showed that tumor uptake was receptor mediated.  Conclusion: Our results suggest that the tumor uptake in vivo of receptor-binding radiopharmaceuticals is controlled to a greater extent by their elimination rate from the blood than by the level of receptor expression on the cancer cells.  Radiolabeled anti-EGFRMAbs would be more effective for tumor imaging in cancer patients than peptide-based radiopharmaceuticals such as hEGF, because they exhibit higher tumor uptake at only moderately lower tumor-to-blood ratios.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqSri3SUsFXPLVg90H21EOLACvtfcHk0liHcfmCnqHqXQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXjslSlsr8%253D&md5=8d4ce22249ecd06e65dcdf411bc670ab</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DReilly%26aufirst%3DR.%2BM.%26aulast%3DKiarash%26aufirst%3DR.%26aulast%3DSandhu%26aufirst%3DJ.%26aulast%3DLee%26aufirst%3DY.%2BW.%26aulast%3DCameron%26aufirst%3DR.%2BG.%26aulast%3DHendler%26aufirst%3DA.%26aulast%3DVallis%26aufirst%3DK.%26aulast%3DGari%25C3%25A8py%26aufirst%3DJ.%26atitle%3DA%2520comparison%2520of%2520EGF%2520and%2520MAb%2520528%2520labeled%2520with%2520111In%2520for%2520imaging%2520human%2520breast%2520cancer%26jtitle%3DJ.%2520Nucl.%2520Med.%26date%3D2000%26volume%3D41%26spage%3D903%26epage%3D911" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Orlova, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">WÃ¥llberg, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stone-Elander, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tolmachev, V.</span></span> <span> </span><span class="NLM_article-title">On the selection of a tracer for PET imaging of HER2-expressing tumors: direct comparison of a 124I-labeled affibody molecule and trastuzumab in a murine xenograft model</span>. <i>J. Nucl. Med.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>50</i></span>,  <span class="NLM_fpage">417</span>â <span class="NLM_lpage">425</span>, <span class="refDoi">Â DOI: 10.2967/jnumed.108.057919</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01340&amp;key=10.2967%2Fjnumed.108.057919" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01340&amp;key=19223403" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01340&amp;key=1%3ACAS%3A528%3ADC%252BD1MXktVynsro%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2009&pages=417-425&author=A.+Orlovaauthor=H.+W%C3%A5llbergauthor=S.+Stone-Elanderauthor=V.+Tolmachev&title=On+the+selection+of+a+tracer+for+PET+imaging+of+HER2-expressing+tumors%3A+direct+comparison+of+a+124I-labeled+affibody+molecule+and+trastuzumab+in+a+murine+xenograft+model&doi=10.2967%2Fjnumed.108.057919"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">On the selection of a tracer for PET imaging of HER2-expressing tumours: direct comparison of a 124I-labeled affibody molecule and trastuzumab in a murine xenograft model</span></div><div class="casAuthors">Orlova, Anna; Waallberg, Helena; Stone-Elander, Sharon; Tolmachev, Vladimir</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Nuclear Medicine</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">50</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">417-425</span>CODEN:
                <span class="NLM_cas:coden">JNMEAQ</span>;
        ISSN:<span class="NLM_cas:issn">0161-5505</span>.
    
            (<span class="NLM_cas:orgname">Society of Nuclear Medicine</span>)
        </div><div class="casAbstract">Human epidermal growth factor receptor type 2 (HER2) is a tyrosine kinase, which is often overexpressed in many carcinomas.  Imaging HER2 expression in malignant tumors can provide important prognostic and predictive diagnostic information.  The use of anti-HER2 tracers labeled with positron-emitting radionuclides may increase the sensitivity of HER2 imaging.  The goal of this study was to compare directly 2 approaches for developing anti-HER2 PET tracers: a 124I-labeled monoclonal antibody and a small (7-kDa) scaffold protein, the Affibody mol.  The anti-HER2 Affibody ZHER2:342 and humanized monoclonal antibody trastuzumab were labeled with 124/125I using p-iodo-benzoate (PIB) as a linker.  Cellular processing of both tracers by HER2-expressing cells was investigated.  The biodistributions of 124I-PIB-ZHER2:342 and 125I-PIB-trastuzumab were compared in BALB/C nu/nu mice bearing HER2-expressing NCI-N87 xenografts using paired labels.  Small-animal PET of 124I-PIB-ZHER2:342 and 124I-PIB-trastuzumab in tumor-bearing mice was performed at 6, 24, and 72 h after injection.  Both radioiodinated ZHER2:342 and trastuzumab bound specifically to HER2-expressing cells in vitro and specifically targeted HER2-expressing xenografts in vivo.  Radioiodinated trastuzumab was more rapidly internalized and degraded, which resulted in better retention of radioactivity delivered by ZHER2:342.  Total uptake of trastuzumab in tumors was higher than that of 124I-PIB-ZHER2:342.  However, tumor-to-organ ratios were appreciably higher for 124I-PIB-ZHER2:342 due to the more rapid clearance of radioactivity from blood and normal organs.  The ex vivo results were confirmed by small-animal PET.  The use of the small scaffold targeting Affibody provides better contrast in HER2 imaging than does the monoclonal antibody.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpAfr9P8kFP6bVg90H21EOLACvtfcHk0liHcfmCnqHqXQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXktVynsro%253D&md5=028d50e7db64a308728979b3e1c1c7a3</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.2967%2Fjnumed.108.057919&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2967%252Fjnumed.108.057919%26sid%3Dliteratum%253Aachs%26aulast%3DOrlova%26aufirst%3DA.%26aulast%3DW%25C3%25A5llberg%26aufirst%3DH.%26aulast%3DStone-Elander%26aufirst%3DS.%26aulast%3DTolmachev%26aufirst%3DV.%26atitle%3DOn%2520the%2520selection%2520of%2520a%2520tracer%2520for%2520PET%2520imaging%2520of%2520HER2-expressing%2520tumors%253A%2520direct%2520comparison%2520of%2520a%2520124I-labeled%2520affibody%2520molecule%2520and%2520trastuzumab%2520in%2520a%2520murine%2520xenograft%2520model%26jtitle%3DJ.%2520Nucl.%2520Med.%26date%3D2009%26volume%3D50%26spage%3D417%26epage%3D425%26doi%3D10.2967%2Fjnumed.108.057919" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Calce, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Monfregola, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sandomenico, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saviano, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Luca, S.</span></span> <span> </span><span class="NLM_article-title">Fluorescence study for selecting specific ligands toward HER2 receptor: an example of receptor fragment approach</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">116</span>â <span class="NLM_lpage">121</span>, <span class="refDoi">Â DOI: 10.1016/j.ejmech.2012.09.024</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01340&amp;key=10.1016%2Fj.ejmech.2012.09.024" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01340&amp;key=23107515" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01340&amp;key=1%3ACAS%3A528%3ADC%252BC38XhsFynur7F" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2013&pages=116-121&author=E.+Calceauthor=L.+Monfregolaauthor=A.+Sandomenicoauthor=M.+Savianoauthor=S.+De+Luca&title=Fluorescence+study+for+selecting+specific+ligands+toward+HER2+receptor%3A+an+example+of+receptor+fragment+approach&doi=10.1016%2Fj.ejmech.2012.09.024"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Fluorescence study for selecting specific ligands toward HER2 receptor: An example of receptor fragment approach</span></div><div class="casAuthors">Calce, Enrica; Monfregola, Luca; Sandomenico, Annamaria; Saviano, Michele; De Luca, Stefania</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">116-121</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Fluorescence titrns. allowed the authors to study the interaction process between Herceptin (Fab)-derived peptides and a synthetic peptide mimicking a subdomain IV of the receptor HER2 (HER2-DIVMP).  For some of the investigated peptide/HER2-DIVMP complexes a nanomolar dissocn. const. was found.  The performed interaction studies were completely immune from interferences of other receptor domains not covered by the design, thus decreasing the possibilities of selecting potential ligands able to bind other subtypes of HER2 receptor family.  The authors' results demonstrate that the adopted receptor fragment approach represents an efficient methodol. for selecting new mols. as lead structures specific for the receptor target.  For these reasons the optimized compds. could be employed as delivery agents for the receptor-mediated anticancer therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqvvVP961zzwrVg90H21EOLACvtfcHk0liHcfmCnqHqXQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhsFynur7F&md5=4e80f6f4f156905c00a785bb2415d572</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2012.09.024&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2012.09.024%26sid%3Dliteratum%253Aachs%26aulast%3DCalce%26aufirst%3DE.%26aulast%3DMonfregola%26aufirst%3DL.%26aulast%3DSandomenico%26aufirst%3DA.%26aulast%3DSaviano%26aufirst%3DM.%26aulast%3DDe%2BLuca%26aufirst%3DS.%26atitle%3DFluorescence%2520study%2520for%2520selecting%2520specific%2520ligands%2520toward%2520HER2%2520receptor%253A%2520an%2520example%2520of%2520receptor%2520fragment%2520approach%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2013%26volume%3D61%26spage%3D116%26epage%3D121%26doi%3D10.1016%2Fj.ejmech.2012.09.024" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Monfregola, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vitale, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amodeo, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Luca, S.</span></span> <span> </span><span class="NLM_article-title">A SPR strategy for high-throughput ligand screenings based on synthetic peptides mimicking a selected subdomain of the target protein: a proof of concept on HER2 receptor</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">7015</span>â <span class="NLM_lpage">7020</span>, <span class="refDoi">Â DOI: 10.1016/j.bmc.2009.08.004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01340&amp;key=10.1016%2Fj.bmc.2009.08.004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01340&amp;key=19733086" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01340&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtFamsbnM" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2009&pages=7015-7020&author=L.+Monfregolaauthor=R.+M.+Vitaleauthor=P.+Amodeoauthor=S.+De+Luca&title=A+SPR+strategy+for+high-throughput+ligand+screenings+based+on+synthetic+peptides+mimicking+a+selected+subdomain+of+the+target+protein%3A+a+proof+of+concept+on+HER2+receptor&doi=10.1016%2Fj.bmc.2009.08.004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">A SPR strategy for high-throughput ligand screenings based on synthetic peptides mimicking a selected subdomain of the target protein: A proof of concept on HER2 receptor</span></div><div class="casAuthors">Monfregola, Luca; Vitale, Rosa Maria; Amodeo, Pietro; De Luca, Stefania</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">7015-7020</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The discovery of pharmaceutical agents is a complex, lengthy and costly process, critically depending on the availability of rapid and efficient screening methods.  In particular, when targets are large, multidomain proteins, their complexity may affect unfavorably tech. feasibility, costs and unambiguity of binding test interpretation.  A possible strategy to overcome these problems relies on mol. design of receptor fragments that are: sensible targets for ligand screenings, conformationally stable also as standalone domains, easily synthesized and immobilized on chip for Biacore expts.  An addnl. desirable feature for new ligands is the ability of selectively targeting alternative conformational states typical of many proteins.  To test the feasibility of such approach on a case with potential applicative interest, we developed a surface plasmon resonance (SPR)-based screening method for drug candidates toward HER2, a Tyr-kinase receptor targeted in anticancer therapies.  HER2 was mimicked by HER2-DIVMP, a modified fragment of it immobilized onto the sensor surface specifically modeling HER2 domain IV in its bounded form, designed by structural comparison of HER2 alone and in complex with Herceptin, a monoclonal therapeutic anti-HER2 antibody.  This design and its implementation in SPR devices was validated by investigating Herceptin- HER2-DIVMP affinity, measuring its dissocn. const. (K D = 19.2 nM).  An efficient synthetic procedure to prep. the HER2-DIVMP peptide was also developed.  The HER2-DIVMP conformational stability suggested by exptl. and computational results, makes it also a valuable candidate as a mold to design new mols. selectively targeting domain IV of HER2.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGopaFRdelSg8rVg90H21EOLACvtfcHk0lgxsEUbgB8bPg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtFamsbnM&md5=f1d4612facfaff1b8e21ea51a3defb46</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2009.08.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2009.08.004%26sid%3Dliteratum%253Aachs%26aulast%3DMonfregola%26aufirst%3DL.%26aulast%3DVitale%26aufirst%3DR.%2BM.%26aulast%3DAmodeo%26aufirst%3DP.%26aulast%3DDe%2BLuca%26aufirst%3DS.%26atitle%3DA%2520SPR%2520strategy%2520for%2520high-throughput%2520ligand%2520screenings%2520based%2520on%2520synthetic%2520peptides%2520mimicking%2520a%2520selected%2520subdomain%2520of%2520the%2520target%2520protein%253A%2520a%2520proof%2520of%2520concept%2520on%2520HER2%2520receptor%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2009%26volume%3D17%26spage%3D7015%26epage%3D7020%26doi%3D10.1016%2Fj.bmc.2009.08.004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Calce, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leone, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Monfregola, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Luca, S.</span></span> <span> </span><span class="NLM_article-title">Lipidated peptides via post-synthetic thioalkylation promoted by molecular sieves</span>. <i>Amino Acids</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>46</i></span>,  <span class="NLM_fpage">1899</span>â <span class="NLM_lpage">1905</span>, <span class="refDoi">Â DOI: 10.1007/s00726-014-1742-y</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01340&amp;key=10.1007%2Fs00726-014-1742-y" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01340&amp;key=24748120" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01340&amp;key=1%3ACAS%3A528%3ADC%252BC2cXmsVKnt74%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2014&pages=1899-1905&author=E.+Calceauthor=M.+Leoneauthor=L.+Monfregolaauthor=S.+De+Luca&title=Lipidated+peptides+via+post-synthetic+thioalkylation+promoted+by+molecular+sieves&doi=10.1007%2Fs00726-014-1742-y"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Lipidated peptides via post-synthetic thioalkylation promoted by molecular sieves</span></div><div class="casAuthors">Calce, Enrica; Leone, Marilisa; Monfregola, Luca; De Luca, Stefania</div><div class="citationInfo"><span class="NLM_cas:title">Amino Acids</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">46</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1899-1905</span>CODEN:
                <span class="NLM_cas:coden">AACIE6</span>;
        ISSN:<span class="NLM_cas:issn">0939-4451</span>.
    
            (<span class="NLM_cas:orgname">Springer-Verlag GmbH</span>)
        </div><div class="casAbstract">A thioalkylation procedure, which uses mol. sieves to promote the reaction, was exploited to provide peptides with useful functional groups (lipidic moieties), naturally occurring on proteins as post-translational modifications.  The procedure was further implemented to synthesize tailor-made lipidated peptides, interesting tools to investigate biol. processes involving their Ras parent proteins.  Moreover, the one-pot prepn. of multi-alkylated peptides confirms the versatility and flexibility of the employed methodol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp-Px105u1SCbVg90H21EOLACvtfcHk0lgxsEUbgB8bPg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXmsVKnt74%253D&md5=3a887e98bd0f0358fb279e8f6536c073</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1007%2Fs00726-014-1742-y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00726-014-1742-y%26sid%3Dliteratum%253Aachs%26aulast%3DCalce%26aufirst%3DE.%26aulast%3DLeone%26aufirst%3DM.%26aulast%3DMonfregola%26aufirst%3DL.%26aulast%3DDe%2BLuca%26aufirst%3DS.%26atitle%3DLipidated%2520peptides%2520via%2520post-synthetic%2520thioalkylation%2520promoted%2520by%2520molecular%2520sieves%26jtitle%3DAmino%2520Acids%26date%3D2014%26volume%3D46%26spage%3D1899%26epage%3D1905%26doi%3D10.1007%2Fs00726-014-1742-y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Langella, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Calce, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saviano, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Luca, S.</span></span> <span> </span><span class="NLM_article-title">Structural identification of HER2 receptor model binding pocket to optimize lead compounds: a combined experimental and computational approach</span>. <i>Mol. BioSyst.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">2159</span>â <span class="NLM_lpage">2167</span>, <span class="refDoi">Â DOI: 10.1039/C6MB00158K</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01340&amp;key=10.1039%2FC6MB00158K" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01340&amp;key=27113673" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01340&amp;key=1%3ACAS%3A528%3ADC%252BC28XmsF2ksr8%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2016&pages=2159-2167&author=E.+Langellaauthor=E.+Calceauthor=M.+Savianoauthor=S.+De+Luca&title=Structural+identification+of+HER2+receptor+model+binding+pocket+to+optimize+lead+compounds%3A+a+combined+experimental+and+computational+approach&doi=10.1039%2FC6MB00158K"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Structural identification of an HER2 receptor model binding pocket to optimize lead compounds: a combined experimental and computational approach</span></div><div class="casAuthors">Langella, Emma; Calce, Enrica; Saviano, Michele; De Luca, Stefania</div><div class="citationInfo"><span class="NLM_cas:title">Molecular BioSystems</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2159-2167</span>CODEN:
                <span class="NLM_cas:coden">MBOIBW</span>;
        ISSN:<span class="NLM_cas:issn">1742-2051</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">The structural investigation of the ligand/target interactions represents a challenging task in the field of drug discovery or lead compd. optimization.  In the present study, a computational approach allowed the identification of the binding site of A9 peptide, within a synthetic model of HER2 receptor (HER2-DIVMP).  To this aim, mol. docking calcns. and mol. dynamics simulations were employed, taking into account exptl. data obtained by fluorescence studies.  The computational model was further validated by performing fluorescence binding studies between the ligand A9 and HER2-DIVMP mutants, prepd. by replacing key amino acid residues.  A new binding pocket of HER2-DIVMP was identified, which could be fruitfully exploited for future lead-optimization studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrPRXJyoMKRM7Vg90H21EOLACvtfcHk0lgxsEUbgB8bPg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XmsF2ksr8%253D&md5=4bac610eb075316e37378f00848ca132</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1039%2FC6MB00158K&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC6MB00158K%26sid%3Dliteratum%253Aachs%26aulast%3DLangella%26aufirst%3DE.%26aulast%3DCalce%26aufirst%3DE.%26aulast%3DSaviano%26aufirst%3DM.%26aulast%3DDe%2BLuca%26aufirst%3DS.%26atitle%3DStructural%2520identification%2520of%2520HER2%2520receptor%2520model%2520binding%2520pocket%2520to%2520optimize%2520lead%2520compounds%253A%2520a%2520combined%2520experimental%2520and%2520computational%2520approach%26jtitle%3DMol.%2520BioSyst.%26date%3D2016%26volume%3D12%26spage%3D2159%26epage%3D2167%26doi%3D10.1039%2FC6MB00158K" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Honarvar, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Calce, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doti, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Langella, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Orlova, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buijs, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DâAmato, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bianco, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saviano, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tolmachev, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Luca, S.</span></span> <span> </span><span class="NLM_article-title">Evaluation of HER2-specific peptide ligand for its employment as radiolabeled imaging probe</span>. <i>Sci. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">2998</span>, <span class="refDoi">Â DOI: 10.1038/s41598-018-21283-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01340&amp;key=10.1038%2Fs41598-018-21283-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01340&amp;key=29445216" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01340&amp;key=1%3ACAS%3A280%3ADC%252BC1Mrhsl2muw%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2018&pages=2998&author=H.+Honarvarauthor=E.+Calceauthor=N.+Dotiauthor=E.+Langellaauthor=A.+Orlovaauthor=J.+Buijsauthor=V.+D%E2%80%99Amatoauthor=R.+Biancoauthor=M.+Savianoauthor=V.+Tolmachevauthor=S.+De+Luca&title=Evaluation+of+HER2-specific+peptide+ligand+for+its+employment+as+radiolabeled+imaging+probe&doi=10.1038%2Fs41598-018-21283-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Evaluation of HER2-specific peptide ligand for its employment as radiolabeled imaging probe</span></div><div class="casAuthors">Honarvar Hadis; Calce Enrica; Doti Nunzianna; Langella Emma; De Luca Stefania; Orlova Anna; Buijs Jos; D'Amato Valentina; Bianco Roberto; Saviano Michele; Tolmachev Vladimir</div><div class="citationInfo"><span class="NLM_cas:title">Scientific reports</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">2998</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">HER2 transmembrane receptor is an important target in immunotherapy treatment of breast and gastroesophageal cancer.  Molecular imaging of HER2 expression may provide essential prognostic and predictive information concerning disseminated cancer and aid in selection of an optimal therapy.  Radiolabeled low molecular weight peptide ligands are particularly attractive as probes for molecular imaging, since they reach and bind to the target and clear from non-target organs and blood stream faster than bulky antibodies.  In this study, we evaluated a potential HER2-imaging probe, an A9 nonapeptide, derived from the trastuzumab-Fab portion.  Its cellular uptake was investigated by mass spectrometry analysis of the cytoplasmic cellular extracts.  Moreover, based on in-silico modeling, DTPA chelator was conjugated to N-terminus of A9. (111)In-labeled A9 demonstrated nanomolar affinity to HER2-expressing BT474 cells and favorable biodistribution profile in NMRI mice.  This study suggests that the peptide A9 represents a good lead candidate for development of molecular probe, to be used for imaging purposes and for the delivery of cytotoxic agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcT4X4RisZQBEPIW7hznt0zpfW6udTcc2eaxRA2KTX0x9bntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1Mrhsl2muw%253D%253D&md5=a9b49d6cec0048c5e63468be3fe800cd</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1038%2Fs41598-018-21283-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41598-018-21283-3%26sid%3Dliteratum%253Aachs%26aulast%3DHonarvar%26aufirst%3DH.%26aulast%3DCalce%26aufirst%3DE.%26aulast%3DDoti%26aufirst%3DN.%26aulast%3DLangella%26aufirst%3DE.%26aulast%3DOrlova%26aufirst%3DA.%26aulast%3DBuijs%26aufirst%3DJ.%26aulast%3DD%25E2%2580%2599Amato%26aufirst%3DV.%26aulast%3DBianco%26aufirst%3DR.%26aulast%3DSaviano%26aufirst%3DM.%26aulast%3DTolmachev%26aufirst%3DV.%26aulast%3DDe%2BLuca%26aufirst%3DS.%26atitle%3DEvaluation%2520of%2520HER2-specific%2520peptide%2520ligand%2520for%2520its%2520employment%2520as%2520radiolabeled%2520imaging%2520probe%26jtitle%3DSci.%2520Rep.%26date%3D2018%26volume%3D8%26spage%3D2998%26doi%3D10.1038%2Fs41598-018-21283-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cho, H. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mason, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramyar, K. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stanley, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gabelli, S. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Denney, D. W.,  Jr.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leahy, D. J.</span></span> <span> </span><span class="NLM_article-title">Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>421</i></span>,  <span class="NLM_fpage">756</span>â <span class="NLM_lpage">760</span>, <span class="refDoi">Â DOI: 10.1038/nature01392</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01340&amp;key=10.1038%2Fnature01392" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01340&amp;key=12610629" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01340&amp;key=1%3ACAS%3A528%3ADC%252BD3sXhsV2rtrw%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=421&publication_year=2003&pages=756-760&author=H.+S.+Choauthor=K.+Masonauthor=K.+X.+Ramyarauthor=A.+M.+Stanleyauthor=S.+B.+Gabelliauthor=D.+W.+Denneyauthor=D.+J.+Leahy&title=Structure+of+the+extracellular+region+of+HER2+alone+and+in+complex+with+the+Herceptin+Fab&doi=10.1038%2Fnature01392"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab</span></div><div class="casAuthors">Cho, Hyun-Soo; Mason, Karen; Ramyar, Kasra X.; Stanley, Ann Marie; Gabelli, Sandra B.; Denney, Dan W.; Leahy, Daniel J.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">421</span>
        (<span class="NLM_cas:issue">6924</span>),
    <span class="NLM_cas:pages">756-760</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">HER2 (also known as Neu, ErbB2) is a member of the epidermal growth factor receptor (EGFR; also known as ErbB) family of receptor tyrosine kinases, which in humans includes HER1 (EGFR, ERBB1), HER2, HER3 (ERBB3) and HER4 (ERBB4).  ErbB receptors are essential mediators of cell proliferation and differentiation in the developing embryo and in adult tissues, and their inappropriate activation is assocd. with the development and severity of many cancers.  Overexpression of HER2 is found in 20-30% of human breast cancers, and correlates with more aggressive tumors and a poorer prognosis.  Anticancer therapies targeting ErbB receptors have shown promise, and a monoclonal antibody against HER2, Herceptin (also known as trastuzumab), is currently in use as a treatment for breast cancer.  Here we report crystal structures of the entire extracellular regions of rat HER2 at 2.4 Ã and human HER2 complexed with the Herceptin antigen-binding fragment (Fab) at 2.5 Ã.  These structures reveal a fixed conformation for HER2 that resembles a ligand-activated state, and show HER2 poised to interact with other ErbB receptors in the absence of direct ligand binding.  Herceptin binds to the juxtamembrane region of HER2, identifying this site as a target for anticancer therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrE9_6F4odgzLVg90H21EOLACvtfcHk0lgcAKz_-9leIA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXhsV2rtrw%253D&md5=cfbf5e782ca461ce28c60ad688afe682</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1038%2Fnature01392&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature01392%26sid%3Dliteratum%253Aachs%26aulast%3DCho%26aufirst%3DH.%2BS.%26aulast%3DMason%26aufirst%3DK.%26aulast%3DRamyar%26aufirst%3DK.%2BX.%26aulast%3DStanley%26aufirst%3DA.%2BM.%26aulast%3DGabelli%26aufirst%3DS.%2BB.%26aulast%3DDenney%26aufirst%3DD.%2BW.%26aulast%3DLeahy%26aufirst%3DD.%2BJ.%26atitle%3DStructure%2520of%2520the%2520extracellular%2520region%2520of%2520HER2%2520alone%2520and%2520in%2520complex%2520with%2520the%2520Herceptin%2520Fab%26jtitle%3DNature%26date%3D2003%26volume%3D421%26spage%3D756%26epage%3D760%26doi%3D10.1038%2Fnature01392" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref39"><div class="reference"><strong class="refLabel"><a href="#ref39" class="rightTabRefNumLink">39</a></strong><div class="NLM_citation" id="rightTab-cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Calce, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sandomenico, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saviano, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruvo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Luca, S.</span></span> <span> </span><span class="NLM_article-title">Cysteine co-oxidation process driven by native peptide folding: on example of HER2 receptor model system</span>. <i>Amino Acids</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>46</i></span>,  <span class="NLM_fpage">1197</span>â <span class="NLM_lpage">1206</span>, <span class="refDoi">Â DOI: 10.1007/s00726-014-1681-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01340&amp;key=10.1007%2Fs00726-014-1681-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01340&amp;key=24493095" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01340&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhs1Kjsrg%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2014&pages=1197-1206&author=E.+Calceauthor=A.+Sandomenicoauthor=M.+Savianoauthor=M.+Ruvoauthor=S.+De+Luca&title=Cysteine+co-oxidation+process+driven+by+native+peptide+folding%3A+on+example+of+HER2+receptor+model+system&doi=10.1007%2Fs00726-014-1681-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Cysteine co-oxidation process driven by native peptide folding: an example on HER2 receptor model system</span></div><div class="casAuthors">Calce, Enrica; Sandomenico, Annamaria; Saviano, Michele; Ruvo, Menotti; De Luca, Stefania</div><div class="citationInfo"><span class="NLM_cas:title">Amino Acids</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">46</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1197-1206</span>CODEN:
                <span class="NLM_cas:coden">AACIE6</span>;
        ISSN:<span class="NLM_cas:issn">0939-4451</span>.
    
            (<span class="NLM_cas:orgname">Springer-Verlag GmbH</span>)
        </div><div class="casAbstract">Synthetic models of receptors that have relevant biol. roles are valuable tools for studying receptors itself and the corresponding ligands.  Their properties can be validated at first by their capacity to fold in soln. under native-like conditions and to assume conformations structurally and functionally equiv. to those in the native receptor.  In this context, a new strategy to prep. the two-fragments synthetic receptor model HER2-DIVMP, an independent structural and functional motif of HER2, has been developed and the folding properties have been investigated.  The strategy is based on a one-step cysteine co-oxidn. procedure in slightly alk. aq. buffers, whereby the two sep. peptide chains are allowed to self-assemble in soln.  Under these conditions, the two chains spontaneously form the expected heterodimer with the correct pattern of disulfide bridges.  To gain insights on the folding mechanism, we investigated the folding of two scrambled variants of the constituent peptide chains.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqEIpYhqc_Tj7Vg90H21EOLACvtfcHk0lgcAKz_-9leIA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhs1Kjsrg%253D&md5=81c9ec130e4b3c413f7413f000a2440c</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1007%2Fs00726-014-1681-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00726-014-1681-7%26sid%3Dliteratum%253Aachs%26aulast%3DCalce%26aufirst%3DE.%26aulast%3DSandomenico%26aufirst%3DA.%26aulast%3DSaviano%26aufirst%3DM.%26aulast%3DRuvo%26aufirst%3DM.%26aulast%3DDe%2BLuca%26aufirst%3DS.%26atitle%3DCysteine%2520co-oxidation%2520process%2520driven%2520by%2520native%2520peptide%2520folding%253A%2520on%2520example%2520of%2520HER2%2520receptor%2520model%2520system%26jtitle%3DAmino%2520Acids%26date%3D2014%26volume%3D46%26spage%3D1197%26epage%3D1206%26doi%3D10.1007%2Fs00726-014-1681-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref40"><div class="reference"><strong class="refLabel"><a href="#ref40" class="rightTabRefNumLink">40</a></strong><div class="NLM_citation" id="rightTab-cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">De
Luca, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verdoliva, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saviano, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fattorusso, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diana, D.</span></span> <span> </span><span class="NLM_article-title">SPR and NMR characterization of the molecular interaction between A9 peptide and a model system of HER2 receptor: A fragment approach for selecting peptide structures specific for their target</span>. <i>J. Pept. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>26</i></span>, <span class="NLM_elocation-id">e3231</span> <span class="refDoi">Â DOI: 10.1002/psc.3231</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01340&amp;key=10.1002%2Fpsc.3231" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01340&amp;key=31749266" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01340&amp;key=1%3ACAS%3A528%3ADC%252BC1MXitFyqsLnF" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2020&author=S.+De%0ALucaauthor=V.+Verdolivaauthor=M.+Savianoauthor=R.+Fattorussoauthor=D.+Diana&title=SPR+and+NMR+characterization+of+the+molecular+interaction+between+A9+peptide+and+a+model+system+of+HER2+receptor%3A+A+fragment+approach+for+selecting+peptide+structures+specific+for+their+target&doi=10.1002%2Fpsc.3231"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">SPR and NMR characterization of the molecular interaction between A9 peptide and a model system of HER2 receptor: A fragment approach for selecting peptide structures specific for their target</span></div><div class="casAuthors">De Luca, Stefania; Verdoliva, Valentina; Saviano, Michele; Fattorusso, Roberto; Diana, Donatella</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Peptide Science</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">e3231</span>CODEN:
                <span class="NLM_cas:coden">JPSIEI</span>;
        ISSN:<span class="NLM_cas:issn">1075-2617</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons Ltd.</span>)
        </div><div class="casAbstract">The binding process of A9 peptide toward HER2-DIVMP, a synthetic model of the receptor domain IV, was studied by using the surface plasmon resonance (SPR) technique, with the aim of validating it as a fast and reliable screening method for selecting peptide ligands specifically targeting a domain of their target.  To investigate the structural basis of A9 binding to the model of HER2-DIVMP, multiple ligand-based NMR (NMR) methods were applied.  The use of satn. transfer difference (STD) and WaterLOGSY NMR expts. identified key residues in the peptide for the receptor binding.  Moreover, the bound conformation of the A9 peptide was obtained using transferred nuclear Overhauser effect spectroscopy (trNOESY) expts.  The NMR data revealed an extended binding surface that confirms an in silico model previously reported.  These structural findings could provide good starting points for future lead structures optimization specific for the receptor target.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo08rwjOqzqqrVg90H21EOLACvtfcHk0lgcAKz_-9leIA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXitFyqsLnF&md5=ba53040e1c423f07696ba5277212ca4a</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1002%2Fpsc.3231&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fpsc.3231%26sid%3Dliteratum%253Aachs%26aulast%3DDe%2BLuca%26aufirst%3DS.%26aulast%3DVerdoliva%26aufirst%3DV.%26aulast%3DSaviano%26aufirst%3DM.%26aulast%3DFattorusso%26aufirst%3DR.%26aulast%3DDiana%26aufirst%3DD.%26atitle%3DSPR%2520and%2520NMR%2520characterization%2520of%2520the%2520molecular%2520interaction%2520between%2520A9%2520peptide%2520and%2520a%2520model%2520system%2520of%2520HER2%2520receptor%253A%2520A%2520fragment%2520approach%2520for%2520selecting%2520peptide%2520structures%2520specific%2520for%2520their%2520target%26jtitle%3DJ.%2520Pept.%2520Sci.%26date%3D2020%26volume%3D26%26doi%3D10.1002%2Fpsc.3231" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref41"><div class="reference"><strong class="refLabel"><a href="#ref41" class="rightTabRefNumLink">41</a></strong><div class="NLM_citation" id="rightTab-cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span><span class="NLM_etal"></span> <span> </span><span class="NLM_article-title">Synthesis and structure determination of seven coordinate KInIII(Hdtpa)Â·3.5H<sub>2</sub>O</span>. <i>Chem. J. Chin. Univ. Chinese Ed.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">1468</span>â <span class="NLM_lpage">1470</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2000&pages=1468-1470&author=J.+Wang&title=Synthesis+and+structure+determination+of+seven+coordinate+KInIII%28Hdtpa%29%C2%B73.5H2O"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DJ.%26atitle%3DSynthesis%2520and%2520structure%2520determination%2520of%2520seven%2520coordinate%2520KInIII%2528Hdtpa%2529%25C2%25B73.5H2O%26jtitle%3DChem.%2520J.%2520Chin.%2520Univ.%2520Chinese%2520Ed.%26date%3D2000%26volume%3D21%26spage%3D1468%26epage%3D1470" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref42"><div class="reference"><strong class="refLabel"><a href="#ref42" class="rightTabRefNumLink">42</a></strong><div class="NLM_citation" id="rightTab-cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hnatowich, D. J.</span></span> <span> </span><span class="NLM_article-title">Label stability in serum of four radionuclides on DTPA-coupled antibodies-an evaluation</span>. <i>Int. J. Rad. Appl. Instrum. B</i> <span class="NLM_year" style="font-weight: bold;">1986</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">353</span>â <span class="NLM_lpage">358</span>, <span class="refDoi">Â DOI: 10.1016/0883-2897(86)90009-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01340&amp;key=10.1016%2F0883-2897%2886%2990009-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01340&amp;key=3793489" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01340&amp;key=1%3ACAS%3A280%3ADyaL2s%252Fot1ynuw%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=1986&pages=353-358&author=D.+J.+Hnatowich&title=Label+stability+in+serum+of+four+radionuclides+on+DTPA-coupled+antibodies-an+evaluation&doi=10.1016%2F0883-2897%2886%2990009-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Label stability in serum of four radionuclides on DTPA-coupled antibodies--an evaluation</span></div><div class="casAuthors">Hnatowich D J</div><div class="citationInfo"><span class="NLM_cas:title">International journal of radiation applications and instrumentation. Part B, Nuclear medicine and biology</span>
        (<span class="NLM_cas:date">1986</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">353-8</span>
        ISSN:<span class="NLM_cas:issn">0883-2897</span>.
    </div><div class="casAbstract">Although DTPA forms strong chelates with many metals, the harsh chemical environment of the serum may nevertheless dissociate metallic radionuclides from DTPA attached to proteins.  We have investigated the stability in 37 degrees C serum of 111In, 99mTc, 90Y and 153Gd chelated to DTPA-coupled antibodies.  Stability was evaluated primarily by affinity chromatography and HPLC analysis of serum incubates; however, the stability of 111In was determined in vivo in patient studies.  Analysis of patient urine showed no evidence for dissociation of DTPA from antibody whereas analysis of serum demonstrated exchange rates of 111In to transferrin of about 9%/day.  When labeled by the described method, 99mTc on DTPA coupled antibodies shows instability in serum but superior stability than 99mTc on antibodies without the attached DTPA.  Both 90Y and 153Gd dissociate in serum at rates which are comparable to that of 111In.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQezmyNaFLJ86cY7HFp97qMfW6udTcc2eYDaFGV2BpLgLntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaL2s%252Fot1ynuw%253D%253D&md5=2a42d54626143bba9a685ad75f53814b</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1016%2F0883-2897%2886%2990009-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0883-2897%252886%252990009-7%26sid%3Dliteratum%253Aachs%26aulast%3DHnatowich%26aufirst%3DD.%2BJ.%26atitle%3DLabel%2520stability%2520in%2520serum%2520of%2520four%2520radionuclides%2520on%2520DTPA-coupled%2520antibodies-an%2520evaluation%26jtitle%3DInt.%2520J.%2520Rad.%2520Appl.%2520Instrum.%2520B%26date%3D1986%26volume%3D13%26spage%3D353%26epage%3D358%26doi%3D10.1016%2F0883-2897%2886%2990009-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref43"><div class="reference"><strong class="refLabel"><a href="#ref43" class="rightTabRefNumLink">43</a></strong><div class="NLM_citation" id="rightTab-cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Groom, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bruno, I. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lightfoot, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ward, S. C.</span></span> <span> </span><span class="NLM_article-title">The cambridge structural database</span>. <i>Acta Crystallogr., Sect. B: Struct. Sci., Cryst. Eng. Mater.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>B72</i></span>,  <span class="NLM_fpage">171</span>â <span class="NLM_lpage">179</span>, <span class="refDoi">Â DOI: 10.1107/S2052520616003954</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01340&amp;key=10.1107%2FS2052520616003954" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=B72&publication_year=2016&pages=171-179&author=C.+R.+Groomauthor=I.+J.+Brunoauthor=M.+P.+Lightfootauthor=S.+C.+Ward&title=The+cambridge+structural+database&doi=10.1107%2FS2052520616003954"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1107%2FS2052520616003954&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1107%252FS2052520616003954%26sid%3Dliteratum%253Aachs%26aulast%3DGroom%26aufirst%3DC.%2BR.%26aulast%3DBruno%26aufirst%3DI.%2BJ.%26aulast%3DLightfoot%26aufirst%3DM.%2BP.%26aulast%3DWard%26aufirst%3DS.%2BC.%26atitle%3DThe%2520cambridge%2520structural%2520database%26jtitle%3DActa%2520Crystallogr.%252C%2520Sect.%2520B%253A%2520Struct.%2520Sci.%252C%2520Cryst.%2520Eng.%2520Mater.%26date%3D2016%26volume%3DB72%26spage%3D171%26epage%3D179%26doi%3D10.1107%2FS2052520616003954" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref44"><div class="reference"><strong class="refLabel"><a href="#ref44" class="rightTabRefNumLink">44</a></strong><div class="NLM_citation" id="rightTab-cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Barta, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Malmberg, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Melicharova, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">StrandgÃ¥rd, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Orlova, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tolmachev, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laznicek, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andersson, K.</span></span> <span> </span><span class="NLM_article-title">Protein interactions with HER-family receptors can have different characteristics depending on the hosting cell line</span>. <i>Int. J. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>40</i></span>,  <span class="NLM_fpage">1677</span>â <span class="NLM_lpage">1682</span>, <span class="refDoi">Â DOI: 10.3892/ijo.2011.1307</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01340&amp;key=10.3892%2Fijo.2011.1307" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01340&amp;key=22200885" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01340&amp;key=1%3ACAS%3A528%3ADC%252BC38XmtlGlurk%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=2012&pages=1677-1682&author=P.+Bartaauthor=J.+Malmbergauthor=L.+Melicharovaauthor=J.+Strandg%C3%A5rdauthor=A.+Orlovaauthor=V.+Tolmachevauthor=M.+Laznicekauthor=K.+Andersson&title=Protein+interactions+with+HER-family+receptors+can+have+different+characteristics+depending+on+the+hosting+cell+line&doi=10.3892%2Fijo.2011.1307"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">Protein interactions with HER-family receptors can have different characteristics depending on the hosting cell line</span></div><div class="casAuthors">Barta, Pavel; Malmberg, Jennie; Melicharova, Ludmila; Strandgard, John; Orlova, Anna; Tolmachev, Vladimir; Laznicek, Milan; Andersson, Karl</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Oncology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">40</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1677-1682</span>CODEN:
                <span class="NLM_cas:coden">IJONES</span>;
        ISSN:<span class="NLM_cas:issn">1019-6439</span>.
    
            (<span class="NLM_cas:orgname">International Journal of Oncology</span>)
        </div><div class="casAbstract">Cell lines are common model systems in the development of therapeutic proteins and in the research on cellular functions and dysfunctions.  In this field, the protein interaction assay is a frequently used tool for assessing the adequacy of a protein for diagnostic and therapeutic purposes.  In this study, we investigated the extent to which the interaction characteristics depend on the choice of cell line for HER-family receptors.  The interaction characteristics of two therapeutic antibodies (trastuzumab and cetuximab) and one Affibody mol. (ZHER2:342), interacting with the intended receptor were characterized with high precision using an automated real-time interaction method, in different cell lines (HaCaT, A431, HEP-G2, SKOV3, PC3, DU-145).  Clear differences in binding affinity and kinetics, up to one order of magnitude, were found for the interaction of the same protein binding to the same receptor on different cells for all three proteins.  For HER-family receptors, it is therefore important to refer to the measured affinity for a protein-receptor interaction together with the hosting cell line.  The ability to accurately measure affinity and kinetics of a protein-receptor interaction on cell lines of different origins may increase the understanding of underlying receptor biol., and impact the selection of candidates in the development of therapeutic or diagnostic agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpYbr3x9EoXh7Vg90H21EOLACvtfcHk0litkh7SVDWZFQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XmtlGlurk%253D&md5=9099fa83ce7504c323df188e7df470cf</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.3892%2Fijo.2011.1307&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3892%252Fijo.2011.1307%26sid%3Dliteratum%253Aachs%26aulast%3DBarta%26aufirst%3DP.%26aulast%3DMalmberg%26aufirst%3DJ.%26aulast%3DMelicharova%26aufirst%3DL.%26aulast%3DStrandg%25C3%25A5rd%26aufirst%3DJ.%26aulast%3DOrlova%26aufirst%3DA.%26aulast%3DTolmachev%26aufirst%3DV.%26aulast%3DLaznicek%26aufirst%3DM.%26aulast%3DAndersson%26aufirst%3DK.%26atitle%3DProtein%2520interactions%2520with%2520HER-family%2520receptors%2520can%2520have%2520different%2520characteristics%2520depending%2520on%2520the%2520hosting%2520cell%2520line%26jtitle%3DInt.%2520J.%2520Oncol.%26date%3D2012%26volume%3D40%26spage%3D1677%26epage%3D1682%26doi%3D10.3892%2Fijo.2011.1307" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref45"><div class="reference"><strong class="refLabel"><a href="#ref45" class="rightTabRefNumLink">45</a></strong><div class="NLM_citation" id="rightTab-cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">BjÃ¶rkelund, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gedda, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barta, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Malmqvist, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andersson, K.</span></span> <span> </span><span class="NLM_article-title">Gefitinib induces epidermal growth factor receptor dimers which alters the interaction characteristics with 125I-EGF</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>6</i></span>, <span class="NLM_elocation-id">e24739</span> <span class="refDoi">Â DOI: 10.1371/journal.pone.0024739</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01340&amp;key=10.1371%2Fjournal.pone.0024739" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01340&amp;key=21931838" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01340&amp;key=1%3ACAS%3A280%3ADC%252BC3MfkvFajsQ%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2011&author=H.+Bj%C3%B6rkelundauthor=L.+Geddaauthor=P.+Bartaauthor=M.+Malmqvistauthor=K.+Andersson&title=Gefitinib+induces+epidermal+growth+factor+receptor+dimers+which+alters+the+interaction+characteristics+with+125I-EGF&doi=10.1371%2Fjournal.pone.0024739"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">Gefitinib induces epidermal growth factor receptor dimers which alters the interaction characteristics with 125I-EGF</span></div><div class="casAuthors">Bjorkelund Hanna; Gedda Lars; Barta Pavel; Malmqvist Magnus; Andersson Karl</div><div class="citationInfo"><span class="NLM_cas:title">PloS one</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">e24739</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The tyrosine kinase inhibitor gefitinib inhibits growth in some tumor types by targeting the epidermal growth factor receptor (EGFR).  Previous studies show that the affinity of the EGF-EGFR interaction varies between hosting cell line, and that gefitinib increases the affinity for some cell lines.  In this paper, we investigate possible mechanisms behind these observations.  Real-time interaction analysis in LigandTracerÂ® Grey revealed that the HER2 dimerization preventing antibody pertuzumab clearly modified the binding of 125I-EGF to EGFR on HER2 overexpressing SKOV3 cells in the presence of gefitinib.  Pertuzumab did not affect the binding on A431 cells, which express low levels of HER2.  Cross-linking measurements showed that gefitinib increased the amount of EGFR dimers 3.0-3.8 times in A431 cells in the absence of EGF.  In EGF stimulated SKOV3 cells the amount of EGFR dimers increased 1.8-2.2 times by gefitinib, but this effect was cancelled by pertuzumab.  Gefitinib treatment did not alter the number of EGFR or HER2 expressed in tumor cell lines A431, U343, SKOV3 and SKBR3.  Real-time binding traces were further analyzed in a novel tool, Interaction Map, which deciphered the different components of the measured interaction and supports EGF binding to multiple binding sites.  EGFR and HER2 expression affect the levels of EGFR monomers, homodimers and heterodimers and EGF binds to the various monomeric/dimeric forms of EGFR with unique binding properties.  Taken together, we conclude that dimerization explains the varying affinity of EGF-EGFR in different cells, and we propose that gefitinib induces EGFR dimmers, which alters the interaction characteristics with 125I-EGF.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQmKCzaldFZyMyail4HZd-ifW6udTcc2eYDaFGV2BpLgLntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3MfkvFajsQ%253D%253D&md5=c2bfe5fe03d421cf313e4c2cac0a23b2</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0024739&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0024739%26sid%3Dliteratum%253Aachs%26aulast%3DBj%25C3%25B6rkelund%26aufirst%3DH.%26aulast%3DGedda%26aufirst%3DL.%26aulast%3DBarta%26aufirst%3DP.%26aulast%3DMalmqvist%26aufirst%3DM.%26aulast%3DAndersson%26aufirst%3DK.%26atitle%3DGefitinib%2520induces%2520epidermal%2520growth%2520factor%2520receptor%2520dimers%2520which%2520alters%2520the%2520interaction%2520characteristics%2520with%2520125I-EGF%26jtitle%3DPLoS%2520One%26date%3D2011%26volume%3D6%26doi%3D10.1371%2Fjournal.pone.0024739" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref46"><div class="reference"><strong class="refLabel"><a href="#ref46" class="rightTabRefNumLink">46</a></strong><div class="NLM_citation" id="rightTab-cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tran, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosik, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">AbrahmsÃ©n, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">SandstrÃ¶m, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">SjÃ¶berg, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">WÃ¥llberg, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahlgren, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Orlova, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tolmachev, V.</span></span> <span> </span><span class="NLM_article-title">Design, synthesis and biological evaluation of a multifunctional HER2-specific affibody molecule for molecular imaging</span>. <i>Eur. J. Nucl. Med. Mol. Imaging</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>36</i></span>,  <span class="NLM_fpage">1864</span>â <span class="NLM_lpage">1873</span>, <span class="refDoi">Â DOI: 10.1007/s00259-009-1176-z</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01340&amp;key=10.1007%2Fs00259-009-1176-z" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01340&amp;key=19504093" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01340&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtlSlu7zJ" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2009&pages=1864-1873&author=T.+A.+Tranauthor=D.+Rosikauthor=L.+Abrahms%C3%A9nauthor=M.+Sandstr%C3%B6mauthor=A.+Sj%C3%B6bergauthor=H.+W%C3%A5llbergauthor=S.+Ahlgrenauthor=A.+Orlovaauthor=V.+Tolmachev&title=Design%2C+synthesis+and+biological+evaluation+of+a+multifunctional+HER2-specific+affibody+molecule+for+molecular+imaging&doi=10.1007%2Fs00259-009-1176-z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">Design, synthesis and biological evaluation of a multifunctional HER2-specific Affibody molecule for molecular imaging</span></div><div class="casAuthors">Tran, Thuy A.; Rosik, Daniel; Abrahmsen, Lars; Sandstroem, Mattias; Sjoeberg, Anna; Wallberg, Helena; Ahlgren, Sara; Orlova, Anna; Tolmachev, Vladimir</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Nuclear Medicine and Molecular Imaging</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">36</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1864-1873</span>CODEN:
                <span class="NLM_cas:coden">EJNMA6</span>;
        ISSN:<span class="NLM_cas:issn">1619-7070</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Purpose. The purpose of this study was to design and evaluate a novel platform for labeling of Affibody mols., enabling both recombinant and synthetic prodn. and site-specific labeling with 99mTc or trivalent radiometals.  Methods. The HER2-specific Affibody mol. PEP05352 was made by peptide synthesis.  The chelator sequence SECG (serine-glutamic acid-cysteine-glycine) was anchored on the C-terminal to allow 99mTc labeling.  The cysteine can alternatively serve as a conjugation site of the chelator DOTA for indium labeling.  The resulting 99mTc- and 111In-labeled Affibody mols. were evaluated both in vitro and in vivo.  Results. Both conjugates retained their capacity to bind to HER2 receptors in vitro and in vivo.  The tumor to blood ratio in LS174T xenografts was 30 at 4 h post-injection for both conjugates.  Biodistribution data showed that the 99mTc-labeled Affibody mol. had a fourfold lower kidney accumulation compared with the 111In-labeled Affibody mol. while the accumulation in other organs was similar.  Gamma camera imaging of the conjugates could clearly visualize the tumors 4 h after injection.  Conclusion. Incorporation of the C-terminal SECG sequence in Affibody mols. provides a general multifunctional platform for site-specific labeling with different nuclides (technetium, indium, gallium, cobalt or yttrium) and for a flexible prodn. (chem. synthesis or recombinant).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqzFLblUMuT1bVg90H21EOLACvtfcHk0ljegUMlnWKOIA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtlSlu7zJ&md5=1e422a4037468bb6fe505a6afdec92bb</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1007%2Fs00259-009-1176-z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00259-009-1176-z%26sid%3Dliteratum%253Aachs%26aulast%3DTran%26aufirst%3DT.%2BA.%26aulast%3DRosik%26aufirst%3DD.%26aulast%3DAbrahms%25C3%25A9n%26aufirst%3DL.%26aulast%3DSandstr%25C3%25B6m%26aufirst%3DM.%26aulast%3DSj%25C3%25B6berg%26aufirst%3DA.%26aulast%3DW%25C3%25A5llberg%26aufirst%3DH.%26aulast%3DAhlgren%26aufirst%3DS.%26aulast%3DOrlova%26aufirst%3DA.%26aulast%3DTolmachev%26aufirst%3DV.%26atitle%3DDesign%252C%2520synthesis%2520and%2520biological%2520evaluation%2520of%2520a%2520multifunctional%2520HER2-specific%2520affibody%2520molecule%2520for%2520molecular%2520imaging%26jtitle%3DEur.%2520J.%2520Nucl.%2520Med.%2520Mol.%2520Imaging%26date%3D2009%26volume%3D36%26spage%3D1864%26epage%3D1873%26doi%3D10.1007%2Fs00259-009-1176-z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref47"><div class="reference"><strong class="refLabel"><a href="#ref47" class="rightTabRefNumLink">47</a></strong><div class="NLM_citation" id="rightTab-cit47"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nock, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maina, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krenning, E. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Jong, M.</span></span> <span> </span><span class="NLM_article-title">To serve and protectâ: enzyme inhibitors as radiopeptide escorts promote tumor targeting</span>. <i>J. Nucl. Med.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">121</span>â <span class="NLM_lpage">127</span>, <span class="refDoi">Â DOI: 10.2967/jnumed.113.129411</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01340&amp;key=10.2967%2Fjnumed.113.129411" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01340&amp;key=24287321" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01340&amp;key=1%3ACAS%3A528%3ADC%252BC2cXjtlCkur0%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2014&pages=121-127&author=B.+A.+Nockauthor=T.+Mainaauthor=E.+P.+Krenningauthor=M.+de+Jong&title=To+serve+and+protect%E2%80%9D%3A+enzyme+inhibitors+as+radiopeptide+escorts+promote+tumor+targeting&doi=10.2967%2Fjnumed.113.129411"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">"To serve and protect": enzyme inhibitors as radiopeptide escorts promote tumor targeting</span></div><div class="casAuthors">Nock, Berthold A.; Maina, Theodosia; Krenning, Eric P.; de Jong, Marion</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Nuclear Medicine</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">121-127</span>CODEN:
                <span class="NLM_cas:coden">JNMEAQ</span>;
        ISSN:<span class="NLM_cas:issn">0161-5505</span>.
    
            (<span class="NLM_cas:orgname">Society of Nuclear Medicine and Molecular Imaging</span>)
        </div><div class="casAbstract">Radiolabeled octreotide analogs are most successfully being applied today in clin. cancer imaging and treatment.  Propagation of this paradigm to other radiopeptide families has been greatly hampered by the inherent poor metabolic stability of systemically administered peptide analogs.  We hypothesized that the in vivo coadministration of specific enzyme inhibitors would improve peptide bioavailability and hence tumor uptake.  Through single coinjection of the neutral endopeptidase inhibitor phosphoramidon (PA), we were able to provoke remarkable rises in the percentages of circulating intact somatostatin, gastrin, and bombesin radiopeptides in mouse models, resulting in a remarkable increase in uptake in tumor xenografts in mice.  Methods: The peptide conjugates [DOTA-Ala1]SS14 (DOTA-Ala-Gly-c[Cys-Lys-Asn-Phe-Phe-Trp-Lys-Thr-Phe-Thr-Ser-Cys]-OH), PanSB1 (DOTA-PEG2-DTyr-Gln-Trp-Ala-Val-Î²Ala-His-Phe-Nle-NH2), and DOTA-MG11 (DOTA-DGlu-Ala-Tyr-Gly-Trp-Met-Asp-Phe-NH2) were labeled with 111In by 20 min of heating at an acidic pH.  Metabolic stability was studied with high-performance liq. chromatog. anal. of blood samples collected 5 min after the injection of the test radiopeptide alone or with PA into mice.  Biodistribution was studied after injection of each 111In-labeled radiopeptide alone or after coinjection of PA in tumor-bearing severe combined immunodeficient (SCID) mice.  Results: The amt. of intact [111In-DOTA-Ala1] SS14 detected in the mouse circulation at 5 min after the injection of PA increased impressively-from less than 2% to 86%-whereas the uptake in AR4-2J xenografts rose from less than 1 percentage injected dose per g of tissue (%ID/g) to 14 %ID/g at 4 h after injection.  Likewise, the coadministration of PA resulted in a marked increase in the amt. of circulating intact 111In-PanSB1-from 12% to 80%-at 5 min after injection, and radioligand uptake in human PC-3 xenografts in SCID mice escalated from less than 4 %ID/g to greater than 21 %ID/g at 4 h after injection.  In a similar manner, the coadministration of PA resulted in an equally impressive increase in intact [111In-DOTA]MG11 levels in the mouse bloodstream-from less than 5% to 70%-at 5 min after injection, leading to a remarkable increase in radiotracer uptake-from 2 %ID/g to greater than 15 %ID/g-in both AR4-2J tumors and A431(CCKR+) tumors (i.e., tumors induced by A431 cells transfected to stably express the human cholecystokinin subtype 2 receptor) in mice at 4 h after injection.  This effect was well visualized by SPECT/CT imaging of AR4-2J tumor-bearing mice at 4 h after injection.  Conclusion: The results of this study clearly demonstrate that the coadministration of key enzyme inhibitors can effectively prolong the survival of radiolabeled peptides in the circulation, securing their safe transit to the target.  This strategy clearly provoked an unprecedented increase in radiolabel accumulation in tumor xenografts in mice; this increase might translate into higher diagnostic sensitivity or improved therapeutic efficacy of radiopeptide drugs in cancer patients.  Hence, our findings provide exciting new opportunities for the application of biodegradable (radio)peptide drugs of either natural or synthetic origin as well as for the rationale design of analogs that are stable in vivo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqTBCeCpf9QNLVg90H21EOLACvtfcHk0ljegUMlnWKOIA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXjtlCkur0%253D&md5=f0a71739c53837fa71c2ce9863cbf668</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.2967%2Fjnumed.113.129411&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2967%252Fjnumed.113.129411%26sid%3Dliteratum%253Aachs%26aulast%3DNock%26aufirst%3DB.%2BA.%26aulast%3DMaina%26aufirst%3DT.%26aulast%3DKrenning%26aufirst%3DE.%2BP.%26aulast%3Dde%2BJong%26aufirst%3DM.%26atitle%3DTo%2520serve%2520and%2520protect%25E2%2580%259D%253A%2520enzyme%2520inhibitors%2520as%2520radiopeptide%2520escorts%2520promote%2520tumor%2520targeting%26jtitle%3DJ.%2520Nucl.%2520Med.%26date%3D2014%26volume%3D55%26spage%3D121%26epage%3D127%26doi%3D10.2967%2Fjnumed.113.129411" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref48"><div class="reference"><strong class="refLabel"><a href="#ref48" class="rightTabRefNumLink">48</a></strong><div class="NLM_citation" id="rightTab-cit48"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chatalic, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Konijnenberg, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nonnekens, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Blois, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoeben, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Ridder, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brunel, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fehrentz, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martinez, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Gent, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nock, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maina, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Weerden, W. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Jong, M.</span></span> <span> </span><span class="NLM_article-title">In vivo stabilization of a gastrin-releasing peptide receptor antagonist enhances PET imaging and radionuclide therapy of prostate cancer in preclinical studies</span>. <i>Theranostics</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">104</span>â <span class="NLM_lpage">117</span>, <span class="refDoi">Â DOI: 10.7150/thno.13580</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01340&amp;key=10.7150%2Fthno.13580" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01340&amp;key=26722377" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01340&amp;key=1%3ACAS%3A528%3ADC%252BC28XntV2msrw%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2016&pages=104-117&author=K.+L.+Chatalicauthor=M.+Konijnenbergauthor=J.+Nonnekensauthor=E.+de+Bloisauthor=S.+Hoebenauthor=C.+de+Ridderauthor=L.+Brunelauthor=J.+A.+Fehrentzauthor=J.+Martinezauthor=D.+C.+van+Gentauthor=B.+A.+Nockauthor=T.+Mainaauthor=W.+M.+van+Weerdenauthor=M.+de+Jong&title=In+vivo+stabilization+of+a+gastrin-releasing+peptide+receptor+antagonist+enhances+PET+imaging+and+radionuclide+therapy+of+prostate+cancer+in+preclinical+studies&doi=10.7150%2Fthno.13580"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">In vivo stabilization of a gastrin-releasing peptide receptor antagonist enhances PET imaging and radionuclide therapy of prostate cancer in preclinical studies</span></div><div class="casAuthors">Chatalic, Kristell L. S.; Konijnenberg, Mark; Nonnekens, Julie; de Blois, Erik; Hoeben, Sander; de Ridder, Corrina; Brunel, Luc; Fehrentz, Jean-Alain; Martinez, Jean; van Gent, Dik C.; Nock, Berthold A.; Maina, Theodosia; van Weerden, Wytske M.; de Jong, Marion</div><div class="citationInfo"><span class="NLM_cas:title">Theranostics</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">104-117</span>CODEN:
                <span class="NLM_cas:coden">THERDS</span>;
        ISSN:<span class="NLM_cas:issn">1838-7640</span>.
    
            (<span class="NLM_cas:orgname">Ivyspring International Publisher</span>)
        </div><div class="casAbstract">A single tool for early detection, accurate staging, and personalized treatment of prostate cancer (PCa) would be a major breakthrough in the field of PCa.  Gastrin-releasing peptide receptor (GRPR) targeting peptides are promising probes for a theranostic approach for PCa overexpressing GRPR.  However, the successful application of small peptides in a theranostic approach is often hampered by their fast in vivo degrdn. by proteolytic enzymes, such as neutral endopeptidase (NEP).  Here we show for the first time that co-injection of a NEP inhibitor (phosphoramidon (PA)) can lead to an impressive enhancement of diagnostic sensitivity and therapeutic efficacy of the theranostic 68Ga-/177Lu-JMV4168 GRPR-antagonist.  Co-injection of PA (300 Î¼g) led to stabilization of 177Lu-JMV4168 in murine peripheral blood.  In PC-3 tumor-bearing mice, PA co-injection led to a two-fold increase in tumor uptake of 68Ga-/177Lu-JMV4168, 1 h after injection.  In positron emission tomog. (PET) imaging with 68Ga-JMV4168, PA co-injection substantially enhanced PC-3 tumor signal intensity.  Radionuclide therapy with 177Lu-JMV4168 resulted in significant regression of PC-3 tumor size.  Radionuclide therapy efficacy was confirmed by prodn. of DNA double strand breaks, decreased cell proliferation and increased apoptosis.  Increased survival rates were obsd. in mice treated with 177Lu-JMV4168 plus PA as compared to those without PA.  This data shows that co-injection of the enzyme inhibitor PA greatly enhances the theranostic potential of GRPR-radioantagonists for future application in PCa patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoIJYrjL-c5s7Vg90H21EOLACvtfcHk0ljegUMlnWKOIA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XntV2msrw%253D&md5=094e700a40c22abd81a44d20d63345b9</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.7150%2Fthno.13580&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.7150%252Fthno.13580%26sid%3Dliteratum%253Aachs%26aulast%3DChatalic%26aufirst%3DK.%2BL.%26aulast%3DKonijnenberg%26aufirst%3DM.%26aulast%3DNonnekens%26aufirst%3DJ.%26aulast%3Dde%2BBlois%26aufirst%3DE.%26aulast%3DHoeben%26aufirst%3DS.%26aulast%3Dde%2BRidder%26aufirst%3DC.%26aulast%3DBrunel%26aufirst%3DL.%26aulast%3DFehrentz%26aufirst%3DJ.%2BA.%26aulast%3DMartinez%26aufirst%3DJ.%26aulast%3Dvan%2BGent%26aufirst%3DD.%2BC.%26aulast%3DNock%26aufirst%3DB.%2BA.%26aulast%3DMaina%26aufirst%3DT.%26aulast%3Dvan%2BWeerden%26aufirst%3DW.%2BM.%26aulast%3Dde%2BJong%26aufirst%3DM.%26atitle%3DIn%2520vivo%2520stabilization%2520of%2520a%2520gastrin-releasing%2520peptide%2520receptor%2520antagonist%2520enhances%2520PET%2520imaging%2520and%2520radionuclide%2520therapy%2520of%2520prostate%2520cancer%2520in%2520preclinical%2520studies%26jtitle%3DTheranostics%26date%3D2016%26volume%3D6%26spage%3D104%26epage%3D117%26doi%3D10.7150%2Fthno.13580" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref49"><div class="reference"><strong class="refLabel"><a href="#ref49" class="rightTabRefNumLink">49</a></strong><div class="NLM_citation" id="rightTab-cit49"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dong, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cui, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhong, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jin, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jia, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, F.</span></span> <span> </span><span class="NLM_article-title"><sup>99m</sup>Tc-Labeled Dimeric Octreotide Peptide: A radiotracer with high tumor uptake for single-photon emission computed tomography imaging of somatostatin receptor subtype 2-positive tumors</span>. <i>Mol. Pharmaceutics</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">2925</span>â <span class="NLM_lpage">2933</span>, <span class="refDoi">Â DOI: 10.1021/mp400040z</span> </span><div class="citationLinks">[<a href="/doi/10.1021/mp400040z" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01340&amp;key=1%3ACAS%3A528%3ADC%252BC3sXpsVGmt74%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2013&pages=2925-2933&author=C.+Dongauthor=H.+Zhaoauthor=S.+Yangauthor=J.+Shiauthor=J.+Huangauthor=L.+Cuiauthor=L.+Zhongauthor=X.+Jinauthor=F.+Liauthor=Z.+Liuauthor=B.+Jiaauthor=F.+Wang&title=99mTc-Labeled+Dimeric+Octreotide+Peptide%3A+A+radiotracer+with+high+tumor+uptake+for+single-photon+emission+computed+tomography+imaging+of+somatostatin+receptor+subtype+2-positive+tumors&doi=10.1021%2Fmp400040z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">99mTc-Labeled Dimeric Octreotide Peptide: A Radiotracer with High Tumor Uptake for Single-Photon Emission Computed Tomography Imaging of Somatostatin Receptor Subtype 2-Positive Tumors</span></div><div class="casAuthors">Dong, Chengyan; Zhao, Huiyun; Yang, Sujuan; Shi, Jiyun; Huang, Jinming; Cui, Liyang; Zhong, Lijun; Jin, Xiaona; Li, Fang; Liu, Zhaofei; Jia, Bing; Wang, Fan</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmaceutics</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2925-2933</span>CODEN:
                <span class="NLM_cas:coden">MPOHBP</span>;
        ISSN:<span class="NLM_cas:issn">1543-8384</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">There is growing interest in the development of radiolabeled multivalent ligands because of their higher tumor uptake vs. that of the corresponding monomer.  This report presents the synthesis of a [Tyr3]octreotide dimer conjugate, HYNIC-E([Tyr3]octreotide)2 {HYNIC-TOC2, HYNIC = 6-[2-(2-sulfonatobenzaldehyde)hydrazono]nicotinyl}, and its biol. evaluation in the AR42J tumor model.  The binding affinity of HYNIC-TOC2 for somatostatin receptor subtype 2 (SSTR2) was detd. in AR42J rat pancreatic cancer cells, using 125I-[Tyr3]octreotide as the radiotracer. 99mTc-HYNIC-TOC2 was prepd. by using tricine and EDDA as coligands (EDDA = ethylenediamine-N,N'-diacetic acid).  Biodistribution and Î³ imaging were performed in nude mice bearing AR42J tumors. 99mTc-HYNIC-TOC2 was obtained in >95% labeling yield with favorable stability.  Compared with those of HYNIC-TOC (IC50 = 3.74 Â± 0.82 nM), HYNIC-TOC2 showed significantly increased SSTR2 binding affinity (IC50 = 0.74 Â± 0.19 nM), and 99mTc-HYNIC-TOC2 showed significantly increased tumor uptake [13.31 Â± 3.14%ID/g vs 5.32 Â± 0.94%ID/g 1 h postinjection (p.i.) and 12.05 Â± 2.92%ID/g vs 5.87 Â± 1.96%ID/g 4 h p.i.].  Although the level of accumulation of 99mTc-HYNIC-TOC2 in kidneys was significantly increased (94.40 Â± 6.51%ID/g vs 32.27 Â± 4.51%ID/g 1 h p.i.), this high uptake was inhibited by the injection of l-lysine before the administration of 99mTc-HYNIC-TOC2 (30.99 Â± 5.05%ID/g 1 h p.i.) while tumor uptake decreased only slightly.  Consistent with biodistribution data, in vivo planar Î³ imaging showed that the tumors were clearly visualized, while the background signal was much weaker except for that of the kidneys and bladder.  The new radiotracer 99mTc-HYNIC-TOC2 with a higher binding affinity and good stability was designed and evaluated.  The higher tumor uptake of 99mTc-HYNIC-TOC2 suggests that 90Y/177Lu-labeled TOC2 might have an advantage for the radiotherapy of SSTR2-pos. tumors.  These data merit the translation of 99mTc-HYNIC-TOC2 to a clin. setting.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpwMXJ8r89uFLVg90H21EOLACvtfcHk0li7nYxqXU6fww"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXpsVGmt74%253D&md5=fb5eb21c0d7bfef7251c71f2927be088</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1021%2Fmp400040z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fmp400040z%26sid%3Dliteratum%253Aachs%26aulast%3DDong%26aufirst%3DC.%26aulast%3DZhao%26aufirst%3DH.%26aulast%3DYang%26aufirst%3DS.%26aulast%3DShi%26aufirst%3DJ.%26aulast%3DHuang%26aufirst%3DJ.%26aulast%3DCui%26aufirst%3DL.%26aulast%3DZhong%26aufirst%3DL.%26aulast%3DJin%26aufirst%3DX.%26aulast%3DLi%26aufirst%3DF.%26aulast%3DLiu%26aufirst%3DZ.%26aulast%3DJia%26aufirst%3DB.%26aulast%3DWang%26aufirst%3DF.%26atitle%3D99mTc-Labeled%2520Dimeric%2520Octreotide%2520Peptide%253A%2520A%2520radiotracer%2520with%2520high%2520tumor%2520uptake%2520for%2520single-photon%2520emission%2520computed%2520tomography%2520imaging%2520of%2520somatostatin%2520receptor%2520subtype%25202-positive%2520tumors%26jtitle%3DMol.%2520Pharmaceutics%26date%3D2013%26volume%3D10%26spage%3D2925%26epage%3D2933%26doi%3D10.1021%2Fmp400040z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref50"><div class="reference"><strong class="refLabel"><a href="#ref50" class="rightTabRefNumLink">50</a></strong><div class="NLM_citation" id="rightTab-cit50"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Maina, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Konijnenberg, M. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">KolencPeitl, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garnuszek, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nock, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaloudi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kroselj, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zaletel, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maecke, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mansi, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Erba, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">von Guggenberg, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hubalewska-Dydejczyk, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mikolajczak, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Decristoforo, C.</span></span> <span> </span><span class="NLM_article-title">Preclinical pharmacokinetics, biodistribution, radiation dosimetry and toxicity studies required for regulatory approval of a phase I clinical trial with (111)In-CP04 in medullary thyroid carcinoma patients</span>. <i>Eur. J. Pharm. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>91</i></span>,  <span class="NLM_fpage">236</span>â <span class="NLM_lpage">242</span>, <span class="refDoi">Â DOI: 10.1016/j.ejps.2016.05.011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01340&amp;key=10.1016%2Fj.ejps.2016.05.011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01340&amp;key=27185299" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01340&amp;key=1%3ACAS%3A528%3ADC%252BC28Xos1Wmt7w%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=91&publication_year=2016&pages=236-242&author=T.+Mainaauthor=M.+W.+Konijnenbergauthor=P.+KolencPeitlauthor=P.+Garnuszekauthor=B.+A.+Nockauthor=A.+Kaloudiauthor=M.+Kroseljauthor=K.+Zaletelauthor=H.+Maeckeauthor=R.+Mansiauthor=P.+Erbaauthor=E.+von+Guggenbergauthor=A.+Hubalewska-Dydejczykauthor=R.+Mikolajczakauthor=C.+Decristoforo&title=Preclinical+pharmacokinetics%2C+biodistribution%2C+radiation+dosimetry+and+toxicity+studies+required+for+regulatory+approval+of+a+phase+I+clinical+trial+with+%28111%29In-CP04+in+medullary+thyroid+carcinoma+patients&doi=10.1016%2Fj.ejps.2016.05.011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">Preclinical pharmacokinetics, biodistribution, radiation dosimetry and toxicity studies required for regulatory approval of a phase I clinical trial with 111In-CP04 in medullary thyroid carcinoma patients</span></div><div class="casAuthors">Maina, Theodosia; Konijnenberg, Mark W.; KolencPeitl, Petra; Garnuszek, Piotr; Nock, Berthold A.; Kaloudi, Aikaterini; Kroselj, Marko; Zaletel, Katja; Maecke, Helmut; Mansi, Rosalba; Erba, Paola; von Guggenberg, Elisabeth; Hubalewska-Dydejczyk, Alicja; Mikolajczak, Renata; Decristoforo, Clemens</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Pharmaceutical Sciences</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">91</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">236-242</span>CODEN:
                <span class="NLM_cas:coden">EPSCED</span>;
        ISSN:<span class="NLM_cas:issn">0928-0987</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">From a series of radiolabeled cholecystokinin (CCK) and gastrin analogs, 111In-CP04 (111In-DOTA-(DGlu)6-Ala-Tyr-Gly-Trp-Met-Asp-Phe-NH2) was selected for further translation as a diagnostic radiopharmaceutical towards a first-in-man study in patients with medullary thyroid carcinoma (MTC).  We herein report on biosafety, in vivo stability, biodistribution and dosimetry aspects of 111In-CP04 in animal models, essential for the regulatory approval of the clin. trial.  Acute and extended single dose toxicity of CP04 was tested in rodents, while the in vivo stability of 111In-CP04 was assessed by HPLC anal. of mouse blood samples.  CP04 was well-tolerated by both mice and rats, with an LD50 > 178.5 Î¼g/kg body wt. for mice and a NOAEL (no-obsd.-adverse-effect-level) of 89 Î¼g/kg body wt. for rats.  After labeling, 111In-CP04 remained > 70% intact in peripheral mouse blood at 5 min pi.  The uptake of 111In-CP04 prepd. from the freeze-dried kit and by wet-labeling were comparable in the A431-CCK2R(+)-xenografts (9.24 Â± 1.35%ID/g and 8.49 Â± 0.39%ID/g, resp.; P > 0.05).  The present study has provided convincing toxicol., biodistribution and dosimetry data for prompt implementation of the freeze-dried kit formulation without or with gelofusine administration in a multicentre clin. trial in MTC patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr2W-Fn82biTLVg90H21EOLACvtfcHk0li7nYxqXU6fww"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xos1Wmt7w%253D&md5=718e368b781ca88f0ab914bf0f0847c9</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1016%2Fj.ejps.2016.05.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejps.2016.05.011%26sid%3Dliteratum%253Aachs%26aulast%3DMaina%26aufirst%3DT.%26aulast%3DKonijnenberg%26aufirst%3DM.%2BW.%26aulast%3DKolencPeitl%26aufirst%3DP.%26aulast%3DGarnuszek%26aufirst%3DP.%26aulast%3DNock%26aufirst%3DB.%2BA.%26aulast%3DKaloudi%26aufirst%3DA.%26aulast%3DKroselj%26aufirst%3DM.%26aulast%3DZaletel%26aufirst%3DK.%26aulast%3DMaecke%26aufirst%3DH.%26aulast%3DMansi%26aufirst%3DR.%26aulast%3DErba%26aufirst%3DP.%26aulast%3Dvon%2BGuggenberg%26aufirst%3DE.%26aulast%3DHubalewska-Dydejczyk%26aufirst%3DA.%26aulast%3DMikolajczak%26aufirst%3DR.%26aulast%3DDecristoforo%26aufirst%3DC.%26atitle%3DPreclinical%2520pharmacokinetics%252C%2520biodistribution%252C%2520radiation%2520dosimetry%2520and%2520toxicity%2520studies%2520required%2520for%2520regulatory%2520approval%2520of%2520a%2520phase%2520I%2520clinical%2520trial%2520with%2520%2528111%2529In-CP04%2520in%2520medullary%2520thyroid%2520carcinoma%2520patients%26jtitle%3DEur.%2520J.%2520Pharm.%2520Sci.%26date%3D2016%26volume%3D91%26spage%3D236%26epage%3D242%26doi%3D10.1016%2Fj.ejps.2016.05.011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref51"><div class="reference"><strong class="refLabel"><a href="#ref51" class="rightTabRefNumLink">51</a></strong><div class="NLM_citation" id="rightTab-cit51"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Duggineni, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mitra, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lamberto, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">An, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pasquale, E. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Z.</span></span> <span> </span><span class="NLM_article-title">Design and synthesis of potent bivalent peptide agonists targeting the ephA2 receptor</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">344</span>â <span class="NLM_lpage">348</span>, <span class="refDoi">Â DOI: 10.1021/ml3004523</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ml3004523" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01340&amp;key=1%3ACAS%3A528%3ADC%252BC3sXitFajur4%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2013&pages=344-348&author=S.+Duggineniauthor=S.+Mitraauthor=I.+Lambertoauthor=X.+Hanauthor=Y.+Xuauthor=J.+Anauthor=E.+B.+Pasqualeauthor=Z.+Huang&title=Design+and+synthesis+of+potent+bivalent+peptide+agonists+targeting+the+ephA2+receptor&doi=10.1021%2Fml3004523"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit51R"><div class="casContent"><span class="casTitleNuber">51</span><div class="casTitle"><span class="NLM_cas:atitle">Design and Synthesis of Potent Bivalent Peptide Agonists Targeting the EphA2 Receptor</span></div><div class="casAuthors">Duggineni, Srinivas; Mitra, Sayantan; Lamberto, Ilaria; Han, Xiaofeng; Xu, Yan; An, Jing; Pasquale, Elena B.; Huang, Ziwei</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">344-348</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Designing potent and selective peptides and small mols. that target Eph receptor tyrosine kinases remains a challenge, and new strategies are needed for developing novel and potent ligands for these receptors.  In this study, we performed a structure-activity relationship study of a previously identified 12 amino acid-long peptide, SWL, by alanine scanning to identify residues important for receptor binding.  To further enhance and optimize the receptor binding affinity of the SWL peptide, we applied the concept of bivalent ligand design to synthesize several SWL-derived dimeric peptides as novel ligands capable of binding simultaneously to two EphA2 receptor mols.  The dimeric peptides possess higher receptor binding affinity than the original monomeric SWL peptide, consistent with bivalent binding.  The most potent dimeric peptide, a SWL dimer with a six-carbon linker, has about 13-fold increased potency as compared to SWL.  Furthermore, similar to SWL, the dimeric peptide is an agonist and can promote EphA2 tyrosine phosphorylation (activation) in cultured cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp5CfG69V9xzLVg90H21EOLACvtfcHk0ljhAl47dUKCXg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXitFajur4%253D&md5=cfde81669466bc1ce0733c0816baf7c9</span></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1021%2Fml3004523&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fml3004523%26sid%3Dliteratum%253Aachs%26aulast%3DDuggineni%26aufirst%3DS.%26aulast%3DMitra%26aufirst%3DS.%26aulast%3DLamberto%26aufirst%3DI.%26aulast%3DHan%26aufirst%3DX.%26aulast%3DXu%26aufirst%3DY.%26aulast%3DAn%26aufirst%3DJ.%26aulast%3DPasquale%26aufirst%3DE.%2BB.%26aulast%3DHuang%26aufirst%3DZ.%26atitle%3DDesign%2520and%2520synthesis%2520of%2520potent%2520bivalent%2520peptide%2520agonists%2520targeting%2520the%2520ephA2%2520receptor%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2013%26volume%3D4%26spage%3D344%26epage%3D348%26doi%3D10.1021%2Fml3004523" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref52"><div class="reference"><strong class="refLabel"><a href="#ref52" class="rightTabRefNumLink">52</a></strong><div class="NLM_citation" id="rightTab-cit52"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Digilio, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barbero, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bracco, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Corpillo, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Esposito, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Piquet, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Traversa, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aime, S.</span></span> <span> </span><span class="NLM_article-title">NMR structure of two novel polyethylene glycol conjugates of the human growth hormone-releasing factor, hGRF (1- 29)- NH<sub>2</sub></span>. <i>J. Am. Chem. Soc.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>125</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">3458</span>â <span class="NLM_lpage">3470</span>, <span class="refDoi">Â DOI: 10.1021/ja021264j</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ja021264j" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01340&amp;key=1%3ACAS%3A528%3ADC%252BD3sXhsVyntrk%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=125&publication_year=2003&pages=3458-3470&issue=12&author=G.+Digilioauthor=L.+Barberoauthor=C.+Braccoauthor=D.+Corpilloauthor=P.+Espositoauthor=G.+Piquetauthor=S.+Traversaauthor=S.+Aime&title=NMR+structure+of+two+novel+polyethylene+glycol+conjugates+of+the+human+growth+hormone-releasing+factor%2C+hGRF+%281-+29%29-+NH2&doi=10.1021%2Fja021264j"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit52R"><div class="casContent"><span class="casTitleNuber">52</span><div class="casTitle"><span class="NLM_cas:atitle">NMR structure of two novel PEG conjugates of the human Growth Hormone-Releasing Factor, hGRF(1-29)-NH2</span></div><div class="casAuthors">Digilio, Giuseppe; Barbero, Luca; Bracco, Chiara; Corpillo, Davide; Esposito, Pierandrea; Piquet, Gilles; Traversa, Silvio; Aime, Silvio</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">125</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">3458-3470</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Two novel mono-PEGylated derivs. of hGRF(1-29)-NH2 [human growth hormone-releasing factor, fragment 1-29] have been synthesized by regio-specific conjugation of Lys12 or Lys21 to a monomethoxy-PEG5000 chain (compds. Lys12PEG-GRF and Lys21PEG-GRF).  The PEG moiety has been covalently linked at the amino group of a norleucine residue via a carbamate bond.  The Lys12PEG-GRF regioisomer was found to be slightly less active in vitro than both the unmodified peptide and Lys21PEG-GRF.  To assess whether the differences in the biol. activity of the PEGylated analogs could be related to conformational rearrangements induced by the PEG moiety, the structure of these PEGylated derivs. has been worked out (TFE soln.) by means of NMR spectroscopy and mol. dynamics.  Secondary structure shifts, hydrogen/deuterium exchange kinetics, temp. coeffs. of amide protons, and NOE-based mol. models point out that hGRF(1-29)-NH2, Lys21PEG-GRF and Lys12PEG-GRF share a remarkably similar pattern of secondary structure.  All three compds. adopt an Î±-helix conformation which spans the whole length of the mol., and which becomes increasingly rigid on going from the N-terminus to the C-terminus.  Residues Lys12 and Lys21 are enclosed in all the compds. considered into well-defined Î±-helical domains, indicating that PEGylation either at Lys12 or Lys21 does not alter the tendency of the peptide to adopt a stable Î±-helix conformation, nor does it induce appreciable conformational mobility in the proximity of the PEGylation sites.  No significant variation of the amphiphilic organization of the Î±-helix is obsd. among the three peptides. Therefore, the different biol. activities obsd. for the PEGylated analogs are not due to conformational effects, but are rather due to steric hindrance effects.  The relationship between the biol. activity of the mono-PEGylated derivs. and steric hindrance is discussed in terms of the topol. of interaction between hGRF(1-29)-NH2 and its receptor.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGojknXc4DDxNLVg90H21EOLACvtfcHk0ljhAl47dUKCXg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXhsVyntrk%253D&md5=1ad044f8f9e383ddd68238c71df5cab8</span></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1021%2Fja021264j&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja021264j%26sid%3Dliteratum%253Aachs%26aulast%3DDigilio%26aufirst%3DG.%26aulast%3DBarbero%26aufirst%3DL.%26aulast%3DBracco%26aufirst%3DC.%26aulast%3DCorpillo%26aufirst%3DD.%26aulast%3DEsposito%26aufirst%3DP.%26aulast%3DPiquet%26aufirst%3DG.%26aulast%3DTraversa%26aufirst%3DS.%26aulast%3DAime%26aufirst%3DS.%26atitle%3DNMR%2520structure%2520of%2520two%2520novel%2520polyethylene%2520glycol%2520conjugates%2520of%2520the%2520human%2520growth%2520hormone-releasing%2520factor%252C%2520hGRF%2520%25281-%252029%2529-%2520NH2%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D2003%26volume%3D125%26issue%3D12%26spage%3D3458%26epage%3D3470%26doi%3D10.1021%2Fja021264j" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref53"><div class="reference"><strong class="refLabel"><a href="#ref53" class="rightTabRefNumLink">53</a></strong><div class="NLM_citation" id="rightTab-cit53"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gioux, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choi, H. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frangioni, J. V.</span></span> <span> </span><span class="NLM_article-title">Image-guided surgery using invisible near-infrared light: fundamentals of clinical translation</span>. <i>Mol. Imaging</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">00034</span>, <span class="refDoi">Â DOI: 10.2310/7290.2010.00034</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01340&amp;key=10.2310%2F7290.2010.00034" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2010&pages=00034&author=S.+Giouxauthor=H.+S.+Choiauthor=J.+V.+Frangioni&title=Image-guided+surgery+using+invisible+near-infrared+light%3A+fundamentals+of+clinical+translation&doi=10.2310%2F7290.2010.00034"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.2310%2F7290.2010.00034&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2310%252F7290.2010.00034%26sid%3Dliteratum%253Aachs%26aulast%3DGioux%26aufirst%3DS.%26aulast%3DChoi%26aufirst%3DH.%2BS.%26aulast%3DFrangioni%26aufirst%3DJ.%2BV.%26atitle%3DImage-guided%2520surgery%2520using%2520invisible%2520near-infrared%2520light%253A%2520fundamentals%2520of%2520clinical%2520translation%26jtitle%3DMol.%2520Imaging%26date%3D2010%26volume%3D9%26spage%3D00034%26doi%3D10.2310%2F7290.2010.00034" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref54"><div class="reference"><strong class="refLabel"><a href="#ref54" class="rightTabRefNumLink">54</a></strong><div class="NLM_citation" id="rightTab-cit54"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Quaglino, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mastini, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Forni, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cavallo, F.</span></span> <span> </span><span class="NLM_article-title">ErbB2 transgenic mice: a tool for investigation of the immune prevention and treatment of mammary carcinomas</span>. <i>Curr. Protoc. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>82</i></span>,  <span class="NLM_fpage">20</span>â <span class="NLM_lpage">29</span>, <span class="refDoi">Â DOI: 10.1002/0471142735.im2009s82</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01340&amp;key=10.1002%2F0471142735.im2009s82" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=82&publication_year=2008&pages=20-29&author=E.+Quaglinoauthor=C.+Mastiniauthor=G.+Forniauthor=F.+Cavallo&title=ErbB2+transgenic+mice%3A+a+tool+for+investigation+of+the+immune+prevention+and+treatment+of+mammary+carcinomas&doi=10.1002%2F0471142735.im2009s82"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.1002%2F0471142735.im2009s82&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252F0471142735.im2009s82%26sid%3Dliteratum%253Aachs%26aulast%3DQuaglino%26aufirst%3DE.%26aulast%3DMastini%26aufirst%3DC.%26aulast%3DForni%26aufirst%3DG.%26aulast%3DCavallo%26aufirst%3DF.%26atitle%3DErbB2%2520transgenic%2520mice%253A%2520a%2520tool%2520for%2520investigation%2520of%2520the%2520immune%2520prevention%2520and%2520treatment%2520of%2520mammary%2520carcinomas%26jtitle%3DCurr.%2520Protoc.%2520Immunol.%26date%3D2008%26volume%3D82%26spage%3D20%26epage%3D29%26doi%3D10.1002%2F0471142735.im2009s82" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref55"><div class="reference"><strong class="refLabel"><a href="#ref55" class="rightTabRefNumLink">55</a></strong><div class="NLM_citation" id="rightTab-cit55"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Aime, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Calabi, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cavallotti, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gianolio, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giovenzana, G. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Losi, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maiocchi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palmisano, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sisti, M.</span></span> <span> </span><span class="NLM_article-title">Gd-AAZTA-: a new structural entry for an improved generation of MRI contrast agents</span>. <i>Inorg. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>43</i></span> (<span class="NLM_issue">24</span>),  <span class="NLM_fpage">7588</span>â <span class="NLM_lpage">7590</span>, <span class="refDoi">Â DOI: 10.1021/ic0489692</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ic0489692" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01340&amp;key=1%3ACAS%3A528%3ADC%252BD2cXptValsb4%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=2004&pages=7588-7590&issue=24&author=S.+Aimeauthor=L.+Calabiauthor=C.+Cavallottiauthor=E.+Gianolioauthor=G.+B.+Giovenzanaauthor=P.+Losiauthor=A.+Maiocchiauthor=G.+Palmisanoauthor=M.+Sisti&title=Gd-AAZTA-%3A+a+new+structural+entry+for+an+improved+generation+of+MRI+contrast+agents&doi=10.1021%2Fic0489692"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit55R"><div class="casContent"><span class="casTitleNuber">55</span><div class="casTitle"><span class="NLM_cas:atitle">[Gd-AAZTA]-: A New Structural Entry for an Improved Generation of MRI Contrast Agents</span></div><div class="casAuthors">Aime, Silvio; Calabi, Luisella; Cavallotti, Camilla; Gianolio, Eliana; Giovenzana, Giovanni B.; Losi, Pietro; Maiocchi, Alessandro; Palmisano, Giovanni; Sisti, Massimo</div><div class="citationInfo"><span class="NLM_cas:title">Inorganic Chemistry</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">43</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">7588-7590</span>CODEN:
                <span class="NLM_cas:coden">INOCAJ</span>;
        ISSN:<span class="NLM_cas:issn">0020-1669</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">An innovative MRI contrast agent based on the unprecedented and easily obtained ligand AAZTA (I) is described.  The simple and straightforward synthesis of the ligand, together with the potentiometric and relaxometric behavior of the corresponding Gd(III) chelate, is reported.  [Gd(AAZTA-4H)]- shows outstanding magnetic properties connected with high thermodn. stability in aq. soln. and a nearly complete inertness toward the influence of bidentate endogenous anions, placing this compd. as one of the most promising candidates for the development of high performance MRI contrast agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpPgrD7a1RlrLVg90H21EOLACvtfcHk0ljhAl47dUKCXg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXptValsb4%253D&md5=321b4e8c6eaee06eb3eed6e6d0d2583a</span></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.1021%2Fic0489692&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fic0489692%26sid%3Dliteratum%253Aachs%26aulast%3DAime%26aufirst%3DS.%26aulast%3DCalabi%26aufirst%3DL.%26aulast%3DCavallotti%26aufirst%3DC.%26aulast%3DGianolio%26aufirst%3DE.%26aulast%3DGiovenzana%26aufirst%3DG.%2BB.%26aulast%3DLosi%26aufirst%3DP.%26aulast%3DMaiocchi%26aufirst%3DA.%26aulast%3DPalmisano%26aufirst%3DG.%26aulast%3DSisti%26aufirst%3DM.%26atitle%3DGd-AAZTA-%253A%2520a%2520new%2520structural%2520entry%2520for%2520an%2520improved%2520generation%2520of%2520MRI%2520contrast%2520agents%26jtitle%3DInorg.%2520Chem.%26date%3D2004%26volume%3D43%26issue%3D24%26spage%3D7588%26epage%3D7590%26doi%3D10.1021%2Fic0489692" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref56"><div class="reference"><strong class="refLabel"><a href="#ref56" class="rightTabRefNumLink">56</a></strong><div class="NLM_citation" id="rightTab-cit56"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Waldron, B. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parker, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burchardt, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yufit, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zimny, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roesch, F.</span></span> <span> </span><span class="NLM_article-title">Structure and stability of hexadentate complexes of ligands based on AAZTA for efficient PET labelling with gallium-68</span>. <i>Chem. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>49</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">579</span>â <span class="NLM_lpage">581</span>, <span class="refDoi">Â DOI: 10.1039/C2CC37544C</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01340&amp;key=10.1039%2FC2CC37544C" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01340&amp;key=23212712" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01340&amp;key=1%3ACAS%3A528%3ADC%252BC38XhvVCju7fN" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2013&pages=579-581&issue=6&author=B.+P.+Waldronauthor=D.+Parkerauthor=C.+Burchardtauthor=D.+S.+Yufitauthor=M.+Zimnyauthor=F.+Roesch&title=Structure+and+stability+of+hexadentate+complexes+of+ligands+based+on+AAZTA+for+efficient+PET+labelling+with+gallium-68&doi=10.1039%2FC2CC37544C"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit56R"><div class="casContent"><span class="casTitleNuber">56</span><div class="casTitle"><span class="NLM_cas:atitle">Structure and stability of hexadentate complexes of ligands based on AAZTA for efficient PET labelling with gallium-68</span></div><div class="casAuthors">Waldron, Bradley P.; Parker, David; Burchardt, Carsten; Yufit, Dmitry S.; Zimny, Melanie; Roesch, Frank</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Communications (Cambridge, United Kingdom)</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">579-581</span>CODEN:
                <span class="NLM_cas:coden">CHCOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-7345</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">Pre-organised tricarboxylate ligands based on 6-amino-perhydro-1,4-diazepine bind 68Ga rapidly and selectively in acetate buffer at pH 4 to 7, forming kinetically stable complexes suitable for use in PET imaging.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp8sLogoR3UOrVg90H21EOLACvtfcHk0ljYFnKMrdzMDg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhvVCju7fN&md5=7059a4137fe7abb2a7b0f366b5dd8d61</span></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=10.1039%2FC2CC37544C&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC2CC37544C%26sid%3Dliteratum%253Aachs%26aulast%3DWaldron%26aufirst%3DB.%2BP.%26aulast%3DParker%26aufirst%3DD.%26aulast%3DBurchardt%26aufirst%3DC.%26aulast%3DYufit%26aufirst%3DD.%2BS.%26aulast%3DZimny%26aufirst%3DM.%26aulast%3DRoesch%26aufirst%3DF.%26atitle%3DStructure%2520and%2520stability%2520of%2520hexadentate%2520complexes%2520of%2520ligands%2520based%2520on%2520AAZTA%2520for%2520efficient%2520PET%2520labelling%2520with%2520gallium-68%26jtitle%3DChem.%2520Commun.%26date%3D2013%26volume%3D49%26issue%3D6%26spage%3D579%26epage%3D581%26doi%3D10.1039%2FC2CC37544C" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref57"><div class="reference"><strong class="refLabel"><a href="#ref57" class="rightTabRefNumLink">57</a></strong><div class="NLM_citation" id="rightTab-cit57"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Baranyai, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uggeri, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maiocchi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giovenzana, G. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cavallotti, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">TakÃ¡cs, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">TÃ³th, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">BÃ¡nyai, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">BÃ©nyei, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brucher, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aime, S.</span></span> <span> </span><span class="NLM_article-title">Equilibrium, kinetic and structural studies of AAZTA complexes with Ga3+, In3+ and Cu2+</span>. <i>Eur. J. Inorg. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>2013</i></span>,  <span class="NLM_fpage">147</span>â <span class="NLM_lpage">162</span>, <span class="refDoi">Â DOI: 10.1002/ejic.201201108</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01340&amp;key=10.1002%2Fejic.201201108" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01340&amp;key=1%3ACAS%3A528%3ADC%252BC38XhslSmtLnK" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2013&publication_year=2013&pages=147-162&author=Z.+Baranyaiauthor=F.+Uggeriauthor=A.+Maiocchiauthor=G.+B.+Giovenzanaauthor=C.+Cavallottiauthor=A.+Tak%C3%A1csauthor=I.+T%C3%B3thauthor=I.+B%C3%A1nyaiauthor=A.+B%C3%A9nyeiauthor=E.+Brucherauthor=S.+Aime&title=Equilibrium%2C+kinetic+and+structural+studies+of+AAZTA+complexes+with+Ga3%2B%2C+In3%2B+and+Cu2%2B&doi=10.1002%2Fejic.201201108"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit57R"><div class="casContent"><span class="casTitleNuber">57</span><div class="casTitle"><span class="NLM_cas:atitle">Equilibrium, Kinetic and Structural Studies of AAZTA Complexes with Ga3+, In3+ and Cu2+</span></div><div class="casAuthors">Baranyai, Zsolt; Uggeri, Fulvio; Maiocchi, Alessandro; Giovenzana, Giovanni B.; Cavallotti, Camilla; Takacs, Anett; Toth, Imre; Banyai, Istvan; Benyei, Attila; Brucher, Erno; Aime, Silvio</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Inorganic Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">2013</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">147-162</span>CODEN:
                <span class="NLM_cas:coden">EJICFO</span>;
        ISSN:<span class="NLM_cas:issn">1434-1948</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">A detailed study of the structures, thermodn. stabilities and kinetics of the dissocn. of Ga3+, In3+ and Cu2+ complexes formed with the heptadentate ligand AAZTA is reported (AAZTA is 6-[bis(hydroxycarbonylmethyl)amino]1,4-bis(hydroxycarbonylmethyl)-6-methylperhydro-1,4-diazepine).  The stability consts. (log KML) of the AAZTA complexes of Ga3+, In3+ and Cu2+ are 22.18, 29.58 and 22.27, resp., which suggests that the seven-membered-ring skeleton is suited to the accommodation of these metal ions.  The solid-state structure of [Cu(H2AAZTA)]Â·H2O shows a distorted octahedral coordination.  The equatorial coordination sites of Cu2+ are occupied by one of the ring N atoms, a water O atom, one of the carboxylate O atoms and the N atom of the iminodiacetate moiety.  The other ring N atom and the carboxylate O atom of the iminodiacetate moiety coordinate to the Cu2+ in the axial positions.  In the pH range 4.5-8.5, Ga3+ is present in the form of the highly stable [Ga(AAZTA)OH]2- (log Î²GaLH-1 = 17.69).  The exchange reactions of [Ga(AAZTA)OH]2- with Cu2+ and transferrin are very slow and mainly occur through the spontaneous dissocn. of the complex close to physiol. conditions.  The half-life for the dissocn. of [Ga(AAZTA)OH]2- is t1/2 = 23 h at pH = 7.5 and 25 Â°C in 0.025 M NaHCO3 and 0.15 M NaCl.  The high conditional stability, fast formation and sufficiently slow dissocn. of [Ga(AAZTA)OH]2- represent promising properties for the complexation and diagnostic applications of radioactive Ga isotopes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrwmyH2ohQABLVg90H21EOLACvtfcHk0ljYFnKMrdzMDg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhslSmtLnK&md5=df01a7ffcd93fae02bee97621c2ed9ca</span></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=10.1002%2Fejic.201201108&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fejic.201201108%26sid%3Dliteratum%253Aachs%26aulast%3DBaranyai%26aufirst%3DZ.%26aulast%3DUggeri%26aufirst%3DF.%26aulast%3DMaiocchi%26aufirst%3DA.%26aulast%3DGiovenzana%26aufirst%3DG.%2BB.%26aulast%3DCavallotti%26aufirst%3DC.%26aulast%3DTak%25C3%25A1cs%26aufirst%3DA.%26aulast%3DT%25C3%25B3th%26aufirst%3DI.%26aulast%3DB%25C3%25A1nyai%26aufirst%3DI.%26aulast%3DB%25C3%25A9nyei%26aufirst%3DA.%26aulast%3DBrucher%26aufirst%3DE.%26aulast%3DAime%26aufirst%3DS.%26atitle%3DEquilibrium%252C%2520kinetic%2520and%2520structural%2520studies%2520of%2520AAZTA%2520complexes%2520with%2520Ga3%252B%252C%2520In3%252B%2520and%2520Cu2%252B%26jtitle%3DEur.%2520J.%2520Inorg.%2520Chem.%26date%3D2013%26volume%3D2013%26spage%3D147%26epage%3D162%26doi%3D10.1002%2Fejic.201201108" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref58"><div class="reference"><strong class="refLabel"><a href="#ref58" class="rightTabRefNumLink">58</a></strong><div class="NLM_citation" id="rightTab-cit58"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Biggin, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harris, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hedt, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jeffery, C.</span></span> <span> </span><span class="NLM_article-title">Radiological properties of next generation theranostics (Cu-64/Cu-67)</span>. <i>J. Nucl. Med.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">1014</span>â <span class="NLM_lpage">1014</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2017&pages=1014-1014&author=C.+Bigginauthor=M.+Harrisauthor=A.+Hedtauthor=C.+Jeffery&title=Radiological+properties+of+next+generation+theranostics+%28Cu-64%2FCu-67%29"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBiggin%26aufirst%3DC.%26aulast%3DHarris%26aufirst%3DM.%26aulast%3DHedt%26aufirst%3DA.%26aulast%3DJeffery%26aufirst%3DC.%26atitle%3DRadiological%2520properties%2520of%2520next%2520generation%2520theranostics%2520%2528Cu-64%252FCu-67%2529%26jtitle%3DJ.%2520Nucl.%2520Med.%26date%3D2017%26volume%3D58%26spage%3D1014%26epage%3D1014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref59"><div class="reference"><strong class="refLabel"><a href="#ref59" class="rightTabRefNumLink">59</a></strong><div class="NLM_citation" id="rightTab-cit59"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Panikar, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">RamÃ­rez-GarcÃ­a, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vallejo-Cardona, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Banu, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">PatrÃ³n-Soberano, O. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cialla-May, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Camacho-Villegas, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de la Rosa, E.</span></span> <span> </span><span class="NLM_article-title">Novel anti-HER2 peptide-conjugated theranostic nanoliposomes combining NaYF4:Yb,Er nanoparticles for NIR-activated bioimaging and chemo-photodynamic therapy against breast cancer</span>. <i>Nanoscale</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">20598</span>â <span class="NLM_lpage">20613</span>, <span class="refDoi">Â DOI: 10.1039/C9NR06535K</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01340&amp;key=10.1039%2FC9NR06535K" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01340&amp;key=31641713" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01340&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhvFeqsrrM" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2019&pages=20598-20613&author=S.+S.+Panikarauthor=G.+Ram%C3%ADrez-Garc%C3%ADaauthor=A.+A.+Vallejo-Cardonaauthor=N.+Banuauthor=O.+A.+Patr%C3%B3n-Soberanoauthor=D.+Cialla-Mayauthor=T.+A.+Camacho-Villegasauthor=E.+de+la+Rosa&title=Novel+anti-HER2+peptide-conjugated+theranostic+nanoliposomes+combining+NaYF4%3AYb%2CEr+nanoparticles+for+NIR-activated+bioimaging+and+chemo-photodynamic+therapy+against+breast+cancer&doi=10.1039%2FC9NR06535K"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit59R"><div class="casContent"><span class="casTitleNuber">59</span><div class="casTitle"><span class="NLM_cas:atitle">Novel anti-HER2 peptide-conjugated theranostic nanoliposomes combining NaYF4:Yb,Er nanoparticles for NIR-activated bioimaging and chemo-photodynamic therapy against breast cancer</span></div><div class="casAuthors">Panikar, Sandeep Surendra; Ramirez-Garcia, Gonzalo; Vallejo-Cardona, Alba A.; Banu, Nehla; Patron-Soberano, Olga A.; Cialla-May, Dana; Camacho-Villegas, Tanya A.; de la Rosa, Elder</div><div class="citationInfo"><span class="NLM_cas:title">Nanoscale</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">43</span>),
    <span class="NLM_cas:pages">20598-20613</span>CODEN:
                <span class="NLM_cas:coden">NANOHL</span>;
        ISSN:<span class="NLM_cas:issn">2040-3372</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">Herein, we reported the fabrication of novel peptide-conjugated ligand-targeted nanoliposomes (LTLs) for chemo-photodynamic therapy against HER2-pos. breast cancer.  The LTL core was utilized for encapsulating doxorubicin (DOX) for chemotherapy, and methylene blue (MB) attached NaYF4:Yb,Er upconversion nanoparticles (UCNPs) for NIR-activated bioimaging and leveraging its visible emission for photoexciting MB for enhanced photodynamic therapy (PDT).  The specificity of our LTLs was achieved by conjugating a newly discovered anti-HER2 peptide screened from a phage display peptide library.  The high selectivity of the peptide-conjugated LTLs was confirmed by confocal imaging of SKBR-3 (HER2-pos.) and MCF-7 (HER2-neg.) breast cancer cell lines, illustrating its target-specific nature.  The energy transfer from UCNPs to MB was verified, thus enabling the generation of reactive oxygen species upon activation with a 975 nm laser source (0.60 W cm-2) under 5 min continuous excitation.  A significant decline in the cell viability by 95% was obsd. using chemo-photodynamic combinational therapy, whereas for chemo-drug alone and PDT alone, the cell proliferation declined by 77% and 84%, resp.  Furthermore, we demonstrated an improved uptake of the LTLs inside a 3D model of SKBR-3 tumor spheroids, where the spheroid cell viability was suppressed by 66% after the use of combinational therapy.  Thus, our results suggest great prospective use of theranostic LTLs for breast cancer management.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoTNV2_Ty2IxrVg90H21EOLACvtfcHk0ljYFnKMrdzMDg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhvFeqsrrM&md5=718bf25079fd24ff5158803f7edc1938</span></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=10.1039%2FC9NR06535K&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC9NR06535K%26sid%3Dliteratum%253Aachs%26aulast%3DPanikar%26aufirst%3DS.%2BS.%26aulast%3DRam%25C3%25ADrez-Garc%25C3%25ADa%26aufirst%3DG.%26aulast%3DVallejo-Cardona%26aufirst%3DA.%2BA.%26aulast%3DBanu%26aufirst%3DN.%26aulast%3DPatr%25C3%25B3n-Soberano%26aufirst%3DO.%2BA.%26aulast%3DCialla-May%26aufirst%3DD.%26aulast%3DCamacho-Villegas%26aufirst%3DT.%2BA.%26aulast%3Dde%2Bla%2BRosa%26aufirst%3DE.%26atitle%3DNovel%2520anti-HER2%2520peptide-conjugated%2520theranostic%2520nanoliposomes%2520combining%2520NaYF4%253AYb%252CEr%2520nanoparticles%2520for%2520NIR-activated%2520bioimaging%2520and%2520chemo-photodynamic%2520therapy%2520against%2520breast%2520cancer%26jtitle%3DNanoscale%26date%3D2019%26volume%3D11%26spage%3D20598%26epage%3D20613%26doi%3D10.1039%2FC9NR06535K" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref60"><div class="reference"><strong class="refLabel"><a href="#ref60" class="rightTabRefNumLink">60</a></strong><div class="NLM_citation" id="rightTab-cit60"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tripepi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Capuana, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gianolio, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kock, F. V. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pagoto, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stefania, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Digilio, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aime, S.</span></span> <span> </span><span class="NLM_article-title">Synthesis of high relaxivity gadolinium AAZTA tetramers as building blocks for bioconjugation</span>. <i>Bioconjugate Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>29</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">1428</span>â <span class="NLM_lpage">1437</span>, <span class="refDoi">Â DOI: 10.1021/acs.bioconjchem.8b00120</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.bioconjchem.8b00120" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01340&amp;key=1%3ACAS%3A528%3ADC%252BC1cXjtFCitbc%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2018&pages=1428-1437&issue=4&author=M.+Tripepiauthor=F.+Capuanaauthor=E.+Gianolioauthor=F.+V.+C.+Kockauthor=A.+Pagotoauthor=R.+Stefaniaauthor=G.+Digilioauthor=S.+Aime&title=Synthesis+of+high+relaxivity+gadolinium+AAZTA+tetramers+as+building+blocks+for+bioconjugation&doi=10.1021%2Facs.bioconjchem.8b00120"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit60R"><div class="casContent"><span class="casTitleNuber">60</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis of High Relaxivity Gadolinium AAZTA Tetramers as Building Blocks for Bioconjugation</span></div><div class="casAuthors">Tripepi, Martina; Capuana, Federico; Gianolio, Eliana; Kock, Flavio Vinicius Crizostomo; Pagoto, Amerigo; Stefania, Rachele; Digilio, Giuseppe; Aime, Silvio</div><div class="citationInfo"><span class="NLM_cas:title">Bioconjugate Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1428-1437</span>CODEN:
                <span class="NLM_cas:coden">BCCHES</span>;
        ISSN:<span class="NLM_cas:issn">1043-1802</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Mol. imaging requires the specific accumulation of contrast agents at the target.  To exploit the superb resoln. of MRI for applications in mol. imaging, gadolinium chelates, as the MRI contrast agents (CA), have to be conjugated to a specific vector able to recognize the epitope of interest.  Several Gd(III)-chelates can be chem. linked to the same binding vector in order to deliver multiple copies of the CA (multimers) in a single targeting event thus increasing the sensitivity of the mol. probe.  Herein three novel bifunctional agents, carrying one functional group for the bioconjugation to targeting vectors and four Gd(III)-AAZTA chelate functions for MRI contrast enhancement (AAZTA = 6-amino-6-methylperhydro-1,4-diazepinetetraacetic acid), are reported.  The relaxivity in the tetrameric derivs. is 16.4 Â± 0.2 mMGd-1 s-1 at 21.5 MHz and 25 Â°C, being 2.4-fold higher than that of parent, monomeric Gd(III)-AAZTA.  These compds. can be used as versatile building blocks to insert preformed, high relaxivity, and high d. Gd-centers to biol. targeting vectors.  As an example, we describe the use of these bifunctional Gd(III)-chelates to label a fibrin-targeting peptide.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpCFBseuEdWkLVg90H21EOLACvtfcHk0lh7QIB9mEipCQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXjtFCitbc%253D&md5=db2799a8f2d32521ad7447a33c28dc25</span></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=10.1021%2Facs.bioconjchem.8b00120&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.bioconjchem.8b00120%26sid%3Dliteratum%253Aachs%26aulast%3DTripepi%26aufirst%3DM.%26aulast%3DCapuana%26aufirst%3DF.%26aulast%3DGianolio%26aufirst%3DE.%26aulast%3DKock%26aufirst%3DF.%2BV.%2BC.%26aulast%3DPagoto%26aufirst%3DA.%26aulast%3DStefania%26aufirst%3DR.%26aulast%3DDigilio%26aufirst%3DG.%26aulast%3DAime%26aufirst%3DS.%26atitle%3DSynthesis%2520of%2520high%2520relaxivity%2520gadolinium%2520AAZTA%2520tetramers%2520as%2520building%2520blocks%2520for%2520bioconjugation%26jtitle%3DBioconjugate%2520Chem.%26date%3D2018%26volume%3D29%26issue%3D4%26spage%3D1428%26epage%3D1437%26doi%3D10.1021%2Facs.bioconjchem.8b00120" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref61"><div class="reference"><strong class="refLabel"><a href="#ref61" class="rightTabRefNumLink">61</a></strong><div class="NLM_citation" id="rightTab-cit61"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pagoto, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stefania, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garello, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arena, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Digilio, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aime, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Terreno, E.</span></span> <span> </span><span class="NLM_article-title">Paramagnetic phospholipid-based micelles targeting VCAM-1 receptors for MRI visualization of inflammation</span>. <i>Bioconjugate Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>27</i></span> (<span class="NLM_issue">8</span>),  <span class="NLM_fpage">1921</span>â <span class="NLM_lpage">1930</span>, <span class="refDoi">Â DOI: 10.1021/acs.bioconjchem.6b00308</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.bioconjchem.6b00308" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01340&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtVSrsrzL" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2016&pages=1921-1930&issue=8&author=A.+Pagotoauthor=R.+Stefaniaauthor=F.+Garelloauthor=F.+Arenaauthor=G.+Digilioauthor=S.+Aimeauthor=E.+Terreno&title=Paramagnetic+phospholipid-based+micelles+targeting+VCAM-1+receptors+for+MRI+visualization+of+inflammation&doi=10.1021%2Facs.bioconjchem.6b00308"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit61R"><div class="casContent"><span class="casTitleNuber">61</span><div class="casTitle"><span class="NLM_cas:atitle">Paramagnetic Phospholipid-Based Micelles Targeting VCAM-1 Receptors for MRI Visualization of Inflammation</span></div><div class="casAuthors">Pagoto, Amerigo; Stefania, Rachele; Garello, Francesca; Arena, Francesca; Digilio, Giuseppe; Aime, Silvio; Terreno, Enzo</div><div class="citationInfo"><span class="NLM_cas:title">Bioconjugate Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1921-1930</span>CODEN:
                <span class="NLM_cas:coden">BCCHES</span>;
        ISSN:<span class="NLM_cas:issn">1043-1802</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Inflammation is signaled by the overexpression of epitopes on the vascular endothelium that primarily aim at recruiting immune cells into the inflamed area.  The intravascular localization of these biomarkers makes them suitable targets for the MRI visualization of inflammation.  Phospholipid-based nanosystems appear excellent candidates in virtue of their good biocompatibility, ability to deliver a high no. of imaging units at the target site, and for the easy functionalization with targeting vectors.  In this work, phospholipid-based micelles (hydrodynamic diam. of 20 nm) loaded with the amphiphilic Gd(III)-complex Gd-DOTAMA(C18)2 were vectorized with a small peptide able to specifically bind VCAM-1 receptors.  The micelles displayed a high longitudinal relaxivity (36.4 s-1mmolGd-1 at 25 Â°C and 0.7 T).  A 1H- and 17O-water relaxometry study indicated that the paramagnetic complex embedded in the nanoparticles adopted two isomeric conformations, likely reflecting the well-known square antiprismatic (SAP) and twisted square antiprismatic (TSAP) configurations typically obsd. in DOTA-like lanthanide complexes.  Interestingly, the TSAP structure, showing a much faster exchange rate for the water mol. coordinated to the metal ion, was the most abundant, thus explaining the high relaxivity of the micellar agent.  The systemic administration of the micelles into a lipopolysaccharide-induced murine model of acute inflammation successfully demonstrated the ability of the targeting agents to detect the diseased area by T1 contrast enhanced MRI.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrKIdHNK-378LVg90H21EOLACvtfcHk0lh7QIB9mEipCQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtVSrsrzL&md5=590c29f60527d3687303058968644696</span></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=10.1021%2Facs.bioconjchem.6b00308&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.bioconjchem.6b00308%26sid%3Dliteratum%253Aachs%26aulast%3DPagoto%26aufirst%3DA.%26aulast%3DStefania%26aufirst%3DR.%26aulast%3DGarello%26aufirst%3DF.%26aulast%3DArena%26aufirst%3DF.%26aulast%3DDigilio%26aufirst%3DG.%26aulast%3DAime%26aufirst%3DS.%26aulast%3DTerreno%26aufirst%3DE.%26atitle%3DParamagnetic%2520phospholipid-based%2520micelles%2520targeting%2520VCAM-1%2520receptors%2520for%2520MRI%2520visualization%2520of%2520inflammation%26jtitle%3DBioconjugate%2520Chem.%26date%3D2016%26volume%3D27%26issue%3D8%26spage%3D1921%26epage%3D1930%26doi%3D10.1021%2Facs.bioconjchem.6b00308" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref62"><div class="reference"><strong class="refLabel"><a href="#ref62" class="rightTabRefNumLink">62</a></strong><div class="NLM_citation" id="rightTab-cit62"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Slaga, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ellerman, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lombana, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vij, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hristopoulos, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clark, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnston, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shelton, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mai, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gadkar, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lo, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koerber, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Totpal, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prell, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spiess, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Junttila, T. T.</span></span> <span> </span><span class="NLM_article-title">Avidity-based binding to HER2 results in selective killing of HER2-overexpressing cells by anti-HER2/CD3</span>. <i>Sci. Transl. Med.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>10</i></span>, <span class="NLM_elocation-id">eaat5775</span> <span class="refDoi">Â DOI: 10.1126/scitranslmed.aat5775</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01340&amp;key=10.1126%2Fscitranslmed.aat5775" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01340&amp;key=30333240" title="">PubMed</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2018&author=D.+Slagaauthor=D.+Ellermanauthor=N.+Lombanaauthor=R.+Vijauthor=J.+Liauthor=M.+Hristopoulosauthor=R.+Clarkauthor=J.+Johnstonauthor=A.+Sheltonauthor=E.+Maiauthor=K.+Gadkarauthor=A.+A.+Loauthor=J.+T.+Koerberauthor=K.+Totpalauthor=R.+Prellauthor=G.+Leeauthor=C.+Spiessauthor=T.+T.+Junttila&title=Avidity-based+binding+to+HER2+results+in+selective+killing+of+HER2-overexpressing+cells+by+anti-HER2%2FCD3&doi=10.1126%2Fscitranslmed.aat5775"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit62&amp;dbid=16384&amp;doi=10.1126%2Fscitranslmed.aat5775&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscitranslmed.aat5775%26sid%3Dliteratum%253Aachs%26aulast%3DSlaga%26aufirst%3DD.%26aulast%3DEllerman%26aufirst%3DD.%26aulast%3DLombana%26aufirst%3DN.%26aulast%3DVij%26aufirst%3DR.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DHristopoulos%26aufirst%3DM.%26aulast%3DClark%26aufirst%3DR.%26aulast%3DJohnston%26aufirst%3DJ.%26aulast%3DShelton%26aufirst%3DA.%26aulast%3DMai%26aufirst%3DE.%26aulast%3DGadkar%26aufirst%3DK.%26aulast%3DLo%26aufirst%3DA.%2BA.%26aulast%3DKoerber%26aufirst%3DJ.%2BT.%26aulast%3DTotpal%26aufirst%3DK.%26aulast%3DPrell%26aufirst%3DR.%26aulast%3DLee%26aufirst%3DG.%26aulast%3DSpiess%26aufirst%3DC.%26aulast%3DJunttila%26aufirst%3DT.%2BT.%26atitle%3DAvidity-based%2520binding%2520to%2520HER2%2520results%2520in%2520selective%2520killing%2520of%2520HER2-overexpressing%2520cells%2520by%2520anti-HER2%252FCD3%26jtitle%3DSci.%2520Transl.%2520Med.%26date%3D2018%26volume%3D10%26doi%3D10.1126%2Fscitranslmed.aat5775" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref63"><div class="reference"><strong class="refLabel"><a href="#ref63" class="rightTabRefNumLink">63</a></strong><div class="NLM_citation" id="rightTab-cit63"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quinn, T. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deutscher, S. L.</span></span> <span> </span><span class="NLM_article-title">Evaluation of an <sup>111</sup>In-Radiolabeled peptide as a targeting and imaging agent for ErbB-2 receptor-expressing breast carcinomas</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>13</i></span> (<span class="NLM_issue">20</span>),  <span class="NLM_fpage">6070</span>â <span class="NLM_lpage">6079</span>, <span class="refDoi">Â DOI: 10.1158/1078-0432.CCR-07-0160</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01340&amp;key=10.1158%2F1078-0432.CCR-07-0160" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01340&amp;key=17947470" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01340&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtFygs7bM" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2007&pages=6070-6079&issue=20&author=S.+R.+Kumarauthor=T.+P.+Quinnauthor=S.+L.+Deutscher&title=Evaluation+of+an+111In-Radiolabeled+peptide+as+a+targeting+and+imaging+agent+for+ErbB-2+receptor-expressing+breast+carcinomas&doi=10.1158%2F1078-0432.CCR-07-0160"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit63R"><div class="casContent"><span class="casTitleNuber">63</span><div class="casTitle"><span class="NLM_cas:atitle">Evaluation of an 111In-Radiolabeled Peptide as a Targeting and Imaging Agent for ErbB-2 Receptor-Expressing Breast Carcinomas</span></div><div class="casAuthors">Kumar, Senthil R.; Quinn, Thomas P.; Deutscher, Susan L.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">6070-6079</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">PURPOSE: The cellular targeting and tumor imaging properties of a novel ErbB-2-avid peptide, discovered from bacteriophage display, were evaluated in human breast carcinoma cells and in breast carcinoma-xenografted mice.  Exptl. Design: The affinity of the ErbB-2 targeting peptide KCCYSL and its alanine substituted counterparts for the extracellular domain (ECD) of purified recombinant ErbB-2 (ErbB-2-ECD) was assessed by fluorescence titrn.  Binding of the KCCYSL peptide to breast and prostate carcinoma cells was analyzed by confocal microscopy.  A DOTA(GSG)-KCCYSL peptide conjugate was radiolabeled with 111In, and stability, target binding, and internalization were analyzed in vitro.  In vivo biodistribution and single-photon emission computed tomog. imaging studies were done with the radiolabeled peptide in MDA-MB-435 human breast tumor-bearing severe combined immunodeficient mice.  RESULTS: KCCYSL peptide exhibited high affinity (295 Â± 56 nmol/L) to ErbB-2-ECD.  Substitution of alanine for lysine, tryptophan, and cysteine reduced the peptide affinity â¼ 1- to 2.4-fold, whereas replacing leucine completely abolished binding.  Both biotin-KCCYSL and 111In-DOTA(GSG)-KCCYSL were capable of binding ErbB-2-expressing human breast carcinoma cells in vitro.  Approx. 11% of the total bound radioactivity was internalized in the carcinoma cells.  Competitive binding studies indicated that the radiolabeled peptide exhibited an IC50 value of 42.5 Â± 2.76 nmol/L for the breast carcinoma cells.  111In-DOTA(GSG)-KCCYSL was stable in serum and exhibited rapid tumor uptake (2.12 Â± 0.32 %ID/g) at 15 min postinjection and extended retention coupled with rapid whole body disappearance, as obsd. by biodistribution and single-photon emission computed tomog. imaging studies, resp.  The DOTA(GSG)-KCCYSL peptide has the potential to be used as a tumor-imaging agent and a vehicle for specific delivery of radionuclide or cytotoxic agents for tumors overexpressing ErbB-2.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr6amYMOtE6XLVg90H21EOLACvtfcHk0lhxQGKmna2fjg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtFygs7bM&md5=2d6f047acc7c4c14e8edbc981b3c78d4</span></div><a href="/servlet/linkout?suffix=cit63&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-07-0160&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-07-0160%26sid%3Dliteratum%253Aachs%26aulast%3DKumar%26aufirst%3DS.%2BR.%26aulast%3DQuinn%26aufirst%3DT.%2BP.%26aulast%3DDeutscher%26aufirst%3DS.%2BL.%26atitle%3DEvaluation%2520of%2520an%2520111In-Radiolabeled%2520peptide%2520as%2520a%2520targeting%2520and%2520imaging%2520agent%2520for%2520ErbB-2%2520receptor-expressing%2520breast%2520carcinomas%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2007%26volume%3D13%26issue%3D20%26spage%3D6070%26epage%3D6079%26doi%3D10.1158%2F1078-0432.CCR-07-0160" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref64"><div class="reference"><strong class="refLabel"><a href="#ref64" class="rightTabRefNumLink">64</a></strong><div class="NLM_citation" id="rightTab-cit64"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yimchuen, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kadonosono, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ota, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sato, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kitazawa, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shiozawa, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuchimaru, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taki, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ito, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakamura, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kizaka-Kondoh, S.</span></span> <span> </span><span class="NLM_article-title">Strategic design to create HER2-targeting proteins with target-binding peptides immobilized on a fibronectin type III domain scaffold</span>. <i>RSC Adv.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">15154</span>â <span class="NLM_lpage">15162</span>, <span class="refDoi">Â DOI: 10.1039/D0RA00427H</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01340&amp;key=10.1039%2FD0RA00427H" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01340&amp;key=1%3ACAS%3A528%3ADC%252BB3cXntlegu78%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2020&pages=15154-15162&author=W.+Yimchuenauthor=T.+Kadonosonoauthor=Y.+Otaauthor=S.+Satoauthor=M.+Kitazawaauthor=T.+Shiozawaauthor=T.+Kuchimaruauthor=M.+Takiauthor=Y.+Itoauthor=H.+Nakamuraauthor=S.+Kizaka-Kondoh&title=Strategic+design+to+create+HER2-targeting+proteins+with+target-binding+peptides+immobilized+on+a+fibronectin+type+III+domain+scaffold&doi=10.1039%2FD0RA00427H"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit64R"><div class="casContent"><span class="casTitleNuber">64</span><div class="casTitle"><span class="NLM_cas:atitle">Strategic design to create HER2-targeting proteins with target-binding peptides immobilized on a fibronectin type III domain scaffold</span></div><div class="casAuthors">Yimchuen, Wanaporn; Kadonosono, Tetsuya; Ota, Yumi; Sato, Shinichi; Kitazawa, Maika; Shiozawa, Tadashi; Kuchimaru, Takahiro; Taki, Masumi; Ito, Yuji; Nakamura, Hiroyuki; Kizaka-Kondoh, Shinae</div><div class="citationInfo"><span class="NLM_cas:title">RSC Advances</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">26</span>),
    <span class="NLM_cas:pages">15154-15162</span>CODEN:
                <span class="NLM_cas:coden">RSCACL</span>;
        ISSN:<span class="NLM_cas:issn">2046-2069</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">Tumor-binding peptides such as human epidermal growth factor receptor 2 (HER2)-binding peptides are attractive therapeutic and diagnostic options for cancer.  However, the HER2-binding peptides (HBPs) developed thus far are susceptible to proteolysis and lose their affinity to HER2 in vivo.  In this report, a method to create a HER2-binding fluctuation-regulated affinity protein (HBP-FLAP) consisting of a fibronectin type III domain (FN3) scaffold with a structurally immobilized HBP is presented.  HBPs were selected by phage-library screening and grafted onto FN3 to create FN3-HBPs, and the HBP-FLAP with the highest affinity (HBP sequence: YCAHNM) was identified after affinity maturation of the grafted HBP.  HBP-FLAP contg. the YCAHNM peptide showed increased proteolysis-resistance, binding to HER2 with a dissocn. const. (KD) of 58 nM in ELISA and 287 nM in biolayer interferometry and specifically detects HER2-expressing cancer cells.  In addn., HBP-FLAP clearly delineated HER2-expressing tumors with a half-life of 6 h after i.v. injection into tumor-bearing mice.  FN3-based FLAP is an excellent platform for developing target-binding small proteins for clin. applications.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpcOXJCjvCC17Vg90H21EOLACvtfcHk0lhxQGKmna2fjg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXntlegu78%253D&md5=563e1822c2f0108bcf9ee5be7283c163</span></div><a href="/servlet/linkout?suffix=cit64&amp;dbid=16384&amp;doi=10.1039%2FD0RA00427H&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FD0RA00427H%26sid%3Dliteratum%253Aachs%26aulast%3DYimchuen%26aufirst%3DW.%26aulast%3DKadonosono%26aufirst%3DT.%26aulast%3DOta%26aufirst%3DY.%26aulast%3DSato%26aufirst%3DS.%26aulast%3DKitazawa%26aufirst%3DM.%26aulast%3DShiozawa%26aufirst%3DT.%26aulast%3DKuchimaru%26aufirst%3DT.%26aulast%3DTaki%26aufirst%3DM.%26aulast%3DIto%26aufirst%3DY.%26aulast%3DNakamura%26aufirst%3DH.%26aulast%3DKizaka-Kondoh%26aufirst%3DS.%26atitle%3DStrategic%2520design%2520to%2520create%2520HER2-targeting%2520proteins%2520with%2520target-binding%2520peptides%2520immobilized%2520on%2520a%2520fibronectin%2520type%2520III%2520domain%2520scaffold%26jtitle%3DRSC%2520Adv.%26date%3D2020%26volume%3D10%26spage%3D15154%26epage%3D15162%26doi%3D10.1039%2FD0RA00427H" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref65"><div class="reference"><strong class="refLabel"><a href="#ref65" class="rightTabRefNumLink">65</a></strong><div class="NLM_citation" id="rightTab-cit65"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cui, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Geng, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fang, Q.</span></span> <span> </span><span class="NLM_article-title">Peptide probes derived from pertuzumab by molecular dynamics modeling for HER2 positive tumor imaging</span>. <i>PLoS Comput. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>13</i></span> (<span class="NLM_issue">4</span>), <span class="NLM_elocation-id">e1005441</span> <span class="refDoi">Â DOI: 10.1371/journal.pcbi.1005441</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01340&amp;key=10.1371%2Fjournal.pcbi.1005441" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01340&amp;key=28406988" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01340&amp;key=1%3ACAS%3A528%3ADC%252BC2sXht1aisb3O" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2017&issue=4&author=X.+Yangauthor=Z.+Wangauthor=Z.+Xiangauthor=D.+Liauthor=Z.+Huauthor=W.+Cuiauthor=L.+Gengauthor=Q.+Fang&title=Peptide+probes+derived+from+pertuzumab+by+molecular+dynamics+modeling+for+HER2+positive+tumor+imaging&doi=10.1371%2Fjournal.pcbi.1005441"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit65R"><div class="casContent"><span class="casTitleNuber">65</span><div class="casTitle"><span class="NLM_cas:atitle">Peptide probes derived from pertuzumab by molecular dynamics modeling for HER2 positive tumor imaging</span></div><div class="casAuthors">Yang, Xiaoliang; Wang, Zihua; Xiang, Zhichu; Li, Dan; Hu, Zhiyuan; Cui, Wei; Geng, Lingling; Fang, Qiaojun</div><div class="citationInfo"><span class="NLM_cas:title">PLoS Computational Biology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">e1005441/1-e1005441/22</span>CODEN:
                <span class="NLM_cas:coden">PCBLBG</span>;
        ISSN:<span class="NLM_cas:issn">1553-7358</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">A high level of HER2 expression in breast cancer correlates with a higher tumor growth rate, high metastatic potential, and a poor long-term patient survival rate.  Pertuzumab, a human monoclonal antibody, can reduce the effect of HER2 overexpression by preventing HER2 dimerization.  In this study, a combination protocol of mol. dynamics modeling and MM/GBSA binding free energy calcns. was applied to design peptides that interact with HER2 based on the HER2-pertuzumab crystal structure.  Based on a Î² hairpin in pertuzumab from Glu46 to Lys65-which plays a key role in interacting with HER2-mutations were carried out in silico to improve the binding free energy of the hairpin that interacts with the Phe256-Lys314 of the HER2 protein.  Combined the use of one-bead-one-compd. library screening, among all the mutations, a peptide (58F63Y) with the lowest binding free energy was confirmed exptl. to have the highest affinity, and it may be used as a new probe in diagnosing and treating HER2-pos. breast cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqmXWRFsjEjD7Vg90H21EOLACvtfcHk0lhxQGKmna2fjg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXht1aisb3O&md5=d05751e1806c42e2ebc91c5dafad5d5b</span></div><a href="/servlet/linkout?suffix=cit65&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pcbi.1005441&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pcbi.1005441%26sid%3Dliteratum%253Aachs%26aulast%3DYang%26aufirst%3DX.%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DXiang%26aufirst%3DZ.%26aulast%3DLi%26aufirst%3DD.%26aulast%3DHu%26aufirst%3DZ.%26aulast%3DCui%26aufirst%3DW.%26aulast%3DGeng%26aufirst%3DL.%26aulast%3DFang%26aufirst%3DQ.%26atitle%3DPeptide%2520probes%2520derived%2520from%2520pertuzumab%2520by%2520molecular%2520dynamics%2520modeling%2520for%2520HER2%2520positive%2520tumor%2520imaging%26jtitle%3DPLoS%2520Comput.%2520Biol.%26date%3D2017%26volume%3D13%26issue%3D4%26doi%3D10.1371%2Fjournal.pcbi.1005441" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><div class="accessionCode mb-5"><div class="toolbar-section accession-codes"><ul><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=1N8Z" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=1N8Z','PDB','1N8Z'); return false;">PDB: 1N8Z</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6SON" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6SON','PDB','6SON'); return false;">PDB: 6SON</a></li></ul></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.0c01340&amp;pbContext=%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2020.63.issue-24%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.0c01340%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.0c01340" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                7MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright Â© 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">Youâve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"6798fcb3ca07d1ab","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
